

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶: C07K 14/47, 14/52, C12N 15/12, 15/19, 15/63, A61K 38/16, 38/19, 48/00	A1	(11) International Publication Number: WO 99/29728 (43) International Publication Date: 17 June 1999 (17.06.99)
(21) International Application Number: PCT/US98/26291 (22) International Filing Date: 11 December 1998 (11.12.98) (30) Priority Data: 60/069,281 11 December 1997 (11.12.97) US (63) Related by Continuation (CON) or Continuation-in-Part (CIP) to Earlier Application US 60/069,281 (CON) Filed on 11 December 1997 (11.12.97) (71) Applicant (for all designated States except US): UNIVERSITY OF MARYLAND BIOTECHNOLOGY INSTITUTE [US/US]; 4321 Hartwick Road, College Park, MD 20740 (US). (72) Inventors; and (75) Inventors/Applicants (for US only): GALLO, Robert, C. [US/US]; 8513 Thornden Terrace, Bethesda, MD 02817 (US). DEVICO, Anthony, L. [US/US]; 4533 Peacock Avenue, Alexandria, VA 22304 (US). GARZINO-DEMO, Alfredo [IT/US]; 601 North Eutaw Street, Baltimore, MD 21201 (US).	(74) Agent: BARRETT, William, A.; Intellectual Property/Technology Law, P.O. Box 14329, Research Triangle Park, NC 27709 (US). (81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>	
(54) Title: METHOD AND COMPOSITION TO ENHANCE THE EFFICACY OF A VACCINE USING CHEMOKINES (57) Abstract <p>The present invention relates to a method to enhance the efficacy of a vaccine in a subject treated with the vaccine comprising administering to the subject in combination with the vaccine a one or more chemokines. The present invention also relates to compositions of vaccines containing chemokines.</p>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

METHOD AND COMPOSITION TO ENHANCE THE EFFICACY OF A VACCINE USING CHEMOKINES

1. CROSS-REFERENCE TO RELATED APPLICATIONS

This application claims priority to U.S. Application Serial No. 60/069,281 filed December 11, 1997.

2. BACKGROUND OF THE INVENTION

The present invention relates to a method to enhance the efficacy of a vaccine by administration of a chemokine, such as macrophage derived chemokine (MDC), in conjunction with the vaccine. The present invention also relates to compositions useful in the method.

2.1. GENERATION OF AN IMMUNE RESPONSE

The introduction of a foreign antigen into an individual elicits an immune response consisting of two major components, the cellular and humoral immune responses, mediated by two functionally distinct populations of lymphocytes known as T and B cells, respectively (see generally Coutinho, 1991, Immune System, *Encyclopedia of Human Biology*, Vol. 4, Ed. Dulbecco, Academic Press, Inc.). A subset of T cells responds to antigen stimulation by producing lymphokines which "help" or activate various other cell types in the immune system.

Another T cell subset is capable of developing into antigen-specific cytotoxic effector cells, which can directly kill antigen-positive target cells. On the other hand, the B cell response is primarily carried out by secretory proteins, antibodies, which directly bind and neutralize antigens.

Helper T cells (TH) can be distinguished from classical cytotoxic T lymphocytes (CTL) and B cells by their cell surface expression of the glycoprotein marker CD4. Although the mechanism by which CD4⁺ TH function has not been fully elucidated, the existence of functionally distinct subsets within the CD4⁺ T cell compartment has been reported (Mosmann and Coffman, 1989, *Ann. Rev. Immunol.*

7:145-173). In the mouse, type 1 helper T cells (TH1) produce interleukin-2 (IL-2) and τ -interferon (τ -IFN) upon activation, while type 2 helper T cells (TH2) produce IL-4 and IL-5. Based on the profile of lymphokine production, TH1 appear to be involved in promoting the activation and proliferation of other T cell subsets including CTL, whereas TH2 specifically regulate B cell proliferation and differentiation, antibody synthesis, and antibody class switching.

A second T cell subpopulation is the classical CTL which express the CD8 surface marker. Unlike most TH, these cells display cytolytic activity upon direct contact with target cells, rather than through the production of lymphokines. *In vivo*, CTL function is particularly important in situations where an antibody response alone is inadequate. Significant experimental evidence indicates that CTL rather than B cells and their antibody products play a principal role in the defense against viral infections and cancer.

A salient feature of both T and B cell responses is their exquisite specificity for the immunizing antigen; however, the mechanisms for antigen recognition differ between these two cell types. B cells recognize antigens by antibodies, either acting as cell surface receptors or as secreted proteins, which bind directly to antigens on a solid surface or in solution, whereas T cells only recognize antigens that have been processed or degraded into small fragments and presented on a solid phase such as the surface of antigen-presenting cells (APC). Additionally, antigenic fragments must be presented to T cells in association with major histocompatibility complex (MHC)-encoded class I or class II molecules. The MHC refers to a cluster of genes that encode proteins with diverse immunological functions. In man, the MHC is known as HLA. Class I gene products are found on all somatic cells, and they were originally discovered as targets of major transplantation rejection responses. Class II gene products are mostly expressed on cells of various hematopoietic lineages, and they are involved in cell-cell interactions in the immune system. Most importantly, MHC-encoded proteins have been shown to function as receptors for processed antigenic fragments on the surface of APC (Bjorkman et al., 1987, *Nature* 329:506-512).

Another level of complexity in the interaction between a T cell and an antigenic fragment is that it occurs only if the MHC molecules involved are the same on the APC and the responding T cells. In other words, a T cell specific for a particular antigenic epitope expresses a receptor having low affinity for self MHC

proteins, which when such MHC proteins on APC are occupied by the epitope, engage the T cell in a stronger interaction leading to antigen-specific T cell activation. The phenomenon of a T cell reacting with a processed antigen only when presented by cells expressing a matching MHC is known as MHC-restriction.

The specificity of T cell immune responses for antigens is a function of the unique receptors expressed by these cells. The T cell receptor (TCR) is structurally homologous to an antibody; it is a heterodimer composed of disulfide-linked glycoproteins. Four TCR polypeptide chains known as α , β , γ , and δ have been identified, although the vast majority of functional T cells express the $\alpha\beta$ heterodimeric TCR. Transfer of α and β genes alone into recipient cells was shown to be both necessary and sufficient to confer antigen specificity and MHC-restriction (Dembic et al., 1986, *Nature* 320:232-238). Thus, the $\alpha\beta$ TCR appears to be responsible for recognizing a combination of antigenic fragment and MHC determinants.

The apparent basis of MHC restriction is that $CD4^+$ T cells express $\alpha\beta$ TCR which recognize antigenic fragments physically associated with MHC class II proteins, while the TCR on $CD8^+$ CTL recognize MHC class I-associated fragments. Thus, $CD4^+$ T cells can recognize only a restricted class of APC that are class II⁺, whereas $CD8^+$ CTL can interact with virtually any antigen-positive cells, since all cells express class I molecules. $CD4^+$ CTL have been identified, and they are MHC class II restricted, and lyse target cells only if the latter express self-MHC class II determinants associated with specific antigenic fragments. Both CD4 and CD8 molecules also contribute to this interaction by binding to monotypic determinants on the MHC class II and I molecules, respectively.

A second type of TCR composed of $\gamma\delta$ heterodimers is expressed by a small percentage of T cells, but the involvement of $\gamma\delta$ T cells in antigen-specific recognition is still poorly understood. Some studies have shown that functionally active $\gamma\delta$ T cells can be cytolytic in a MHC non-restricted manner.

In summary, the generation of an immune response begins with the sensitization of $CD4^+$ and $CD8^+$ T cell subsets through their interaction with APC that express MHC-class I or class II molecules associated with antigenic fragments. The sensitized or primed $CD4^+$ T cells produce lymphokines that participate in the activation of B cells as well as various T cell subsets. The sensitized $CD8^+$ T cells increase in numbers in response to lymphokines and are capable of destroying any

cells that express the specific antigenic fragments associated with matching MHC-encoded class I molecules. For example, in the course of a viral infection, CTL eradicate virally-infected cells, thereby limiting the progression of virus spread and disease development.

2.2. ANTIGEN PRESENTING CELLS

The presentation of antigens to T cells is carried out by specialized cell populations referred to as antigen presenting cells (APC). Typically, APC include macrophages/monocytes, B cells, and bone marrow-derived dendritic cells (DC). APC are capable of internalizing exogenous antigens, cleaving them into smaller fragments in enzyme-rich vesicles, and coupling the fragments to MHC-encoded products for expression on the cell surface (Goldberg and Rock, 1992, *Nature* 357:375-379). Since APC express both MHC-encoded class I and class II glycoproteins, they can present antigenic fragments to both CD4⁺ and CD8⁺ T cells for the initiation of an immune response.

By definition, APC not only can present antigens to T cells with antigen-specific receptors, but can provide all the signals necessary for T cell activation. Such signals are incompletely defined, but probably involve a variety of cell surface molecules as well as cytokines or growth factors. Further, the factors necessary for the activation of naive or unprimed T cells may be different from those required for the re-activation of previously primed memory T cells. The ability of APC to both present antigens and deliver signals for T cell activation is commonly referred to as an accessory cell function. Although monocytes and B cells have been shown to be competent APC, their antigen presenting capacities *in vitro* appear to be limited to the re-activation of previously sensitized T cells. Hence, they are not capable of directly activating functionally naive or unprimed T cell populations.

Although it had been known for a long time that APC process and present antigens to T cells, it was not shown until relatively recently that small antigenic peptides could directly bind to MHC-encoded molecules (Babbitt et al., 1985, *Nature* 317:359; Townsend et al., 1986, *Cell* 44:959). However, it is believed that, normally, complex antigens are proteolytically processed into fragments inside the APC, and become physically associated with the MHC-encoded proteins intracellularly prior to

trafficking to the cell surface as complexes. Two distinct pathways for antigen presentation have been proposed (Braciale et al., 1987, *Immunol. Rev.* 98:95-114). It was thought that exogenous antigens were taken up by APC, processed and presented by the exogenous pathway to class II restricted CD4⁺ T cells, while the endogenous pathway processed intracellularly synthesized proteins, such as products of viral genes in virally-infected cells, for association with MHC class I proteins and presentation to CD8⁺ CTL. However, although the two pathways in antigen processing and presentation may still be correct in some respects, the distinction is blurred in light of recent findings that exogenously added antigens may also be presented to class I-restricted CTL (Moore et al., 1988, *Cell* 54:777).

The term "dendritic cells" (DC) refers to a diverse population of morphologically similar cell types found in a variety of lymphoid and non-lymphoid tissues (Steinman, 1991, *Ann. Rev. Immunol.* 9:271-296). These cells include lymphoid DC of the spleen, Langerhans cells of the epidermis, and veiled cells in the blood circulation. Although they are collectively classified as a group based on their morphology, high levels of surface MHC-class II expression, and absence of certain other surface markers expressed on T cells, B cells, monocytes, and natural killer cells, it is presently not known whether they derive from a common precursor or can all function as APC in the same manner. Further, since the vast majority of published reports have utilized DC isolated from the mouse spleen, results from these studies may not necessarily correlate with the function of DC obtained from other tissue types. (Inaba et al., 1997, *J. Exp. Med.* 166:182-194; Hengel et al., 1987, *J. Immunol.*, 139:4196-4202; Kaut et al., 1988, *J. Immunol.*, 140:3186-3193; Romani et al., 1989, *J. Exp. Med.* 169:1169-1178; Macatonia et al., 1989, *J. Exp. Med.* 169:1255-1264; Inaba et al., 1990, *J. Exp. Med.* 172:631-6640). For example, despite high levels of MHC-class II expression, mouse epidermal Langerhans cells, unlike splenic DC, are not active APC in mixed leucocyte reaction (MLR), unless cultured with granulocyte-macrophage colony stimulating factor (GM-CSF) (Witmer-Pock et al., 1987, *J. Exp. Med.* 166:1484-1498; Heufler et al., 1988, *J. Exp. Med.* 167:700-705). Most human Langerhans cells express the CD1 and CD4 markers, while blood DC do not. Additionally, it has not been established the extent to which the functional characteristics observed with mouse DC are applicable to human DC, especially the DC obtained from non-splenic tissues; in part, due to inherent differences between the

human and murine immune systems.

Recently, a few studies have described the isolation of human DC from the peripheral blood, which involves the use of sheep red blood cells and/or fetal calf serum (Young and Steinman, 1990, *J. Exp. Med.* 171:1315-1332; Freudenthal and Steinman, 1990, *Proc. Natl. Acad. Sci. USA* 87:7698-7702; Macatonia et al., 1989 *Immunol.* 67:285-289; Markowicz and Engleman, 1990, *J. Clin. Invest.* 85:955-961). Engleman et al. described a partial purification procedure of DC from human blood, which does not involve the use of sheep red blood cells and/or fetal calf serum, and showed that the partially purified human DC can, in fact, present exogenous antigens to naive T cells (PCT Publication WO 94/02156 dated February 3, 1994 at page 9, lines 5-32).

Recent studies have indicated that DCs are superior APCs as compared to other APCs such as macrophages and monocytes. First, the potent accessory cell function of DCs provides for an antigen presentation system for virtually any antigenic epitopes which T and B cells are capable of recognizing through their specific receptors. For example, Engleman et al. demonstrate that human DCs can present both complex protein antigens and small peptides to CD4⁺ T cells as well as to CD8⁺ CTL (PCT Publication WO 94/02156 dated February 3, 1994, Example 7, from page 29, line 10 to page 34, line 16). Engleman et al. also show that the *in vitro* priming effect of DCs does not require the addition of exogenous lymphokines, indicating that DCs produce all of the necessary signals in antigen presentation leading to the activation of T cells (PCT Publication WO 94/02156 dated February 3, 1994, from page 32, line 36 to page 33, line 2). More importantly, DCs can induce a primary CD4⁺ T cell-mediated proliferative response when similarly prepared monocytes can not induce such a response (PCT Publication WO 94/02156 dated February 3, 1994 at page 31, lines 23-30). Similarly, when DCs and monocytes were compared for their ability to present antigens for re-activating secondary T cell response, it was observed that DCs were capable of stimulating a stronger response than monocytes (PCT Publication WO 94/02156 dated February 3, 1994 at page 32, lines 12-16).

2.3. CHEMOKINES

Chemokines, or chemoattractant cytokines, are a subgroup of immune factors

that have been shown to mediate chemotactic and other pro-inflammatory phenomena (see, Schall, 1991, *Cytokine* 3:165-183). Chemokines are small molecules of approximately 70-80 residues in length and can generally be divided into two subgroups, α which have two N-terminal cysteines separated by a single amino acid (CxC) and β which have two adjacent cysteines at the N terminus (CC). RANTES, MIP-1 α and MIP-1 β are members of the β subgroup (reviewed by Horuk, R., 1994, *Trends Pharmacol. Sci.* 15:159-165; Murphy, P.M., 1994, *Annu. Rev. Immunol.* 12:593-633; Baggiolini et al. *Annu. Rev. Immunol.* 1997, 15:675-705).

MCP-1 has been shown to attract monocytes but not neutrophils. MCP-1, MCP-2, and MCP-3 share a pyroglutamate proline NH₂-terminal motif and are structurally closely related to each other and to eotaxin (56% to 71% amino acid sequence identity). MCP-1, MCP-2, and MCP-3 attract monocytes, CD4⁺ and CD8⁺ T lymphocytes (Loetscher et al. *FAESB J.* 1994, 8:1055-60), as well as basophil leukocytes. MCP-2, MCP-3, and MCP-4 (but not MCP-1) attracts eosinophil leukocytes. All four MCPs attract activated T lymphocytes, natural killer (NK) cells, and dendritic cells (see Baggiolini et al. *Annu. Rev. Immunol.* 1997, 15:675-705).

Eotaxin acts on eosinophils and is inactive on neutrophils and monocytes, but has weak-to-moderate chemotactic activity toward IL-2-conditioned T lymphocytes (see Baggiolini et al. *Annu. Rev. Immunol.* 1997, 15:675-705). Due to its preferential, powerful action on eosinophils and its occurrence in different species, eotaxin is considered to be an important chemokine in the pathophysiology of allergic conditions and asthma (See Baggiolini et al. *Annu. Rev. Immunol.* 1997, 15:675-705).

IP10 is a CXC chemokine attracts human monocytes, T lymphocytes, and NK cells, and Mig attracts tumor-infiltrating T lymphocytes. It has been suggested that IP10 and Mig may also be involved in the regulation of lymphocyte recruitment and the formation of the lymphoid infiltrates observed in autoimmune inflammatory lesions, delayed-type hypersensitivity, some viral infections, and certain tumors (Baggiolini et al. *Annu. Rev. Immunol.* 1997, 15:675-705).

SDF-1 (stromal cell-derived factor 1), including SDF-1 and SDF-1 β stimulates the proliferation of B cell progenitors, and attracts mature dendritic cells (Finkel et al. *Immunobiology* 1998, 198:490-500). Synthetic human SDF-1 stimulates monocytes, neutrophils, and peripheral blood lymphocytes, as is indicated by [Ca²⁺]_i changes and chemotaxis. SDF-1 is also a powerful HIV-suppressive factor (See Baggiolini et al.

Annu. Rev. Immunol. 1997, 15:675-705).

The amino terminus of the β chemokines RANTES, MCP-1, and MCP-3 has been implicated in the mediation of cell migration and inflammation induced by these chemokines. This involvement is suggested by the observation that the deletion of the amino terminal 8 residues of MCP-1, amino terminal 9 residues of MCP-3, and amino terminal 8 residues of RANTES and the addition of a methionine to the amino terminus of RANTES, antagonize the chemotaxis, calcium mobilization and/or enzyme release stimulated by their native counterparts (Gong et al., 1996, *J. Biol. Chem.* 271:10521-10527; Proudfoot et al., 1996 *J. Biol. Chem.* 271:2599-2603). Additionally, α chemokine-like chemotactic activity has been introduced into MCP-1 via a double mutation of Tyr 28 and Arg 30 to leucine and valine, respectively, indicating that internal regions of this protein also play a role in regulating chemotactic activity (Beall et al., 1992, *J. Biol. Chem.* 267:3455-3459).

The monomeric forms of all chemokines characterized thus far share significant structural homology, although the quaternary structures of α and β groups are distinct. While the monomeric structures of the β and α chemokines are very similar, the dimeric structures of the two groups are completely different. An additional chemokine, lymphotactin, which has only one N terminal cysteine has also been identified and may represent an additional subgroup (γ) of chemokines (Yoshida et al., 1995, *FEBS Lett.* 360:155-159; and Kelner et al., 1994, *Science* 266:1395-1399).

Receptors for chemokines belong to the large family of G-protein coupled, 7 transmembrane domain receptors (GCR's) (See, reviews by Horuk, R., 1994, *Trends Pharmacol. Sci.* 15:159-165; and Murphy, P.M., 1994, *Annu. Rev. Immunol.* 12:593-633). Competition binding and cross-desensitization studies have shown that chemokine receptors exhibit considerable promiscuity in ligand binding. Examples demonstrating the promiscuity among β chemokine receptors include: CCR-1, which binds RANTES and MIP-1 α (Neote et al., 1993, *Cell* 72:415-425), CCR-4, which binds RANTES, MIP-1 α , and MCP-1 (Power et al., 1995, *J. Biol. Chem.* 270:19495-19500), and CCR-5, which binds RANTES, MIP-1 α , and MIP-1 β (Alkhatib et al., 1996, *Science* 272:1955-1958 and Dragic et al., 1996, *Nature* 381:667-674). Erythrocytes possess a receptor (known as the Duffy antigen) which binds both α and β chemokines (Horuk et al., 1994, *J. Biol. Chem.* 269:17730-17733; Neote et al., 1994, *Blood* 84:44-52; and Neote et al., 1993, *J. Biol. Chem.* 268:12247-12249). Thus the sequence and

structural homologies evident among chemokines and their receptors allow some overlap in receptor-ligand interactions.

Godiska et al. identified and described the nucleic acid and amino acid sequences of an additional β chemokine designated macrophage derived chemokine (MDC) (PCT Publication WO 96/40923 dated December 19, 1996, and 1997, *J. Exp. Med.* 185:1595-1604). PCT publication WO 96/40923 further provides materials and methods for the recombinant production of the chemokine, the purified and isolated chemokine protein, and polypeptide analogues thereof. The PCT publication WO 96/40923 does not disclose that the human MDC has chemotactic activity upon DC. While Godiska et al. (1997, *J. Exp. Med.* 185:1595-1604) showed that, in a microchamber migration assay, monocyte-derived DC migrated toward the human MDC, the reference fails to teach that MDC can enhance an immune response to an antigen *in vivo*.

Chang et al. (1997, *J. Biol. Chem.* 272(40):25229-25237), isolated a stimulated T cell chemotactic protein (STCP-1) from an activated macrophage cDNA library. The nucleotide sequence of the STCP-1 is identical to that of the MDC isolated by Godiska et al. (PCT Publication WO 96/40923 dated December 19, 1996, and 1997, *J. Exp. Med.* 185:1595-1604). However, unlike the results observed by Godiska et al. (1997, *J. Exp. Med.* 185:1595-1604), Chang et al. (1997, *J. Biol. Chem.* 272(40):25229-25237) showed that although the STCP-1 acted as a mild chemoattractant for primary activated T lymphocytes and a potent chemoattractant for chronically activated T lymphocytes, the STCP-1 has no chemoattractant activity for monocytes, neutrophils, eosinophils and resting T lymphocytes. Chang et al. further showed that the STCP-1 does not induce Ca^{2+} mobilization in monocytes, dendritic cells, neutrophils, eosinophils, lipopolysaccharide-activated B lymphocytes, and freshly isolated resting T lymphocytes.

2.4. HIV VACCINES

Human immunodeficiency virus (HIV) induces a persistent and progressive infection leading, in the vast majority of cases, to the development of the acquired immunodeficiency syndrome (AIDS) (Barre-Sinoussi et al., 1983, *Science* 220:868-870; Gallo et al., 1984, *Science* 224:500-503). The HIV envelope surface glycoproteins are

synthesized as a single 160 kilodalton precursor protein which is cleaved by a cellular protease during viral budding into two glycoproteins, gp41 and gp120. gp41 is a transmembrane glycoprotein and gp120 is an extracellular glycoprotein which remains non-covalently associated with gp41, possibly in a trimeric or multimeric form (Hammerskjold, M. and Rekosh, D., 1989, *Biochem. Biophys. Acta* 989:269-280). The V3 loop of gp120 is the major determinant of sensitivity to chemokine inhibition of infection or replication (Cocchi et al., 1996, *Nature Medicine* 2:1244-1247; and Oravecz et al., 1996, *J. Immunol.* 157:1329-1332).

Although considerable effort is being put into the design of effective therapeutics, currently no curative anti-retroviral drugs against AIDS exist. The HIV-1 envelope proteins (gp160, gp120, gp41) have been shown to be the major antigens for neutralizing anti-HIV antibodies present in AIDS patients (Barin et al., 1985, *Science* 228:1094-1096). Thus far, therefore, these proteins seem to be the most promising candidates to act as antigens for anti-HIV vaccine development. Several groups have begun to use various portions of gp160, gp120, and/or gp41 as immunogenic targets for the host immune system (see, for example, Ivanoff et al., U.S. Pat. No. 5,141,867; Saith et al., PCT publication WO 92/22654; Shafferman, A., PCT publication WO 91/09872; Formoso et al., PCT publication WO 90/07119). Therefore, methods to increase the efficacy of vaccines against HIV, especially vaccines using gp120 as the antigen, are needed.

Additionally a novel vaccine technology, designated genetic vaccination, nucleic acid vaccination or DNA vaccination, has been explored to induce immune responses *in vivo*. Injection of cDNA expression cassettes results in *in vivo* expression of the encoded proteins (Dubensky et al., 1984, *Proc. Natl. Acad. Sci. USA* 81:7529-7533; Raz et al., 1993, *Proc. Natl. Acad. Sci. USA* 90:4523; Wolff et al., 1990, *Science* 247:1465-1468), with the concomitant development of specific cellular and humoral immune responses directed against the encoded antigen(s) (Wang et al., 1995, *Hum. Gene Ther.* 6:407-418; Ulmer et al., 1993, *Science* 259:1745-1749; Tang et al., 1992, *Nature* 356:152-154; Michel et al., 1995, *Proc. Natl. Acad. Sci. USA* 92:5307-5311; and Lowrie et al., 1994, *Vaccine* 12:1537-1540). Humoral and cellular responses have been induced to HIV-1 and SIV antigens through various applications of this technology in macaques (Wang et al., 1995, *Virology* 221:102-112; Wang et al., 1993, *Proc. Natl. Acad. Sci. USA* 90:4156-4160; and Boyer et al., 1996, *J. Med.*

Primatol. 25:242-250) as well as mice (Wang et al., 1995, *Virology* 221:102-112; Lu et al., 1995, *Virology* 209:147-154; Haynes et al., 1994, *AIDS Res. Hum. Retroviruses* 10 (Suppl. 2):S43-S45; Okuda et al., 1995, *AIDS Res. Hum. Retroviruses* 11:933-943).

Recently, Lekutis et al. (1997, *J. Immunol.* 158:4471-4477), assessed the TH cell response elicited by an HIV-1 gp120 DNA vaccine in rhesus monkeys by isolation of gp120-specific, MHC class II-restricted CD4⁺ T cell lines from the vaccinated animals. Lekutis et al. showed that the isolated cell lines proliferated in response to APC in the presence of recombinant gp120, as well as to APC expressing HIV encoded env protein. Lekutis et al. further showed that these cell lines responded to env by secreting IFN- γ and IFN- α without appreciable IL-4 production. These results demonstrate that the animals exhibited a cellular immune response to the DNA vaccine.

Boyer et al. (1997, *Nature Medicine* 3:625-532), inoculated chimpanzees with an HIV-1 DNA vaccine encoding env, rev, and gag/pol, and found that the immunized animals developed specific cellular and humoral immune responses to these proteins. After challenging the immunized animals with a heterologous chimpanzee titrated stock of HIV-1 SF2, Boyer et al. further found, using a Reverse Transcriptase-Polymerase Chain Reaction (RT-PCR) assay, that those animals vaccinated with the DNA vaccine were protected against infection whereas the control animals were not so protected.

Kim et al., (1997 *J. Immunol.* 158:816-826), investigated the role of co-delivery of genes for IL-12 and GM-CSF along with DNA vaccine formulation for HIV-1 antigens env and gag/pol in mice. Kim et al. observed a dramatic increase in specific CTL response from the mice immunized with the HIV-1 DNA vaccine and IL-12. Kim et al. also observed that the co-delivery of IL-12 genes resulted in the reduction of specific antibody response, whereas the codelivery of GM-CSF genes resulted in the enhancement of specific antibody response. Kim et al. further observed that co-delivery of IL-12 gene with a HIV DNA vaccine results in splenomegaly (Kim et al. 1997, *J. Immunol.*, 158:816-826), which has been shown in mice to have toxic effects such as weight reduction or even death (Eng et al., 1995, *J. Exp. Med.* 181:1893; Stevensen et al., 1995, *J. Immunol.* 155:2545; and Orange et al., 1995, *J. Exp. Med.* 181:901).

Notwithstanding the recent developments of the HIV DNA vaccine, there still

exists a need for a method to enhance the efficacy of a vaccine, especially an HIV DNA vaccine. For instance, for efficacious vaccine against HIV-1 one preferably induces both cellular and humoral immune responses to control the infection (Boyer et al., 1997, *Nature Medicine* 3:625-532). The induction of both cellular and humoral immune response by the Berjer et al. method is still quite low because only one of the three immunized chimpanzees developed both cellular and humoral responses. Similarly, although co-delivery of an IL-12 encoding gene with a HIV DNA vaccine, as described in Kim et al. (1997, *J. Immun.* 158:816-826), may have enhanced the cellular immune response, this co-delivery also decreased the humoral response.

Citation of a reference hereinabove shall not be construed as an admission that such reference is prior art to the present invention.

3. SUMMARY OF THE INVENTION. SUMMARY OF THE INVENTION. . SUMMARY OF THE INVENTION

The present invention is based upon the ability of chemokines, such as MDC, Rantes, MIP-1d, MIP-1B, and I-309, to enhance the immune response to an antigen, particularly a vaccine. Accordingly, in a first aspect, the present invention provides a method for enhancing the efficacy of a vaccine, which method comprises administration to a subject of one or more purified chemokines, or biologically active fragments, analogues or derivatives thereof, either concurrently with one or more purified antigens against which an immune response is desired or within a time period either before or after administration of the antigens such that the immune response against the antigens is enhanced.

In a second aspect, the present invention provides a method to enhance the efficacy of a vaccine, which method comprises administration to a subject of a first set of one or more purified nucleic acids comprising one or more nucleotide sequences encoding one or more chemokines, or fragments, derivatives, analogues, and/or truncation isoforms thereof, and a second purified nucleic acid comprising a nucleotide sequence encoding one or more antigens against which an immune response is desired, such that, the one or more chemokine(s) and the antigen(s) are expressed in a coordinated manner upon introduction into a suitable cell. Alternatively, the nucleotide sequences encoding one or more chemokines, or

fragments, derivatives, and/or analogues thereof, and the antigens against which an immune response is desired are present on the same nucleic acid.

In a preferred embodiment, the invention provides a method to enhance the efficacy of an HIV vaccine.

In yet another aspect, the present invention provides a composition comprising an immunogenic amount of one or more purified antigens, an amount of one or more purified chemokines, or a fragments, derivatives, analogues and/or truncation isoforms thereof, effective to enhance the immune response to the antigen. In another aspect, the present invention provides a composition comprising a first set of one or more purified nucleic acids comprising one or more nucleotide sequences encoding one or more chemokines, fragments, derivatives analogues and or truncation isoforms thereof, and a second set of purified nucleic acids comprising one or more nucleotide sequences encoding one or more antigens against which an immune response is desired, such that, the chemokine(s) and the antigen are expressed in a coordinated manner upon introduction into a suitable cell. In a preferred embodiment, the antigen is an HIV antigen. In another preferred embodiment, the chemokine is selected from the group consisting of: Macrophage-derived chemokine, Monocyte chemotactic protein 1, Monocyte chemotactic protein 2, Monocyte chemotactic protein 3, Monocyte chemotactic protein 4, activated macrophage specific chemokine 1, Macrophage inflammatory protein 1 alpha, Macrophage inflammatory protein 1 beta, Macrophage inflammatory protein 1 gamma, Macrophage inflammatory protein 1 delta, Macrophage inflammatory protein 2 alpha, Macrophage inflammatory protein 3 alpha, Macrophage inflammatory protein 3 beta, Regulated upon activation, normal T cell expressed and secreted (and its variants), I-309, EBI1-ligand chemokine, Pulmonary and activation regulated chemokine, Liver and activation-regulated chemokine, Thymus and activation regulated chemokine, Eotaxin (and variants), Human CC chemokine 1, Human CC chemokine 2, Human CC chemokine 3, IL-10-inducible chemokine, liver-expressed chemokine, 6Ckine, Exodus 1, Exodus 2, Exodus 3, thymus-expressed chemokine, Secondary Lymphoid tissue chemokine, Lymphocyte and Monocyte chemoattractant; Monotactin, Activation-induced, chemokine-related molecule, Myeloid progenitor inhibitory factor-1, Myeloid progenitor inhibitory factor-2, Stromal cell-derived factor 1 alpha, Stromal cell-derived factor 1 beta, B-cell-attracting chemokine 1, HuMIG, H174, Interferon-stimulated T-cell alpha

chemoattractant, Interleukin-8, IP-10, platelet factor 4, growth-regulated gene-alpha, growth-regulated gene-beta, growth-regulated gene-gamma, Neutrophil-activating protein 2, ENA-78, granulocyte chemotactic protein 2, LYMPHOTACTIN, and Fractalkine/neurotactin.

4. DESCRIPTION OF FIGURES

Figures 1A and 1B. The nucleotide and amino acid sequences of MDC. 1A depicts the nucleotide sequence of MDC (SEQ ID NO:1), with the coding region indicated by the appearance of the amino acid sequence in the line below; and 1B depicts the amino acid of MDC (SEQ ID NO:2) from GenBank accession no. U83171 (Godiska et al., 1997, *J. Exp. Med.* 185:1595-1604).

5. DETAILED DESCRIPTION OF THE INVENTION

The present invention relates to a method for enhancing the efficacy of a vaccine in a subject comprising administering to the subject one or more purified antigens in conjunction with one or more purified chemokines, or more purified fragments, derivatives or analogues and/or truncation isoforms thereof.

While any chemokine may be employed according to the present invention, the chemokine is preferably selected from the following table:

Chemokine Class	Chemokines	Abbreviations	Accession Number
CC Chemokines	Macrophage-derived chemokine	MDC/STCP-1	u83171; u83239
	Monocyte chemotactic protein 1	MCP-1	x14768
	Monocyte chemotactic protein 2	MCP-2	X99886
	Monocyte chemotactic protein 3	MCP-3	x72308; s57464
	Monocyte chemotactic protein 4	MCP-4	u46767
	activated macrophage specific chemokine 1	AMAC-1	Y13710
	Macrophage inflammatory protein 1 alpha	MIP-1 α	AF043339; X03754; D90144

Chemokine Class	Chemokines	Abbreviations	Accession Number
CC Chemokines (continued)	Macrophage inflammatory protein 1 beta	MIP-1 β	j04130; d90145
	Macrophage inflammatory protein 1 gamma	MIP-1 γ	
	Macrophage inflammatory protein 1 delta	MIP-1 δ	AF031587
	Macrophage inflammatory protein 2 alpha	MIP-2 α	AF043340
	Macrophage inflammatory protein 3 alpha	MIP-3 α	u77035
	Macrophage inflammatory protein 3 beta	MIP-3 β	u77180
	Regulated upon activation, normal T cell expressed and secreted (and its variants)	RANTES	M21211
	I-309		M57502
	EBI1-ligand chemokine	ELC	AB000887
	Pulmonary and activation regulated chemokine	PARC/DC-CK-1/MIP4	AB000221
	Liver and activation-regulated chemokine	LARC	D86955
	Thymus and activation regulated chemokine	TARC	D43767
	Eotaxin (and variants)		D49372; Z69291; Z75669; Z75668
	Human chemokine 1	HCC1; NCC2	Z49270; z49269
	Human chemokine 2	HCC2; NCC3, MIP-5, MIP-1 δ	Z70292
	Human chemokine 3	HCC3	Z70293
	IL-10-inducible chemokine	HCC4	U91746
	liver-expressed chemokine	LEC; HCC4;NCC4	AB007454
	6Ckine		AF001979
	Exodus 1		u64197
	Exodus 2		U88320
	Exodus 3		U88321
	thymus-expressed chemokine	TECK	U86358
	Secondary Lymphoid tissue chemokine	SLC	AB002409

Chemokine Class	Chemokines	Abbreviations	Accession Number
CC Chemokines (continued)	Lymphocyte and Monocyte chemoattractant; Monotactin	LMC	AF055467
	Activation-induced, chemokine-related molecule	ATAC	x86474
	Myeloid progenitor inhibitory factor-1	MPIF-1; MIP-3 or ckbeta8	u85767
	Myeloid progenitor inhibitory factor-2	MPIF-2	u85768
	Stromal cell-derived factor 1 alpha	SDF-1 α ; PBSF	L36034
CXC chemokines	Stromal cell-derived factor 1 beta	SDF-1 β ; PBSF	L36033
	B-cell-attracting chemokine 1	BLC	AJ002211
	HuMIG		x72755 s60728
	H174		AF002985
	Interferon-stimulated T-cell alpha chemoattractant	I-TAC	AF030514
	Interleukin-8	IL-8	m17017; y00787
	IP-10		X02530
	platelet factor 4	PF4	M20901
	growth-regulated gene-alpha	GRO- α	J03561
	growth-regulated gene-beta	GRO- β	M36820
	growth-regulated gene-gamma	GRO- γ	M36821
	Neutrophil-activating protein 2	NAP-2; CTAP-3	M54995; M38441
	ENA-78		L37036
	granulocyte chemotactic protein 2	GCP-2	Y08770
C-CHEMOKINES	LYMPHOTACTIN	SCM-1	D63789 D63790
CXC-CHEMOKINES	Fractalkine/neurotactin		U91835 U84487

The present invention also relates to the use of fragments, analogues and derivatives of the foregoing chemokines, as well as truncation isoforms of such chemokines which are known in the art.

The present invention also relates to therapeutic compositions comprising one or more chemokines, nucleic acids encoding one or more chemokines, derivatives, analogues, and/or truncation isoforms thereof, and nucleic acids encoding the same, that are effective to enhance the immune response of a subject to a vaccine.

In another preferred embodiment of the invention, nucleic acids comprising

nucleotide sequences encoding one or more chemokines or fragments or derivatives, including truncation isoforms, thereof, and encoding one or more antigens against which an immune response is desired, which coding sequences are operatively linked to gene regulatory sequences capable of directing the expression of the one or more chemokines and the one or more antigens upon introduction into a suitable cell, for example, but not limited to, the cell (of a subject), are administered to a subject such that the one or more chemokines, or fragments or derivatives, including truncation isoforms, thereof, and one or more antigens, are expressed in the subject.

For clarity of disclosure, and not by way of limitation, the detailed description of the invention is divided into the subsections which follow.

5.1. METHODS AND COMPOSITIONS TO ENHANCE THE EFFICACY OF A VACCINE

The present invention provides methods for enhancing the efficacy of a vaccine in a subject, which methods comprise administering to a subject an immunogenic amount of one or more purified antigens against which an immune response is desired in the subject in conjunction with an amount of one or more purified chemokines, or fragments, derivatives, analogues and/or truncation isoforms thereof, effective to enhance the immune response against the antigen. In one aspect, the purified chemokine(s), or fragment(s), derivative(s), analogue(s) and/or truncation isoforms thereof, are administered to the subject concurrently with (e.g., in the same composition with) the purified antigen or antigens against which an immune response is desired. In another, aspect, the purified chemokine(s), or fragment(s), derivative(s), analogue(s) and/or truncation isoforms thereof, are administered either before or after the administration of one or more purified antigens against which immunity is desired in the subject, but is administered within such time that the chemokine(s) enhance the immune response to the one or more antigens. For example, but not by way of limitation, the purified chemokine(s) are administered during the time that the subject mounts an immune response against the administered one or more antigens, or, the purified MDC is administered within, for example, but not limited to, 30 minutes, 1 hour, 5 hours, 10 hours, 1 day, 2 days of (preferably, after) administration of the one or more purified antigens against which immunity is desired.

In a preferred embodiment, the present invention provides compositions comprising an immunogenic amount of one or more purified antigens and an amount of purified MDC, or one or more fragments, derivatives or analogues thereof, effective to enhance the immune response to said antigen and, preferably, the composition further comprises a pharmaceutically acceptable carrier.

A preferred chemokine for use in the methods and compositions of the present invention is any MDC protein, fragment or derivative thereof, that is capable of enhancing the efficacy of a vaccine (for example, but not limited to, as determined by the assays described in Section 5.4, *infra*). In one specific embodiment, the MDC is purified full length MDC, preferably full length MDC having the amino acid sequence of SEQ ID NO: 2 (Figure 1B). In another embodiment, the MDC is a purified protein, the amino acid sequence of which consists of amino acid numbers 2-69 of SEQ ID NO: 2 (Figure 1B). In another specific embodiment, the MDC is a purified protein, the amino acid sequence of which consists of amino acid numbers 3-69 of SEQ ID NO: 2 (Figure 1B). In still another specific embodiment, the MDC is a purified protein, the N-terminal amino acid sequence of which consists of the amino acid sequence Tyr-Gly-Ala-Asn-Met-Glu-Asp-Ser-Val-Cys-Cys-Arg-Asp-Tyr-Val-Arg-Tyr-Arg-Leu (portion of SEQ ID NO: 2). In yet another specific embodiment, the MDC is a purified protein, the N-terminal amino acid sequence of which consists of the amino acid sequence Pro-Tyr-Gly-Ala-Asn-Met-Glu-Asp-Ser-Val-Cys-Cys-Arg (portion of SEQ ID NO: 2). In yet another specific embodiment, the MDC is a purified derivative of a protein, the N-terminal amino acid sequence of which protein consists of the amino acid sequence Tyr-Gly-Ala-Asn-Met-Glu-Asp-Ser-Val-Cys-Cys-Arg-Asp-Tyr-Val-Arg-Tyr-Arg-Leu (SEQ ID NO: 2), which derivative has activity to enhance the efficacy of the vaccine. In yet another specific embodiment, the MDC is a purified derivative of a protein, the N-terminal amino acid sequence of which protein consists of the amino acid sequence Pro-Tyr-Gly-Ala-Asn-Met-Glu-Asp-Ser-Val-Cys-Cys-Arg (SEQ ID NO: 2), which derivative has activity to enhance the efficacy of the vaccine.

In yet another specific embodiment, the chemokine is a purified derivative of the protein, which derivative has one or more insertions of or substitutions with one or more non-classical amino acids relative to a corresponding wildtype chemokine, which derivative will enhance the efficacy of the vaccine. In yet another specific

embodiment, the chemokine is a purified derivative of the protein that has only one or more conservative substitutions in sequence relative a corresponding wildtype chemokine, which derivative will enhance the efficacy of the vaccine. The chemokines useful in the present invention may be derived from any suitable source and obtained by any method known in the art, for example but not limited to the methods described in Section 5.2 *infra*.

Preferably, the chemokine(s) are of the same species as the subject to which the vaccine is administered. In a preferred embodiment, one or more human chemokines are administered to a human subject, e.g., human MDC is administered to a human subject, alone or in combination with another chemokine.

The present invention also provides a method to enhance the efficacy of a vaccine in a subject, which method comprises administering to a subject a purified first nucleic acid comprising a nucleotide sequence encoding an antigen against which an immune response is desired in a subject and a purified second nucleic acid comprising a nucleotide sequence encoding one or more chemokines, or fragment(s), derivative(s) or analogue(s) thereof, where the expression of the encoded antigen(s) and chemokine(s), or fragment(s), derivative(s) or analogue(s) thereof, are under control of one or more appropriate gene regulatory elements (which regulatory elements can be any regulatory element known in the art, for example, but not limited to, those regulatory elements described in Section 5.2 *supra*), such that, upon introduction of said first and second nucleic acids into a suitable cell (e.g., a cell of the subject), the antigen and chemokine(s), or fragment(s), derivative(s) or analogue(s) thereof, are coordinately expressed, *i.e.*, are expressed either at the same time or within an appropriate time period (*i.e.*, sufficient for the chemokine(s) to enhance the immune response against the antigen relative to a corresponding immune response in the absence of the chemokine) and the antigen(s) are expressed in an immunogenic amount and the chemokine(s), or fragment(s), derivative(s) or analogue(s) thereof, are expressed in an amount sufficient to enhance the immune response against the antigen(s). In a specific embodiment, the nucleotide sequences encoding the chemokine(s) and the antigen are present on separate nucleic acids. In another embodiment, the nucleotide sequences encoding the chemokine(s) and the antigen(s) are present on the same nucleic acid.

The present invention also provides compositions to enhance the

efficacy of a vaccine in a subject, which compositions comprise a purified first nucleic acid comprising a nucleotide sequence encoding one or more antigen(s) and a purified second nucleic acid comprising a nucleotide sequence encoding one or more chemokines, or fragments or derivatives, including truncation isoforms, thereof, wherein the nucleotide sequences encoding the antigens and the chemokine(s) are operably linked to one or more gene regulatory elements such that, upon introduction of said first and second nucleic acids into a suitable cell (e.g., a cell of the subject), the antigen(s) and chemokine(s) are expressed in a coordinated manner and the antigen(s) are expressed in an immunogenic amount and the chemokine(s) are expressed in an amount effective to enhance the immune response against the antigen, relative to a corresponding immune response in the absence of such chemokine(s).

The present invention also provides compositions to enhance the efficacy of a vaccine in a subject, which compositions comprise a purified first set of one or more purified nucleic acids comprising one or more nucleotide sequences encoding one or more antigens and a purified second set of one or more purified nucleic acids comprising a nucleotide sequence encoding one or more chemokines, or fragments, analogues, derivatives, (including truncation isoforms) thereof, wherein the nucleotide sequence(s) encoding the antigen(s) and the chemokine(s) are operably linked to one or more gene regulatory elements such that, upon introduction of said first and second sets of nucleic acids into a suitable cell (e.g., a cell of the subject), the antigen(s) and chemokine(s) are expressed in a coordinated manner and the antigen(s) are expressed in an immunogenic amount and the chemokine(s) are expressed in an amount effective to enhance the immune response against the antigen, relative to a corresponding immune response in the absence of such chemokine(s).

The present invention also provides compositions to enhance the efficacy of a vaccine in a subject, which compositions comprise a purified nucleic acid comprising a first set of one or more nucleotide sequences encoding one or more antigens and a second set of one or more nucleotide sequence encoding one or more chemokines, or fragments, derivatives, or analogues thereof (including truncation isoforms), wherein the first and second sets of nucleotide sequences are operably linked to one or more gene regulatory elements such that, upon introduction into a suitable cell, the antigen(s) and the chemokine(s) are expressed in a coordinated manner and the antigen(s) are expressed in an immunogenic amount and the chemokine(s) are

expressed in an amount effective to enhance the immune response against the antigen(s).

Any nucleic acid comprising a nucleotide sequence encoding one or more chemokine proteins, or fragments or derivatives, thereof (including truncation isoforms), that are capable of enhancing the immune response to the antigen (for example, but not limited to, as determined by any of the assays described in Section 5.2., *infra*) can be used in the methods and compositions of the present invention.

In a preferred embodiment, the nucleotide sequence encodes MDC. In another embodiment, the MDC-encoding nucleotide consists of the nucleotide sequence of SEQ ID NO:1 (Figure 1A). In another specific embodiment, the method or composition of the invention uses a nucleic acid encoding an MDC derivative having deletional, insertional or substitutional mutations and combination thereof, which derivative has activity to enhance the immune response against an antigen in a subject.

Such compositions of nucleic acids encoding an antigen are often referred to as DNA vaccines.

Such DNA vaccines are produced by any method known in the art for constructing an expression plasmid vector containing the nucleotide sequences of the antigen(s) and/or chemokine(s) to be expressed which vector is suitable for expression of the encoded proteins in the subject or in cells recombinant for the expression vector, which cells are to be provided to the subject. Such expression vectors may contain various promoters, terminators and polyadenylation coding regions to control the expression of the encoded protein.

The DNA vaccine can be administered by any method known in the art for administration of DNA. The DNA vaccine may be delivered either directly, in which case the subject is directly exposed to the DNA vaccine such that the DNA enters and is expressed in cells of the subject, or indirectly, in which case, the DNA vaccine is first introduced into suitable cells by any method known in the art *in vitro*, then the cells containing the DNA vaccine are transplanted into the subject.

In a specific embodiment, the DNA vaccine is directly administered *in vivo*, where it is expressed to produce the encoded antigens and chemokine(s). This can be accomplished by any of numerous methods known in the art, e.g., by constructing it as part of an appropriate nucleic acid expression vector and administering it so that it becomes intracellular, e.g., by infection using a defective or attenuated retroviral or

other viral vector (see U.S. Patent No. 4,980,286), or by direct injection of naked DNA, or by use of microparticle bombardment (e.g., a gene gun; Biolistic, Dupont), or coating with lipids or cell-surface receptors or transfecting agents, encapsulation in liposomes, microparticles, or microcapsules, or by administering it in linkage to a peptide which is known to enter the nucleus, by administering it in linkage to a ligand subject to receptor-mediated endocytosis (see e.g., Wu and Wu, *J. Biol. Chem.* 262:4429-4432 (1987)) (which can be used to target cell types specifically expressing the receptors), etc. In another embodiment, a nucleic acid-ligand complex can be formed in which the ligand comprises a fusogenic viral peptide to disrupt endosomes, allowing the nucleic acid to avoid lysosomal degradation. In a preferred embodiment, the nucleic acid of a DNA vaccine is injected into the muscle of the subject to be immunized.

Another approach is to introduce the nucleic acid of the DNA vaccine into a cell prior to administration *in vivo* of the resulting recombinant cell. Such introduction can be carried out by any method known in the art, including but not limited to transfection, electroporation, microinjection, infection with a viral or bacteriophage vector containing the nucleic acid sequences, cell fusion, chromosome-mediated gene transfer, microcell-mediated gene transfer, spheroplast fusion, etc. Numerous techniques are known in the art for the introduction of foreign nucleic acid into cells (see e.g., Loeffler and Behr, *Meth. Enzymol.* 217:599-618 (1993); Cohen et al., *Meth. Enzymol.* 217:618-644 (1993); Cline, *Pharmac. Ther.* 29:69-92 (1985)) and may be used in accordance with the present invention. Usually, the method of transfer includes the transfer of a selectable marker to the cells. The cells are then placed under selection to isolate those cells that have taken up and are expressing the transferred gene.

Cells into which a DNA vaccine can be introduced for purposes of immunization encompass any desired, available cell type, and include but are not limited to epithelial cells, endothelial cells, keratinocytes, fibroblasts, muscle cells, hepatocytes; blood cells such as T lymphocytes, B lymphocytes, monocytes, macrophages, neutrophils, eosinophils, megakaryocytes, granulocytes; various stem or progenitor cells, in particular hematopoietic stem or progenitor cells, e.g., as obtained from bone marrow, umbilical cord blood, peripheral blood, fetal liver, etc.

The resulting recombinant cells can be delivered to a subject by various

methods known in the art. In a preferred embodiment, the recombinant cells are injected, e.g., subcutaneously. In another embodiment, recombinant skin cells may be applied as a skin graft onto the patient. Recombinant blood cells (e.g., hematopoietic stem or progenitor cells) are preferably administered intravenously. The cells can also be encapsulated in a suitable vehicle and then implanted in the subject (see, e.g., Dionne et al. PCT Publication WO 92/19195, dated November 12, 1992). The amount of cells envisioned for use depends on the desired effect, subject state, etc., and can be determined by one skilled in the art.

By way of example, and not by way of limitation a DNA vaccine may be generated as described by Lekutis et al. for an HIV DNA vaccine (1997, *J. Immunol.* 158:4471-4477). Briefly, an expression vector is constructed with the promoter, enhancer and intron A of human cytomegalovirus (CMV) and the termination and polyadenylation sequences of bovine growth hormone in a plasmid backbone. Additionally, the nucleotide sequence for signal sequence of tissue plasminogen activator is either substituted for the signal sequence of the antigen, if the antigen has a signal sequence or is added onto the amino-terminus of the antigen, thereby eliminating the dependence on viral proteins for expression (e.g., in the case of gp120 expression, rev and env proteins are required unless the HIV-1 signal sequence is so substituted). The resulting formulation is then injected intra-muscularly.

Further examples of DNA vaccines are set forth in Boyer et al. (1996, *J. Med. Primatol.*, 25:242-250), which describes the construction of a plasmid encoding the HIV-1 gp160 envelope glycoprotein as well as the rev-tax region cloned into pMAMneoBlue vector (Clontech, Inc., Palo Alto, CA), and a vector encoding the envelope glycoprotein and rev from HIV-1 strain MN under the control of the CMV promoter. Another vector which can be used in the present invention is as described in Boyer et al. (1997, *Nature Medicine* 3:526-532) and contains expression cassettes encoding the envelope and Rev proteins of HIV-1 strain MN, and encoding the Gag/Pol proteins of HIV-1 strain IIIB.

For the practice of the present invention, the nucleotide sequence for the one or more chemokines, or fragments, derivatives, or analogues thereof, can either be incorporated into the same expression vector containing the nucleotide sequence encoding the antigen in such a manner that the chemokine(s) are expressed. Alternatively, the nucleotide sequence encoding the chemokine(s), or fragment(s),

derivative(s) or analogue(s) thereof, can be cloned into a separate expression vector (e.g., as described above for the expression vector containing the sequences coding for antigen) and the expression vector that expresses the antigen(s) mixed with the expression vector that expresses the chemokine(s). The mixture of the two expression vectors can then be administered to the subject.

The methods and compositions of the present invention may be used as a vaccine in a subject in which immunity for the antigen(s) is desired. Such antigens can be any antigen known in the art to be useful in a vaccine formulation. The methods and compositions of the present invention can be used to enhance the efficacy of any vaccine known in the art. The vaccine of the present invention may be used to enhance an immune response to infectious agents and diseased or abnormal cells, such as but not limited to bacteria, parasites, fungi, viruses, tumors and cancers. The compositions of the invention may be used to either treat or prevent a disease or disorder amenable to treatment or prevention by generating an immune response to the antigen provided in the composition. In one preferred embodiment, the antigen(s) are proteins, fragments or derivatives, including truncation isoforms, thereof, encoded by any genes of the HIV genome including the *env*, *gag*, *pol*, *nef*, *vif*, *rev*, and *tat* genes. In a more preferred embodiment, the antigen is an HIV-associated gp120 protein.

The methods and compositions of the present invention may be used to elicit a humoral and/or a cell-mediated response against the antigen(s) of the vaccine in a subject. In one specific embodiment, the methods and compositions elicit a humoral response against the administered antigen in a subject. In another specific embodiment, the methods and compositions elicit a cell-mediated response against the administered antigen in a subject. In a preferred embodiment, the methods and compositions elicit both a humoral and a cell-mediated response.

The subjects to which the present invention is applicable may be any mammalian or vertebrate species, which include, but are not limited to, cows, horses, sheep, pigs, fowl (e.g., chickens), goats, cats, dogs, hamsters, mice and rats, monkeys, rabbits, chimpanzees, and humans. In a preferred embodiment, the subject is a human. The compositions and methods of the invention can be used to either prevent a disease or disorder, or to treat a particular disease or disorder, where an immune response against a particular antigen or antigens is effective to treat or prevent the

disease or disorder. Such diseases and disorders include, but are not limited to, viral infections, such as HIV, CMV, hepatitis, herpes virus, measles, etc, bacterial infections, fungal and parasitic infections, cancers, and any other disease or disorder amenable to treatment or prevention by eliciting an immune response against a particular antigen or antigens. In another preferred embodiment, the subject is infected or at risk of being infected with HIV virus.

In another preferred embodiment the invention provides methods and compositions to enhance the efficacy of an HIV vaccine, such a vaccine can be administered to either prevent or treat HIV.

5.2. CHEMOKINE GENES AND PROTEINS

Chemokine proteins and nucleic acids can be obtained by any method known in the art. Chemokine nucleotide and amino acid sequences are available in public databases such as Genbank and are also published in various references known to those of skill in the art. The gene bank accession numbers for the preferred chemokines of the present invention are provided in Table I, in Section 5 above. The ensuing discussion uses MDC by way of example, but applies equally to other chemokines as well.

The MDC nucleotide and amino acid sequences for, *inter alia*, human, are available in the public databases (e.g. Genbank accession No. U83171) also published in Godiska et al., 1997, *J. Exp. Med.* 185:1595-1604. The nucleotide sequence and the amino acid sequence for the human MDC are provided in Figures 1A and B (SEQ ID NOS:1 and 2, respectively).

Chemokines used herein include, but are not limited to, chemokines from mice, hamsters, dogs, cats, monkeys, rabbits, chimpanzees, and human. In one preferred embodiment, the chemokine is of human origin.

Any vertebrate cell potentially can serve as the nucleic acid source for the isolation of chemokine nucleic acids. The nucleic acid sequences encoding the chemokine(s) can be isolated from vertebrate, mammalian, human, porcine, bovine, feline, avian, equine, canine, as well as additional primate sources, etc. The DNA may be obtained by standard procedures known in the art from cloned DNA (e.g., a

DNA "library"), by chemical synthesis, by cDNA cloning, or by the cloning of genomic DNA, or fragments thereof, purified from the desired cell (see, for example, Sambrook et al., 1989, *Molecular Cloning, A Laboratory Manual*, 2d Ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York; Glover, D.M. (ed.), 1985, *DNA Cloning: A Practical Approach*, MRL Press, Ltd., Oxford, U.K. Vol. I, II.) Clones derived from genomic DNA may contain regulatory and intron DNA regions in addition to coding regions; clones derived from cDNA will contain only exon sequences. Whatever the source, the gene should be molecularly cloned into a suitable vector for propagation of the gene.

In the molecular cloning of the gene from cDNA, cDNA is generated from totally cellular RNA or mRNA by methods that are well known in the art. The gene may also be obtained from genomic DNA, where DNA fragments are generated (e.g. using restriction enzymes or by mechanical shearing), some of which will encode the desired gene. The linear DNA fragments can then be separated according to size by standard techniques, including but not limited to, agarose and polyacrylamide gel electrophoresis and column chromatography.

Once the DNA fragments are generated, identification of the specific DNA fragment containing all or a portion of the chemokine gene may be accomplished in a number of ways.

A preferred method for isolating a chemokine gene is by the polymerase chain reaction (PCR), which can be used to amplify the desired chemokine sequence in a genomic or cDNA library or from genomic DNA or cDNA that has not been incorporated into a library. Oligonucleotide primers which would hybridize to chemokine sequences can be used as primers in PCR.

Additionally, a portion of the chemokine (of any species) gene or its specific RNA, or a fragment thereof, can be purified (or an oligonucleotide synthesized) and labeled, the generated DNA fragments may be screened by nucleic acid hybridization to the labeled probe (Benton, W. and Davis, R., 1977, *Science* 196:180; Grunstein, M. And Hogness, D., 1975, *Proc. Natl. Acad. Sci. U.S.A.* 72:3961). Those DNA fragments with substantial homology to the probe will hybridize. Chemokine nucleic acids can be also identified and isolated by expression cloning using, for example, anti-chemokine antibodies for selection.

Alternatives to obtaining the chemokine DNA by cloning or amplification

include, but are not limited to, chemically synthesizing the gene sequence itself from the known chemokine sequence or making cDNA to the mRNA which encodes the chemokine protein. Other methods are possible and within the scope of the invention. Once a clone has been obtained, its identity can be confirmed by nucleic acid sequencing (by any method well known in the art) and comparison to known chemokine sequences. DNA sequence analysis can be performed by any techniques known in the art, including but not limited to the method of Maxam and Gilbert (1980, *Meth. Enzymol.* 65:499-560), the Sanger dideoxy method (Sanger, F., et al., 1977, *Proc. Natl. Acad. Sci. U.S.A.* 74:5463), the use of T7 DNA polymerase (Tabor and Richardson, U.S. Patent No. 4,795,699), use of an automated DNA sequenator (e.g., Applied Biosystems, Foster City, CA) or the method described in PCT Publication WO 97/15690.

Nucleic acids which are hybridizable to a chemokine nucleic acid, or to a nucleic acid encoding a chemokine derivative can be isolated, by nucleic acid hybridization under conditions of low, high, or moderate stringency (see also Shilo and Weinberg, 1981, *Proc. Natl. Acad. Sci. USA* 78:6789-6792). For example, the nucleic acid of SEQ ID No: 1 is hybridizable to an MDC nucleic acid.

Chemokine proteins and derivatives, analogs and fragments of chemokine proteins can be obtained by any method known in the art, including but not limited to recombinant expression methods, purification from natural sources, and chemical synthesis.

For example, chemokines can be obtained by recombinant protein expression techniques. For recombinant expression, the chemokine gene or portion thereof is inserted into an appropriate cloning vector for expression in a particular host cell. A large number of vector-host systems known in the art may be used. Possible vectors include, but are not limited to, plasmids or modified viruses, but the vector system must be compatible with the host cell used. Such vectors include, but are not limited to, bacteriophages such as lambda derivatives, or plasmids such as pBR322 or pUC plasmid derivatives or the Bluescript vector (Stratagene). The insertion into a cloning vector can, for example, be accomplished by ligating the DNA fragment into a cloning vector which has complementary cohesive termini. However, if the complementary restriction sites used to fragment the DNA are not present in the cloning vector, the ends of the DNA molecules may be enzymatically modified. Alternatively, any site

desired may be produced by ligating nucleotide sequences (linkers) onto the DNA termini; these ligated linkers may comprise specific chemically synthesized oligonucleotides encoding restriction endonuclease recognition sequences. In an alternative method, the cleaved vector and chemokine gene may be modified by homopolymeric tailing. Recombinant molecules can be introduced into host cells via transformation, transfection, infection, electroporation, etc., so that many copies of the gene sequence are generated.

In an alternative method, the desired gene may be identified and isolated after insertion into a suitable cloning vector in a "shot gun" approach. Enrichment for the desired gene, for example, by size fractionation, can be done before insertion into the cloning vector.

In specific embodiments, transformation of host cells with recombinant DNA molecules that incorporate the isolated chemokine gene, cDNA, or synthesized DNA sequence enables generation of multiple copies of the gene. Thus, the gene may be obtained in large quantities by growing transformants, isolating the recombinant DNA molecules from the transformants and, when necessary, retrieving the inserted gene from the isolated recombinant DNA.

The nucleotide sequence coding for a chemokine protein or a functionally active analog or fragment or other derivative thereof, can be inserted into an appropriate expression vector, i.e., a vector which contains the necessary elements for the transcription and translation of the inserted protein-coding sequence. The necessary transcriptional and translational signals can also be supplied by the native chemokine gene and/or its flanking regions. A variety of host-vector systems may be utilized to express the protein-coding sequence. These include but are not limited to mammalian cell systems infected with virus (e.g., vaccinia virus, adenovirus, etc.); insect cell systems infected with virus (e.g., baculovirus); microorganisms such as yeast containing yeast vectors, or bacteria transformed with bacteriophage, DNA, plasmid DNA, or cosmid DNA. The expression elements of vectors vary in their strengths and specificities. Depending on the host-vector system utilized, any one of a number of suitable transcription and translation elements may be used.

Any of the methods previously described for the insertion of DNA fragments into a vector may be used to construct expression vectors containing a chimeric gene consisting of appropriate transcriptional/translational control signals and the protein

coding sequences. These methods may include *in vitro* recombinant DNA and synthetic techniques and *in vivo* recombinants (genetic recombination). Expression of nucleic acid sequence encoding a chemokine protein or peptide fragment may be regulated by a second nucleic acid sequence so that the chemokine protein or peptide is expressed in a host transformed with the recombinant DNA molecule. For example, expression of a chemokine protein may be controlled by any promoter/enhancer element known in the art. Promoters which may be used to control chemokine expression include, but are not limited to, the SV40 early promoter region (Bernoist and Chambon, 1981, Nature 290:304-310), the promoter contained in the 3' long terminal repeat of Rous sarcoma virus (Yamamoto, et al., 1980, Cell 22:787-797), the herpes thymidine kinase promoter (Wagner et al., 1981, Proc. Natl. Acad. Sci. U.S.A. 78:1441-1445), the regulatory sequences of the metallothionein gene (Brinster et al., 1982, Nature 296:39-42), prokaryotic expression vectors such as the β -lactamase promoter (Villa-Komaroff, et al., 1978, Proc. Natl. Acad. Sci. U.S.A. 75:3727-3731), or the *tac* promoter (DeBoer, et al., 1983, Proc. Natl. Acad. Sci. U.S.A. 80:21-25); see also "Useful proteins from recombinant bacteria" in Scientific American, 1980, 242:74-94; promoter elements from yeast or other fungi such as the Gal 4 promoter, the ADC (alcohol dehydrogenase) promoter, PGK (phosphoglycerol kinase) promoter, alkaline phosphatase promoter, and the following animal transcriptional control regions, which exhibit tissue specificity and have been utilized in transgenic animals: elastase I gene control region which is active in pancreatic acinar cells (Swift et al., 1984, Cell 38:639-646; Ornitz et al., 1986, Cold Spring Harbor Symp. Quant. Biol. 50:399-409; MacDonald, 1987, Hepatology 7:425-515); insulin gene control region which is active in pancreatic beta cells (Hanahan, 1985, Nature 315:115-122), immunoglobulin gene control region which is active in lymphoid cells (Grosschedl et al., 1984, Cell 38:647-658; Adames et al., 1985, Nature 318:533-538; Alexander et al., 1987, Mol. Cell. Biol. 7:1436-1444), mouse mammary tumor virus control region which is active in testicular, breast, lymphoid and mast cells (Leder et al., 1986, Cell 45:485-495), albumin gene control region which is active in liver (Pinkert et al., 1987, Genes and Devel. 1:268-276), alpha-fetoprotein gene control region which is active in liver (Krumlauf et al., 1985, Mol. Cell. Biol. 5:1639-1648; Hammer et al., 1987, Science 235:53-58; alpha 1-antitrypsin gene control region which is active in the liver (Kelsey et al., 1987, Genes and Devel. 1:161-171), beta-globin gene control region

which is active in myeloid cells (Mogram et al., 1985, Nature 315:338-340; Kollias et al., 1986, Cell 46:89-94), myelin basic protein gene control region which is active in oligodendrocyte cells in the brain (Readhead et al., 1987, Cell 48:703-712), myosin light chain-2 gene control region which is active in skeletal muscle (Sani, 1985, Nature 314:283-286), and gonadotropic releasing hormone gene control region which is active in the hypothalamus (Mason et al., 1986, Science 234:1372-1378).

For example, a vector can be used that comprises a promoter operably linked to an chemokine-encoding nucleic acid, one or more origins of replication, and, optionally, one or more selectable markers (e.g., an antibiotic resistance gene).

In a specific embodiment, an expression construct is made by subcloning a chemokine coding sequence into the *EcoRI* restriction site of each of the three pGEX vectors (Glutathione S-Transferase expression vectors; Smith and Johnson, 1988, Gene 7:31-40). This allows for the expression of the chemokine protein product from the subclone in the correct reading frame.

Expression vectors containing chemokine gene inserts can be identified by three general approaches: (a) nucleic acid hybridization, (b) presence or absence of "marker" gene functions, and (c) expression of inserted sequences. In the first approach, the presence of a chemokine gene inserted in an expression vector can be detected by nucleic acid hybridization using probes comprising sequences that are homologous to an inserted chemokine gene. In the second approach, the recombinant vector/host system can be identified and selected based upon the presence or absence of certain "marker" gene functions (e.g., thymidine kinase activity, resistance to antibiotics, transformation phenotype, occlusion body formation in baculovirus, etc.) caused by the insertion of a chemokine gene in the vector. For example, if the chemokine gene is inserted within the marker gene sequence of the vector, recombinants containing the chemokine insert can be identified by the absence of the marker gene function. In the third approach, recombinant expression vectors can be identified by assaying the product expressed by the recombinant. Such assays can be based, for example, on the physical or functional properties of the chemokine protein in *in vitro* assay systems, e.g., binding with anti-chemokine antibody or the chemokine's receptor.

Once a particular recombinant DNA molecule is identified and isolated, several methods known in the art may be used to propagate it. Once a suitable host

system and growth conditions are established, recombinant expression vectors can be propagated and prepared in quantity. As previously explained, the expression vectors which can be used include, but are not limited to, the following vectors or their derivatives: human or animal viruses such as vaccinia virus or adenovirus; insect viruses such as baculovirus; yeast vectors; bacteriophage vectors (e.g., lambda), and plasmid and cosmid DNA vectors, to name but a few.

In addition, a host cell strain may be chosen which modulates the expression of the inserted sequences, or modifies and processes the gene product in the specific fashion desired. Expression from certain promoters can be elevated in the presence of certain inducers; thus, expression of the genetically engineered protein may be controlled. Furthermore, different host cells have characteristic and specific mechanisms for the translational and post-translational processing and modification (e.g., glycosylation, phosphorylation of proteins. Appropriate cell lines or host systems can be chosen to ensure the desired modification and processing of the foreign protein expressed. For example, expression in a bacterial system can be used to produce an unglycosylated core protein product. Expression in yeast will produce a glycosylated product. Expression in mammalian cells can be used to ensure "native" glycosylation of a heterologous protein. Furthermore, different vector/host expression systems may effect processing reactions to different extents.

In other specific embodiments, the chemokine protein(s), fragment(s), analogue(s), or derivative(s) may be expressed as a fusion, or chimeric protein product (comprising the protein, fragment, analog, or derivative joined via a peptide bond to a heterologous protein sequence (of a different protein)). Such a chimeric product can be made by ligating the appropriate nucleic acid sequences encoding the desired amino acid sequences to each other by methods known in the art, in the proper coding frame, and expressing the chimeric product by methods commonly known in the art. Alternatively, such a chimeric product may be made by protein synthetic techniques, e.g., by use of a peptide synthesizer. In a specific embodiment, a chimeric protein containing all or a portion of the chemokine is joined via a peptide bond to all or a portion of an antigen against which immunity is desired.

Both cDNA and genomic sequences can be cloned and expressed.

The chemokine protein(s) may also be isolated and purified by standard methods including chromatography (e.g., ion exchange, affinity, and sizing column

chromatography), centrifugation, differential solubility, or by any other standard technique for the purification of proteins. The functional properties may be evaluated using any suitable assay (see Section 5.5). Alternatively, the protein can be synthesized by standard chemical methods known in the art (e.g., see Hunkapiller, M., et al., 1984, *Nature* 310:105-111). The chemokine-encoding nucleic acid sequence(s) can be mutated *in vitro* or *in vivo*, to create and/or destroy translation, initiation, and/or termination sequences, or to create variations in coding regions. Any technique for mutagenesis known in the art can be used, including, but not limited to, *in vitro* site-directed mutagenesis (Hutchinson et al., 1978, *J. Biol. Chem.* 253:6551), use of TAB linkers (Pharmacia), mutation-containing PCR primers, etc.

The experimentation involved in mutagenesis consists primarily of site-directed mutagenesis followed by phenotypic testing of the altered gene product. Some of the more commonly employed site-directed mutagenesis protocols take advantage of vectors that can provide single stranded as well as double stranded DNA, as needed. Generally, the mutagenesis protocol with such vectors is as follows. A mutagenic primer, i.e., a primer complementary to the sequence to be changed, but consisting of one or a small number of altered, added, or deleted bases, is synthesized. The primer is extended *in vitro* by a DNA polymerase and, after some additional manipulations, the now double-stranded DNA is transfected into bacterial cells. Next, by a variety of methods, the desired mutated DNA is identified, and the desired protein is purified from clones containing the mutated sequence. For longer sequences, additional cloning steps are often required because long inserts (longer than 2 kilobases) are unstable in those vectors. Protocols are known to those skilled in the art and kits for site-directed mutagenesis are widely available from biotechnology supply companies, for example from Amersham Life Science, Inc. (Arlington Heights, IL) and Stratagene Cloning Systems (La Jolla, CA).

In other specific embodiments, the chemokine derivative(s) or analogue(s) may be expressed as a fusion, or chimeric protein product (comprising the protein, fragment, analogue, or derivative joined via a peptide bond to a heterologous protein sequence (of a different protein)). Such a chimeric product can be made by ligating the appropriate nucleic acid sequences encoding the desired amino acid sequences to each other by methods known in the art, in the proper coding frame, and expressing the chimeric product by methods commonly known in the art.

In addition, chemokine proteins, derivatives (including fragments and chimeric proteins), and analogues can be chemically synthesized. See, e.g., Clark-Lewis et al., 1991, *Biochem.* 30:3128-3135 and Merrifield, 1963, *J. Amer. Chem. Soc.* 85:2149-2156. For example, chemokines, derivatives and analogues can be synthesized by solid phase techniques, cleaved from the resin, and purified by preparative high performance liquid chromatography (e.g., see Creighton, 1983, *Proteins, Structures and Molecular Principles*, W.H. Freeman and Co., N.Y., pp. 50-60). Chemokines, derivatives and analogues that are proteins can also be synthesized by use of a peptide synthesizer. The composition of the synthetic peptides may be confirmed by amino acid analysis or sequencing (e.g., the Edman degradation procedure; see Creighton, 1983, *Proteins, Structures and Molecular Principles*, W.H. Freeman and Co., N.Y., pp. 34-49).

The chemokine proteins, derivatives, or analogues of the invention may be synthesized in their entirety by the sequential addition of amino acid residues or alternatively as fragment subcomponents which may be combined using techniques well known in the art, such as, for example, fragment condensation (Shin et al., 1992, *Biosci. Biotech. Biochem.* 56:404-408; Nyfeler et al., 1992, *Peptides*, Proc. 12th Amer. Pep. Soc., Smith and Rivier (eds), Leiden, pp 661-663); and Nokihara et al., 1990, Protein Research Foundation, Yanaihara (ed), Osaka, pp 315-320).

In a less preferred embodiment, chemokine derivatives can be obtained by proteolysis of the protein followed by purification using standard methods such as those described above (e.g., immunoaffinity purification).

In another alternate embodiment, native chemokine proteins can be purified from natural sources, by standard methods such as those described above (e.g., immunoaffinity purification).

5.3. COMPOSITION FORMULATIONS AND METHODS OF ADMINISTRATION

The composition formulations of the invention comprise an effective immunizing amount of an immunologically active ingredient, i.e., one or more antigens, and an amount of one or more chemokine(s), or fragment(s) or derivative thereof, effective to enhance the immune response against the antigen in a subject, and a pharmaceutically acceptable carrier or excipient. In a specific embodiment, the

chemokines are selected from the group consisting of Macrophage-derived chemokine, Monocyte chemotactic protein 1, Monocyte chemotactic protein 2, Monocyte chemotactic protein 3, Monocyte chemotactic protein 4, activated macrophage specific chemokine 1, Macrophage inflammatory protein 1 alpha, Macrophage inflammatory protein 1 beta, Macrophage inflammatory protein 1 gamma, Macrophage inflammatory protein 1 delta, Macrophage inflammatory protein 2 alpha, Macrophage inflammatory protein 3 alpha, Macrophage inflammatory protein 3 beta, Regulated upon activation, normal T cell expressed and secreted (and its variants), I-309, EB11-ligand chemokine, Pulmonary and activation regulated chemokine, Liver and activation-regulated chemokine, Thymus and activation regulated chemokine, Eotaxin (and variants), Human CC chemokine 1, Human CC chemokine 2, Human CC chemokine 3, IL-10-inducible chemokine, liver-expressed chemokine, 6Ckine, Exodus 1, Exodus 2, Exodus 3, thymus-expressed chemokine, Secondary Lymphoid tissue chemokine, Lymphocyte and Monocyte chemoattractant; Monotactin, Activation-induced, chemokine-related molecule, Myeloid progenitor inhibitory factor-1, Myeloid progenitor inhibitory factor-2, Stromal cell-derived factor 1 alpha, Stromal cell-derived factor 1 beta, B-cell-attracting chemokine 1, HuMIG, H174, Interferon-stimulated T-cell alpha chemoattractant, Interleukin-8, IP-10, platelet factor 4, growth-regulated gene-alpha, growth-regulated gene-beta, growth-regulated gene-gamma, Neutrophil-activating protein 2, ENA-78, granulocyte chemotactic protein 2, LYMPHOTACTIN, and Fractalkine/neurotactin.

Pharmaceutically acceptable carriers or excipients are well known in the art and include but are not limited to saline, buffered saline, dextrose, water, glycerol, ethanol, sterile isotonic aqueous buffer, and combinations thereof. One example of such an acceptable carrier is a physiologically balanced culture medium containing one or more stabilizing agents such as stabilized, hydrolyzed proteins, lactose, etc. The carrier is preferably sterile. The formulation should suit the mode of administration.

In addition, if desired, the vaccine or composition preparation may also include minor amounts of auxiliary substances such as wetting or emulsifying agents, pH buffering agents, and/or adjuvants which enhance the effectiveness of the vaccine or composition. Suitable adjuvants may include, but are not limited to: mineral gels,

e.g., aluminum hydroxide; surface active substances such as lysolecithin, pluronic polyols; polyanions; peptides; oil emulsions; alum, MDP, N-acetyl-muramyl-L-threonyl-D-isoglutamine (thr-MDP), N-acetyl-nor-muramyl-L-alanyl-D-isoglutamine, and N-acetylmuramyl-L-alanyl-D-isoglutaminyl-L-alanine-2-(1'-2'-dipalmitoyl-sn-glycero-3-hydroxyphosphoryloxy)-ethylamine. The effectiveness of an adjuvant may be determined by comparing the induction of antibodies directed against a MDC-containing composition in the presence and in the absence of various adjuvants.

In instances where the recombinant antigen is a hapten, i.e., a molecule that is antigenic in that it can react selectively with cognate antibodies, but not immunogenic in that it cannot elicit an immune response, the hapten may be covalently bound to a carrier or immunogenic molecule; for instance, a large protein such as serum albumin will confer immunogenicity to the hapten coupled to it. The hapten-carrier may be formulated for use as a vaccine.

The composition can be a liquid solution, suspension, emulsion, tablet, pill, capsule, sustained release formulation, or powder. Oral formulation can include standard carriers such as pharmaceutical grades of mannitol, lactose, starch, magnesium stearate, sodium saccharine, cellulose, magnesium carbonate, etc.

The chemokinè(s), or fragment(s) or derivative(s) thereof, and/or the antigen(s) may be formulated into the composition as neutral or salt forms. Pharmaceutically acceptable salts include the acid addition salts (formed with free amino groups of the peptide) and which are formed with inorganic acids, such as, for example, hydrochloric or phosphoric acids, or organic acids such as acetic, oxalic, tartaric, maleic, and the like. Salts formed with free carboxyl groups may also be derived from inorganic bases, such as, for example, sodium potassium, ammonium, calcium, or ferric hydroxides, and such organic bases as isopropylamine, trimethylamine, 2-ethylamino ethanol, histidine, procaine and the like.

The vaccines of the invention may be multivalent or univalent. Multivalent vaccines are made from recombinant viruses that direct the expression of more than one antigen.

An effective dose (immunizing amount) is that amount sufficient to produce an immune response to the antigen(s) in the host to which the vaccine preparation is administered. The precise dose of the composition to be employed in the formulation will depend on the route of administration, and the nature of the subject to be

immunized, and should be decided by the practitioner according to standard clinical techniques. Effective doses of the vaccines or compositions of the present invention may also be extrapolated from dose-response curves derived from animal model test systems.

The invention also provides a pharmaceutical pack or kit comprising one or more containers comprising one or more of the ingredients of the composition formulations of the invention. Associated with such container(s) can be a notice in the form prescribed by a governmental agency regulating the manufacture, use or sale of pharmaceuticals or biological products, which notice reflects approval by the agency of manufacture, use or sale for human administration.

Generally, the ingredients are supplied either separately or mixed together in unit dosage form, for example, as a dry lyophilized powder or water free concentrate in a hermetically sealed container such as an ampoule or sachette indicating the quantity of active agent. Where the composition is administered by injection, an ampoule of sterile diluent can be provided so that the ingredients may be mixed prior to administration.

In a specific embodiment, a lyophilized immunologically active ingredient and one or more chemokine polypeptide(s) of the invention are provided in a first container; a second container comprises diluent consisting of an aqueous solution of 50% glycerin, 0.25% phenol, and an antiseptic (e.g., 0.005% brilliant green).

Many methods may be used to introduce the composition formulations of the invention; these include but are not limited to oral, intradermal, intramuscular, intraperitoneal, intravenous, subcutaneous, intranasal routes, and via scarification (scratching through the top layers of skin, e.g., using a bifurcated needle).

The DNA vaccines of the invention can be administered by any method known in the art for delivery of DNA to subject (for example, as described in Section 5.3 *supra*)

5.4. DETERMINATION OF COMPOSITION EFFICACY

The activity of one or more chemokines, or a fragment, derivative or analogue thereof, to enhance immune response to an antigen can be determined by monitoring the immune response in test animals following immunization with a composition containing the chemokine(s) and an antigen and comparing the response to that following immunization with the antigen in the absence of the chemokine(s). Generation of a humoral (antibody) response and/or cell-mediated immunity, may be taken as an indication of an immune response. Test animals may include mice, hamsters, dogs, cats, monkeys, rabbits, chimpanzees, etc., and eventually human subjects. Assays for humoral and cell-mediated immunity are well known in the art.

Methods of introducing the composition may include oral, intracerebral, intradermal, intramuscular, intraperitoneal, intravenous, subcutaneous, intranasal or any other standard routes of immunization. The immune response of the test subjects can be analyzed by various approaches well known in the art, such as but not limited to: testing the reactivity of the resultant immune serum to the antigen of the chemokine-containing vaccine, as assayed by known techniques, e.g., immunosorbant assay (ELISA), immunoblots, radioimmunoprecipitations, etc.

As one example of suitable animal testing, a composition of the present invention may be tested in mice for the ability to enhance an antibody response to an antigen (using for example, but not limited to, the method as described in Section 6, *infra*) and the delayed-type hypersensitivity (DTH) response (also described in Section 6 *infra*), measured by an increase in footpad swelling after inoculation in the footpad of the test animal, as compared to the measurements in animals administered the antigen in a composition not containing chemokine. For example, as test animals BALB/c mice may be used. The test group each receives an inoculation with fixed amount of antigen and varying amount of one or more chemokines. The control group receives an inoculation of comparable amount of antigen alone.

Serum samples may be drawn from the mice after the final inoculation (for example every one or two weeks after inoculation), and serum is analyzed for antibodies against the antigen using known methods in the art, e.g., using an ELISA. DTH responses to the antigen may be measured after the final inoculation (e.g. within 1-7 days). An increase in the serum titer of antibodies recognizing the antigen and/or

an increase in footpad swelling in the animals receiving the antigen-compositions containing the chemokine(s) as compared to the serum titer of antibodies against the antigen and/or the footpad swelling in the animals receiving the antigen composition not containing the chemokine(s), indicates that the chemokine(s) enhance the immune response to antigen. An increase in the serum titer of antibodies recognizing the antigen and/or an increase in footpad swelling in the animals receiving the antigen-compositions containing the chemokines as compared to the serum titer of antibodies against the antigen and/or the footpad swelling in the animals receiving the antigen composition not containing chemokine(s), indicates that the chemokine(s) enhances the immune response to antigen. An increase in the serum titer of antibodies recognizing the antigen and/or an increase in footpad swelling in the animals receiving the antigen-compositions containing MDC as compared to the serum titer of antibodies against the antigen and/or the footpad swelling in the animals receiving the antigen composition not containing MDC, indicates that the MDC enhances the immune response to antigen. An increase in the serum titer of antibodies recognizing the antigen and/or an increase in footpad swelling in the animals receiving the antigen-compositions containing MDC as compared to the serum titer of antibodies against the antigen and/or the footpad swelling in the animals receiving the antigen composition not containing MDC, indicates that the MDC enhances the immune response to antigen.

6. EXAMPLE: IMMUNIZATION WITH MDC-CONTAINING COMPOSITION

The following experiment illustrates the evaluation of whether MDC will act as an adjuvant for a protein antigen and enhance the efficacy of a vaccine. However, it will be appreciated that the description applies equally to other chemokines and combinations of chemokines.

6.1. MATERIALS AND METHODS

6.1.1. ANIMALS AND REAGENTS

BALB/c mice are purchased from Harlan-Sprague-Dawley (Indianapolis, IN).

Human MDC (hMDC) was obtained from CD8⁺ T cell clones immortalized *in vitro* prepared as previously described (Markham et al., 1983 *Int. J. Cancer* 31:413; Markham et al. 1984, *Int. J. Cancer* 33:13). One such immortalized CD8⁺ T cell clone, F3b Clone 19, was adapted to growth in serum-free medium by the following procedure and used for further studies. F3b Clone 19 cells were grown in complete medium containing rIL-2 (16 ng/ml) at 37°C in a CO₂ incubator. After expanding the culture to 200 ml, the cells were pelleted and resuspended in RPMI medium containing HB101 (Irvine Scientific) supplemented with 16 ng/ml of rIL-2, 1% glutamine and 1% penicillin/streptomycin. The cells were grown to full confluence and the medium harvested by centrifugation at 670 x g for 10 minutes.

Human MDC (hMDC) was purified from F3b Clone 19 as described in Pal et al., 1997, *Science* 278:695-698. Briefly, the cell free culture supernatant from F3b Clone 19 was clarified by high speed centrifugation and fractionated by heparin affinity chromatography, taking advantage of the heparin binding characteristics of chemokines (Witt and Lander, 1994, *Current Biology* 4:394; Proost et al., 1996, *Method: A Companion to Methods in Enzymology* 10:82). Culture supernatant (1200 ml) from F3b Clone 19, grown to high cell density in serum-free medium supplemented with rIL-2 was clarified by high speed centrifugation (100,000 x g for 60 minutes at 4°C) and applied to a 5 ml HiTrap heparin affinity FPLC column (Pharmacia) equilibrated in 10 mM Tris-HCl, pH 7.6 containing 0.1 M NaCl (column buffer). The column was then washed extensively with column buffer and the bound proteins eluted from the column with 10 mM Tris-HCl, pH 7.6 containing 2.0 M NaCl at a flow rate of 0.5 to 1 ml/minute. Virtually all of the HIV suppressive activity effective against primary NSI and SI isolates and HIV-1_{IIIb} was recovered in the column eluate (data not shown). The heparin affinity column eluate was brought to pH 2.0 by addition of trifluoroacetic acid (TFA) and subjected to reversed phase HPLC on a PEEK C-18 column (Waters Instruments) equilibrated in H₂O containing 0.1 % TFA. Proteins bound to the column were eluted with a 5 minute linear gradient of aqueous acetonitrile (0 to 35 %) containing 0.1% TFA. After 10 minutes at 35% acetonitrile, the column was further developed with a 60 minute linear gradient of 35-70% aqueous acetonitrile in TFA. The flow rate was maintained at 0.5 to 1 ml/minute. The fractions obtained were then tested for suppressor activity in the acute infectivity assay using HIV-1_{IIIb}. Active fractions were pooled, diluted twofold in H₂O with 0.1 % TFA

and reapplied to the column. The column was then developed with a 30 minute linear aqueous acetonitrile gradient (0-60%) containing 0.1% TFA at a flow rate of 0.5 to 1 ml/minute. The fractions obtained were assayed as above. Active fractions were pooled, diluted with H₂O/0.1 % TFA and fractionated under the same conditions to obtain a single protein peak. The fraction corresponding to the peak and flanking fractions were tested in the infectivity assay to verify that suppressor activity was cofractionated with the protein.

Suppressive activity against HIV-1_{IIIIB} in the absence of cytotoxic effects consistently copurified with a single protein peak that appeared as a homogeneous 8 kDa band when analyzed by SDS-polyacrylamide gel electrophoresis. This protein was not reactive in ELISAs for RANTES, MIP-1 α or MIP-1 β (R&D Systems).

Recombinant gp120 protein derived from HIV-1 IIIIB isolate is purchased from Intracel (Foster City, CA).

6.1.2 IMMUNIZATION OF MICE

The hMDC and the gp120 is resuspended in a total volume of 50 μ l of phosphate-buffered saline (PBS). Mice are divided into 5 groups with 3-4 mice in each group. Groups 1-4 are inoculated with 10 μ g gp120 and 0.3 μ g, 0.1 μ g, 0.03 μ g, and 0.01 μ g of hMDC, respectively. As a control, group 5 is inoculated with 10 μ g of gp120 in the absence of hMDC. For primary inoculation, each group of mice is inoculated with 10 μ l of the hMDC and gp120 solution via footpad. Two to three weeks after the primary inoculation, each mouse is given the same dose of hMDC/gp120 that is used in primary inoculation.

6.1.3 ELISA ASSAY

Serum samples are collected one week after the second inoculation via tail vein bleed. gp120 serum responses are measured using standard gp120 antibody ELISA assays.

6.1.4 DTH ASSAY

The delayed-type hypersensitivity (DTH) response is measured from 1-7 days after the second inoculation. A caliper is to be used to measure footpad swelling.

6.2. RESULTS

Mice inoculated with hMDC/gp120 are expected to have greater serum antibody and DTH responses than mice inoculated with gp120 alone. The improved responses will be reflected in either increased titers of serum antibody responses or increased footpad swelling. A dose response effect is expected - increasing the dose of hMDC used is expected to cause a corresponding improvement in the serum and DHT gp120-specific responses.

7. EXAMPLE: OTHER CHEMOKINES AND COMBINATIONS OF CHEMOKINES

The foregoing experiments can be repeated using other chemokines and combinations of chemokines. For example, the experiments are preferably repeated using one or more chemokines selected from the group consisting of: Macrophage-derived chemokine, Monocyte chemotactic protein 1, Monocyte chemotactic protein 2, Monocyte chemotactic protein 3, Monocyte chemotactic protein 4, activated macrophage specific chemokine 1, Macrophage inflammatory protein 1 alpha, Macrophage inflammatory protein 1 beta, Macrophage inflammatory protein 1 gamma, Macrophage inflammatory protein 1 delta, Macrophage inflammatory protein 2 alpha, Macrophage inflammatory protein 3 alpha, Macrophage inflammatory protein 3 beta, Regulated upon activation, normal T cell expressed and secreted (and its variants), I-309, EB11-ligand chemokine, Pulmonary and activation regulated chemokine, Liver and activation-regulated chemokine, Thymus and activation regulated chemokine, Eotaxin (and variants), Human CC chemokine 1, Human CC chemokine 2, Human CC chemokine 3, IL-10-inducible chemokine, liver-expressed chemokine., 6Ckine, Exodus 1, Exodus 2, Exodus 3, thymus-expressed chemokine, Secondary Lymphoid tissue chemokine, Lymphocyte and Monocyte chemoattractant; Monotactin, Activation-induced, chemokine-related molecule, Myeloid progenitor inhibitory factor-1, Myeloid progenitor inhibitory factor-2, Stromal cell-derived factor 1 alpha, Stromal cell-derived factor 1 beta, B-cell-attracting chemokine 1, HuMIG, H174, Interferon-stimulated T-cell alpha chemoattractant, Interleukin-8, IP-10, platelet factor 4, growth-regulated gene-alpha, growth-regulated gene-beta, growth-regulated gene-gamma, Neutrophil-activating protein 2, ENA-78, granulocyte chemotactic protein 2, LYMPHOTACTIN, and Fractalkine/neurotactin.

The present invention is not to be limited in scope by the specific embodiments described herein. Indeed, various modifications of the invention in addition to those described herein will become apparent to those skilled in the art from the foregoing description. Such modifications are intended to fall within the scope of the appended claims.

Various references are cited herein, the disclosures of which are incorporated by reference in their entireties.

THE CLAIMS:

1. A method to enhance the efficacy of a vaccine in a subject comprising administering to the subject an immunogenic amount of one or more purified antigens against which an immune response is desired in the subject and an amount of one or more chemokines, or purified fragments or derivatives thereof, effective to enhance the efficacy of said vaccine.
2. The method of claim 1, wherein the one or more chemokines are selected from a chemokine class selected from the group consisting of: CC, CXC, C-C and CX3C.
3. The method of claim 1, wherein the one or more chemokines are selected from the group consisting of: Macrophage-derived chemokine, Monocyte chemotactic protein 1, Monocyte chemotactic protein 2, Monocyte chemotactic protein 3, Monocyte chemotactic protein 4, activated macrophage specific chemokine 1, Macrophage inflammatory protein 1 alpha, Macrophage inflammatory protein 1 beta, Macrophage inflammatory protein 1 gamma, Macrophage inflammatory protein 1 delta, Macrophage inflammatory protein 2 alpha, Macrophage inflammatory protein 3 alpha, Macrophage inflammatory protein 3 beta, Regulated upon activation, normal T cell expressed and secreted (and its variants), I-309, EBI1-ligand chemokine, Pulmonary and activation regulated chemokine, Liver and activation-regulated chemokine, Thymus and activation regulated chemokine, Eotaxin (and variants), Human CC chemokine 1, Human CC chemokine 2, Human CC chemokine 3, IL-10-inducible chemokine, liver-expressed chemokine, 6Ckine, Exodus 1, Exodus 2, Exodus 3, thymus-expressed chemokine, Secondary Lymphoid tissue chemokine, Lymphocyte and Monocyte chemoattractant; Monotactin, Activation-induced, chemokine-related molecule, Myeloid progenitor inhibitory factor-1, Myeloid progenitor inhibitory factor-2, Stromal cell-derived factor 1 alpha, Stromal cell-derived factor 1 beta, B-cell-attracting chemokine 1, HuMIG, H174, Interferon-stimulated T-cell alpha chemoattractant, Interleukin-8, IP-10, platelet factor 4, growth-regulated gene-alpha, growth-

- regulated gene-beta, growth-regulated gene-gamma, Neutrophil-activating protein 2, ENA-78, granulocyte chemotactic protein 2, LYMPHOTACTIN, and Fractalkine/neurotactin.
4. The method of claim 1, wherein the one or more chemokines are selected from the group consisting of: MDC, SDF-1, BLC, and MCP-1.
 5. The method of claim 1 wherein the fragment(s) or derivative(s) are truncation isoforms.
 6. The method of claim 1, wherein the one or more chemokines include MDC comprising the amino acid sequence of SEQ ID NO: 2.
 7. The method of claim 1, wherein the one or more chemokine fragment includes an MDC fragment selected from the group consisting of amino acid numbers 2-69, 3-69, 5-69, 7-69 and 9-69 of SEQ ID NO: 2.
 8. The method of claim 1, wherein the one or more chemokine fragment includes an MDC fragment selected from the group consisting of amino acid numbers 2-69, 3-69, 5-69, 7-69 and 9-69 of SEQ ID NO: 2., which derivative has activity to enhance the efficacy of the vaccine.
 9. The method of claim 1, wherein the one or more chemokine derivatives has one or more insertions or substitutions with one or more non-classical amino acids relative to a corresponding wildtype chemokine, which derivative has activity to enhance the efficacy of the vaccine.
 10. The method of claim 1, including a chemokine derivative having one or more conservative substitutions in sequence relative a wildtype MDC, which derivative has activity to enhance the efficacy of the vaccine.
 11. The method of claim 1, wherein the one or more chemokines include a human chemokine.

12. The method of claim 1, wherein the purified chemokine(s) or purified fragment(s) or derivative(s) thereof is/are administered concurrently with the purified antigen(s).
13. The method of claim 1 wherein the purified chemokine(s) or purified fragment(s) or derivative(s) thereof, are administered within a time period before or after administration of the purified antigen, which time period permits the purified MDC or purified fragment or derivative thereof MDC to enhance the efficacy of the vaccine.
14. The method of claim 1, wherein the antigen is an HIV antigen.
15. The method of claim 14, wherein the HIV antigen is HIV-associated gp120 protein.
16. The method of claim 1, wherein the subject is a human.
17. The method of claim 1, wherein the subject is infected or at risk of being infected with HIV virus.
18. The method of claim 1, wherein the vaccine elicits a humoral response against the antigen in the subject.
19. The method of claim 1, wherein the vaccine elicits a cell-mediated response against the antigen in the subject.
20. The method of claim 1, wherein the vaccine elicits both a humoral and a cell-mediated response against the antigen in the subject.
21. The method of claim 1, wherein the vaccine further comprises pharmaceutically acceptable excipient, auxiliary substance, adjuvant, wetting or emulsifying agent, or pH buffering agent.

22. A method to enhance the efficacy of a vaccine in a subject comprising administering to the subject a first amount of a first set of one or more purified nucleotide sequences encoding one or more antigens against which an immune response is desired in the subject and a second second set of one or more purified nucleic acids, each comprising a nucleotide sequence encoding one or more chemokines, or fragments or derivatives thereof, wherein the antigen(s) and the chemokine(s) are expressed in a coordinated manner upon introduction into a suitable cell, said first amount is immunogenic and said second amount is effective in enhancing the efficacy of the vaccine.
23. The method of claim 22, wherein the one or more chemokines are selected from a chemokine class selected from the group consisting of: CC, CXC, C-C and CX3C.
24. The method of claim 22, wherein the one or more chemokines are selected from the group consisting of: Macrophage-derived chemokine, Monocyte chemotactic protein 1, Monocyte chemotactic protein 2, Monocyte chemotactic protein 3, Monocyte chemotactic protein 4, activated macrophage specific chemokine 1, Macrophage inflammatory protein 1 alpha, Macrophage inflammatory protein 1 beta, Macrophage inflammatory protein 1 gamma, Macrophage inflammatory protein 1 delta, Macrophage inflammatory protein 2 alpha, Macrophage inflammatory protein 3 alpha, Macrophage inflammatory protein 3 beta, Regulated upon activation, normal T cell expressed and secreted (and its variants), I-309, EBI1-ligand chemokine, Pulmonary and activation regulated chemokine, Liver and activation-regulated chemokine, Thymus and activation regulated chemokine, Eotaxin (and variants), Human CC chemokine 1, Human CC chemokine 2, Human CC chemokine 3, IL-10-inducible chemokine, liver-expressed chemokine, 6Ckine, Exodus 1, Exodus 2, Exodus 3, thymus-expressed chemokine, Secondary Lymphoid tissue chemokine, Lymphocyte and Monocyte chemoattractant; Monotactin, Activation-induced, chemokine-related molecule, Myeloid progenitor inhibitory factor-1, Myeloid progenitor inhibitory factor-2, Stromal cell-derived factor 1 alpha, Stromal cell-derived factor 1 beta, B-cell-attracting chemokine

- 1, HuMIG, H174, Interferon-stimulated T-cell alpha chemoattractant, Interleukin-8, IP-10, platelet factor 4, growth-regulated gene-alpha, growth-regulated gene-beta, growth-regulated gene-gamma, Neutrophil-activating protein 2, ENA-78, granulocyte chemotactic protein 2, LYMPHOTACTIN, and Fractalkine/neurotactin.
25. The method of claim 22, wherein the one or more chemokines are selected from the group consisting of: MDC, SDF-1, BLC, and MCP-1.
26. The method of claim 22 wherein the fragment(s) or derivative(s) are truncation isoforms.
27. The method of claim 22, wherein the nucleotide sequence encoding one or more chemokines comprises the nucleotide sequence of SEQ ID NO:1.
28. The method of claim 22, wherein one or more of the chemokine derivative(s) have deletional, insertional or substitutional mutations and combination thereof, which derivative has activity to enhance the efficacy of the vaccine.
29. The method of claim 22, wherein the vaccine elicits a humoral response against the antigen in the subject.
30. The method of claim 22, wherein the vaccine elicits a cell-mediated response against the antigen in the subject.
31. The method of claim 22, wherein the vaccine elicits both a humoral and a cell-mediated response against the antigen in the subject.
32. The method of claim 22, wherein the vaccine further comprises pharmaceutically acceptable excipient, auxiliary substance, adjuvant, wetting or emulsifying agent, or pH buffering agent.
33. A composition comprising: an immunogenic amount of one or more purified antigens and an amount of one or more purified chemokines, or purified

- fragments or derivatives thereof, effective to enhance the immune response to said antigen(s); and a pharmaceutically acceptable carrier.
34. The composition of claim 33, wherein the one or more chemokines are selected from the group consisting of: MDC, SDF-1, BLC, and MCP-1.
 35. The composition of claim 33, wherein the one or more chemokines are selected from a chemokine class selected from the group consisting of: CC, CXC, C-C and CX3C.
 36. The composition of claim 33, wherein the one or more chemokines are selected from the group consisting of: Macrophage-derived chemokine, Monocyte chemotactic protein 1, Monocyte chemotactic protein 2, Monocyte chemotactic protein 3, Monocyte chemotactic protein 4, activated macrophage specific chemokine 1, Macrophage inflammatory protein 1 alpha, Macrophage inflammatory protein 1 beta, Macrophage inflammatory protein 1 gamma, Macrophage inflammatory protein 1 delta, Macrophage inflammatory protein 2 alpha, Macrophage inflammatory protein 3 alpha, Macrophage inflammatory protein 3 beta, Regulated upon activation, normal T cell expressed and secreted (and its variants), I-309, EBI1-ligand chemokine, Pulmonary and activation regulated chemokine, Liver and activation-regulated chemokine, Thymus and activation regulated chemokine, Eotaxin (and variants), Human CC chemokine 1, Human CC chemokine 2, Human CC chemokine 3, IL-10-inducible chemokine, liver-expressed chemokine, 6CKine, Exodus 1, Exodus 2, Exodus 3, thymus-expressed chemokine, Secondary Lymphoid tissue chemokine, Lymphocyte and Monocyte chemoattractant; Monotactin, Activation-induced, chemokine-related molecule, Myeloid progenitor inhibitory factor-1, Myeloid progenitor inhibitory factor-2, Stromal cell-derived factor 1 alpha, Stromal cell-derived factor 1 beta, B-cell-attracting chemokine 1, HuMIG, H174, Interferon-stimulated T-cell alpha chemoattractant, Interleukin-8, IP-10, platelet factor 4, growth-regulated gene-alpha, growth-regulated gene-beta, growth-regulated gene-gamma, Neutrophil-activating

- protein 2, ENA-78, granulocyte chemotactic protein 2, LYMPHOTACTIN, and Fractalkine/neurotactin.
- 37. The composition of claim 33, wherein the fragment(s) or derivative(s) are truncation isoforms.
- 38. The composition of claim 33, wherein the one or more chemokine fragment includes an MDC fragment selected from the group consisting of amino acid numbers 2-69, 3-69, 5-69, 7-69 and 9-69 of SEQ ID NO: 2.
- 39. The composition of claim 33, wherein the one or more chemokine fragment includes an MDC fragment selected from the group consisting of amino acid numbers 2-69, 3-69, 5-69, 7-69 and 9-69 of SEQ ID NO: 2, which derivative has activity to enhance the efficacy of the vaccine.
- 40. The composition of claim 33, wherein the one or more chemokine derivatives has one or more insertions of or substitutions with one or more non-classical amino acids relative to a corresponding wildtype chemokine, which derivative has activity to enhance the efficacy of the vaccine.
- 41. The composition of claim 33, wherein the one or more chemokine derivatives has one or more conservative substitutions in sequence relative a corresponding wildtype chemokine, which derivative has activity to enhance the efficacy of the vaccine.
- 42. The composition of claim 33, wherein the chemokine is a human chemokine.
- 43. The composition of claim 33, wherein the antigen is an HIV antigen.
- 44. The composition of claim 43, wherein the antigen is HIV associated gp120 protein.
- 45. A composition comprising an amount of a first set of purified nucleic acids comprising one or more nucleotide sequences encoding one or more antigens

- and a second set of purified nucleic acids comprising one or more nucleotide sequences encoding one or more chemokines, or fragments or derivatives thereof, wherein the antigen(s) and the chemokine(s), or fragment(s) or derivative(s) thereof, are expressed from said first set of nucleic acid(s) and second set of nucleic acid(s) in a coordinated manner such that upon introduction into a suitable cell, the amount of said first set of nucleic acid(s) is sufficient to express an immunogenic amount of the antigen and the amount of the said second set of nucleic acid(s) is effective in enhancing the efficacy of the vaccine; and a pharmaceutically acceptable carrier.
46. The composition of claim 45, wherein the chemokine is MDC and the nucleic acid encoding the MDC comprises the nucleotide sequence of SEQ ID NO: 1.
47. The composition of claim 45, wherein the chemokine derivative(s) have deletional, insertional or substitutional mutations and/or combinations thereof, and the derivative(s) have activity to enhance the efficacy of the vaccine.
48. The composition of claim 45, further comprising pharmaceutically acceptable excipient, auxiliary substance, adjuvant, wetting or emulsifying agent, or pH buffering agent.
49. A composition comprising a first set of purified nucleotide sequences encoding one or more antigens and a second set of purified nucleotide sequences encoding one or more chemokines, or fragments or derivatives thereof, wherein the antigen(s) and the chemokine(s) are expressed in a coordinated manner such that upon introduction into a suitable cell, the sets produce an amount of said antigen(s) that is immunogenic and an amount of chemokine(s), or fragment(s) or derivative(s) thereof, that is effective in enhancing the efficacy of the vaccine relative to a corresponding vaccine composition without such chemokine(s), fragment(s) or derivative(s) thereof.
50. The composition of claim 49, wherein the one or more chemokines are selected from the group consisting of: Macrophage-derived chemokine,

Monocyte chemotactic protein 1, Monocyte chemotactic protein 2, Monocyte chemotactic protein 3, Monocyte chemotactic protein 4, activated macrophage specific chemokine 1, Macrophage inflammatory protein 1 alpha, Macrophage inflammatory protein 1 beta, Macrophage inflammatory protein 1 gamma, Macrophage inflammatory protein 1 delta, Macrophage inflammatory protein 2 alpha, Macrophage inflammatory protein 3 alpha, Macrophage inflammatory protein 3 beta, Regulated upon activation, normal T cell expressed and secreted (and its variants), I-309, EB11-ligand chemokine, Pulmonary and activation regulated chemokine, Liver and activation-regulated chemokine, Thymus and activation regulated chemokine, Eotaxin (and variants), Human CC chemokine 1, Human CC chemokine 2, Human CC chemokine 3, IL-10-inducible chemokine, liver-expressed chemokine, 6Ckine, Exodus 1, Exodus 2, Exodus 3, thymus-expressed chemokine, Secondary Lymphoid tissue chemokine, Lymphocyte and Monocyte chemoattractant; Monotactin, Activation-induced, chemokine-related molecule, Myeloid progenitor inhibitory factor-1, Myeloid progenitor inhibitory factor-2, Stromal cell-derived factor 1 alpha, Stromal cell-derived factor 1 beta, B-cell-attracting chemokine 1, HuMIG, H174, Interferon-stimulated T-cell alpha chemoattractant, Interleukin-8, IP-10, platelet factor 4, growth-regulated gene-alpha, growth-regulated gene-beta, growth-regulated gene-gamma, Neutrophil-activating protein 2, ENA-78, granulocyte chemotactic protein 2, LYMPHOTACTIN, and Fractalkine/neurotactin.

51. The method of claim 49, wherein the one or more chemokines are selected from a chemokine class selected from the group consisting of: CC, CXC, C-C and CX3C.
52. The method of claim 49, wherein the one or more chemokines are selected from the group consisting of: MDC, SDF-1, BLC, and MCP-1.
53. The composition of claim 49, wherein the fragment(s) or derivative(s) are truncation isoforms.

- 54. The composition of claim 49, wherein the nucleic acid is administered directly to the subject.
- 55. The composition of claim 49, wherein the nucleic acid is introduced into a suitable host cell and said suitable host cell is introduced into the subject.

GAGACATACA GGACAGAGC ATG GCT CGC CTA CAG ACT GCA CTC CTG GTT GTC	52
Met Ala Arg Leu Gln Thr Ala Leu Val Val	
-24 -20 -15	
CTC GTC CTC CTT GCT GTG GCG CTT CAA GCA ACT GAG GCA GGC CCC TAC	100
Leu Val Leu Leu Ala Val Ala Val Ala Leu Gln Ala Thr Glu Ala Gly Pro Tyr	
-10 -5 1	
GGC GCC AAC ATG GAA GAC AGC AGC GTC TGC TGC CGT GAT TAC GTC CGT TAC	148
Gly Ala Asn Met Glu Asp Ser Val Cys Cys Arg Asp Tyr Val Arg Tyr	
5 10 15	
CGT CTG CCC CTG CGC GTG GTG AAA CAC TTC TAC TGG ACC TCA GAC TCC	196
Arg Leu Pro Leu Arg Val Val Lys His Phe Tyr Trp Thr Ser Asp Ser	
20 25 30 35	
TGC CCG AGG CCT GGC GTG GTG TTG CTA ACC TTC AGG GAT AAG GAG ATC	244
Cys Pro Arg Pro Gly Val Val Leu Leu Thr Phe Arg Asp Lys Glu Ile	
40 45 50	
TGT GCC GAT CCC AGA GTG CCC TGG GTG AAG ATG ATT CTC AAT AAG CTG	292
Cys Ala Asp Pro Arg Val Pro Trp Val Lys Met Ile Leu Asn Lys Leu	
55 60 65	

AGC CAA TGAAGAGCCT ACTCTGATGA CCGTGGCCTT GGCTCCTCCA GGAAGGCTCA 348

Ser Gln

GGAGCCCTAC CTCCCTGCCA TTATAGCTGC TCCCCGCCAG AAGCTGTGC CAACTCTCTG 408

CATTCCCTGA TCTCCATCCC TGIGGCTGTC ACCCTGGTC ACCTCCGTGC TGTCAC TGCC 468

ATCTCCCCC TGACCCCTCT AACCCATCCT CTGCCTCCCT CCCTGCAGTC AGAGGGTCCT 528

GTTCCCATCA GCGATTCCCC TGCTTAAACC CTTCCATGAC TCCCCACTGC CCTAAGCTGA 588 ^{2/6}

GGTCAGTCTC CCAAGCCTGG CATGTGGCCC TCTGGATCTG GGTTCCATCT CTGTCTCCAG 648

CCTGCCCACT TCCCTTCATG AATGTTGGGT TCTAGCTCCC TGTTCTCCAA ACCCATACTA 708

CACATCCAC TTCTGGGTCT TTGCCCTGGGA TGTTGCTGAC ACTCAGAAAG TCCCACCACC 768

TGCACATGTG TAGCCCCACC AGCCCTCCAA GGCATTGCTC GCCCAAGCAG CTGGTAATTC 828

CATTTCATGT ATTAGATGTC CCGTGGCCCT CTGTCCCCCTC TTAATAACCC TAGTCACAGT 888

CTCCGCAGAT TCTTGGGATT TGGGGTTTT CTCCCCCACC TCTCCACTAG TTGGACCAAG 948

FIG. 1A-2

<u>GTTTCTAGCT</u>	<u>AAGTTACTCT</u>	<u>AGTCTCCAAG</u>	<u>CCTCTAGCAT</u>	<u>AGAGCACTGC</u>	<u>AGACAGGCC</u>	1008
TGGCTCAGAA	TCAGAGCCCA	GAAAGTGGCT	GCAGACAAA	TCAATAAAC	TAATGTCCCT	1068
CCCCCTCTCC	TGCCAAAAGG	CAGTTACATA	TCAATACAGA	GACTCAAGGT	CACTAGAAAT	1128
GGGCCAGCTG	GGTCAATGTG	AAGCCCCAA	TTTGCCCAGA	TTACCTTTC	TTCCCCACT	1188
CCCTTTTTTT	TTTTTTTTTT	TTTGAGATGG	AGTTTCGCTC	TTGTCACCCA	CGCTGGAGTG	1248
CAATGGTGTG	GTCCTGGCTT	ATTGAAGCCT	CTGCCCTCCTG	GGTTCAAGTG	ATTCTCTTGC	1308
CTCAGCCTCC	TGAGTAGCTG	GGATTACAGG	TTCTTGCTAC	CACGCCCAGC	TAATTTTGT	1368
ATTTTtagTA	GAGACGAGGC	TTCACCATGT	TGGCCAGGCT	GGTCTCGAAC	TCCTGTCTCTC	1428
AGGTAATCCG	CCCACCTCAG	CCTCCCAAAG	TGCTGGGATT	ACAGGCGTGA	GCCACAGTGC	1488
CTGGCCTCTT	CCCTCTCCCC	ACTGCCCCCC	CCAACCTTTT	TTTTTTTTTT	ATGGCAGGGT	1548
CTCACTCTGT	CGCCCAGGCT	GGAGTGCAGT	GGCGTGATCT	CGGCTCACTA	CAACCTCGAC	1608
<u>CTCCTGGGTT</u>	<u>CAAGTGATTC</u>	<u>TCCCACCCCA</u>	<u>GCCTCCCAAG</u>	<u>TAGCTGGGAT</u>	<u>TACAGGTGTG</u>	1668

FIG. 1A-3

4/6

TGCCACTACG	GCTGGCTAAT	TTTTGTATTT	TTAGTAGAGA	CAGGTTTCAC	CATATTGGCC	1728
AGGCTGGTCT	TGAACTCCTG	ACCTCAAGTG	ATCCACCTTC	CTTGTGCTCC	CAAAGTGCTG	1788
AGATTACAGG	CGTGAGCTAT	CACACCCAGC	CTCCCCCCTTT	TTTTCCCTAAT	AGGAGACTCC	1848
TGTACCTTTC	TTCGTTTTAC	CTATGTGTCG	TGCTGCTTA	CATTTCCTTC	TCCCCCTCAGG	1908
CTTTTTTTGG	GTGGTCCTCC	AACCTCCAAT	ACCCAGGCCT	GGCCTCTTCA	GAGTACCCCC	1968
CATTCCACTT	TCCCTGCCTC	CTTCCTTAAA	TAGCTGACAA	TCAAATTCAT	GCTATGGTGT	2028
GAAAGACTAC	CTTTGACTTG	GTATTATAAG	CTGGAGTTAT	ATATGTATTT	GAAAACAGAG	2088
TAAATACTTA	AGAGGCCAAA	TAGATGAATG	GAAGAATTTT	AGGAACTGTG	AGAGGGGGAC	2148
AAGGTGAAGC	TTTCCTGGCC	CTGGGAGGAA	GCTGGCTGTG	GTAGCGTAGC	GCTCTCTCTC	2208
TCGTCTGTG	GCAGGAGCCA	AAGAGTAGGG	TGTAATTGAG	TGAAGGAATC	CTGGGTAGAG	2268
ACCATTCCTA	GGTGGTTGGG	CCAGGCTAAA	GACTGGGAGT	TGGGTCTATC	TATGCCCTTC	2328
TGGCTGATTT	TTGTAGAGAC	GGGGTTTTGC	CATGTTACCC	AGGCTGGTCT	CAAACTCCCTG	2388

FIG. 1A-4

GGCTCAAGCG ATCCTCCTGG CTCAGCCTCC CAAAGTGCTG GGATTACAGG CGTGAATCAC	2448
TGCGCCTGGC TTCCTCTTCC TCTTGAGAAA TATTCTTTTC ATACAGCAAG TATGGGACAG	2508
CAGTGTCCCA GGTAAGGAC ATAAATGTTA CAAGTGCTG GTCCTTTCTG AGGGAGGCTG	2568
GTGCCGCTCT GCAGGGTATT TGAACCTGTG GAATTGGAGG AGGCCATTTC ACTCCCTGAA	2628
CCCAGCCTGA CAAATCACAG TGAGAAATGTT CACCTTATAG GCTTGCTGTG GGGCTCAGGT	2688
TGAAAGTGTG GGGAGTGACA CTGCCTAGGC ATCCAGCTCA GTGTCATCCA GGGCCTGTGT	2748 ^{5/6}
CCCTCCCGAA CCCAGGGTCA ACCTGCCTGC CACAGGCACT AGAAGGACGA ATCTGCCTAC	2808
TGCCCATGAA CGGGGCCCTC AAGCGTCCTG GGATCTCCTT CTCCCTCCTG TCCTGTCCTT	2868
GCCCCTCAGG ACTGCTGGAA AATAAATCCT TTAAATAAGT AAAAAAAAAA AAAA	2923

FIG. 1A-5

FIG. 1A

FIG. 1A-1
FIG. 1A-2
FIG. 1A-3
FIG. 1A-4
FIG. 1A-5

[illegible]

FIG. 18

SEQUENCE LISTING

(1) GENERAL INFORMATION

- (i) APPLICANT: Gallo, Robert C.
DeVico, Anthony L.
Garzino, Alfredo
- (ii) TITLE OF THE INVENTION: METHOD AND COMPOSITION TO ENHANCE
THE EFFICACY OF A VACCINE USING MACROPHAGE DERIVED CHEMOKINE
- (iii) NUMBER OF SEQUENCES: 2
- (iv) CORRESPONDENCE ADDRESS:
(A) ADDRESSEE: Pennie & Edmonds LLP
(B) STREET: 1155 Avenue of the Americas
(C) CITY: New York
(D) STATE: New York
(E) COUNTRY: USA
(F) ZIP: 10036/2711
- (v) COMPUTER READABLE FORM:
(A) MEDIUM TYPE: Diskette
(B) COMPUTER: IBM Compatible
(C) OPERATING SYSTEM: DOS
(D) SOFTWARE: FastSEQ Version 2.0
- (vi) CURRENT APPLICATION DATA:
(A) APPLICATION NUMBER: To be assigned
(B) FILING DATE: Herewith
(C) CLASSIFICATION:
- (vii) ATTORNEY/AGENT INFORMATION:
(A) NAME: Misrock, S. Leslie
(B) REGISTRATION NUMBER: 18,872
(C) REFERENCE/DOCKET NUMBER: 8769-029
- (ix) TELECOMMUNICATION INFORMATION:
(A) TELEPHONE: 212-790-9090
(B) TELEFAX: 212-869-8864
(C) TELEX: 66141 PENNIE
- (2) INFORMATION FOR SEQ ID NO:1:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 2923 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA
(ix) FEATURE:
(A) NAME/KEY: mat_peptide
(B) LOCATION: 92..298

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

GAGACATACA GGACAGAGC ATG GCT CGC CTA CAG ACT GCA CTC CTG GTT GTC	52
Met Ala Arg Leu Gln Thr Ala Leu Val	
-24 -20 -15	
CTC GTC CTC CTT GCT GTG GCG CTT CAA GCA ACT GAG GCA GGC CCC TAC	100
Leu Val Leu Ala Val Ala Leu Gln Ala Thr Glu Ala Gly Pro Tyr	
-10 -5 1	
GGC GCC AAC ATG GAA GAC AGC GTC TGC CGT GAT TAC GTC CGT TAC	148
Gly Ala Asn Met Glu Asp Ser Val Cys Arg Asp Tyr Val Arg Tyr	
5 10 15	
CGT CTG CCC CTG CGC GTG AAA CAC TTC TAC TGG ACC TCA GAC TCC	196
Arg Leu Pro Leu Arg Val Lys His Phe Tyr Trp Thr Ser Asp Ser	
20 25 30 35	
TGC CCG AGG CCT GGC GTG TTG CTA ACC TTC AGG GAT AAG GAG ATC	244
Cys Pro Arg Pro Gly Val Leu Thr Phe Arg Asp Lys Glu Ile	
40 45 50	
TGT GCC GAT CCC AGA GTG CCC TGG GTG AAG ATG ATT CTC AAT AAG CTG	292
Cys Ala Asp Pro Arg Val Pro Trp Val Lys Met Ile Leu Asn Lys Leu	
55 60 65	
AGC CAA TGAAGAGCCT ACTCTGATGA CCGTGGCCTT GGCTCCTCCA GGAAGGCTCA	348
Ser Gln	

GGAGCCCTAC CTCCCTGCCA TTATAGCTGC TCCCCGCCAG AAGCCTGTGC CAACTCTCTG 408
 CATTCCCTGA TCTCCATCCC TGTTGGCTGTC ACCCTTGGTC ACCTCCGTGC TGTCACCTGCC 468
 ATCTCCCCC TGACCCCTCT AACCCATCCT CTGCCTCCCT CCCTGCAGTC AGAGGGTCCCT 528
 GTTCCCATCA GCGATTCCCC TGCTTAAACC CTTCCATGAC TCCCCACTGC CCTAAGCTGA 588
 GGTCACTCTC CCAAGCCTGG CATGTGGCCC TCTGGATCTG GGTTCATCT CTGTCTCCAG 648
 CCTGCCCACT TCCCTTCATG AATGTTGGGT TCTAGCTCCC TGTCTCCAA ACCCATACTA 708
 CACATCCCAC TTCTGGGTCT TTGGCTGGGA TGTGTCTGAC ACTCAGAAAG TCCCACCACC 768
 TGCACATGTG TAGCCCCACC AGCCCTCCAA GGCATTGCTC GCCCAAGCAG CTGGTAATTC 828
 CATTTCATGT ATTAGATGTC CCCTGGCCCT CTGTCCCTCT TTAATAACCC TAGTCACAGT 888
 CTCCGCCTCC TCTTGGGATP TGGGGGTTTT CTCCCCACC TCTCCACTAG TTGGACCAAG 948
 GTTCTAGCT AAGTTACTCT AGTCTCCAAG CCTCTAGCAT AGAGCACTGC AGACAGGCCC 1008
 TGGCTCAGAA TCAGAGCCCA GAAAGTGGCT GCAGACAAA TCAATAAAAC TAATGTCCCT 1068
 CCCCTCCTCC TGCCAAAAGG CAGTTACATA TCAATACAGA GACTCAAGGT CACTAGAAAT 1128
 GGGCCAGCTG GGTCAATGTG AAGCCCCAAA TTTGCCCAGA TTCACCTTTC TTCCCCCACT 1188
 CCCTTTTTTT TTTTTTTTTT TTTGAGATGG AGTTTCGCTC TTGTACCCA CGCTGGAGTG 1248
 CAATTGGTGT GTCTTGGCTT ATTGAAGCCT CTGCCTCTG GGTCAAGTG ATTCTCTTG 1308
 CTCAGCCTCC TGAGTAGCTG GGATTACAGG TTCCTGCTAC CACGCCACGC TAATTTTTGT 1368
 ATTTTATGTA GAGACGAGGC TTCACCATGT TGGCCAGGCT GGTCTCGAAC TCCTGTCTC 1428
 AGGTAATCCG CCCACCTCAG CCTCCCAAAG TGCTGGGATT ACAGGCGTGA GCCACAGTGC 1488
 CTGGCCTCTT CCCTCTCCCC ACTGCCCCC CCAACTTTTT TTTTTTTTTT ATGGCAGGGT 1548
 CTCACCTCTG CGCCCAAGCT GGAGTGCAGT GGCCTGATCT CGGCTCACTA CAACCTCGAC 1608
 CTCTTGGGTT CAAGTGATTC TCCCACCCCA GCCTCCCAAG TAGCTGGGAT TACAGGTGTG 1668
 TGCCACTACG GCTGGCTAAT TTTTGTATTT TTAGTAGAGA CAGGTTTCAC CATATTGGCC 1728
 AGGCTGGTCT TGAACCTCTG ACCTCAAGTG ATCCACCTTC CTGTGTCTCC CAAAGTGCTG 1788
 AGATTACAGG CGTGAGCTAT CACACCCAGC CTCCCCCTTT TTTTCTTAAT AGGAGACTCC 1848
 TGTACCTTTC TTCGTTTTAC CTATGTGTCG TGTCTGCTTA CATTTCCTTC TCCCCCAGG 1908
 CTTTTTTTGG GTGGTCTCTC AACCTCCAAT ACCCAGGCTT GGCCTCTTCA GAGTACCCCC 1968
 CATTCCACTT TCCCTGCCTC CTTCCTTAAA TAGCTGACAA TCAAAATTCAT GCTATGGTGT 2028
 GAAAGACTAC CTTTGACTTG GTATTATAAG CTGGAGTTAT ATATGTATTT GAAAACAGAG 2088
 TAAATACTTA AGAGGCCAAA TAGATGAATG GAAGAAATTT AGGAACCTGT AGAGGGGGAC 2148
 AAGGTGAAGC TTTCTGGGCC CTGGGAGGAA GCTGGCTGTG GTAGCGTAGC GCTCTCTCTC 2208
 TCTGTCTGTG GCAGGAGCCA AAGAGTAGGG TGTAATTGAG TGAAGGAATC CTGGGTAGAG 2268
 ACCATTCTCA GGTGGTTGGG CCAGGCTAAA GACTGGGAGT TGGGTCTATC TATGCCTTTC 2328
 TGGCTGATTT TTGTAGAGAG GGGGTTTTGC CATGTTACCC AGGCTGGTCT CAACTCCTG 2388
 GGCTCAAGCG ATCCTCCTGG CTCAGCCTCC CAAAGTGCTG GGATTACAG CGTGAATCAC 2448
 TGCCTCTGGC TTCTCTTCTC TCTTGAGAAA TATTCCTTTC ATACAGCAAG TATGGGACAG 2508
 CAGTGTCCCA GGTAAAGGAC ATAAATGTTA CAAGTGTCTG GTCCTTCTG AGGGAGGCTG 2568
 GTGCCGCTCT CTAGGCTATT TGAACCTGTG GAATTGGAGG AGGCCATTTC ACTCCCTGAA 2628
 CCCAGCCTGA CAAATCACAG TGAGAATGTT CACCTTATAG GCTTGTGTG GGGCTCAGGT 2688
 TGAAAGTGTG GGGAGTGACA CTGCCTAGGC ATCCAGCTCA GTGTACATCA GGGCTGTGT 2748
 CCCTCCCGAA CCCAGGGTCA ACCTGCCTGC CACAGGCACT AGAAGGACGA ATCTGCCTAC 2808
 TGCCCATGAA CGGGGCCCTC AAGCGTCTCT GGATCTCCTT CTCCCTCTG TCCTGTCTT 2868
 GCCCTCAGG ACTGCTGGA AATAAATCCT TTAATAAGT AAAAAAAAAA AAAAA 2923

(2) INFORMATION FOR SEQ ID NO:2:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 93 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

Met Ala Arg Leu Gln Thr Ala Leu Val Leu Val Leu Ala
 -24 -20 -15 -10
 Val Ala Leu Gln Ala Thr Glu Ala Gly Pro Tyr Gly Ala Asn Met Glu
 -5 1 5
 Asp Ser Val Cys Arg Asp Tyr Val Arg Tyr Arg Leu Pro Leu Arg
 10 15 20
 Val Lys His Phe Tyr Trp Thr Ser Asp Ser Cys Pro Arg Pro Gly
 25 30 35 40
 Val Leu Thr Phe Arg Asp Lys Glu Ile Cys Ala Asp Pro Arg
 45 50 55
 Val Pro Trp Val Lys Met Ile Leu Asn Lys Leu Ser Gln
 60 65

C-CHEMOKINES

LYMPHOTACTIN

(SCM-1)

D63789 D63790

CX3C-chemokines

Fractalkine/neurotactin

U91835 U84487

LOCUS HSU83171 2923 bp mRNA PRI 31-MAY-1997
 DEFINITION Human macrophage-derived chemokine precursor (MDC) mRNA,
 complete
 ACCESSION U83171
 NID g1931580
 KEYWORDS
 SOURCE human.
 ORGANISM Homo sapiens
 Eukaryotae; mitochondrial eukaryotes; Metazoa; Chordata;
 Vertebrata; Mammalia; Eutheria; Primates; Catarrhini;
 Hominidae; Homo.
 REFERENCE 1 (bases 1 to 2923)
 AUTHORS Godiska, R., Chantry, D., Raport, C.J., Sozzani, S., Allavena, P.,
 Leviten, D., Mantovani, A. and Gray, P.W.
 TITLE Human macrophage-derived chemokine (MDC), a novel
 chemoattractant for monocytes, monocyte-derived dendritic cells, and natural
 killer cells
 JOURNAL J. Exp. Med. 185 (9), 1595-1604 (1997)
 MEDLINE 97296313
 REFERENCE 2 (bases 1 to 2923)
 AUTHORS Godiska, R. and Gray, P.W.
 TITLE Direct Submission
 JOURNAL Submitted (23-DEC-1996) ICOS Corporation, 22021 20th Avenue SE,
 Bothell, WA 98021, USA
 FEATURES
 source Location/Qualifiers
 1..2923
 /organism="Homo sapiens"
 /db_xref="taxon:9606"
 /chromosome="16"
 gene 20..301
 /gene="MDC"
 sig_peptide 20..91
 /gene="MDC"
 CDS 20..301
 /gene="MDC"
 /function="chemotactic for dendritic cells and natural
 killer cells"
 /codon_start=1
 /product="macrophage-derived chemokine precursor"
 /db_xref="PID:g1931581"
 /translation="MARLQTALLVVLVLLAVALQATEAGPYGANMEDSVCCRDYVRYR
 LPLRVVVKHFYWTSDSCPRPGVLLTFRDKEICADPRVPWVKMILNKLSQL"
 mat_peptide 92..298
 /gene="MDC"
 /product="macrophage-derived chemokine"
 repeat_region complement(1194..1805)
 /rpt_family="ALU"
 repeat_region complement(2335..2443)
 /rpt_family="ALU"
 BASE COUNT 605 a 861 c 669 g 788 t
 ORIGIN
 1 gagacatata ggacagagca tggtctgcct acagactgca ctctctggtg tctctgtcct
 61 ccttgctgtg gcgcttcaag caactgagc aggccctac ggcgccaaca tggagacag
 121 cgtctgtctg cgtgattacg tccgttaccg tctgcccctg cgcgtggtga aacacttcta
 181 ctggacctca gactcctgcc cgaggcctgg cgtggtggtg ctaaccttca gggataagga
 241 gatctgtgcc gatcccagag tgccctgggt gaagatgatt ctcaataagc tgagccaatg
 301 aagagcctac tctgatgacc gtggccttgg ctctccagg aaggctcagg agccctacct
 361 ccttgccatt atagctgctc cccgccagaa gctgtgcca actctctgca ttccctgac
 421 tccatccctg tggctgtcac ccttggtcac ctccgtgctg tcaactgcat ctccccctg
 481 accctctaa cccatcctct gcctccctcc ctgcagtcag agggctcctg tcccatcagc
 541 gattccctct cttaaacctt tccatgactc cccactgccc taagctgagg tcagctctccc
 601 aagcctggca tgtggccctc tggatctggg ttccatctct gtctccagcc tgcccacttc
 661 ccttcattga tgttgggttc tagctccctg ttctccaaac ccatactaca catcccactt
 721 ctgggtcttt gcctgggatg ttgctgacac tcagaaaagc ccaccacctg cacatgtgta
 781 gccccaccag cctccaagg cattgctcgc ccaagcagct ggtaattcca ttcatgtat
 841 tagatgtccc ctggccctct gtccctcttt aataacccta gtcacagtct ccgcagattc

```

901 ttgggatttg ggggttttct cccccacctc tccactagtt ggaccaaggt ttctagctaa
961 gttactctag tctccaagcc tctagcatag agcactgcag acaggccctg gctcagaatc
1021 agagcccaga aagtggctgc agacaaaatc aataaaaacta atgtccctcc cctctccctg
1081 ccaaaaggca gttacatata aatacagaga ctcaagggtca ctgaaatgg gccagctggg
1141 tcaatgtgaa gccccaaatt tgcccagatt cacttttctt cccccactcc cttttttttt
1201 tttttttttt tgagatggag ttctgctctt gtcacccacg ctggagtgcg atgggtgtgtg
1261 cttggcttat tgaagcctct gcttcttggg ttcaagtgat tctcttgctt cagcctcctg
1321 agtagctggg attacaggtt cctgctacca cgtccagcta atttttgtat ttttagtaga
1381 gacgaggctt caccatgttg gccaggctgg tctcgaactc ctgtctcag gtaatccgcc
1441 cacctcagcc tcccaaagtg ctgggattac aggcgtgagc cacagtgcct ggcctcttcc
1501 ctctcccccac tgcccccccc aacttttttt ttttttttat ggcagggtct cactctgtcg
1561 cccaggctgg agtgcagtgg cgtgatctcg gctcactaca acctcgacct cctgggttca
1621 agtgattctc ccaccccagc ctcccaagta gctgggatta caggtgtgtg ccactacggc
1681 tggctaattt ttgtattttt agtagagaca ggtttcacca tattggccag gctgtgtctg
1741 aactcctgac ctcaagtgat ccaccttctt tgtgtctcca aagtgtgtg attacaggcg
1801 ttgagctatca caccacgctt cccctttttt ttcttaatag gagactcctg tacctttctt
1861 cgttttacct atgtgtcgtg tctgtctaca ttctcttctc cctcagggtt ttttttgggt
1921 ggtctctcaa cctccaatac ccaggcctgg cctcttcaga gtacccccca ttccactttc
1981 cctgctcctt tctttaataa gctgacaatc aaattcatgc tatggtgtga aagactacct
2041 ttgacttggg attataagct ggagttatat atgtatttga aaacagagta aatacttaag
2101 aggccaaaata gatgaatgga agaatttttag gaactgtgag agggggacaa ggtgaagctt
2161 tcctggccct gggagggaagc tggctgtgtg agcgtagcgc tctctctctc tgtctgtggc
2221 agggagccaaa gagtaggggtg taattgagtg aaggaatcct gggtagagac cattctcagg
2281 tggttggggcc aggtctaaaga ctgggagttg ggtctatcta tgcctttctg gctgattttt
2341 gtagagacgg ggttttgcca tgttaccag gctgggtctc aactcctggg ctcaagcgat
2401 cctcctgggt cagcctccca aagtgtgtgg attacaggcg tgaatcactg cgcttggtt
2461 cctcttctctc ttgagaaata ttcttttcat acagcaagta tgggacagca gtgtcccagg
2521 taaaggacat aaatgttaca agtgtctggt cctttctgag ggaggctggg gccgtctctg
2581 aggggtatttg aacctgtgga attggaggag gccatttcac tccctgaacc cagcctgaca
2641 aatcacagtg agaattgttca ccttataggc ttgctgtggg gctcaggttg aaagtgtggg
2701 gagtgcact gcctaggcat ccagctcagt gtcattccagg gctgtgttcc ctcccgaacc
2761 caggggtcaac ctgcttgcca caggcactag aaggacgaat ctgcctactg cccatgaacg
2821 gggccctcaa gcgtcctggg atctccttct cctcctctgc ctgtccttgc ccctcaggac
2881 tgctggaaaa taaatccttt aaaatagtaa aaaaaaaaaa aaa

//
LOCUS HSU83239 932 bp mRNA PRI 02-MAY-1997
DEFINITION Human CC chemokine STCP-1 mRNA, complete cds.
ACCESSION U83239
NID g2062424
KEYWORDS
SOURCE human.
ORGANISM Homo sapiens
Eukaryotae; mitochondrial eukaryotes; Metazoa; Chordata;
Vertebrata; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1 (bases 1 to 932)
AUTHORS Chang,M.S., McNinch,J., Elias III,C., Manthey,C.L.,
Grosshans,D., Meng,T., Boone,T. and Andrew,D.P.
TITLE Molecular cloning and functional characterization of a novel CC
chemokine STCP-1 which specifically acts on activated T
lymphocytes
JOURNAL Unpublished
REFERENCE 2 (bases 1 to 932)
AUTHORS Chang,M.S., McNinch,J., Elias III,C., Manthey,C.L.,
Grosshans,D., Meng,T., Boone,T. and Andrew,D.P.
TITLE Direct Submission
JOURNAL Submitted (26-DEC-1996) Research Computing, Amgen Institute,
620 University Ave, Suite 706, Toronto, ON M5G 2C1, Canada
FEATURES
Location/Qualifiers
source 1..932
/organism="Homo sapiens"
/note="Amgen EST program"
/db_xref="taxon:9606"
CDS 15..296
/codon_start=1
/product="CC chemokine STCP-1"
/db_xref="PID:g2062425"
/translation="MARLQTALLVVLVLLAVALQATEAGPYGANMEDSVCCRDYVRYR

```



```

                                LPLRVVKHFYWTSDSCPRGVLLTFRDKEICADPRVPWVKMILNKLSQL
BASE COUNT      166 a      330 c      201 g      235 t
ORIGIN
    1 atacaggaca gagcatggct cgcctacaga ctgcactcct gggtgtcctc gtcctccttg
   61 ctgtggcgct tcaagcaact gaggcaggcc cctacggcgc caacatggaa gacagcgtct
  121 gctgccgtga ttacgtccgt taccgtctgc cctgcgcggt ggtgaaacac ttctactgga
  181 cctcagactc ctgcccaggg cctggcgctg tggtgctaac cttcagggat aaggagattc
  241 gtgccgatcc cagagtgcgc tgggtgaaga tgattctcaa taagctgagc caatgaagag
  301 cctactctga tgaccgtggc cttggctcct ccaggaaggc tcaggagccc tacctccttg
  361 ccattatagc tgctccccgc cagaagcctg tgccaactct ctgcattccc tgatctccat
  421 cctgtgggct gtcacccttg gtcacctccg tgctgtcact gccatctccc ccctgacccc
  481 tctaaccat cctctgcctc cctccctgca gtcagagggt cctgttccca tcagcgattc
  541 ccctgcttaa acccttccat gactccccac tgccttaagc tgaggtcagt ctcccaagcc
  601 tggcatgtgg cctctggat ctgggttcca tctctgtctc cagcctgccc acttcccttc
  661 atgaatgttg ggttctagct cctgttctc caaaccata ctacacatcc cacttctggg
  721 tctttgcttg gtagttgct gacactcaga aagtcaccac acctgcacat gtgtagcccc
  781 accagccctc caaggcattg ctgcccgaag cagctggtaa ttccatttca tgtattagat
  841 gtcccttgge cctctgtccc ctcttaataa cctagtcac agtctccgca gattcttggg
 901 atttgggggt tttctcccc acctctccac ta

//
LOCUS      HSMCP1      725 bp      RNA      PRI      03-APR-1995
DEFINITION H. sapiens mRNA for monocyte chemoattractant protein 1 (MCP-1).
ACCESSION  X14768
NID        g34513
KEYWORDS   monocyte chemoattractant protein 1.
SOURCE     human.
ORGANISM   Homo sapiens
            Eukaryotae; mitochondrial eukaryotes; Metazoa; Chordata;
            Vertebrata; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE  1 (bases 1 to 725)
AUTHORS    Yoshimura,T., Yuhki,N., Moore,S.K., Appella,E., Lerman,M.I. and
            Leonard,E.J.
TITLE      Human monocyte chemoattractant protein-1 (MCP-1). Full-length
cDNA
            cloning, expression in mitogen-stimulated blood mononuclear
            leukocytes, and sequence similarity to mouse competence gene JE
JOURNAL    FEBS Lett. 244 (2), 487-493 (1989)
MEDLINE    89153605
COMMENT    ZAPII.
FEATURES   Location/Qualifiers
            source          1..725
                        /organism="Homo sapiens"
                        /db_xref="taxon:9606"
                        /cell_type="glioma cells"
                        /cell_line="U105MG"
                        /clone_lib="lambda"
            sig_peptide     54..122
                        /note="signal peptide (AA -23 to -1)"
            CDS              54..353
                        /codon_start=1
                        /product="monocyte chemoattractant preprotein"
                        /db_xref="PID:g34514"
                        /db_xref="SWISS-PROT:P13500"
            /translation="MKVSAALLCLLLIAATFIPQGLAQPDAINAPVTCCYNFTNRKIS
VQRLASYRRITSSKCPKEAVIFKTIVAKEICADPKQKWVQDSMDHLQKQTQTPKT"
            mat_peptide      123..350
                        /note="MCP-1 (AA 1 - 76)"
            misc_feature      162..170
                        /note="pot. N-linked glycosylation site"
            misc_feature      707..712
                        /note="pot. polyA signal"
            polyA_site        725
                        /note="polyA site"
BASE COUNT      208 a      171 c      126 g      220 t
ORIGIN
    1 ctaaccacaga aacatccaat tctcaaaactg aagctcgcac tctcgcctcc agcatgaaag
   61 tctctgccgc ccttctgtgc ctgctgctca tagcagccac ctctattccc caagggctcg
  121 ctccagccaga tgcaatcaat gccccagtc cctgctgtta taacttcacc aataggaaga
  181 tctcagtgca gaggtcgcg agctatagaa gaatcaccag cagcaagtgt cccaaagaag

```

```

241 ctgtgatctt caagaccatt gtggccaagg agatctgtgc tgacccaag cagaagtggg
301 ttcaggattc catggaccac ctggacaagc aaacccaac tccgaagact tgaacactca
361 ctccacaacc caagaatctg cagctaactt atttcccct agctttcccc agacaccctg
421 ttttatttta ttataatgaa ttttgtttgt tgatgtgaaa cattatgcct taagtaatgt
481 taattcttat ttaagttatt gatgttttaa gtttatcttt catggtacta gtgttttta
541 gatacagaga cttggggaaa ttgcttttcc tcttgaacca cagttctacc cctgggatgt
601 tttgagggtc tttgcaagaa tcattaatac aaagaatttt ttttaacatt ccaatgcatt
661 gctaaaatat tattgtggaa atgaatattt tgtaactatt acaccaaata aatatatttt
721 tgtac

```

```

//
LOCUS      HSMCP2      2991 bp      DNA      PRI      20-MAR-1997
DEFINITION H.sapiens MCP-2 gene.
ACCESSION  X99886
NID        g1905800
KEYWORDS   MCP-2 gene; monocyte chemotactic protein 2; SCYA10 gene.
SOURCE     human.
  ORGANISM Homo sapiens
            Eukaryotae; mitochondrial eukaryotes; Metazoa; Chordata;
            Vertebrata; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE  1 (bases 1 to 2991)
AUTHORS    Van Coillie,E., Fiten,P., Nomiya,H., Sakaki,Y., Miura,R.,
            Yoshie,O., Van Damme,J. and Opdenakker,G.
TITLE      The human MCP-2 gene (SCYA8): cloning, sequence analysis,
tissue     expression, and assignment to the CC chemokine gene contig on
            chromosome 17q11.2
JOURNAL     Genomics 40 (2), 323-331 (1997)
MEDLINE     97237052
REFERENCE   2 (bases 1 to 2991)
AUTHORS     Opdenakker,G.M.M.
TITLE       Direct Submission
JOURNAL     Submitted (07-AUG-1996) G.M.M. Opdenakker, Rega Institute for
            Medical Research, Minderbroedersstraat 10, B 3000 Leuven.

BELGIUM
FEATURES   Location/Qualifiers
            source      1..2991
                        /organism="Homo sapiens"
                        /db_xref="taxon:9606"
                        /chromosome="17"
                        /map="q11.2"
            repeat_region 209..219
                        /note="DR-A"
                        /rpt_type=DIRECT
            repeat_region 240..248
                        /note="DR-B"
                        /rpt_type=DIRECT
            CAAT_signal   296..300
            repeat_region 310..318
                        /note="IR-A"
                        /rpt_type=INVERTED
            repeat_region 406..415
                        /note="DR-B"
                        /rpt_type=DIRECT
            repeat_region 407..416
                        /note="IR-B"
                        /rpt_type=INVERTED
            repeat_region 425..435
                        /note="DR-A"
                        /rpt_type=DIRECT
            repeat_region 429..437
                        /note="IR-B"
                        /rpt_type=INVERTED
            repeat_region 455..465
                        /note="IR-C"
                        /rpt_type=INVERTED
            TATA_signal   467..472
            repeat_region 492..502
                        /note="IR-C"
                        /rpt_type=INVERTED
            repeat_region 492..500
                        /note="IR-A"

```

```

/rpt_type=INVERTED
exon      534..639
          /gene="MCP-2 (SCYA10)"
          /number=1
gene      534..1969
          /gene="MCP-2 (SCYA10)"
CDS       join(534..639,1331..1448,1864..1969)
          /gene="MCP-2 (SCYA10)"
          /codon_start=1
          /product="monocyte chemotactic protein-2"
          /db_xref="PID:e279930"
          /db_xref="PID:g1905801"

/translation="MLKLTPLPSKMKVSAALLCLLLMAATFSPQGLAQPDVSIPITC
CFNVINRKIPIQRLESYTRITNIQCPKEAVIFKTRQGEKVCADPKERWVRDSMKHLDO
IFQNLKP"
intron    640..1330
          /gene="MCP-2 (SCYA10)"
          /number=1
exon      1331..1448
          /gene="MCP-2 (SCYA10)"
          /number=2
intron    1449..1863
          /gene="MCP-2 (SCYA10)"
          /number=2
exon      1864..1969
          /gene="MCP-2 (SCYA10)"
          /number=3
BASE COUNT      799 a      709 c      632 g      851 t
ORIGIN
1  agattctggg gcattaagac ttagttccag gattctgtca ttctgccaac gttctgtggc
61  tggggttcta aaggagcttg cctggcttag aactgcaagt gactctagtg tgatggagag
121  caccagcaaa gccttagggc ccatccctgg cctcctgtta cccacagagg ggtaagcctt
181  ggctctcttc cactatgacg tcagcttcca ttcttctctt cttatagaca attttccatt
241  tcaaggaaat cagagccctt aatagttcag tgaggctact ttgctgagca caatcccata
301  ccttccagcc tctgctccac agagcctaag caaaagatag aaactcaciaa cttccttgtt
361  ttgttatctg gaaattatcc caggatctgg tgcttactca gcatattcaa ggaaggctctt
421  acttcattct tccttgattg tgaccatgcc caggctctct gctccctata aaaggcaggc
481  agagccaccg aggagcagag aggttgagaa caaccagaa accttcacct cctatgctga
541  agctcacacc cttgccctcc aagatgaagg ttctgcagc gcttctgtgc ctgctgtcga
601  tggcagccac ttccagccct cagggacttg ctccagccagg taagacctct ccttttttaa
661  ggggagacca aaagaggaat taagaagagc cattatgtca cagctcatta ggaacaaaaa
721  cagaactaaa ggctcaggtc actgaggctg gttcccttga tctttcttga cccagctttt
781  gggaggagac agtggagccg ctacagcaac aaccctccca ttgtttgggg aaataatcca
841  gaacgaagaa ctgtttctca ctgtgggtgt aaaggacatt tcaggccgta gtggagaggg
901  agaaactatt gcctgaagct tcaaattttg gttatgttcc agtgtacctt ccagaacagt
961  ggctgtgtaa agaggatgag gacccagagg aatctcagcg tatggcatag gctaactcta
1021  aagcccatga ggaatgaaag ctgggaagca aggtattgga acttatgttc ccagtgtcag
1081  aagttttggg ttagtagaca aggaactagt tgttactcaa aatgtttcca aaccagtgca
1141  acaatgacgg gccgcagagt tcaatagagg aaagagactc acaggcaaca ttttatctct
1201  gggatctgga ctaagacact gaacttggga tgggtacttc ttgggtcttct ccttcttctt
1261  cttcttttcc ttacaaatgc acacttacgg tgggtcctaa atgtctcatt ctttgcaaaa
1321  tttctttcag attcagtttc cattccaate acctgctgct ttaacgtgat caataggaaa
1381  attcctatcc agaggctgga gagctacaca agaataccca acatccaatg tcccaaggaa
1441  gctgtgatgt gagtggacag tgctggcac cccattcaa aagttctgat ggacaacata
1501  gagaagtcaa gattcatgtc catatgagtc ggatgcataa aacttctate caaaggggccc
1561  ctctacccca tagagaaact cagtccgtga gaaggagtcc ataactgtct taggattccc
1621  ttctaggggc ttggtgaaac taaccaata tctgtagcca ggacctgga gggtttcacc
1681  tggacagcaa gagcagagct tccttctgga gcttcttctt cccactcttc ccttccctcc
1741  tctcccggtt cgggttcctt cacttaagga ccaagggtct atcagtccta gggaccaatg
1801  gccacagtc ctgtgcagga tcttcaaagt cttccatcta attgtgcccc ctctccccc
1861  cagcttcaag acccaacggg gcaaggaggt ctgtgctgac cccaaggaga gatgggtcag
1921  ggattccatg aagcatctgg accaaatatt tcaaaatctg aagccatgag ccttcataca
1981  tggactgaga gtcagagctt gaagaaaagc ttatttattt tccccacctt cccccagggt
2041  cagtgtgaca ttattttatt ataacatcca caaagagatt atttttaaac aatttaaaagc
2101  ataatttttc ttaaaaagta ttaattata ttaagttgt tgatgtttta actctatctg
2161  tcatacatcc tagtgaatgt aaaatgcaaa atcctgggtga tgtgtttttt gtttttgttt
2221  tctgtgagc tcaactaagt tcacggcaaa atgtcattgt tctccctctc acctgtctgt
2281  agtgttgttg ggtcctccca tggatcatca aggtgaaaca ctttgttatt ctttggcaat
2341  cagtgtctct gtaagtcaaa tgtgtgcttt gtactgctgt tgttgaaatt gatgttactg

```

```

2401 tatataacta tgggaattttg aaaaaaaatt tcaaaaagaa aaaaatatat ataatttaac
2461 actacttagt cttattcttc ttggggtaac atttagctgg gagtgagttt tgggcatcat
2521 ggggtgacagt ttgggcatgg acggggccatt tttaagaat gtcttctggc tacgctggac
2581 tcaaccaagg ttctcagaga acttgggtgg accaggccag gatgttccag ctctctgact
2641 ctagtcccta acttcagcag ccctgattcg cttagcctctc ttgtttctct tgtttatata
2701 ttatccagcc taagggtattt tggttatagct gcccaaaaag actaagataa tctccatcac
2761 tctaccccca accccaatcc caagaacttg caagcatcca tttaaaggcg tgggaacctct
2821 tctttttgac agccttttaa ggtcaagatt cccctgtact tagtgagctt agctgaatct
2881 tcttacaac atgtgacctg ccatattgag ccatacatc cgagcttatt atttttccag
2941 cttattggga aaacacgtct aaggcaaaaca aatttattgt actgttgaac c
//LOCUS      HSY16645      1368 bp      mRNA      PRI      25-SEP-1998
DEFINITION   Homo sapiens mRNA for monocyte chemotactic protein-2.
ACCESSION    Y16645
NID          g2916795
KEYWORDS     MCP-2 gene; monocyte chemotactic protein 2.
SOURCE       human.
ORGANISM     Homo sapiens
              Eukaryota; Metazoa; Chordata; Vertebrata; Mammalia; Eutheria;
              Primates; Catarrhini; Hominidae; Homo.
REFERENCE    1 (bases 1 to 1368)
AUTHORS      Van Coillie, E.
TITLE        Functional comparison of two human monocyte chemotactic
protein-2
              isoforms, role of the amino-terminal pyroglutamic acid and
              processing by CD26/dipeptidyl peptidase IV
JOURNAL      Biochemistry 37, 12672-12680 (1998)
REFERENCE    2 (bases 1 to 1368)
AUTHORS      Van Coillie, E.
TITLE        Direct Submission
JOURNAL      Submitted (23-FEB-1998) E. Van Coillie, Rega Institute for
Medical
              Research, Minderbroedersstraat 10, 3000 Leuven, BELGIUM
COMMENT      Related sequences: X99886, Y10802.
FEATURES
  source      Location/Qualifiers
              1..1368
              /organism="Homo sapiens"
              /db_xref="taxon:9606"
              /chromosome="17"
              /tissue_type="testis"
              /clone_lib="Clontech"
              /clone="HL1142q"
              /map="ql1.2"
  gene        473..772
              /gene="MCP-2"
  sig_peptide 473..541
              /gene="MCP-2"
  CDS         473..772
              /gene="MCP-2"
              /codon_start=1
              /product="monocyte chemotactic protein-2"
              /db_xref="PID:e1253690"
              /db_xref="PID:g2916796"
/translation="MKVSAALLCLLLMAATFSPQGLAQPDVSVIPITCCFNVINRKIP
IQRLSYTRITNIQCPKEAVIFKTKRGKEVCADPKERWVRDSMKHLDQIFQNLKP"
mat_peptide  542..769
              /gene="MCP-2"
variation     677
              /gene="MCP-2"
              /note="polymorphism, Lys -> Gln"
              /replace="c"
BASE COUNT   457 a      292 c      243 g      376 t
ORIGIN
1 atccattgtg ctctaaagtg atggagagca ccagcaaagc cttagggccc atccctggcc
61 tcctgttacc cacagagggg taggcccttg gctctcttc actatgacgt cagcttccat
121 tcttccttcc ttatagacaa ttttccattt caaggaaatc agagccctta atagtccagt
181 gaggtcactt tgctgagcac aatcccatac ccttcagcct ctgctccaca gaggcctaagc
241 aaaagataga aactcacaac ttccttggtt tgttatctgg aaattatccc aggatctggg
301 gcttactcag catattcaag gaaggtctta cttcattctt ccttgattgt gaccatgccc
361 aggcctctct ctccctataa aaggcaggca gagccaccga ggagcagaga ggttgagaac

```

```

421 aaccagaaa ccttcacctc tcattgtgaa gctcacaccc ttgccctcca agatgaaggt
481 ttctgcagcg cttctgtgccc tgctgctcat ggcagccact ttcagccctc agggacttgc
541 tcagccagat tcagtttcca ttccaatcac ctgctgcttt aacgtgatca ataggaaaaat
601 tcctatccag aggtctggaga gctacacaag aatcaccaac atccaatgtc ccaaggaagc
661 tgtgatcttc aagaccaaac ggggcaagga ggtctgtgct gaccccaagg agagatgggt
721 cagggattcc atgaagcatc tggacaaaat atttcaaaat ctgaagccat gagccttcat
781 acatggactg agagtcagag cttgaagaaa agcttattta ttttcccca cctccccag
841 gtgcagtgtg acattatttt attataacat ccacaaagag attattttta aataatttaa
901 agcataatat ttcttaaaaa gtattttaatt atatttaagt tgttgatgtt ttaactctat
961 ctgtcataca tcctagttaa tgtaaaatgc aaaatcctgg tgatgtgttt tttgtttttg
1021 ttttctgtg agctcaacta agttcacggc aaaatgtcat tgttctcct cctacctgtc
1081 tgtagtgttg tggggtcttc ccatggatca tcaaggtgaa acactttggg attctttggc
1141 aatcagtgtc cctgtaagtc aaatgtgtgc tttgtactgc tgttggtgaa attgatgtta
1201 ctgtatataa ctatggaaatt ttgaaaaaaa atttcaaaaa gaaaaaaaat tatataattt
1261 aaaactaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa
1321 aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa
//LOCUS      HSMCP3A      1085 bp      DNA      PRI      25-JUL-1994
DEFINITION   H.sapiens MCP-3 mRNA for monocyte chemotactic protein-3.
ACCESSION    X72308 S57464
NID          g313707
KEYWORDS     monocyte chemotactic protein 3.
SOURCE       human.
ORGANISM     Homo sapiens
              Eukaryotae; mitochondrial eukaryotes; Metazoa; Chordata;
              Vertebrata; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE    1 (bases 1 to 1085)
AUTHORS      Opdenakker,G., Froyen,G., Fiten,P., Proost,P. and Van Damme,J.
TITLE        Human monocyte chemotactic protein-3 (MCP-3): molecular cloning
of           the cDNA and comparison with other chemokines
              Biochem. Biophys. Res. Commun. 191 (2), 535-542 (1993)
JOURNAL      93213290
MEDLINE
REFERENCE    2 (bases 1 to 1085)
AUTHORS      Opdenakker,G.M.
TITLE        Direct Submission
JOURNAL      Submitted (27-MAY-1993) G.M. Opdenakker, Rega Institute,
University   of Leuven, Minderbroedersstraat 10, B-3000 Leuven, BELGIUM
REFERENCE    3 (bases 1 to 1085)
AUTHORS      Opdenakker,G., Fiten,P., Nys,G., Froyen,G., Van Roy,N.,
              Speleman,F., Laureys,G. and Van Damme,J.
TITLE        The human MCP-3 gene (SCYA7): cloning, sequence analysis, and
              assignment to the C-C chemokine gene cluster on chromosome
              17q11.2-q12
JOURNAL      Genomics 21 (2), 403-408 (1994)
MEDLINE      94375065
FEATURES
  source      Location/Qualifiers
              1..1085
              /organism="Homo sapiens"
              /db_xref="taxon:9606"
  gene        299..810
              /gene="MCP-3"
  CDS         299..628
              /gene="MCP-3"
              /codon_start=1
              /product="monocyte chemotactic protein-3"
              /db_xref="PID:g313708"
              /db_xref="SWISS-PROT:P80098"
/translation="MWKPMPSPSNMKASALLCLLLTAAAFSPQGLAQPVGINTSTTC
CYRFINKKIPKQRLESYRRTTSSHCPREAVIFKTKLDKEICADPTQKWQDFMKHLDK
  sig_peptide 299..397
              /gene="MCP-3"
  mat_peptide 398..625
              /gene="MCP-3"
              /product="monocyte chemotactic protein-3"
  polyA_signal 806..810
              /gene="MCP-3"
BASE COUNT   314 a      214 c      229 g      328 t

```

ORIGIN

```

1  gggtttctatt gacttggggtt aatcgtgtga ccgcggtggc tggcacgaaa ttgaccaacc
61  ctgggggttag tatagcttag ttaaactttc gtttattgct aaagggttaat cactgctgtt
121 tcccgtgggg gtgtggcttag gctaagcgtt ttgagctgca ttgctgctgt cttgatgctt
181 gtcccttttg atcgtgggtga tttagagggt gaactcactg gaatggggat gcttgcatgt
241 gtaatcttac taagagctaa tagaaaggct aggaccaaac cagaaacctc caattctcat
301 gtggaagccc atgccctcac cctccaacat gaaagcctct gcagcacttc tgtgtctgct
361 gctcacagca gctgctttca gccccaggg gcttgctcag ccagttggga ttaatacttc
421 aactacctgc tgctacagat ttatcaataa gaaaatccct aagcagaggc tggagagcta
481 cagaaggacc accagtagcc actgtccccc ggaagctgta atcttcaaga ccaaaactgga
541 caaggagatc tgtgctgacc ccacacagaa gtgggtccag gactttatga agcacctgga
601 caagaaaacc caaactccaa agctttgaac attcatgact gaactgaaaa caagccatga
661 cttgagaaaac aaataatttg tataccctgt cctttctcag agtgggtctg agattatttt
721 aatctaattc taaggaatat gagctttatg taataatgtg aatcatggtt tttcttagta
781 gatttttaaaa gttattaata ttttaattta atcttccatg gattttgggt gggtttgaac
841 ataaagcctt ggatgtatat gtcatctcag tgcgtgaaaa actgtgggat gctcctcctt
901 tctctacctc atgggggtat tgtataagtc cttgcaagaa tcagtgcaaa gatttgcctt
961 aattgtttaag atatgatgtc cctatgggag catattgtta ttatataatt acatatttgc
1021 atatgtatga ctcccaaatt ttcacataaa atagattttt gtataacaaa aaaaaaaaaa
1081 aaaaa

```

//

```

LOCUS      HSMCP3A      1085 bp      DNA      PRI      25-JUL-1994
DEFINITION H.sapiens MCP-3 mRNA for monocyte chemotactic protein-3.
ACCESSION  X72308 S57464
NID        g313707
KEYWORDS   monocyte chemotactic protein 3.
SOURCE     human.
ORGANISM   Homo sapiens
            Eukaryotae; mitochondrial eukaryotes; Metazoa; Chordata;
            Vertebrata; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE  1 (bases 1 to 1085)
AUTHORS    Opdenakker,G., Froyen,G., Fiten,P., Proost,P. and Van Damme,J.
TITLE      Human monocyte chemotactic protein-3 (MCP-3): molecular cloning
of         the cDNA and comparison with other chemokines
JOURNAL    Biochem. Biophys. Res. Commun. 191 (2), 535-542 (1993)
MEDLINE    93213290
REFERENCE  2 (bases 1 to 1085)
AUTHORS    Opdenakker,G.M.
TITLE      Direct Submission
JOURNAL    Submitted (27-MAY-1993) G.M. Opdenakker, Rega Institute,
University of Leuven, Minderbroedersstraat 10, B-3000 Leuven, BELGIUM
REFERENCE  3 (bases 1 to 1085)
AUTHORS    Opdenakker,G., Fiten,P., Nys,G., Froyen,G., Van Roy,N.,
            Speleman,F., Laureys,G. and Van Damme,J.
TITLE      The human MCP-3 gene (SCYA7): cloning, sequence analysis, and
            assignment to the C-C chemokine gene cluster on chromosome
            17q11.2-q12
JOURNAL    Genomics 21 (2), 403-408 (1994)
MEDLINE    94375065
FEATURES   Location/Qualifiers
            source          1..1085
                        /organism="Homo sapiens"
                        /db_xref="taxon:9606"
            gene            299..810
                        /gene="MCP-3"
            CDS             299..628
                        /gene="MCP-3"
                        /codon_start=1
                        /product="monocyte chemotactic protein-3"
                        /db_xref="PID:g313708"
                        /db_xref="SWISS-PROT:P80098"

/translation="MWKPMPSPSNMKASAALLCLLLTAAFSPQGLAQVPGINTSTTC
CYRFINKKIPKQRLSYRRRTSSHCPREAVIFKTKLDKEICADPTQKWVQDFMKHLDK
KTQTPKL"
sig_peptide 299..397
            /gene="MCP-3"
mat_peptide 398..625

```

```

        /gene="MCP-3"
polyA_signal  /product="monocyte chemotactic protein-3"
              806..810
              /gene="MCP-3"
BASE COUNT   314 a    214 c    229 g    328 t
ORIGIN
1  ggtttctatt gacttgggtt aatcgtgtga ccgcggtggc tggcacgaaa ttgaccaacc
61  ctgggggttag tatagcttag ttaaactttc gtttattgct aaaggttaat cactgctggt
121  tcccgtgggg gtgtggctag gctaagcgtt ttgagctgca ttgctgcgtg cttgatgctt
181  gtcccttttg atcgtggtga tttagagggt gaactcactg gaatgggatg gcttgcatgt
241  gtaatcttac taagagctaa tagaaaggct aggaccaaac cagaaacctc caatttcat
301  gtggaagccc atgccctcac cctccaacat gaaagcctct gcagcacttc tgtgtctgct
361  gctcacagca gctgctttca gccccagggt gcttgctcag ccagtggga ttaatacttc
421  aactacctgc tgctacagat ttatcaataa gaaaatccct aagcagaggc tggagagcta
481  cagaaggacc accagtagcc actgtccccg ggaagctgta atcttcaaga ccaaactgga
541  caaggagatc tgtgctgacc ccacacagaa gtgggtccag gactttatga agcacctgga
601  caagaaaacc caaactccaa agctttgaac attcatgact gaactgaaaa caagccatga
661  cttgagaaac aaataatttg tatacctgtt cctttctcag agtggttctg agattatatt
721  aatctaattc taagggaatat gagctttatg taataatgtg aatcatgggt tttcttagta
781  gattttaaaa gttattaata ttttaattta atcttccatg gattttgggt gggtttgaac
841  ataaagcctt ggtatgtatat gtcattctcag tgctgtaaaa actgtgggat gctcctcctt
901  tctctacctc atgggggtat tgtataagtc cttgcaagaa tcagtgcaaa gatttgcttt
961  aattgttaag atatgatgtc cctatggaag catattgtta ttatataatt acatatttgc
1021  atatgtatga ctcccaaatt ttcacataaa atagattttt gtataacaaa aaaaaaaaaa
1081  aaaaa

//LOCUS      HSU46767      825 bp      mRNA      PRI      16-DEC-1996
DEFINITION   Human monocyte chemoattractant protein-4 precursor (MCP-4)
mRNA,
complete cds.
ACCESSION    U46767
NID          gl732122
KEYWORDS
SOURCE       human.
ORGANISM     Homo sapiens
              Eukaryotae; mitochondrial eukaryotes; Metazoa; Chordata;
              Vertebrata; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE    1 (bases 1 to 825)
AUTHORS      Garcia-Zepeda, E.A., Combadiere, C.C., Rothenberg, M.E.,
Sarafi, M.N.,
              Lavigne, F., Hamid, Q., Murphy, P. and Luster, A.D.
TITLE        Human monocyte chemoattractant Protein (MCP)-4: A novel CC
              chemokine with activities on monocytes, eosinophils, and
basophils
              induced in allergic and non-allergic inflammation that signals
              through the CC chemokine receptors CCR-2 and 3
JOURNAL      J. Immunol. 158 (1996) In press
REFERENCE    2 (bases 1 to 825)
AUTHORS      Garcia-Zepeda, E.A. and Luster, A.D.
TITLE        Direct Submission
JOURNAL      Submitted (22-JAN-1996) Eduardo A. Garcia-Zepeda, Infectious
              Disease Unit, Massachusetts General Hospital, 149 13th St.,
              Charlestown, MA 02129, USA
FEATURES
source       Location/Qualifiers
              1..825
              /organism="Homo sapiens"
              /db_xref="taxon:9606"
              /tissue_type="heart"
              /clone_lib="EG3.16"
sig_peptide  34..102
              /gene="MCP-4"
CDS          34..330
              /gene="MCP-4"
              /note="small cytokine; intercrine/chemokine; C-C
subfamily    signature; chemoattractant for monocytes, eosinophils"
              /codon_start=1
              /product="monocyte chemoattractant protein-4"
precursor    /db_xref="PID:gl732123"

/translation="MKVSAVLLCLLLMTAAFNPGLAQPDALNVPSTCCFTFSSKKIS

```

LQRLKSYVITTSRCPQKAVIFRTKLGKEICADPKEKWQNYMKHLGRKAHTLKT"

gene 34..330
/gene="MCP-4"
mat_peptide 103..327
/gene="MCP-4"

BASE COUNT 221 a 175 c 185 g 244 t
ORIGIN

```

1 acattgtgaa atctccaact cttaaccctc aacatgaaag tctctgcagt gcttctgtgc
61 ctgctgctca tgacagcagc tttcaacccc cagggacttg ctcagccaga tgcactcaac
121 gtcccatcta cttgctgctt cacatttagc agtaagaaga tctccttgca gaggctgaag
181 agctatgtga tcaccaccag caggtgtccc cagaaggctg tcattctcag aaccaaactg
241 ggcaaggaga tctgtgctga cccaaaggag aagtgggtcc agaattatat gaaacacctg
301 ggccggaaag ctcacaccct gaagacttga actctgtctac ccctactgaa atcaagctgg
361 agtacgtgaa atgacttttc cattctcctc tggcctcctc ttctatgctt tgggaatactt
421 ctaccataat tttcaaatag gatgcattcg gttttgtgat tcaaaatgta ctatgtgtta
481 agtaatatgg gctattattt gacttggtgc tgggttgagg tttatttgag tattgctgat
541 cttttctaaa gcaaggcctt gagcaagtag gttgctgtct ctaagcccc ttcccttcca
601 ctatgagctg ctggcagtgg gttgtattcg gttcccaggg gttgagagca tgcctgtggg
661 agtcatggac atgaagggat gctgcaatgt aggaaggaga gctctttgtg aatgtgaggt
721 tgttgctaaa ttattgttta ttgtggaaag atgaatgcaa tagtaggact gctgacattt
781 tgcagaaaaa acatttttatt taaaaatctc taaaaaaaaa aaaaa

```

//LOCUS HSAMAC1 803 bp RNA PRI 10-AUG-1997
DEFINITION Homo sapiens mRNA for alternative activated macrophage specific CC

chemokine 1.
ACCESSION Y13710
NID g2326515
KEYWORDS AMAC-1 gene; CC-chemokine 1.
SOURCE human. ORGANISM Homo sapiens
Eukaryotae; mitochondrial eukaryotes; Metazoa; Chordata;
Vertebrata; Mammalia; Eutheria; Primates; Catarrhini;

Hominidae;

REFERENCE 1 (bases 1 to 803)
AUTHORS Politz,O.

TITLE Direct Submission

JOURNAL Submitted (10-JUN-1997) Politz O., Dermatology, Free University
Benjamin Franklin Medical Center, Hindenburgdamm 30; 12200
Berlin

GERMANY
REFERENCE 2 (bases 1 to 803)
AUTHORS Kodolja,V., Mueller,C., Politz,O., Hakiy,N., Orfanos,C.E. and
Goerdts,S.

TITLE Cloning of alternative activated macrophage associated CC
chemokine

1 (AMAC-1)
JOURNAL Unpublished

FEATURES Location/Qualifiers

source 1..803
/organism="Homo sapiens"
/db_xref="taxon:9606"
/cell_type="macrophage"
sig_peptide 71..133
/gene="amac-1"
CDS 71..340
/gene="amac-1"
/note="macrophage specific"
/codon_start=1
/product="CC-chemokine 1"
/db_xref="PID:e321838"
/db_xref="PID:g2326516"

/translation="MKGLAAALLVLVCTMALCSCAQVGTNKLCCLVYTSWQIPQKFI
VDYSETSPQCPKPGVILLTKRGRQICADPNKKWVQKYISDLKLNA"
gene 71..340
/gene="amac-1"
mat_peptide 134..337
/gene="amac-1"

BASE COUNT 214 a 213 c 160 g 216 t
ORIGIN


```

1  ccggcacgag aggagttgtg agtttccaag cccagctca ctctgaccac ttctctgcct
61  gccagcatc atgaagggcc ttgcagctgc cctcctctgtc ctctgtctgca ccatggccct
121 ctgctcctgt gcacaagttg gtaccaacaa agagctctgc tgctcgtct atacctcctg
181 gcagattcca caaaagttca tagttgacta ttctgaaacc agccccagc gccccaagcc
241 aggtgtcatc ctctaacca agagaggccg gcagatctgt gctgacccca ataagaagtg
301 ggtccagaaa tacatcagcg acctgaagct gaatgcctga ggggcctgga agctgcgagg
361 gccagtgaa cttggtgggc ccaggaggga acaggagcct gagccagggc aatggccctg
421 ccaccctgga ggccacctct tctaagagtc ccatctgcta tgcccagcca cattaactaa
481 ctttaatctt agtttatgca tcatatttca ttttgaatt gatttctatt gttgagctgc
541 attatgaaat tagtattttc tctgacatct catgacattg tctttatcat cctttccctt
601 ttcccttcaa ctcttcgtac attcaatgca tggatcaatc agtgtgatta gctttctcag
661 cagacattgt gccatatgta tcaaatgaca aatctttatt gaatggttt gctcagcacc
721 accttttaat atattggcag tactatttat ataaaaggta aaccagcatt ctactgtga
781 aaaaaaaaaa aaaaaaaaaa aaa

```

//

```

LOCUS      HUMLD78A      3176 bp      DNA                      PRI      17-JAN-1992
DEFINITION Human LD78 alpha gene.
ACCESSION  D90144
NID        g219905
KEYWORDS   LD78; LD78 alpha; cytokine; inducible gene family; secreted
           peptide.
SOURCE     Human blood lymphocyte DNA, clone Lm LD-3.
ORGANISM   Homo sapiens
           Eukaryotae; mitochondrial eukaryotes; Metazoa; Chordata;
           Vertebrata; Mammalia; Eutheria; Primates; Catarrhini;
Hominidae; Homo.
REFERENCE  1 (bases 1 to 3176)
AUTHORS   Nakao,M., Nomiyama,H. and Shimada,K.
TITLE     Structures of human genes coding for cytokine LD78 and their
           expression
JOURNAL    Mol. Cell. Biol. 10 (7), 3646-3658 (1990)
MEDLINE    90287155
COMMENT    These data kindly submitted in computer readable form by:
Hisayuki

```

```

Nomiyama
Department of Biochemistry
Kumamoto University Medical School
2-2-1 Honjo, Kumamoto 860
Japan
Phone: 096-344-2111
Fax: 096-372-6140.

```

```

FEATURES             Location/Qualifiers
     source            1..3176
                       /organism="Homo sapiens"
                       /db_xref="taxon:9606"
     TATA_signal       1041..1045
     exon              1069..1227
                       /number=1
     prim_transcript   1069..2957
                       /note="LD78 alpha mRNA and introns"
     sig_peptide        1155..1220
                       /note="LD78 alpha signal peptide"
     CDS                join(1155..1227,1916..2030,2451..2541)
                       /codon_start=1
                       /product="LD78 alpha precursor"
                       /db_xref="PID:d1014875"
                       /db_xref="PID:g219906"

/translation="MQVSTAALAVLLCTMALCNQFSASLAADTPTACCFSTSRQIPQ
mat_peptide          NFIADYFETSSQCSKPGVIFLTKRSRQVCADPSEEWVQKYVSDLELSA"
                       join(1218..1227,1916..2030,2451..2538)
                       /partial
                       /note="LD78 alpha mature peptide"
     intron            1228..1915
     exon              1916..2030
                       /partial
                       /number=2
     intron            2031..2450
     exon              2451..2957
                       /number=3

```

BASE COUNT	833 a	741 c	752 g	850 t			
ORIGIN	1	accaggagac	ctatcacaca	aatataagaa	ctattcattc	tttaaggcat	gtatttccaa
	61	gcctttgtat	ttttttccat	gcttaggggt	ggcaaggaat	atataatat	ttgtacaaat
	121	atatatgtgt	atatgtacaa	atacatgtat	atatagtaca	aatatatata	tatatttgta
	181	caattcttca	gactttgtag	aatttgtata	atgtcgtatc	ttgtcttttt	taaccactga
	241	tggtataagc	atatttatgc	cacttcattc	attttagaga	cttaataata	aatgatctag
	301	tggataattt	atcattccct	gatggagaaa	aatttagctt	tgtttatatt	agagttataa
	361	acgatgctgg	gtcagggtatc	tttatgtttg	aagatggctc	catatttggg	ttgtttccac
	421	agaactcttt	cctagaaatg	ctttttctag	gttaatggct	acagatattt	ctaggcacct
	481	gacatattga	caccacacct	taaagtattt	ttatgatcca	caactagcgt	ttaacacagc
	541	gccctagtc	ctacatgact	aataaataga	caaatgactg	aaacatgacc	tcattgctttc
	601	tattcctcca	gctttcattc	agttctttgc	ctctgggagg	aggaaggggt	gtgcagccct
	661	ccacagcatc	agcccatcaa	ccctatccct	gtggttatag	cagctgagga	agcagaattg
	721	cagctctgtg	ggaaggaatg	gggctggaga	gttcatgcac	agaccagttc	ttatgagaag
	781	ggactgacta	agaatagcct	tgggttgaca	tatacccttc	ttcacactca	caggagaana
	841	catttcccta	tgaaactata	acaagtcatg	agttgagagc	tgagagttag	agaatagctc
	901	aaagatgcta	ttcttgata	tcctgagccc	ctgtgggtcac	cagggaccct	gagttgtgca
	961	acttagcatg	acagcatcac	tacgttataa	aatttccctc	ctcaccctca	gattccattt
	1021	ccccatccgc	cagggtctgc	tataaagagg	agagctgggt	tcagacttca	gaagacacag
	1081	ggcagcagac	agtggctcagt	cctttcttgg	ctctgctgac	actcgagccc	acattccgct
	1141	acctgctcag	aatcatgcag	gtctccactg	ctgcccctgc	tgctctcttc	tgccacctgg
	1201	ctctctgcaa	ccagttctct	gcctcacgtg	agttctgagt	tcgttctggg	tatccacct
	1261	ctctggccat	ggtttagacca	catcaatctt	ttcttctggc	ctaaaagccc	ccaagagaaa
	1321	agagaacttc	ttaaaagggt	gccaacatc	ttggtctttc	tccttaagac	ttttattttt
	1381	atctctagaa	gggggtcttag	ccccctagtc	tcagggtatg	agaatctagg	caggggcagg
	1441	ggagttacag	tcctttttac	agatagaaaa	acaggggtcg	aaacgaatca	gttagcaga
	1501	ggcagaatcc	aggggtgctt	acttcccagt	gggggtatgt	gttccactct	cagctcactc
	1561	taggtctccc	aggagctctg	tcctttggat	gtcttatgag	agatgtccaa	ggcttctctt
	1621	gggttgggtt	atgacttctt	gaaccagaca	aaattccctg	aagagaactg	agataagaga
	1681	acagtcctgt	caggtatctg	gatcacacag	agaaacagag	aaccacttat	gaagagtcaa
	1741	ggagaaagaa	ggatacacag	agaaacaaag	agacatttct	cagcaaaaaa	gccccaaatg
	1801	cttccagtc	cttgggtctga	gcaagcctgc	cttctcaaac	tgctcgggga	tcagaagctg
	1861	cctggccttt	tcttctgagc	tgtgactcgg	gtctattctc	ttccttcttc	cacagttgct
	1921	gctgacacgc	cgaccgcctg	ctgcttcagc	tacacctccc	ggcagattcc	acagaatttc
	1981	atagctgact	actttgagac	gagcagccag	tgctccaagc	ccggtgtcat	gtaagtcca
	2041	gtcttctg	tcacctctat	ggaggtaggg	agggctcagg	ttggggcaga	gacaggccag
	2101	aaggctatcc	tggaaggcc	cagccttcag	gagcctatcg	gggatacagg	acgcagggct
	2161	ccgaggtgtg	acctgacttg	gagctggagt	gaggcatgtg	ttacagagtc	aggaagggtc
	2221	gccccagccc	agaggaaagg	gacaggaaga	aggaggcagc	gggacactct	gagggccacc
	2281	cctactgagt	cactgagaga	agctctctag	acagagatag	gcagggggcc	cctgaaagag
	2341	gagcaagccc	tgagctgccc	aggacagaga	gcagaatggg	ggggccatgg	tgggccagg
	2401	attccccctg	tggaattccc	agtgttaaac	tcttctctcc	ttctccacag	cttcttaacc
	2461	aagcgaagcc	ggcaggtctg	tgctgacccc	agtgaggagt	gggtccagaa	atatgtcagc
	2521	gacctggagc	tgagtgcctg	aggggtccag	aagcttccag	gcccagcgac	ctcgggtggc
	2581	ccagtgggga	ggagcaggag	cctgagcctt	gggaacatgc	gtgtgacctc	cacagctacc
	2641	ctctctatgg	actggttggt	gccaacacag	cacactgtgg	gactcttctt	aacttaatt
	2701	tttaatttat	tataactatt	agttttttgt	atttattttc	gatttcacag	tgtgtttgtg
	2761	attgtttgct	ctgagagttc	ccctgtcccc	tcccccttcc	ctcacaccgc	gtctggtgac
	2821	aaccgagtg	ctgtcatcag	cctgtgtagg	cagtcattgc	accaaagcca	ccagactgac
	2881	aaatgtgtat	cggtgctttt	gtttcagggc	tgtgatcggc	ctggggaaat	aataaagatg
	2941	ctctttttaa	aggtaaacca	gtattgagtt	tggttttggt	tttctggcaa	atcaaaatca
	3001	ctgggttaaga	ggaatcatag	gcaaagatta	ggaagagggt	aaatggaggg	aaattgggag
	3061	agatggggag	ggctaccaca	gagttatcca	ctttacaacg	gagacacagt	tctggaacat
	3121	tgaaactacg	aatatgttat	aactcaaatc	ataacatgca	tgctctagga	gaattc

//
 LOCUS AF043339 225 bp mRNA PRI 23-FEB-1998
 DEFINITION Homo sapiens macrophage inflammatory protein 1 alpha (MIP1a)
 mRNA,
 partial cds.
 ACCESSION AF043339
 NID g2905627
 KEYWORDS
 SOURCE human.
 ORGANISM Homo sapiens
 Eukaryotae; Metazoa; Chordata; Vertebrata; Mammalia; Eutheria;
 Primates; Catarrhini; Hominidae; Homo.
 REFERENCE 1 (bases 1 to 225)
 AUTHORS Jang, J.S. and Kim, B.E.
 TITLE Direct Submission
 JOURNAL Submitted (15-JAN-1998) Protein Engineering, General Institute

of
Technology, Hyundai Pharm. Ind. Co., Ltd., 213 Sosa Bon 1-dong,
Sosa-gu, Bucheon 422-231, Korea

COMMENT forward primer (5'-tgcgcatcacttgctgctgaca-3')
reverse primer (5'-cttctggaccctcaggcact-3').

FEATURES Location/Qualifiers
source 1..225
/organism="Homo sapiens"
/db_xref="taxon:9606"
/cell_type="PHA-treated peripheral blood leukocyte"
gene <1..225
/gene="MIPl1a"
primer_bind <1..19
/gene="MIPl1a"
/PCR_conditions="94C-1min, 50C-1min, 72C-3min, 30
cycles;
DeltaCycler II from Ericomp"
CDS <1..213
/gene="MIPl1a"
/function="CC chemokine"
/function="proinflammatory cytokine involved in
inflammation"
/note="8-10 kDa"
/codon_start=1
/product="macrophage inflammatory protein 1 alpha"
/db_xref="PID:g2905628"

/translation="ASLAADTPTACCFSTYTSRQIPQNFADYFETSSQCSKPGVIFLT
KRSRQVCADPSEEWVQKYVSDLELSA"
primer_bind complement(205..225)
/gene="MIPl1a"

BASE COUNT 50 a 68 c 62 g 45 t
ORIGIN
1 gcacacattg ctgctgacac gccgaccgcc tgctgcttca gctacacctc ccggcagatt
61 ccacagaatt tcatagctga ctactttgag acgagcagcc agtgctccaa gcccggtgct
121 atcttctctaa ccaagcgaag ccggcaggtc tctgctgacc ccagtgagga gtgggtccag
181 aaatatgtca gcgacctgga gctgagtgcc tgaggggtcc agaag

//
LOCUS HUMLD78B 3112 bp DNA PRI 17-JAN-1992
DEFINITION Human LD78 beta gene.
ACCESSION D90145
NID g219907
KEYWORDS LD78; LD78 beta; cytokine; inducible gene family; secreted
peptide.
SOURCE Human placenta DNA, clone Lm LD-1.
ORGANISM Homo sapiens
Eukaryotae; mitochondrial eukaryotes; Metazoa; Chordata;
Vertebrata; Mammalia; Eutheria; Primates; Catarrhini;
Hominidae;
Homo.
REFERENCE 1 (bases 1 to 3112)
AUTHORS Nakao,M., Nomiya,H. and Shimada,K.
TITLE Structures of human genes coding for cytokine LD78 and their
expression
JOURNAL Mol. Cell. Biol. 10 (7), 3646-3658 (1990)
MEDLINE 90287155
COMMENT These data kindly submitted in computer readable form by:
Hisayuki
Nomiya
Department of Biochemistry
Kumamoto University Medical School
2-2-1 Honjo, Kumamoto 860
Japan
Phone: 096-344-2111
Fax: 096-372-6140.

FEATURES Location/Qualifiers
source 1..3112
/organism="Homo sapiens"
/db_xref="taxon:9606"
repeat_unit 498..797
/note="Alu repeat"

```

TATA_signal      1078..1082
prim_transcript  1106..2995
                  /note="LD78 beta mRNA and introns"
exon              1106..1267
                  /note="LD78 beta precursor, coding region of exon 1"
                  /number=1
CDS               join(1192..1267,1953..2067,2488..2578)
                  /partial
                  /codon_start=1
                  /product="LD78 beta precursor"
                  /db_xref="PID:d1014876"
                  /db_xref="PID:g219908"

/translation="MQVSTAALAVLLCTMALCNQVLSAPLAADTPTACCFSYTSRQIP
              QNFIADYFETSSQCSKPSVIFLTRGRQVCADPSEEWVQKYVSDLELSA"
sig_peptide      1192..1260
                  /partial
                  /note="LD78 beta signal peptide"
mat_peptide       join(1258..1267,1953..2067,2488..2575)
                  /partial
                  /note="LD78 beta mature peptide"
intron           1268..1952
exon              1953..2067
                  /number=2
intron           2068..2487
exon              2488..2955
                  /number=3

BASE COUNT      756 a    775 c    780 g    801 t
ORIGIN
1   ttagagactt aataataaag gatcttgtgg ataatttatt attccctgat agagaaaaat
61  ttagctttgc ttatttttaga gttataaag atgctgggtc aggtatcttt atgtttgaag
121 atggctccat atttgggttg tttccacaga actctttccc agaaatgctt tttctaggtt
181 aatggctaca catatttcta ggcacctgac atactgacac ccacctctaa agtattttta
241 tgatccacaa cttagcgttta acacagcgcc ccagtcactc cgagactaat aaatagacaa
301 atgactgaaa cgtgacctca tgctttctat tcctccagct ttcattgagt tcctttcctc
361 tgggaggact ggggggttgc tagccctcca cagcatcagc ccattgaccc tatccttggtg
421 gttatagcag ctgaggaagc agaattacag ctctgtggga aggaatgggg ctggagagtt
481 catgcataga ccaattcttt tttttttttt tttttgagat ggagtttcac ttttgttgcc
541 caggctggag tgcaatggca tgatctcagc tcaccacagc cccacacctc tgggttcaag
601 cgattctcct gccctcagcc tcccgagtag ctgggattac aggcattgtc caccacgctt
661 gactactttt gtatttttag tagagatgga gtttctcttt ctgtgtcagg ttggtctcaa
721 actctgacc tcaggtgata cgcagcctcg gcctcccaaa gtgttgggat tacaggtgtg
781 agcgaccatg cctggctgca tagaccagtt cttatgagaa gggatcaact aagaatagcc
841 ttgggttgac acacaccctt ctccacactc acaggagaaa ccccatgaag ctgaaaccag
901 tcatgagttg agagctgaga gttagagagt agctcagaga tgctattctt ggatctctg
961 agccctgtg gtcaccaggg accctgagtt gtgcaactac cagcatgaca gcatactact
1021 acttaaaaaa ttcctctctc acccccagat tccatttccc catccgccag ggctgcttat
1081 aaagaggaga gatggcttca gacatcagaa ggacgcagcc agcaaagagt agtcagctcc
1141 ttcttggttc tgctgacctc cgagcccaca tctcatcacc tgctcccaat catgcaggtc
1201 tccactgctg ccttgccgtt cctcctctgc accatggctc tctgcaacca ggtcctctct
1261 gcaccacgtg agtccatggt gttgttgtgg gtatcaccac tctctggcca tgggttagacc
1321 acatcagttt ttttttgctg cctgagagcc ccgaagagaa aagaaggaaag ttcttaaaagc
1381 gctgccaaac accttggtct ttttcttcac aacttttatt tttatctcta gaaggggtct
1441 tagccctcct agtctccagg tatgagaatc taggcagggg caggggagtt acagtcctct
1501 gtacagatag aaaaacaggg ttcaaaacga atcagtttgc aagaggcaga atccagggtt
1561 gcttacttcc cagtgggttc tgttgttcac tctccagctc accctagggt tcccaggagc
1621 cctgtccctt ggatgtctta tgagagatgt ccagggtctt tcttgggtct gggatagact
1681 tcttgaaccg acaaaattcc atgaagagag ctaagagaa acgtccattca ggtatctgga
1741 tcacatagag aaacagagaa cccactatga agagtcaagg ggaagaggga atatagacag
1801 aaacaaagag acatttctct gcaaaaaccc ccaaatgcct tgcaagtcact tgggtctgagc
1861 aagcctgccc tcttcaacca ctcagggtatc agaagctgcc tggccttttc tctgagctg
1921 tgactcgggc ttattctctc ctttctccgc agttgtgtgt gacacgcgga ccgctgctg
1981 cttcagctac acctcccgac agattccaca gaatttcata gctgactact ttgagacgag
2041 cagccagtg cccaagccca gtgtcatgta agtgccagtc ttcctgtcta cctctaggga
2101 ggtaggaggt gtcagggtgg gggcagaaac aggccagaaag gccatcctgg aaaggccag
2161 ccttcaggag cctatcgggg atacaggagc cagggcactg aggtgtgacc tgacttgggg
2221 ctggagtgag gtgggtgtta cagagtcagg aagggtgcc ccaggccaga ggaaaggaac
2281 aggaagaagg aggcagcagg acactctgag ggcctctgag cctggagtc ctgagagaag
2341 ctctctagac ggagataggg agggggcccc tgagagagga gcaggccttg agctgcccag
2401 gacagagagc aggatgtcag gccatggtgg gccaggatt ccccggtctg attccccagt
2461 gcttaactct tctcccttc tccacagctt cctaaccaag agaggccggc aggtctgtgc

```

```

2521 tgacccagct gaggagtggg tccagaaata cgtcagtgac ctggagctga gtgcctgagg
2581 ggtccagaag cttcgaggcc cagcgacctc agtgggcccc gtggggagga gcaggagcct
2641 gagccttggg aacatgcgtg tgacctctac agctacctct tctatggact gggtattgcc
2701 aaacagccac actgtgggac tcttcttaac ttaaatttta atttatttat actatttagt
2761 ttttataatt tatttttgat ttcacagtgt gtttgtgatt gtttgcctg agagttcccc
2821 ctgtcccttc cacttccctt cacagtgtgt ctggtgacga ccgagtggct gtcacggcc
2881 tgtgtaggca gtcattggc caaagccacc agactgacaa atgtgtatca gatgctttg
2941 ttcagggtct tgatcggcct ggggaaataa taaagatgtt cttttaaacg gtaaacagct
3001 attgagtttg gttttgtttt tctggcaaat caaaatcact agttaagagg aatcataggg
3061 aaagattagg aagaggtgaa atggagggaa actgggagag atggggagcg ct

```

```

//
LOCUS      HUMACT2A      696 bp      mRNA      PRI      30-OCT-1994
DEFINITION Human activation (Act-2) mRNA, complete cds.
ACCESSION  J04130
NID        g178017
KEYWORDS   act2 gene; immune activation gene.
SOURCE     Human (Hut-102B2 library) activated T cells, cDNA to mRNA.
ORGANISM   Homo sapiens
            Eukaryotae; mitochondrial eukaryotes; Metazoa; Chordata;
            Vertebrata; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE  1 (bases 1 to 696)
AUTHORS    Lipes,M.A., Napolitano,M., Jeang,K.T., Chang,N.T. and
Leonard,W.J.
TITLE      Identification, cloning, and characterization of an immune
            activation gene
JOURNAL    Proc. Natl. Acad. Sci. U.S.A. 85 (24), 9704-9708 (1988)
MEDLINE    89071764
COMMENT    Draft entry and computer-readable sequence [1] kindly submitted
            by
            W.Leonard, 09-JAN-1989.
FEATURES   Location/Qualifiers
            source          1..696
                        /organism="Homo sapiens"
                        /db_xref="taxon:9606"
                        /map="Unassigned"
            mRNA            <1..696
                        /note="act-2 mRNA"
            sig_peptide     109..177
                        /gene="LAG2"
                        /note="act-2 protein signal peptide"
            gene            109..387
                        /gene="LAG2"
            CDS             109..387
                        /gene="LAG2"
                        /note="act-2 protein precursor"
                        /codon_start=1
                        /db_xref="GDB:G00-127-452"
                        /db_xref="PID:g178018"
            /translation="MKLCVTVLSLLMLVAAFCSAPMSGSDPPTACCFSTARKLP
            RNFVVDYYETSSLCSQPAVVFTKRSKQVCADPSESWWQEYVYDLELN"
            mat_peptide     178..384
                        /gene="LAG2"
                        /note="act-2 protein"
BASE COUNT 157 a 203 c 139 g 197 t
ORIGIN      Unreported.
            1 tccccccccc cccccccccc ccccgcccga gcacaggaca cagctggggt ctgaagcttc
            61 tgagttctgc agcctcacct ctgagaaaac ctcttttcca ccaataccat gaagctctgc
            121 gtgactgtcc tgtctctcct catgctagta gctgccttct gctctccagc gctctcagca
            181 ccaatgggct cagaccctcc caccgcctgc tgcctttctt acaccgcgag gaagcttctt
            241 cgcaactttg tggtagatta ctatgagacc agcagcctct gctcccagcc agctgtggta
            301 ttccaaacca aaagaagcaa gcaagtctgt gctgatccca gtgaatcctg ggtccaggag
            361 tacgtgtatg acctggaact gaactgagct gctcagagac aggaagtctt cagggaaggt
            421 cactgagcc cggatgcttc tccatgagac acatctcttc catactcagg actcctctcc
            481 gcagttctct tcccttctct taatttaatc ttttttatgt gccgtgttat tgtattaggt
            541 gtcatctctt ttatttatat tagtttagcc aaaggataag tgcctatgg ggatggcca
            601 ctgtcactgt ttctctgctg ttgcaaatat atggataaca catttgattc tgtgtgtttt
            661 ccataataaa actttaaaat aaaatgcaga cagtta
//
LOCUS      AF031587      481 bp      mRNA      PRI      02-JAN-1998
DEFINITION Homo sapiens MIP-1 delta mRNA, complete cds.

```

ACCESSION AF031587
 NID g2739163
 KEYWORDS .
 SOURCE human.
 ORGANISM Homo sapiens
 Eukaryotae; Metazoa; Chordata; Vertebrata; Mammalia; Eutheria;
 Primates; Catarrhini; Hominidae; Homo.
 REFERENCE 1 (bases 1 to 481)
 AUTHORS Wang, W.
 TITLE Molecular cloning and characterization of a new CC chemokine
 MIP-1
 delta
 JOURNAL Unpublished
 REFERENCE 2 (bases 1 to 481)
 AUTHORS Wang, W.
 TITLE Direct Submission
 JOURNAL Submitted (27-OCT-1997) Immunobiology, DNAX Research Institute,
 901
 California Ave, Palo Alto, CA 94304, USA
 FEATURES Location/Qualifiers
 source 1..481
 /organism="Homo sapiens"
 /db_xref="taxon:9606"
 /chromosome="17"
 CDS 1..342
 /note="CC or beta chemokine"
 /codon_start=1
 /product="MIP-1 delta"
 /db_xref="PID:g2739164"
 /translation="MKVSVAAALSCLMLVAVLGSQAQFINDAETELMMSKLPLENPVVL
 NSFHFAADCCTSYISQSIPLCSLMKSYFETSSECSKPGVIFLTKKGRQVCAKPSGPGVQ
 DCMKKLKPYSI"
 BASE COUNT 140 a 112 c 100 g 129 t
 ORIGIN
 1 atgaaggtct cctggtctgc cctctcctgc ctcattgttg ttgctgtcct tggatcccag
 61 gcccagttca taaatgatgc agagacagag ttaatgatgt caaagcttcc actggaaaaat
 121 ccagtagttc tgaacagctt tcactttgct gctgactgct gcacctccta catctcacia
 181 agcatcccgt gttcactcat gaaaagtatt ttgaaacga gcagcgagt ctccaagcca
 241 ggtgtcatat tcctcaccaa gaaggggagg caagtctgtg ccaaaccag tggctccggga
 301 gtccaggatt gcatgaaaaa gctgaagccc tactcaatat aataataag agacaaaaga
 361 gggcagccac ccacctcaa cactcctgt gagtttctg gtctgaaata cttaaaaaat
 421 atatatttg ttgtgtctgg taatgaaagt aatgcatcta ataaagagta ttaattttt
 481 t
 //
 LOCUS AF043340 234 bp mRNA PRI 23-FEB-1998
 DEFINITION Homo sapiens macrophage inflammatory protein 2 alpha (MIP2a)
 mRNA,
 partial cds.
 ACCESSION AF043340
 NID g2905629
 KEYWORDS .
 SOURCE human.
 ORGANISM Homo sapiens
 Eukaryotae; Metazoa; Chordata; Vertebrata; Mammalia; Eutheria;
 Primates; Catarrhini; Hominidae; Homo.
 REFERENCE 1 (bases 1 to 234)
 AUTHORS Jang, J.S. and Kim, B.E.
 TITLE Direct Submission
 JOURNAL Submitted (15-JAN-1998) Protein Engineering, General Institute
 of
 Technology, Hyundai Pharm. Ind. Co., Ltd., 213 Sosa Bon 1-dong,
 Sosa-gu, Bucheon 422-231, Korea
 COMMENT forward primer (5'-tgcgacccctggccactgaactg-3')
 reverse primer (5'-ccttccttctggtcagttgga-3').
 FEATURES Location/Qualifiers
 source 1..234
 /organism="Homo sapiens"
 /db_xref="taxon:9606"
 /cell_type="PHA-treated peripheral blood leukocyte"

```

gene          <1..234
              /gene="MIP2a"
primer_bind   <1..21
              /gene="MIP2a"
cycles;       /PCR_conditions="94C-1min, 50C-1min, 72C-3min, 30
CDS           DeltaCycler II from Ericomp"
              <1..222
              /gene="MIP2a"
              /function="CXC chemokine"
              /function="proinflammatory cytokine involved in
inflammation"
              /note="8-10 kDa"
              /codon_start=1
              /product="macrophage inflammatory protein 2 alpha"
              /db_xref="PID:g2905630"

/translation="APLATELRQCQLQTLOGIHLKNIQSVKVKSPGPHCAQTEVIATL
KNGQKACLNPA SP MVKKIIEKMLKNGKSN"
primer_bind   complement(214..234)
              /gene="MIP2a"
BASE COUNT    74 a    70 c    54 g    36 t
ORIGIN
1 gcaccctg ccactgaact gcgctgccag tgcttcgaga ccctgcaggg aattcacctc
61 aagaacatcc aaagtgtgaa ggtgaagtcc cccggacccc actgcgcca aaccgaagtc
121 atagccacac tcaagaatgg gcagaaagct tgtctcaacc ccgcatcgcc catgggtaag
181 aaaatcatcg aaaagatgct gaaaaatgac aaatccaact gaccagaagg aagg
//
LOCUS          HSU77035      764 bp    mRNA          PRI      23-JAN-1997
DEFINITION     Human macrophage inflammatory protein 3 alpha (MIP-3a) mRNA,
complete cds.
ACCESSION      U77035
NID            g1790924
KEYWORDS
SOURCE         human.
ORGANISM       Homo sapiens
               Eukaryotae; mitochondrial eukaryotes; Metazoa; Chordata;
               Vertebrata; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE      1 (bases 1 to 764)
AUTHORS        Rossi,D.L., Vicari,A.P., Franz-Bacon,K., McClanahan,T.K. and
               Zlotnik,A.
TITLE          Identification through bioinformatics of two new macrophage
proinflammatory human chemokines: MIP-3alpha and MIP-3beta
JOURNAL        J. Immunol. 158 (3), 1033-1036 (1997)
MEDLINE        97166046
REFERENCE      2 (bases 1 to 764)
AUTHORS        Rossi,D.L. and Zlotnik,A.
TITLE          Direct Submission
JOURNAL        Submitted (31-OCT-1996) Immunology, DNAX Research Institute,
901
               California Ave., Palo Alto, CA 94304, USA
FEATURES       Location/Qualifiers
               source          1..764
                           /organism="Homo sapiens"
                           /db_xref="taxon:9606"
                           /cell_type="elutriated monocytes activated with
                           LPS/IFN-GAMMA"
               gene           1..291
                           /gene="MIP-3a"
               CDS            1..291
                           /gene="MIP-3a"
                           /note="chemokine"
                           /codon_start=1
                           /product="macrophage inflammatory protein 3 alpha"
                           /db_xref="PID:g1790925"

/translation="MCCTKSLLLAALMSVLLHLGGESEASNFDCCLGYTDRIHPK
FIVGFTRQLANEGCDINAIIFHTKKKLSVCANPKQTWVKYIVRLLSKVKVNM"
BASE COUNT    235 a    121 c    146 g    260 t    2 others
ORIGIN
1 atgtgctgta ccaagagttt gctcctggct gctttgatgt cagtgtgct actccacctc

```

```

61  tgcggcgaat  cagaagcagc  aagcaacttt  gactgctgtc  ttggatacac  agaccgtatt
121 cttcatccta  aattttattgt  gggcttcaca  cggcagctgg  ccaatgaagg  ctgtgacatc
181 aatgctatca  tctttcacac  aaagaaaaag  ttgtctgtgt  gcgcaaatcc  aaaacagact
241 tgggtgaaat  atattgtgcg  tctcctcagt  aaaaaagtca  agaacatgta  aaaactgtgg
301 cttttctgga  atggaattgg  acatagccca  agaacagaaa  gaaccttgct  ggggttggag
361 gtttcacttg  cacatcatgg  aggggttagt  gcttatctaa  tttgtgcctc  actggacttg
421 tccaattaat  gaagttgatt  catattgcat  catagttagc  tttgtttaag  catcacatta
481 aagttaaact  gtattttatg  ttatttatag  ctgtagggtt  tctgtgttta  gctatttaat
541 actaattttc  cataagctat  tttggtttag  tgcaaagtat  aaaattatat  ttggggggga
601 ataagattat  atggactttt  ttgcaagcaa  caagctattt  tttaaaamma  actatttaac
661 attcttttgt  ttatattgtt  ttgtctccta  aattgttgta  attgcattat  aaaataagaa
721 aaatattaat  aagacaaata  ttgaaaataa  agaaacaaaa  agtt

```

```

//
LOCUS      HSU77180      545 bp      mRNA      PRI      23-JAN-1997
DEFINITION Human macrophage inflammatory protein 3 beta (MIP-3beta) mRNA,
complete cds.
ACCESSION  U77180
NID        g1791002
KEYWORDS
SOURCE     human.
ORGANISM   Homo sapiens
            Eukaryotae; mitochondrial eukaryotes; Metazoa; Chordata;
            Vertebrata; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE  1 (bases 1 to 545)
AUTHORS    Rossi,D.L., Vicari,A.P., Franz-Bacon,K., McClanahan,T.K. and
            Zlotnik,A.
TITLE      Identification through bioinformatics of two new macrophage
            proinflammatory human chemokines: MIP-3alpha and MIP-3beta
JOURNAL    J. Immunol. 158 (3), 1033-1036 (1997)
MEDLINE    97166046
REFERENCE  2 (bases 1 to 545)
AUTHORS    Vicari,A. and Zlotnik,A.
TITLE      Direct Submission
JOURNAL    Submitted (01-NOV-1996) Immunology, DNAX Research Institute,
901        California Ave, Palo Alto, CA 94304, USA
FEATURES   Location/Qualifiers
            source      1..545
                        /organism="Homo sapiens"
                        /db_xref="taxon:9606"
                        /cell_type="macrophages activated with LPS or IFNg"
                        /chromosome="9"
            gene        1..297
                        /gene="MIP-3beta"
            CDS          1..297
                        /gene="MIP-3beta"
                        /function="chemokine"
                        /codon_start=1
                        /product="macrophage inflammatory protein 3 beta"
                        /db_xref="PID:g1791003"

/translation="MALLLALSLVLWTSPAPTLSGTNDACCLSVTQKPIPGYIVR

```

NFHYLLIKDGCVRPAVVFTTLRGRQLCAPPDQPWVERIIQRLQRTSAKMKRRSS"

BASE COUNT 125 a 160 c 153 g 107 t

```

ORIGIN
1  atggccctgc  tactggccct  cagcctgctg  gttctctgga  cttccccagc  cccaactctg
61  agtggcacca  atgatgctga  agactgctgc  ctgtctgtga  cccagaaacc  catccctggg
121  tacatcgtga  ggaacttcca  ctaccttctc  atcaaggatg  gctgcagggt  gcctgctgta
181  gtgttcacca  cactgagggg  ccgccagctc  tgtgcacccc  cagaccagcc  ctgggtagaa
241  cgcacatccc  agagactgca  gaggacctca  gccaaagatg  agcgccgcag  cagttaacct
301  atgaccgtgc  agagggagcc  cggagtccga  gtcaagcatt  gtgaattatt  acctaacctg
361  ggggaaccgag  gaccagaagg  aaggaccagg  cttccagctc  ctctgcacca  gacctgacca
421  gccaggacag  ggccctgggt  gtgtgtgagt  gtgagtgtga  gcgagagggg  gagtgtggtc
481  tagagtaaag  ctgctccacc  cccagattgc  aatgctacca  ataaagccgc  ctgggtgtta
541  caact

```

```

//
LOCUS      HUMTCSM      1160 bp      mRNA      PRI      15-JUN-1989
DEFINITION Human T cell-specific protein (RANTES) mRNA, complete cds.
ACCESSION  M21121
NID        g339420

```


KEYWORDS Alu repeat; T-cell-specific protein.
 SOURCE Human peripheral blood (T lymphocyte) cell line AH2, cDNA to mRNA,
 clone 228.
 ORGANISM Homo sapiens
 Eukaryotae; mitochondrial eukaryotes; Metazoa; Chordata;
 Vertebrata; Eutheria; Primates; Catarrhini; Hominidae; Homo.
 REFERENCE 1 (bases 1 to 1160)
 AUTHORS Schall,T.J., Jongstra,J., Dyer,B.J., Jorgensen,J.,
 Clayberger,C., Davis,M.M. and Krensky,A.M.
 TITLE A human T cell-specific molecule is a member of a new gene family
 JOURNAL J. Immunol. 141, 1018-1025 (1988)
 MEDLINE 88285659
 COMMENT Draft entry and computer-readable sequence for [1] kindly provided
 by A.M.Krensky, 24-OCT-1988.

FEATURES
 source Location/Qualifiers
 1..1160
 /organism="Homo sapiens"
 /db_xref="taxon:9606"
 CDS
 27..302
 /note="T cell-specific protein precursor"
 /codon_start=1
 /db_xref="PID:g339421"
 /translation="MKVSAARLAVILIATALCAPASAPYSSDTPCCFAYIARPLPR
 AHIKEYFYTSGKCSNPVVFVTRKNRQVCANPEKKWVREYINSLEMS"
 sig_peptide 27..95
 /note="T cell-specific protein signal peptide"
 mat_peptide 96..299
 /note="T cell-specific protein"
 repeat_region 450..950
 /note="Alu-related repeats"
 BASE COUNT 298 a 332 c 295 g 235 t
 ORIGIN 276 bp upstream of RsaI site.
 1 cctccgacag cctctccaca ggtaccatga aggtctccgc ggcacgcctc gctgtcatcc
 61 tcattgctac tgccctctgc gctcctgcat ctgcctcccc atattcctcg gacaccacac
 121 cctgtgtgctt tgccctacatt gcccgccac tgcccggtgc ccacatcaag gagtatttct
 181 acaccagtgg caagtgtctc aaccagcag tcgtctttgt caccgcaaag aaccgccaag
 241 tgtgtgccaa cccagagaag aaatgggttc gggagtacat caactctttg gagatgagct
 301 aggatggaga gtccttgaac ctgaacttac acaaatttgc ctgtttctgc ttgctcttgt
 361 cctagcttgg gaggtctccc ctactatcc taccaccacc gctccttgaa gggcccagat
 421 tctgaccacg acgagcagca gttacaaaaa cttccccag gctggacgtg gtggctcagc
 481 cttgtaatcc cagcactttg ggaggccaag gtgggtggat cacttgaggt caggagttcg
 541 agacagcctg gccaacatga tgaaacccca tgtgtactaa aaatacaaaa aattagccgg
 601 gcgtggtagc gggcgctgt agtccagct actcgggagg ctgaggcagg agaattggct
 661 gaacccggga gcggagcttg cagttagccg agatcgcgcc actgcactcc agcctgggcg
 721 acagagcgag actccgtctc aaaaaaaaaa aaaaaaaaaa aaaaaatata aaaattagcc
 781 gcgtgggtgc ccacgcctgt aatcccagct actcgggagg ctaaggcagg aaaattgttt
 841 gaacccagga ggtggaggct gcagttagct gagattgtgc cacttcactc cagcctgggt
 901 gacaaagtga gactccgtca caacaacaac aacaaaaagc ttccccaact aaagcctaga
 961 agagcttctg aggcgtgct ttgtcaaaaag gaagtctcta ggttctgagc tctggctttg
 1021 ccttggcttt gcaagggctc tgtgacaagg aaggaagtca gcatgcctct agaggcaagg
 1081 aagggaggaa cactgcactc ttaagcttcc gccgtctcaa cccctcacag gagcttactg
 1141 gcaaacatga aaatcgggg

//
 LOCUS HUMTLI309 520 bp mRNA PRI 14-JAN-1995
 DEFINITION Human secreted protein (I-309) mRNA, complete cds.
 ACCESSION M57502
 NID g339728
 KEYWORDS secreted protein.
 SOURCE Human T-cell, cDNA to mRNA.
 ORGANISM Homo sapiens
 Eukaryotae; mitochondrial eukaryotes; Metazoa; Chordata;
 Vertebrata; Eutheria; Primates; Catarrhini; Hominidae; Homo.
 REFERENCE 1 (bases 1 to 520)
 AUTHORS Miller,M.D., Hata,S., De Waal Malefyt,R. and Krangel,M.S.
 TITLE A novel polypeptide secreted by activated human T lymphocytes
 JOURNAL J. Immunol. 143 (9), 2907-2916 (1989)

MEDLINE 90038522

FEATURES Location/Qualifiers
 source 1..520
 /organism="Homo sapiens"
 /db_xref="taxon:9606"
 /cell_type="T-cell"
 /germline
 /map="17"
 mRNA <1..520
 /gene="SCYA1"
 /note="G00-118-872"
 gene 1..520
 /gene="SCYA1"
 CDS 51..341
 /gene="SCYA1"
 /codon_start=1
 /db_xref="GDB:G00-118-872"
 /product="secreted protein I-309"
 /db_xref="PID:g339729"

/translation="MQIITALLVCLLLAGMWPEDVDSKSMQVPFSRCCFSFAEQEIPL
 RAILCYRNTSSICSNEGLIFKLKRGKEACALDTVGWVQRHRKMLRHCPSKRK"

BASE COUNT 140 a 137 c 122 g 121 t
 ORIGIN

1 accaggctca tcaagctgc tccaggaagg cccaagccag accagaagac atgcagatca
 61 tcaccacagc cctgggtgtgc ttgctgctag ctgggatgtg gccggaagat gtggacagca
 121 agagcatgca ggtacccttc tccagatggt gcttctcatt tgcggagcaa gagattcccc
 181 tgagggcaat cctgtgttac agaaatacca gctccatctg ctccaatgag ggcttaatat
 241 tcaagctgaa gagaggcaaa gaggcctgcg ccttggacac agttggatgg gtccagagge
 301 acagaaaaat gctgaggcac tgcccgtcaa aaagaaaatg agcagatttc ttccattgt
 361 gggctctgga aaccacatgg cttcacctgt ccccgaaact accagcccta caccattcct
 421 tctgccctgc ttttgctagg tcacagagga tctgcttggt cttgataagc tatgttggtg
 481 cactttaaac atttaaatta tacaatcatc aaccccaac

//
 LOCUS AB000887 687 bp mRNA PRI 05-JUN-1997
 DEFINITION Human mRNA for EB11-ligand chemokine, complete cds.
 ACCESSION AB000887
 NID g2189952
 KEYWORDS EB11-ligand chemokine; ELC.
 SOURCE Homo sapiens fetal tissue_lib:lung cDNA to mRNA.
 ORGANISM Homo sapiens
 Eukaryotae; mitochondrial eukaryotes; Metazoa; Chordata;
 Vertebrata; Mammalia; Eutheria; Primates; Catarrhini;
 Hominidae;
 Homo.
 REFERENCE 1 (bases 1 to 687)
 AUTHORS Yoshida,R., Imai,T., Hieshima,K., Kusuda,J., Baba,M.,
 Kitaura,M., Nishimura,M., Kakizaki,M., Nomiya,H. and Yoshie,O.
 TITLE Direct Submission
 JOURNAL Submitted (05-FEB-1997) to the DDBJ/EMBL/GenBank databases.
 Hisayuki Nomiya, Kumamoto University Medical School,
 Department of Biochemistry; Honjo 2-2-1, Kumamoto, Kumamoto 860, Japan
 (E-mail:nomiya@gpo.kumamoto-u.ac.jp, Tel:+81-96-373-5063)
 REFERENCE 2 (sites)
 AUTHORS Yoshida,R., Imai,T., Hieshima,K., Kusuda,J., Baba,M.,
 Kitaura,M., Nishimura,M., Kakizaki,M., Nomiya,H. and Yoshie,O.
 TITLE Molecular cloning of a novel human CC chemokine EB11-ligand
 chemokine that is a specific functional ligand for EB11, CCR7
 J. Biol. Chem. 272 (21), 13803-13809 (1997)
 MEDLINE 97298088

FEATURES Location/Qualifiers
 source 1..687
 /organism="Homo sapiens"
 /db_xref="taxon:9606"
 /dev_stage="fetal"
 /tissue_lib="lung"
 gene 139..435
 /gene="ELC"

```

CDS          139..435
              /gene="ELC"
              /note="CC chemokine"
              /codon_start=1
              /product="EBI1-ligand chemokine"
              /db_xref="PID:d1021215"
              /db_xref="PID:g2189953"

/translation="MALLLLALLVLTSPAPTLSGTNDACCLSVTQKPIPGYIVR
NFHYLLIKDGCVRPAVVFTTLRGRQLCAPPDQPWVERIIQRLQRTSAKMKRSS"
mat_peptide  202..432
              /gene="ELC"
              /product="EBI1-ligand chemokine"
polyA_signal  657..662
BASE COUNT   154 a    223 c    173 g    137 t
ORIGIN
1  cattcccagc ctcacatcac tcacaccttg catttcaccc ctgcatccca gtcgccctgc
61 agcctcacac agatcctgca cacacccaga cagctggcgc tcacacattc accgttggcc
121 tgcctctgtt caccctccat ggccctgcta ctggccctca gcctgctggt tctctggact
181 tccccagccc caactctgag tggcaccaat gatgctgaag actgtgcctt gtctgtgacc
241 cagaaaccca tccctgggta catcgtgagg aacttccact accttctcat caaggatggc
301 tgcaggggtg ctgctgtagt gttcaccaca ctgagggggc gccagctctg tgcaccccca
361 gaccagccct gggtagaacg catcatccag agactgcaga ggacctcagc caagatgaag
421 gcgcgcagca gttaacctat gaccgtgcag agggagcccg gagtccgagt caagcattgt
481 gaattattac ctaacctggg gaaccgagga ccagaaggaa ggaccaggct tccagctcct
541 ctgcaccaga cctgaccagc caggacaggg cctgggggtg gtgtgagtg gtgtgtgagc
601 gagagggtga gtgtggtcag agtaaaagctg ctccaccccc agattgcaat gctaccaata
661 aagccgcctg gtgtttacaa ctaattg

//
LOCUS       AB000221      760 bp      mRNA          PRI          31-JUL-1997
DEFINITION  Homo sapiens mRNA for CC chemokine, complete cds.
ACCESSION   AB000221
NID         g2289718
KEYWORDS    CC chemokine; PARC; pulmonary and activation-regulated
            chemokine.
SOURCE      Homo sapiens lung cDNA to mRNA.
ORGANISM    Homo sapiens
            Eukaryotae; mitochondrial eukaryotes; Metazoa; Chordata;
            Vertebrata; Mammalia; Eutheria; Primates; Catarrhini;
Hominidae; Homo.
REFERENCE   1 (bases 1 to 760)
AUTHORS    Nomiya, H.
TITLE      Direct Submission
JOURNAL    Submitted (04-JAN-1997) to the DDBJ/EMBL/GenBank databases.
            Hisayuki Nomiya, Kumamoto University Medical School,
Department of Biochemistry; Honjo 2-2-1, Kumamoto, Kumamoto 860, Japan
            (E-mail:nomiyama@gpo.kumamoto-u.ac.jp. Tel:81-96-373-5063,
            Fax:81-96-372-6140)
REFERENCE   2 (sites)
AUTHORS    Hieshima, K., Imai, T., Baba, M., Shoudai, K., Ishizuka, K.,
            Nakagawa, T., Tsuruta, J., Takeya, M., Sakaki, Y., Takatsuki, K.,
            Miura, R., Opdenakker, G., Damme, J., Yoshie, O. and Nomiya, H.
TITLE      A novel human CC chemokine PARC that is most homologous to
            macrophage-inflammatory protein-lalpha/LD78alpha and
chemotactic for T lymphocytes, but not for monocytes
JOURNAL    J. Immunol. 159 (3), 1140-1149 (1997)
MEDLINE    97376836
FEATURES    Location/Qualifiers
            source          1..760
                        /organism="Homo sapiens"
                        /db_xref="taxon:9606"
                        /tissue_type="lung"
            gene            64..333
                        /gene="PARC"
            CDS              64..333
                        /gene="PARC"
                        /note="pulmonary and activation-regulated chemokine"

```

/codon_start=1
 /product="CC chemokine"
 /db_xref="PID:d1022520"
 /db_xref="PID:g2289719"

/translation="MKGLAAALLVLVCTMALCSAQVGTNKLCLVYTSWQIPQKFI
 VDYSETSPQCPKPGVILLTKRGRQICADPNKKWVQKYISDLKLNA"

BASE COUNT 186 a 208 c 155 g 211 t
 ORIGIN

```

1 gccaggagtt gtgagtttcc aagccccagc tcactctgac cacttctctg cctgcccagc
61 atcatgaagg gccttgacgc tgccctcctt gtcctcgtct gcaccatggc cctctgctcc
121 tgtgcacaag ttggtacca ccaagagctc tgcctgcctc tctatacctc ctggcagatt
181 ccacaaaagt tcatagtga ctattctgaa accagcccc agtgcccaa gccagggtgc
241 atcctcctaa ccaagagagg ccggcagatc tgtgctgacc ccaataagaa gtgggtccag
301 aaatacatca ggcacctgaa gctgaatgcc tgaggggccc ggaagctgcg agggcccagt
361 gaacttggtg ggcccaggag ggaacaggag cctgagccag ggcaatggcc ctgccaccct
421 ggaggccacc tcttctaaga gtcccatctg ctatgccag ccacattaac taactttaat
481 cttagtttat gcatcatatt tcattttgaa attgatttct attgttgagc tgcattatga
541 aattagtatt ttctctgaca tctcatgaca ttgtctttat catcctttcc cctttccctt
601 caactcttcg tacattcaat gcattggata atcagtgatg ttagctttct cagcagacat
661 tgtgccatat gtatcaaatg acaaatcttt attgaatggt ttgtctcagc accacctttt
721 aatatattgg cagtacttat tatataaaag gtaaacaccg

```

//
 LOCUS D86955 799 bp mRNA PRI 06-MAR-1997
 DEFINITION Human mRNA for CC chemokine LARC precursor, complete cds.
 ACCESSION D86955
 NID g1871138
 KEYWORDS CC chemokine LARC precursor.
 SOURCE Homo sapiens cDNA to mRNA.
 ORGANISM Homo sapiens
 Eukaryotae; mitochondrial eukaryotes; Metazoa; Chordata;
 Vertebrata; Mammalia; Eutheria; Primates; Catarrhini;

Hominidae;
 Homo.
 REFERENCE 1 (sites)
 AUTHORS Hieshima,K., Imai,T., Opdenakker,G., Van Damme,J., Kusuda,J.,
 Tei,H., Sakaki,Y., Takatsuki,K., Miura,R., Yoshie,O. and
 Nomiya,H.
 TITLE Molecular cloning of a novel human CC chemokine liver and
 activation-regulated chemokine (LARC) expressed in liver.
 Chemotactic activity for lymphocytes and gene localization on
 chromosome 2
 JOURNAL J. Biol. Chem. 272 (9), 5846-5853 (1997)
 MEDLINE 97190319
 REFERENCE 2 (bases 1 to 799)
 AUTHORS Hieshima,K., Imai,T., Opdenakker,G., Van Damme,J., Kusuda,J.,
 Tei,H., Sakaki,Y., Takatsuki,K., Miura,R., Yoshie,O. and
 Nomiya,H.
 JOURNAL Unpublished (1996)
 REFERENCE 3 (bases 1 to 799)
 AUTHORS Nomiya,H.
 TITLE Direct Submission
 JOURNAL Submitted (08-AUG-1996) to the DDBJ/EMBL/GenBank databases.
 Hisayuki Nomiya, Kumamoto University Medical School,

Department of Biochemistry; Honjo 2-2-1, Kumamoto, Kumamoto 860, Japan
 (E-mail:nomiya@gpo.kumamoto-u.ac.jp, Tel:+81-96-373-5063)

FEATURES
 source Location/Qualifiers
 1..799
 /organism="Homo sapiens"
 /db_xref="taxon:9606"
 /chromosome="2"
 /map="q33-37"
 sig_peptide 59..136
 /gene="LARC"
 CDS 59..349
 /gene="LARC"
 /codon_start=1
 /product="CC chemokine LARC precursor"
 /db_xref="PID:d1013880"
 /db_xref="PID:g1871139"

```

/translation="MCCTKSLLLAALMSVLLHLGGESEAA SNFDCCLGYTDRILHPK
FIVGFTRQLANEGCDINAIIFHTKKLSVCANPKQTWVKYIVRLLSKVKNM"
gene          59..349
mat_peptide   /gene="LARC"
              137..346
              /gene="LARC"
              /product="CC chemokine LARC"
BASE COUNT    240 a    138 c    153 g    268 t
ORIGIN
1  cactcccaaa gaactgggta ctcaacactg agcagatctg ttctttgagc taaaaaccat
61 gtgctgtacc aagagtttgc tcctgggtgc tttgatgtca gtgctgctac tccacctctg
121 cggcgaaatca gaagcagcaa gcaactttga ctgctgtctt ggatacacag accgtattct
181 tcatacctaaa ttattgtggt gcttcacacg gcagctggcc aatgaaggct gtgacatcaa
241 tgctatcatc ttccacacaa agaaaaagtt gtctgtgtgc gcaaatccaa aacagacttg
301 ggtgaaatat attgtgcgtc tcctcagtaa aaaagtcaag aacatgtaaa aactgtggct
361 ttcttggaat ggaattggac atagcccaag aacagaaaga accttgctgg ggttggaggt
421 ttcacttgca catcatggag ggtttagtgc ttatctaatt tgtgcctcac tggacttgtc
481 caattaatga agttgattca tattgcatca tagtttgctt tgtttaagca tcacattaaa
541 gttaaaactgt attttatggt atttatagct gtaggttttc tgtgtttagc tatttaatac
601 taattttcca taagctattt tggtttagtg caaagtataa aattatattt gggggggaat
661 aagattatat ggactttctt gcaagcaaca agctattttt taaaaaaact atttaacatt
721 cttttgttta tattgttttg tctcctaaat tgttgtaatt gcattataaa ataagaaaaa
781 cattaataag acaaatatt

//
LOCUS          HUMAR          538 bp    mRNA          PRI          11-SEP-1996
DEFINITION     Human mRNA for chemokine, complete cds.
ACCESSION      D43767
NID            g1536878
KEYWORDS       chemokine, thymus and activation-regulated; chemokine.
SOURCE         Homo sapiens male peripheral blood cDNA to mRNA, clone:D3A.
ORGANISM       Homo sapiens
               Eukaryotae; mitochondrial eukaryotes; Metazoa; Chordata;
               Vertebrata; Mammalia; Eutheria; Primates; Catarrhini;
               Hominidae;
               Homo.
REFERENCE      1 (sites)
AUTHORS        Imai,T., Yoshida,T., Baba,M., Nishimura,M., Kakizaki,M. and
               Yoshie,O.
TITLE          Molecular cloning of a novel T cell-directed CC chemokine
expressed      in thymus by signal sequence trap using Epstein-Barr virus
vector
JOURNAL        J. Biol. Chem. 271 (35), 21514-21521 (1996)
MEDLINE        96355526
REFERENCE      2 (bases 1 to 538)
AUTHORS        Imai,T.
JOURNAL        Unpublished (1996)
REFERENCE      3 (bases 1 to 538)
AUTHORS        Imai,T.
TITLE          Direct Submission
JOURNAL        Submitted (07-DEC-1994) to the DDBJ/EMBL/GenBank databases.
Toshio
               Imai, Shionogi Institute for Medical Science; 2-5-1 Mishima,
               Settsu, Osaka 566, Japan (Tel:06-382-2612, Fax:06-382-2598)
FEATURES
  source       1..538
               /organism="Homo sapiens"
               /db_xref="taxon:9606"
               /clone="D3A"
               /sex="male"
               /tissue_type="peripheral blood"
  CDS          53..337
               /note="thymus and activation regulated"
               /codon_start=1
               /product="chemokine"
               /db_xref="PID:d1008410"
               /db_xref="PID:g1536879"

/translation="MAPLKMALVLTLLGASLQHIHAARGTNVGRECCLEYFKGA IPL
RK LKTWYQTS EDCSRDAIVFVTVQGRAICSDPNNKRVKNAVKYLQSLERS"

```

```

BASE COUNT      118 a      168 c      149 g      103 t
ORIGIN
    1 ccctgagcag agggacctgc acacagagac tccctcctgg gctcctggca ccatggcccc
   61 actgaagatg ctggccctgg tcacctcctt cctgggggct tctctgcagc acatccacgc
  121 agctcgaggg accaatgtgg gccgggagtg ctgcctggag tacttcaagg gagccattcc
  181 ccttagaaag ctgaagacgt ggtaccagac atctgaggac tgctccaggg atgccatcgt
  241 ttttctaact gtgcagggca gggccatctg ttcggacccc aacaacaaga gagtgaagaa
  301 tgcagttaaa tacctgcaaa gccttgagag gtcttgaagc ctccctaccc cagactcctg
  361 actgtctccc gggactacct gggacctcca cgttgggtgt tcaccgcccc caccctgagc
  421 gcctgggtcc agggggaggcc ttccagggac gaagaagagc cacagtgagg gagatcccat
  481 ccccttgtct gaactggagc catgggcaca aaggggccag attaaagtct ttatcctc

```

//

```

LOCUS      HUMEOTAXIN      807 bp      mRNA      PRI      25-SEP-1996
DEFINITION Human mRNA for eotaxin, complete cds.
ACCESSION  D49372
NID        gl552240
KEYWORDS   eotaxin; eosinophil-selective CC chemokine; chemoattractant.
SOURCE     Homo sapiens Small intestine, proximal cDNA to mRNA, clone:141.
ORGANISM   Homo sapiens
            Eukaryotae; mitochondrial eukaryotes; Metazoa; Chordata;
            Vertebrata; Mammalia; Eutheria; Primates; Catarrhini;
Hominidae;

```

```

REFERENCE  1 (bases 1 to 807)
AUTHORS    Kitaura,M., Nakajima,T., Imai,T., Harada,S., Combadiere,C.,
            Tiffany,H.L., Murphy,P.M. and Yoshie,O.
TITLE      Molecular cloning of human eotaxin, an eosinophil-selective CC
            chemokine, and identification of a specific eosinophil eotaxin
            receptor, CC chemokine receptor 3
JOURNAL     J. Biol. Chem. 271 (13), 7725-7730 (1996)
MEDLINE     96205964
REFERENCE  2 (bases 1 to 807)
AUTHORS    Yoshie,O.
TITLE      Direct Submission
JOURNAL     Submitted (15-FEB-1995) to the DDBJ/EMBL/GenBank databases.
Osamu

```

```

Yoshie, Shionogi Institute for Medical Science; 2-5-1 Mishima,
Settsu, Osaka 566, Japan (E-mail:osamu.yoshie@shionogi.co.jp,
Tel:06-382-2612, Fax:06-382-2598)

```

```

COMMENT     On Sep 20, 1996 this sequence version replaced gi:1313900.

```

```

FEATURES
    source          1..807
                    /organism="Homo sapiens"
                    /db_xref="taxon:9606"
                    /clone="141"
                    /tissue_type="Small intestine, proximal"
    CDS              99..392
                    /codon_start=1
                    /product="eotaxin"
                    /db_xref="PID:d1008966"
                    /db_xref="PID:gl552241"

```

```

/translation="MKVSAALLWLLLIAAAFSPQGLAGPASVPTTCCFNLANRKIPLO
RLESYRRITSGKCPQKAVIFKTKLAKDICADPKKKWVQDSMKYLDQKSPTPKP"
misc_signal        548..557
                    /note="mRNA destabilization signal"
polyA_signal       775..780
polyA_site         807

```

```

BASE COUNT      229 a      198 c      147 g      233 t
ORIGIN

```

```

    1 gcattttttc aagtttttatg atttatttaa cttgtggaac aaaaataaac cagaaaccac
   61 cacctctcac gccaaagctc acaccttcag cctccaacat gaaggtctcc gcagcatttc
  121 tgtggctgct gctcatagca gctgccttca gccccagggt gctcgctggg ccagctttctg
  181 tcccaaccac ctgctgcttt aacctggcca ataggaagat acccttccag cgactagaga
  241 gctacaggag aatcaccagt ggcaaatgtc cccagaaagc tgtgatcttc aagaccaaac
  301 tggccaagga tatctgtgcc gaccccaaga agaagtgggt gcaggattcc atgaagtatc
  361 tggacaaaaa atctccaact ccaaagccat aaataatcac catttttgaa accaaaccag
  421 agcctgagtg ttgcctaatt tgttttcctt tcttacaatg cattctgagg taacctcatt
  481 atcagtccaa agggcatggg ttttattata tatatatata tttttttttt aaaaaaaac
  541 gtattgcatt taattttattg aggcctttaa acttatcctc catgaatatc agttattttt

```

```

601 aaactgtaaa gctttgtgca gattctttac cccctgggag cccaattcg atcccctgtc
661 acgtgtgggc aatgttcccc ctctcctctc ttctccctg gaattctgta aaggtcctgg
721 caaagatgat cagtatgaaa atgtcattgt tcttgtgaac ccaaagtgtg actcattaaa
781 tggaagtaaa tggtgtttta ggaatac

```

```

//
LOCUS      HSCCCHM      232 bp      RNA      PRI      10-SEP-1996
DEFINITION H.sapiens mRNA for CC-chemokine.
ACCESSION  Z69291
NID        g1181148
KEYWORDS   CC-chemokine.
SOURCE     human.
ORGANISM   Homo sapiens
            Eukaryotae; mitochondrial eukaryotes; Metazoa; Chordata;
            Vertebrata; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE  1 (bases 1 to 232)
AUTHORS    Bartels,J.H., Schlueter,C., Richter,E., Christophers,E. and
            Schroeder,J.M.
TITLE      Cloning of a novel human chemokine homologous to human monocyte
            chemoattractant proteins and rodent eotaxins
JOURNAL    Unpublished
REFERENCE  2 (bases 1 to 232)
AUTHORS    Bartels,J.H.
TITLE      Direct Submission
JOURNAL    Submitted (01-FEB-1996) Bartels J. H.,
            Christian-Albrechts-Universitaet zu Kiel,
            Dermatology/Hautklinik,
            Mol.Biol.Lab.609, Schittenhelmstr. 7, Kiel, Schleswig-Holstein,
            Germany, D-24105
REFERENCE  3 (bases 1 to 232)
AUTHORS    Bartels,J., Schluter,C., Richter,E., Noso,N., Kulke,R.,
            Christophers,E. and Schroeder,J.M.
TITLE      Human dermal fibroblasts express eotaxin: molecular cloning,
            mRNA
            expression, and identification of eotaxin sequence variants
JOURNAL    Biochem. Biophys. Res. Commun. 225 (3), 1045-1051 (1996)
MEDLINE    96374440
FEATURES   Location/Qualifiers
            source          1..232
                             /organism="Homo sapiens"
                             /db_xref="taxon:9606"
                             /clone="clones 4(9512),
                             14(9512),15(9512),10(9601),11(9601)"
                             /tissue_type="foreskin"
                             /cell_type="fibroblast"
                             /sex="Male"
            mRNA            <1..>232
                             /citation=[1]
                             /product="CC-chemokine"
            sig_peptide     56..109
                             /citation=[1]
            CDS              56..>232
                             /function="putative chemoattractant protein"
                             /note="sequence homology to human MCP-1, MCP-2 and
            MCP-3           and to rodent eotaxins"
                             /citation=[1]
                             /codon_start=1
                             /product="CC-chemokine, preprotein"
                             /db_xref="PID:e221070"
                             /db_xref="PID:g1181149"
                             /db_xref="SWISS-PROT:P50877"
            /translation="MKVSAALLWLLLIAAFSPQGLAGPASVPTCCFNLANRKIPLQ
            RLESYRRITSGKCPQ"
            mat_peptide      110..>232
                             /citation=[1]
                             /function="putative chemoattractant protein"
                             /product="CC-chemokine"
BASE COUNT 55 a      82 c      50 g      42 t      3 others
ORIGIN
1 accaaaccag aaaccwccam ytctcagccc aaagtcaca ccttcagcct ccaacatgaa

```

```

        61 ggtctccgca ggcgttctgt ggctgtgct catagcggct gccttcagcc cccaggggct
       121 cgctgggcca gcttctgtcc caaccacctg ctgctttaac ctggccaata ggaagatacc
       181 ccttcagcga ctagagagct acaggagaat caccagtggc aaatgtcccc ag
//
LOCUS      HSHCC1GEN      4037 bp      DNA      PRI      01-OCT-1995
DEFINITION H.sapiens gene for chemokine HCC-1.
ACCESSION  Z49269
NID        g1004266
KEYWORDS   chemokine.
SOURCE      human.
ORGANISM    Homo sapiens
             Eukaryotae; mitochondrial eukaryotes; Metazoa; Chordata;
             Vertebrata; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE  1 (bases 1 to 4037)
AUTHORS     Pardigol,A., Maegert,H.J., Cieslak,A., Hill,O., Schulz-
Knappe,P.
TITLE       and Forssmann,W.G.
             Nucleotide Sequence of the Gene for the Human Chemokine HCC-1
JOURNAL     Unpublished
REFERENCE  2 (bases 1 to 4037)
AUTHORS     Pardigol,A.
TITLE       Direct Submission
JOURNAL     Submitted (18-MAY-1995) Andreas Pardigol, Molecular Biology,
Lower
             Saxony Institute for Peptide Research, Feodor-Lynen-Strasse 31,
             Hannover, Lower Saxon, 30625, Germany
FEATURES
  source          Location/Qualifiers
                   1..4037
                   /organism="Homo sapiens"
                   /db_xref="taxon:9606"
                   /clone="ph3b7"
                   /dev_stage="adult"
                   /tissue_type="placenta"
                   /clone_lib="lambda FIX II, Cat.Nr. 946203, Stratagene"
                   /sex="male"
  TATA_signal     727..733
                   /note="putative, determined by consensus rules."
  5'UTR           764..833
                   /note="first base determined by means of consensus
rules"
  exon            764..912
                   /note="first base determined by means of consensus
rules;"
                   base 780 is the first base of cDNA (Z49270)"
                   /number=1
  CDS             join(834..912,3021..3135,3585..3672)
                   /codon_start=1
                   /product="chemokine HCC-1"
                   /db_xref="PID:g1004267"
/translation="MKISVAAIPFFLLITIALGKTESSSRGPYHPSECCFTYTTYKI
PRQRIMDYIYETNSQCSKPGIVFITKRGHSVCTNPSPDKWQDYIKDMKEN"
  intron          913..3020
                   /number=1
  exon            3021..3135
                   /number=2
  intron          3136..3584
                   /number=2
  exon            3585..3817
                   /number=3
  3'UTR           3673..3817
BASE COUNT      1023 a 1048 c 1004 g 962 t
ORIGIN
1 gagctccggtt gggagtccca tgtttcttta tggcataatg ggtgagaaca cagacttgga
61 agccaaacca cctgaatttg aaccccagtt ccatttacca actgtcaaaa gcttaggctt
121 tgattctaag cctgtttcct caactgctgt tctaaagatt aaataggcta atattcataa
181 ggcaactggg acagtggcct gtgtgtatag caaccattat ataagtgaat tatctactga
241 gcaccacagc acttcttcac tccatgggtg ggtgaccaga atggagatga gacagagaac
301 tgcagggttct gcttcgagtt taagttagga ttcccttga ccaatgagac ctgacttgga
361 ggagtccctg cctcattcca ttaccccaaa caccctctag tctctagatg aacagatcct
421 gaatgtccag gcccccagtg gcctgttcta aggcctgaga tggaaattgga tacaggacac

```



```

481 atccagcctt gagatctttt gctaagtgtg acacagtggc cccagccctg tgctcatgtt
541 catgcctagg gaaaggcttc tatcaaaaga gttgaacttc tccccactgg ggaagggaaga
601 ccatttctct ccttaaacct tggctctccc tgcttctctc agggccacca caacacatgt
661 gcaggatag aaattgctga ggcactactg ctttctact tcccccca gtctcagctc
721 ccttatttta aaaaatattt ggcctcaatg atcatttctc aacaattcct caccgcagga
781 gcctctgaag ctcccaccag gccagctctc ctcccacaac agcttccac agcatgaaga
841 tctccgtggc tgccattccc ttcttctctc tcaccacctc cgccctaggg accaagactg
901 aatcctctct acgtgagtg acgtgagtg aatgccttgt cttccttcca acctagagcc tgcagggaaga
961 taagcaggag tgaggttggg gctcaggagg agaccaggag cagggactca gaaaggaggg
1021 ctggtatctt cttgaaattg tgtgtatagc aacattatat aaatgaatta tctactgagc
1081 accacagcac ttcaccccat ggtgtgtgtg gcaggatgga gatgagactt aggactgtag
1141 gttctgctta agagttaag ttgggatctt ccagccttga ccaatgagac ttgacttggg
1201 agactccagg cttcatttcca ctaccccaaa tgccctctag tctccaaata aacagatcct
1261 gaatctccag gcctcacatg gccttgatct cttatcattg cccccaggga ccagtcctctc
1321 cttgccctca aggacatgga gtgagaccag cctgctctct tactcctca atttctctct
1381 ctttgccgct aagcaaaaga gtggccacc ccatttgggg tatatttctt caggagattt
1441 aggagcagtg tcttgagccc ctcaagggca ttttctattt ggcctcttga ggtttggggc
1501 cagcctgctt ccagcgtcac ctgtgcccag tgagtgcagc attgcttggg tatgggctgg
1561 ggggaaacac gacagtgtgg ggtccatcct agggccctct tctcagctg atttcttaga
1621 ataagctgcc tttagagata accaaaacta ttatcactc ttccatttta cctactctcc
1681 ttttcagaaa ctggggggaa accgaagggt gttaaaatag agctaaagt ggtaggttag
1741 tgcacagttt gacttgccct ctccgatgtc atttgtcagc tcagaggaaac aagggtgggag
1801 agtataggag ctctgactgg gtctcaggaa acagggggcc cttatgccgt tctttggatg
1861 gtgaggatgc tgccctggaat ggagctggaa aacaggatga gaccttcca ccagacatc
1921 tggccaccct cagtgcctc tgaggccatt gtgatgcaca tccatgattc tatgaagcag
1981 ggtcacataa catgcacaca cctgatttct ccactccata accacaacat gtgcctgttt
2041 gtacagggtc cttggcctac aatgtccttc ctgctacctc tataattcaa gcttggggtg
2101 gctgctgtca ccttgcttct cctataaaag ccatgaaact tctcaatcag aaaaatagatg
2161 aaaaaatcac ccaatccagt gattttttaa actttttaga ccacaaaacc ttttctcaa
2221 gcaatatctt ccacagaggc ccaatatgta aaacagaaaa aatgggttga gtaggggtaca
2281 agacaccact ctcaaatgca gcaaggcctc cacaatagtc cctgaggccc ccagagctca
2341 gtgtaaaaac cactgatgca gtccaaaggc ctcatttaca gaggagggaa cagggggaaa
2401 gtataaatggc cacagtacac aggaagcaca ggcaagggtt ggttaggatt tgggtgcctt
2461 gactctgtgg ctttctctct tggggcttgc tgtgggcac cgtctctctc tgcaggttgt
2521 cggttcaatg gggacatggg cagggtggag cactaggagg ggctgggttt gcatcccaa
2581 atggcatgtc tccaaatccc tattgggatt tcttccaaat attcctccta tttggagcac
2641 ctttcccgaa taaggcatga aggcctgcat atattggcca agtccctagc cttctctgcc
2701 agtcggcccc cagagatggt gtaagaagat ctgagtgtgc tgctctcaa tctggagtt
2761 gaaagtcac caccagtctt tccaagaggg gttgaagaaa aggaggaagg gtgattgatg
2821 atgaggagg agaaaaagaa gagcccagga gtaccatgga gaaggagaag agaagatgag
2881 gaaagcctac tctccctcc aagtctctag gggctgtctc ctcttctct cctctctcca
2941 tgccctcagc ttgcaggagc agccaatggt atggccttta acaaggggccc cctctcagc
3001 atctgatgct ctctctcag ggggacctta ccacctca gatgtctgt tcaactacac
3061 tacctacaag atcccgcgtc agcggattat ggattactat gagaccaaca gccagtgtct
3121 caagcccga attgtgtagg tggtagacac acatcacact ggggggagag ggagccagca
3181 gggcctcctg gaggaaagca gggagtgtgt gtggaatggg gacccccagc gtacctcca
3241 ggtgtgacta catggggaga ggcagctgag gggcaatctg agcgtcttct ggctggagcc
3301 tgaggagacc atggggaaac tgaccccatg gatggggaga tgacagagaa gggagaagaa
3361 ggcaagagg cacttctca gggggacaca gagactagat ggttctagg gtcctaggaa
3421 ccgaagagta tgtctcagag aggagactgg ctctaagctg cctctgtgga agaaaggaaa
3481 agcagtatag gtcaggtggg gaatttagga gggagggaag atgggctgtc tcttccggcc
3541 actgggcccc tcggtttgtg atccttctcc ctcttctctc acagcttcat caccaaaagg
3601 ggccattccg tctgtaccaa ccccagtgc aagtgggtcc aggtactat caaggacatg
3661 aaggagaact gagtgacca gaaggggtgg cgaaggcaca gctcagagac ataaagagaa
3721 gatgccaagg cccctcctc caccaccgc taactctcag cccagtcac cctcttggag
3781 cttcctctgt ttgaattaaa gaccactcat gctcttccct ggctctattc cttctacg
3841 gatttactca ttggccatgc actgaggaca ccagggtgtg gcaccctcgg catcaagcct
3901 cgctctgcag aagttttggg ggagcctggg acaaaaaata ggtcaggcct gcaatgcagg
3961 tagtgagaag cagaaagtga gaaagaaaag cagtgtaaag accgtctcct cctcagcagc
4021 aacagtagca gaccccc

```

```

//
LOCUS       HSCC21             925 bp      mRNA             PRI             30-JUN-1998
DEFINITION  H. sapiens mRNA for chemokine CC-2 and CC-1.
ACCESSION  Z70292
NID        g1296608
KEYWORDS   chemokine CC-1; chemokine CC-2.
SOURCE     human.
  ORGANISM  Homo sapiens
            Eukaryota; Metazoa; Chordata; Vertebrata; Mammalia; Eutheria;
            Primates; Catarrhini; Hominidae; Homo.
REFERENCE  1 (bases 1 to 925)

```

AUTHORS Pardigol,A., Forssmann,U., Zucht,H.D., Loetscher,P.,
 Schulz-Knappe,P., Baggiolini,M., Forssmann,W.G. and Magert,H.J.
 TITLE HCC-2, a human chemokine: gene structure, expression pattern,
 and biological activity
 JOURNAL Proc. Natl. Acad. Sci. U.S.A. 95 (11), 6308-6313 (1998)
 MEDLINE 98263352
 REFERENCE 2 (bases 1 to 925)
 AUTHORS Pardigol,A.
 TITLE Direct Submission
 JOURNAL Submitted (25-MAR-1996) Andreas Pardigol, IV - Molecular
 Biology,
 Lower Saxony Institute for Peptide Research, Feodor-Lynen-
 Strasse
 31, Hannover, Lower Saxony, 30625, Germany
 FEATURES Location/Qualifiers
 source 1..925
 /organism="Homo sapiens"
 /db_xref="taxon:9606"
 /dev_stage="adult"
 /tissue_type="liver"
 /clone_lib="PCR fragments"
 5'UTR 1..55
 CDS 56..397
 /note="putative; first coding region of a bicistronic
 mRNA"
 /codon_start=1
 /product="chemokine CC-2"
 /db_xref="PID:e233855"
 /db_xref="PID:g1296609"
 /db_xref="SWISS-PROT:Q16663"
 /translation="MKVSVAAALSCLMLVAVLGSQAQFTNDAETELMMSKLPLENPVVL
 NSFHFAADCCTSYISQSIPLCSLMKSYFETSSECSKPGVIFLTKKGRQVCAKPSGPGVQ
 DCMKKLKPYSI"
 misc_feature 398..498
 /note="spacing region between two coding regions of
 the bicistronic mRNA"
 CDS 499..780
 /codon_start=1
 /evidence=experimental
 /product="chemokine CC-1"
 /db_xref="PID:e233856"
 /db_xref="PID:g1296610"
 /db_xref="SWISS-PROT:Q16627"
 /translation="MKISVAAIPFFLLITIALGKTESSSRGPYHPSECCFTYTTYKI
 PRQRIMDYETNSQCSKPGIVFITKRGHSVCTNPSDKWVQDYIKDMKEN"
 3'UTR 781..925
 polyA_signal 902..908
 BASE COUNT 240 a 296 c 199 g 190 t
 ORIGIN
 1 ccaggaagca gtgagccag gagtctctcg ccagccctgc ctgcccacca ggaggatgaa
 61 ggtctccgtg gctgccctct cctgcctcat gcttggtgct gtccttggat cccaggccca
 121 gttcacaaat gatgcagaga cagagttaat gatgtcaaa gcttccactgg aaaaatccagt
 181 agttctgaac agctttcact ttgctgctga ctgctgcacc tcctacatct cacaaagcat
 241 cccgtgttca ctcatgaaaa gttattttga aacgagcagc gagtgtctca agccaggtgt
 301 catattcctc accaagaagg ggcggaagt ctgtgcaaa cccagtggtc cgggagttca
 361 ggattgcatg aaaaagctga agccctactc aatataataa taaagagaca aaagaggcca
 421 gccacccacc tccaacacct cctgagcctc tgaagctccc accaggccag ctctcctccc
 481 acaacagctt cccacagcat gaagatctcc gtggctgcca ttccctctct cctcctcatc
 541 accatcgccc tagggacca gactgaatcc tcttcacggg gaccttacca cccctcagag
 601 tgctgcttca cctacactac ctacaagatc ccgcgtcagc ggattatgga ttactatgag
 661 accaacagcc agtgctccaa gcccggaatt gtcttcatca ccaaaagggg ccattccgtc
 721 tgtaccaacc ccagtgacaa gtgggtccag gactatatca aggacatgaa ggagaactga
 781 gtgaccgaga aggggtggcg aaggcacagc tcagagacat aaagagaaga tgccaaggcc
 841 cctcctccca cccaccgcta actctcagcc ccagtcaccc tcttgagct tccctgcttt
 901 gaattaaaga ccaactcatgc tcttc

LOCUS HSCC23 973 bp RNA PRI 03-MAY-1996
 DEFINITION H.sapiens mRNA for chemokine CC-2 and CC-3.
 ACCESSION Z70293
 NID g1296611
 KEYWORDS Human chemokine CC-2; Human chemokine CC-3.
 SOURCE human.
 ORGANISM Homo sapiens
 Eukaryotae; mitochondrial eukaryotes; Metazoa; Chordata;
 Vertebrata; Eutheria; Primates; Catarrhini; Hominidae; Homo.
 REFERENCE 1 (bases 1 to 973)
 AUTHORS Pardigol,A., Maegert,H.J., Zucht,HD., Forssmann,W.G. and
 Schulz-Knappe,P.
 TITLE Transcription of a Human Tandem Gene results in a Mature
 Bicistronic mRNA encoding two Novel CC-Chemokines
 JOURNAL Unpublished
 REFERENCE 2 (bases 1 to 973)
 AUTHORS Pardigol,A.
 TITLE Direct Submission
 JOURNAL Submitted (25-MAR-1996) Andreas Pardigol, IV - Molecular
 Biology,
 Lower Saxony Institute for Peptide Research, Feodor-Lynen-
 Strasse
 31. Hannover, Lower Saxony, 30625, Germany
 FEATURES
 source Location/Qualifiers
 1..973
 /organism="Homo sapiens"
 /db_xref="taxon:9606"
 /dev_stage="adult"
 /tissue_type="liver"
 /clone_lib="PCR fragments"
 5'UTR 1..55
 CDS 56..397
 /note="putative; first coding region of a bicistronic
 mRNA"
 /codon_start=1
 /product="chemokine CC-2"
 /db_xref="PID:e233857"
 /db_xref="PID:g1296612"
 /translation="MKVSVAALSCLMLVAVLGSQAQFTNDAETELMMSKLPLENPVVL
 NSFHFAADCTSYISQSIPLCSLMKSYFETSSSECSKPGVIFLTKKGRQVCAKPSGPGVQ
 DCMKKLKPYSI"
 misc_feature 398..498
 /note="spacing region between two coding regions of
 the
 bicistronic mRNA"
 CDS 499..828
 /note="putative"
 /codon_start=1
 /product="chemokine CC-3"
 /db_xref="PID:e233858"
 /db_xref="PID:g1296613"
 /translation="MKISVAAIPFFLLITIALGKTKESSSQTGKPKVVKIQLKLVG
 PYHPSECCFTYTYKIPRQIRIMDYETNSQCSKPGIVFITKRHGSVCTNP SDKWVQDY
 IKDMKEN"
 3'UTR 829..973
 polyA_signal 950..956
 BASE COUNT 257 a 301 c 215 g 200 t
 ORIGIN
 1 ccaggaagca gtgagcccag gagtcctcgg ccagccctgc ctgcccacca ggaggatgaa
 61 ggtctccgtg gctgccctct cctgcctcat gcttggtgct gtccttgat cccaggccca
 121 gttcacaagt gatgcagaga cagagttaat gatgtcaaag ctccactgga aaaatccagt
 181 agttctgaac agctttcact ttgctgctga ctgctgcacc tcctacatct cacaagcat
 241 cccgtgttca ctcatgaaaa gttattttga aacgagcagc gagggtctca agccagggtg
 301 catattcctc accaagaagg ggcggcaagt ctgtgccaaa cccagtggtc cgggagttca
 361 ggattgcatt aaaaagctga agccctactc aatataataa taaagagaca aaagaggcca
 421 gccacccacc tccaacacct cctgagcctc tgaagctccc accaggccag ctctcctccc

```

481 acaacagctt cccacagcat gaagatctcc gtggctgcca ttccttctt cctcctcatc
541 accatcgccc tagggaccaa gactgaatcc tcctcacaaa ctggggggaa accgaagggt
601 gttaaaatac agctaaagtt ggtgggggga ccttaccacc cctcagagt ctgcttcacc
661 tacactacct acaagatccc gcgtcagcgg attatggatt actatgagac caacagccag
721 tgctccaagc ccggaattgt cttcatcacc aaaaggggcc attccgtctg taccaacccc
781 agtgacaagt ggggccagga ctatatcaag gacatgaagg agaactgagt gaccagaag
841 ggggtggcgaa ggcacagctc agagacataa agagaagatg ccaaggcccc ctctccacc
901 caccgctaac tctcagcccc agtcaccctc ttggagcttc cctgctttga attaaagacc
961 actcatgctc ttc

```

//

```

LOCUS      HSU91746      1430 bp      mRNA      PRI      12-MAR-1998
DEFINITION Homo sapiens IL-10-inducible chemokine (HCC-4) mRNA, complete
            cds.
ACCESSION  U91746
NID        g2581780
KEYWORDS
SOURCE     human.
ORGANISM   Homo sapiens
            Eukaryotae; mitochondrial eukaryotes; Metazoa; Chordata;
            Vertebrata; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE  1 (bases 1 to 1430)
AUTHORS    Hedrick,J.A., Helms,A., Gorman,D. and Zlotnik,A.
TITLE      Identification of a novel human CC chemokine upregulated by IL-
10
JOURNAL    Blood (1998) In press
REFERENCE  2 (bases 1 to 1430)
AUTHORS    Hedrick,J.A., Helms,A., Gorman,D. and Zlotnik,A.
TITLE      Direct Submission
JOURNAL    Submitted (02-MAR-1997) Immunology, DNAX Research Institute,
901        California Ave, Palo Alto, CA 94304, USA
FEATURES   Location/Qualifiers
            source          1..1430
                        /organism="Homo sapiens"
                        /db_xref="taxon:9606"
                        /chromosome="17"
            gene            1..1430
                        /gene="HCC-4"
            CDS              1..363
                        /gene="HCC-4"
                        /note="CC or beta chemokine family member"
                        /codon_start=1
                        /product="IL-10-inducible chemokine"
                        /db_xref="PID:g2581781"

/translation="MKVSEAA LSLVLIL IITSASRSQPKVPEWVNT PSTCCLKYYEK
VLPRLRVVGYRKALNCHLPAIIFVTKRNRVCTNPNDWVQYIKDPNLP LLPTRNLS
TVKIIITAKNGQPQLLSQ"
BASE COUNT      401 a      351 c      293 g      385 t
ORIGIN
1 atgaaggctc ccgaggctgc cctgtctctc cttgtctctc tccttatcat tacttcggct
61 tctcgcagcc agccaaaagt tcctgagtggt gtgaacaccc catccacctg ctgcctgaag
121 tattatgaga aagtgttgcc aaggagacta gtgggtggat acagaaaggc cctcaactgt
181 cacctgccag caatcatctt cgtcaccaag aggaaccgag aagtctgcac caaccccaat
241 gacgactggg tccaagagta catcaaggat cccaacctac ctttgcctgc taccaggaac
301 ttgtccacgg ttaaaattat tacagcaaag aatggtcaac cccagctcct caactcccag
361 tgatgaccag gctttagtgg aagcccttgt ttacagaaga gaggggtaaa cctatgaaaa
421 caggggaagc cttattaggt tgaaactagc cagtcacatt gagagaagca gaacaatgat
481 caaaataaag gagaagtatt tcgaatatct tctcaatctt aggaggaaat accaaagtta
541 agggacgtgg gcagagggtac gctcttttat ttttatattt atatttttat ttttttgaga
601 taggtcttac tctgtcacc caggctggag gcagtggtgt gatcttggct cacttgatct
661 tggctcactg taacctccac ctcccaggct caagtgatcc tcccacccca gcctcccag
721 tagctgggac tacaggcttg cgccaccaca cctggctaatt tttgtattt ttggtagaga
781 cgggattcta ccatgttgcc caggctgggt tcaaaactcg gtgcccagc aatccacctg
841 cctcagcctt ccaaaagtgc tgggattaca ggcgtgagcc accacatccg gccagtgac
901 tcttaataca cagaaaaata tatttcacat ccttctctg ctctctttca attctcact
961 tcacaccagt acacaagcca ttctaaatac ttagccagtt tccagcctc cagatgatct
1021 tggcctctg ggtcttgacc cattaagagc cccatagaac tcttgatttt tctgtccat
1081 ctttatggat tttcttgat ctatatcttc ttcaattatt ctttcatttt ataattgaac

```

```

1141 tttttcatag gaagtcgga tgggaatatt cacattaatc atttttgcag agactttgct
1201 agatcctctc atattttgtc ttcctcaggg tggcaggggt acagagagtg cctgattgga
1261 aaaaaaaaaa aaagagagag agagagaaga agaagaagaa gagacacaaa tctctacctc
1321 ccatgttaag ctttcagga cagggaaga aagggtatga gacacggcta ggggtaaact
1381 cttagtccaa aaccaagca tgcaataaat aaaactcctc tatttgacaa
//

```

```

LOCUS      AB007454      1503 bp      mRNA                      PRI      09-APR-1998
DEFINITION Homo sapiens mRNA for chemokine LEC precursor, complete cds.
ACCESSION  AB007454
NID        g2723285
KEYWORDS   chemokine LEC precursor.
SOURCE      Homo sapiens liver cDNA to mRNA.
ORGANISM    Homo sapiens
            Eukaryota; Metazoa; Chordata; Vertebrata; Mammalia; Eutheria;
            Primates; Catarrhini; Hominidae; Homo.
REFERENCE  1 (sites)
AUTHORS     Shoudai,K., Hieshima,K., Fukuda,S., Iio,M., Miura,R., Imai,T.,
            Yoshie,O. and Nomiyama,H.
TITLE       Isolation of cDNA encoding a novel human CC chemokine NCC-4/LEC
JOURNAL      Biochim. Biophys. Acta 1396 (3), 273-277 (1998)
MEDLINE      98207719
REFERENCE  2 (bases 1 to 1503)
AUTHORS      Nomiyama,H.
TITLE        Direct Submission
JOURNAL      Submitted (19-SEP-1997) to the DDBJ/EMBL/GenBank databases.
            Hisayuki Nomiyama, Kumamoto University Medical School,
Department  of Biochemistry; Honjo 2-2-1, Kumamoto, Kumamoto 860-0811,
Japan        (E-mail:nomiyama@gpo.kumamoto-u.ac.jp, Tel:81-96-373-5063,
            Fax:81-96-372-6140)
FEATURES
  source      Location/Qualifiers
              1..1503
              /organism="Homo sapiens"
              /db_xref="taxon:9606"
              /tissue_type="liver"
  sig_peptide 77..145
  CDS         77..439
              /codon_start=1
              /product="chemokine LEC precursor"
              /db_xref="PID:d1024963"
              /db_xref="PID:g2723286"
/translation="MKVSEALSLVLILIIITSASRSQPKVPEWVNTPTSCCLKYYEK
VLPRLVVG YRKALNCHLP AII FVT KRNREVCTNPND DWVQEYIKDPNLP LPLPTRNLS
TVKIIITAKNGQPQLLSQ"
  mat_peptide 146..436
  polyA_signal 560..565
  polyA_signal 1485..1490
BASE COUNT  417 a      374 c      312 g      400 t
ORIGIN
1 gttggcaagc ggaccaccag caacagacaa catcttcatt cggctctccc tgaagctgta
61 ctgcctcgct gagaggatga aggtctccga ggctgccctg tctctccttg tcctcatcct
121 tatcattact tcggcttctc gcagccagcc aaaagttcct gagtgggtga acaccccatc
181 cacctgctgc ctgaagtatt atgagaaagt gttgccaagg agactagtgg tgggatacag
241 aaaggccctc aactgtcacc tgccagcaat catcttcgtc accaagagga accgagaagt
301 ctgcaccaac cccaatgacg actgggtcca agagtacatc aaggatccca acctaccttt
361 gctgcctacc aggaacttgt ccacggttaa aattattaca gcaaagaatg gtcaacccca
421 gctcctcaac tcccagtgat gaccaggctt tagtggaagc ccttgtttac agaagagagg
481 ggtaaaccta tgaaaacagg ggaagcctta ttaggctgaa actagccagt cacattgaga
541 gaagcagaac aatgatcaaa ataaaggaga agtatttcga atattttctc aatcttagga
601 ggaaatacca aagttaaggg acgtgggcag aggtacgctc ttttattttt atatttatat
661 ttttattttt ttgagatagg gtcttactct gtcacccagg ctggagtgca gtggtgtgat
721 cttggctcac ttgatcttgg ctactgttaa cctccacctc ccaggctcaa gtgatcctcc
781 caccacagcc tcccagtagt ctgggactac aggcctgcgc caccacacct ggctaatttt
841 tgtatttttg gtagagacgg gattctacca tgttggccag gctgggtctca aactcgtgtg
901 cccaagcaat ccacctgcct cagccttcca aaagtgcctg gattacaggc gtgagccacc
961 acatccggcc agtgcactct taatacacag aaaaaatata ttcacatcct tctcctgctc
1021 tctttcaatt cctcacttca caccagtaca caagccattc taaatactta gccagtttcc

```

```

1081 agccttccag atgatctttg ccctctgggt cttgacccat taagagcccc atagaactct
1141 tgatttttcc tgtccatctt tatggatttt tctggatcta tattttcttc aattattctt
1201 tcattttata atgcaacttt ttcataaggaa gtccggatgg gaattattcac attaatcatt
1261 tttgcagaga ctttgctaga tcctctcata ttttgtcttc ctcagggttg cagggtgata
1321 gagatgtcct gattggaaaa aaaaaaaaaa gagagagaga gagaagaaga agaagaagag
1381 acacaaatct ctacctccca tgtaagctt tgcaggacag ggaaagaag ggtagagac
1441 acggctaggg gtaaactctt agtccaaaac ccaagcatgc aataataaaa actcccttat
1501 ttg

```

//

```

LOCUS      AF001979      800 bp      mRNA      PRI      20-NOV-1997
DEFINITION Homo sapiens beta chemokine mRNA, complete cds.
ACCESSION  AF001979
NID        g2624924
KEYWORDS
SOURCE     human.
ORGANISM   Homo sapiens
            Eukaryotae; Metazoa; Chordata; Vertebrata; Mammalia; Eutheria;
            Primates; Catarrhini; Hominidae; Homo.
REFERENCE  1 (bases 1 to 800)
AUTHORS    Hedrick, J.A. and Zlotnik, A.
TITLE      Identification and characterization of a novel beta chemokine
            containing six conserved cysteines
JOURNAL    J. Immunol. 159 (4), 1589-1593 (1997)
MEDLINE    97400322
REFERENCE  2 (bases 1 to 800)
AUTHORS    Hedrick, J.A. and Zlotnik, A.
TITLE      Direct Submission
JOURNAL    Submitted (01-MAY-1997) Immunobiology, DNAX Research Institute,
901        California Ave, Palo Alto, CA 94304, USA
FEATURES   Location/Qualifiers
            source          1..800
                        /organism="Homo sapiens"
                        /db_xref="taxon:9606"
            CDS             1..405
                        /note="6Ckine; CC chemokine"
                        /codon_start=1
                        /product="beta chemokine"
                        /db_xref="PID:g2624925"

```

/translation="MAQSLALSLLILVLAFGIPRTQGS DGAQDCLKYSQRKIPAKV

```

VRSYRKQEPSLGC SIPAILFLPRKRSQAELCADPKELWVQQLMQHLDKTPSPQKPAQG
CRKDRGASKTGKKGKSGSKGCKRTERSQTTPKGP"

```

```

BASE COUNT      203 a      248 c      210 g      139 t
ORIGIN
1 atggctcagt cactggctct gagcctcctt atcctgggttc tggccttttg aatccccagg
61 acccaaggca gtgatggagg ggctcaggac tgttgccctca agtacagcca aaggaagatt
121 ccgccaagg ttgtccgcag ctaccggaag caggaaccaa gcttaggctg ctccatccca
181 gctatcctgt tcttgccccg caagcgctct caggcagagc tatgtgcaga cccaaaggag
241 ctctgggtgc agcagctgat gcagcatctg gacaagacac catccccaca gaaaccagcc
301 cagggtgca ggaaggacag gggggcctcc aagactggca agaaaggaaa gggctccaaa
361 ggctgcaaga ggactgagcg gtcacagacc cctaaagggc catagcccag tgagcagcct
421 ggagccctgg agacccacc agcttcacca gcgcttgaag cctgaaccca agatgcaaga
481 aggaggctat gctcaggggc cctggagcag ccaccccatg ctggccttgc cacactcttt
541 ctctgtcttt aaccacccca tctgcatctc cagctctacc ctgcatggct gagctgcca
601 cagcaggcca ggtccagaga gaccgaggag ggagagtctc ccaggagca tgagaggagg
661 cagcaggact gtcccttga aggagaatca tcaggaccct ggacctgata cggctcccca
721 gtacacccca cctcttctt gttaaataatga ttataccta actgaataaaa aagctgttct
781 gtcttccac ccaaaaaaaaa

```

//

```

LOCUS      HSU64197      821 bp      mRNA      PRI      25-JUN-1997
DEFINITION Homo sapiens chemokine exodus-1 mRNA, complete cds.
ACCESSION  U64197
NID        g1778716
KEYWORDS
SOURCE     human.
ORGANISM   Homo sapiens
            Eukaryotae; mitochondrial eukaryotes; Metazoa; Chordata;

```

Hominidae; Vertebrata; Mammalia; Eutheria; Primates; Catarrhini;
 Homo.
 REFERENCE 1 (bases 1 to 821)
 AUTHORS Hromas, R., Gray, P.W., Chantry, D., Godiska, R., Krathwohl, M.,
 Fife, K., Bell, G.I., Takeda, J., Aronica, S., Gordon, M.,
 Cooper, S., Broxmeyer, H.E. and Klemsz, M.J.
 TITLE Cloning and characterization of exodus, a novel beta-chemokine
 JOURNAL Blood 89 (9), 3315-3322 (1997)
 MEDLINE 97275143
 REFERENCE 2 (bases 1 to 821)
 AUTHORS Hromas, R.A.
 TITLE Direct Submission
 JOURNAL Submitted (17-JUL-1996) Indiana University Medical Center,
 Medicine, 975 W. Walnut St., Indianapolis, IN 46202, USA
 FEATURES Location/Qualifiers
 source 1..821
 /organism="Homo sapiens"
 /db_xref="taxon:9606"
 /clone="Exodus-1"
 /cell_type="islet"
 /tissue_type="pancreas"
 /dev_stage="adult"
 CDS 43..330
 /function="inhibits proliferation of hematopoietic
 progenitors and HIV"
 /codon_start=1
 /product="chemokine exodus-1"
 /db_xref="PID:g1778717"
 /translation="MCCTKSLLLAALMSVLLLLHLCGESEASNFDCCCLGYTDRILHPKF
 IVGFTRQLANEGCDINAIIFHTKKLSVCANPKQTWVKYIVRLLSKVKNM"
 variation 121^122
 /note="insertion of an extra codon GCA at nt 121,
 encoding for an alanine after the alanine at amino acid
 position 26, represents the allelic difference of the
 transcript isolated from macrophages"
 BASE COUNT 258 a 134 c 156 g 273 t
 ORIGIN
 1 ggtactcaac actgagcaga tctgttcttt gagctaaaaa ccatgtgctg taccaagagt
 61 ttgctccttg ctgctttgat gtcagtgtcg ctactccacc tctgcggcga atcagaagca
 121 agcaactttg actgctgtct tggatacaca gaccgtattc ttcatcctaa atttattgtg
 181 ggcttcacac ggcagctggc caatgaaggg tgtgacatca atgctatcat ctttcacaca
 241 aagaaaaagt tgtctgtgtg cgcaaatcca aaacagactt gggtgaaata tattgtgcgt
 301 ctccctcagta aaaaagtcaa gaacatgtaa aaactgtggc ttttctggaa tggaattgga
 361 catagcccaa gaacagaaag aaccttgctg gggttggagg ttccacttgc acatcatgga
 421 ggggttagtg cttatctaat ttgtgcctca cctggacttg tccaattaat gaagttgatt
 481 catattgcat catagtttgc ttgtttaaag catcacatta aagtgaact gtattttatg
 541 ttatttatag ctgtagggtt tctgtgttta gctatttaac actaattttc cataagctat
 601 tttggttag tgcaaaagtat aaaattatat ttggggggga ataagattat atggactttc
 661 ttgcaagcaa caagctattt tttaaaaaaa actatttaac attcttttgt ttatattgtt
 721 ttgtctccta aattgttgta atgtcattat aaaataagaa aaatattaat aagacaaata
 781 ttgaaaataa agaaacaaaa agtgcttctg tttaaaaaaa a
 //
 LOCUS HSU88320 828 bp mRNA PRI 18-DEC-1997
 DEFINITION Human beta chemokine Exodus-2 mRNA, complete cds.
 ACCESSION U88320
 NID g2196919
 KEYWORDS
 SOURCE human.
 ORGANISM Homo sapiens
 Eukaryotae; Metazoa; Chordata; Vertebrata; Mammalia; Eutheria;
 Primates; Catarrhini; Hominidae; Homo.
 REFERENCE 1 (bases 1 to 828)
 AUTHORS Hromas, R., Kim, C.H., Klemsz, M., Krathwohl, M., Fife, K.,
 Cooper, S.,

TITLE Schnizlein-Bick, C. and Broxmeyer, H.E.
 chemokine Isolation and characterization of Exodus-2, a novel C-C
 with a unique 37-amino acid carboxyl-terminal extension
 JOURNAL J. Immunol. 159 (6), 2554-2558 (1997)
 MEDLINE 97444139
 REFERENCE 2 (bases 1 to 828)
 AUTHORS Hromas, R.A.
 TITLE Direct Submission
 JOURNAL Submitted (04-FEB-1997) Medicine, Indiana University Medical
 Center, 975 West Walnut, Indianapolis, IN 46202, USA
 FEATURES Location/Qualifiers
 source 1..828
 /organism="Homo sapiens"
 /note="PCR amplified from activated THP-1 cells"
 /db_xref="taxon:9606"
 /clone_lib="Soares human placenta cDNA"
 /cell_line="THP-1"
 /cell_type="monoblast"
 CDS 15..419
 /codon_start=1
 /product="beta chemokine Exodus-2"
 /db_xref="PID:g2196920"
 /translation="MAQSLALSLILVLAFGIPRTQGS DGGAQDCCLKYSQRKIPAKV
 VRSYRKQEPSLGCSIPAILFLPRKRSQAELCADPKELWVQQLMQHLDKTPSPQKPAQG
 CRKDRGASKTGKKGKSGKCKRTERSQTPKGP"
 BASE COUNT 218 a 255 c 216 g 139 t
 ORIGIN
 1 ggacagaggc agacatggct cagtcaactg ctctgagcct ccttatcctg gttctggcct
 61 ttggcatccc caggacccaa ggagtgatg gaggggctca ggactgttgc ctcaagtaca
 121 gccaaaggaa gattcccgcc aaggttgtcc gcagctaccg gaagcaggaa ccaagcttag
 181 gctgctccat ccagctatc ctgttcttgc cccgcaagcg ctctcaggca gagctatgtg
 241 cagaccctaa ggagctcttg gtgcagcagc tgatgcagca tctggacaag acaccatccc
 301 cacagaaacc agcccagggc tgcaggaagg acaggggggc ctccaagact ggcaagaaag
 361 gaaagggctc caaaggctgc aagaggactg agcggtcaca gaccctaaa gggccatagc
 421 ccagttagca gcctggagcc ctggagaccc caccagcctc accagcgctt gaagcctgaa
 481 cccaagatgc aagaaggagg ctatgctcag gggccctgga gcagccaccc catgctggcc
 541 ttgccacact ctttctcctg ctttaaccac cccatctgca tccccagctc tcaccctgca
 601 tggcttagtc tgcccacagc agggccaggtc cagagagacc gaggaggag agtctccag
 661 ggagcatgag aggaggcagc aggaactgtcc ccttgaagga gaatcatcag gaccctggag
 721 ctgatacggc tccccagtac accccacctc ttccttgtaa atatgattta tacctaactg
 781 aataaaaagc tgttctgtct tcccacccaa aaaaaaaaaa aaaaaaaaaa
 //
 LOCUS HSU88321 502 bp mRNA PRI 22-JUN-1998
 DEFINITION Human beta chemokine Exodus-3 mRNA, complete cds.
 ACCESSION U88321
 NID g2196921
 KEYWORDS
 SOURCE human.
 ORGANISM Homo sapiens
 Eukaryotae; Metazoa; Chordata; Vertebrata; Mammalia; Eutheria;
 Primates; Catarrhini; Hominidae; Homo.
 REFERENCE 1 (bases 1 to 502)
 AUTHORS Hromas, R.A., Gray, P., Klemsz, M., Fife, K. and Broxmeyer, H.
 TITLE DCCL chemokines represent a novel beta chemokine subfamily
 JOURNAL Unpublished
 REFERENCE 2 (bases 1 to 502)
 AUTHORS Hromas, R.A.
 TITLE Direct Submission
 JOURNAL Submitted (04-FEB-1997) Medicine, Indiana University Medical
 Center, 975 West Walnut, Indianapolis, IN 46202, USA
 REFERENCE 3 (bases 1 to 502)
 AUTHORS Hromas, R.A.
 TITLE Direct Submission
 JOURNAL Submitted (22-JUN-1998) Medicine, Indiana University Medical
 Center, 975 West Walnut, Indianapolis, IN 46202, USA
 REMARK Amino acid sequence updated by submitter
 FEATURES Location/Qualifiers
 source 1..502


```

/organism="Homo sapiens"
/note="PCR amplified from THP-1 cells"
/db_xref="taxon:9606"
/cell_line="THP-1"
/cell_type="monoblast"
/dev_stage="adult"
120..416
/note="Mip-3alpha/ELC/CKbeta11"
/codon_start=1
/product="beta chemokine Exodus-3"
/db_xref="PID:g3243080"

```

CDS

```

/translation="MALLLALLVLTWTSPTLSGTNDACCLSVTKPIPGYIVR

```

```

NFHYLLIKDGCRCVPAVVFTTLRGRQLCAPPDQPWVERIIQLRQRTSAKMKRRSS-

```

```

BASE COUNT      113 a      170 c      121 g      98 t
ORIGIN

```

```

1  ctcacacctt gcatttcacc cctgcatccc atgcgccctg cagcctcaca cagatcctgc
61 acacacccag acagctggcg ctcacacatt caccgttggc ctgcctctgt tcaccctcca
121 tggccctgct actggccctc agcctgctgg ttctctggac ttccccagcc ccaactctga
181 gtggcaccaa tgatgctgaa gactgctgcc tgtctgtgac ccagaaaccc atccctgggt
241 acatcgtgag gaacttccac taccttctca tcaaggatgg ctgcagggtg cctgctgtag
301 tggtcaccac actgaggggc cgccagctct gtgcaccccc agaccagccc tgggtagaac
361 gcacatcca gagactgcag aggacctcag ccaagatgaa gcgccgcagc agttaacctt
421 tgaccgtgca gagggagccc cgagtcagg tcaagcattg tgaattatta ctaactggga
481 acgaggacag aaggaaggac ag

```

//

```

LOCUS      HSU86358      879 bp      mRNA      PRI      11-SEP-1997
DEFINITION Human chemokine (TECK) mRNA, complete cds.
ACCESSION  U86358
NID        g2388626
KEYWORDS
SOURCE     human.
ORGANISM   Homo sapiens
            Eukaryotae; Metazoa; Chordata; Vertebrata; Mammalia; Eutheria;
            Primates; Catarrhini; Hominidae; Homo.
REFERENCE  1 (bases 1 to 879)
AUTHORS    Vicari,A.P., Figueroa,D.J., Hedrick,J.A., Foster,J.S.,
Singh,K.P., Menon,S., Copeland,N.G., Gilbert,D.J., Jenkins,N.A., Bacon,K.B.
and
            Zlotnik,A.
TITLE      TECK: a novel cc chemokine specifically expressed by thymic
            dendritic cells and potentially involved in T cell development
JOURNAL    Immunology 7, 291-301 (1997)
REFERENCE  2 (bases 1 to 879)
AUTHORS    Vicari,A.P. and Zlotnik,A.
TITLE      Direct Submission
JOURNAL    Submitted (21-JAN-1997) Immunology, DNAX Research Institute,
901
            California Ave., Palo Alto, CA 94304, USA
FEATURES   Location/Qualifiers
            source      1..879
                        /organism="Homo sapiens"
                        /db_xref="taxon:9606"
                        /chromosome="4"
                        /tissue_type="thymus"
            gene        1..879
                        /gene="TECK"
            CDS          1..453
                        /gene="TECK"
                        /codon_start=1
                        /product="chemokine"
                        /db_xref="PID:g2388627"
/translation="MNLWLLACLVLGAWAPAVHTQGVFEDCLAYHYPIGWAVLR
RAWTYRIQEVSGSCNLPAAIFYLPKRHRKVCNPKSREVQRAMKLLDARNKVFALH
NMOTFQAGPHAVKKLSSGSKLSSSKFSNPISSSKRNVSLLISANSGL-
BASE COUNT      191 a      264 c      218 g      206 t

```

ORIGIN

```

1 atgaacctgt ggctcctggc ctgcctgggt gccggcttcc tgggagcctg ggcccccgct
61 gtccacaccc aaggtgtctt tgaggactgc tgctggcct accactaccc cattgggtgg
121 gctgtgctcc ggcgcgcctg gacttaccgg atccaggagg tgagcgggag ctgcaatctg
181 cctgctgcga tattctacct cccaagaga cacaggaagg tgtgtgggaa ccccaaaagc
241 agggagggtg agagagccat gaagctcctg gatgctcgaa ataaggtttt tgcaaagctc
301 caccacaaca tgcagacctt ccaagcaggc cctcatgctg taaagaagtt gagttctgga
361 aactccaagt tatcatcatc caagtttagc aatcccatca gcagcagcaa gaggaatgtc
421 tccctcctga tatcagctaa ttcaggactg tgagccggct catttctggg ctccatcggc
481 acaggagggg cgggatcttt ctccgataaa accgtcgccc tacagaccca gctgtcccca
541 cgctctctgc ttttgggtca agtcttaac cctgcacctg agttggctct ccctctgcac
601 ccccaccacc tcctgcccgt ctggcaactg gaaagaagga gttggcctga ttttaacctt
661 ttgcccgtcc ggggaacagc acaatcctgg gcagccagtg gctctttag agaaaactta
721 ggatacctct ctcaactttt gtttcttgcc gtccaccctg ggccatgccg gtgtgtcctc
781 tgggtccctt ccaaaaatct ggtcattcaa ggatccctc ccaaggctat gcttttctat
841 aacttttaaa taaaccttgg ggggtgaatg gaataaaaa

```

//

```

LOCUS      AB002409      852 bp      mRNA      PRI      15-AUG-1997
DEFINITION Homo sapiens mRNA for SLC, complete cds.
ACCESSION  AB002409
NID        g2335034
KEYWORDS   SLC; mature ELC.
SOURCE     Homo sapiens cDNA to mRNA.
ORGANISM   Homo sapiens
            Eukaryotae; mitochondrial eukaryotes; Metazoa; Chordata;
            Vertebrata; Mammalia; Eutheria; Primates; Catarrhini;
Hominidae; Homo.
REFERENCE  1 (bases 1 to 852)
AUTHORS    Nomiya,H.
TITLE      Direct Submission
JOURNAL    Submitted (28-MAR-1997) to the DDBJ/EMBL/GenBank databases.
            Hisayuki Nomiya, Kumamoto University Medical School,
Department of Biochemistry; Honjo 2-2-1, Kumamoto, Kumamoto 860, Japan
            (E-mail:nomiya@gpo.kumamoto-u.ac.jp, Tel:81-96-373-5063,
            Fax:81-96-372-6140)
REFERENCE  2 (bases 1 to 852)
AUTHORS    Nagira,M., Imai,T., Hieshima,K., Kusuda,J., Ridanpaa,M.,
            Takagi,S., Nishimura,M., Kakizaki,M., Nomiya,H. and Yoshie,O.
TITLE      Molecular Cloning of a Novel Human CC Chemokine Secondary
            Lymphoid-Tissue Chemokine (SLC) That is an Efficient
            Chemoattractant for Lymphocytes and Mapped to Chromosome 9p13
JOURNAL    Unpublished (1997)
FEATURES   Location/Qualifiers
            source      1..852
                        /organism="Homo sapiens"
                        /db_xref="taxon:9606"
            CDS          59..463
                        /codon_start=1
                        /product="SLC"
                        /db_xref="PID:d1022673"
                        /db_xref="PID:g2335035"
/translation="MAQSLALSLILVLAFGIPRTQGS DGAQDCCLKYSQRKIPAKV
VRSYRKQEPSLGC SIPAILFLPRKRSQAELCADPKELWVQQLMQHLDKTPSPQKPAQG
CRKDRGASKTGKKKGKSGCKRTERSQT PKGP"
            mat_peptide  <107..460
                        /product="mature ELC"
            polyA_site   823..828
BASE COUNT 205 a      279 c      217 g      151 t
ORIGIN
1 cttgcagctg ccacctcac cctcagctct gccctcttac tcaccctcta ccacagacat
61 ggctcagtcg ctggctctga gctcctttat cctggttctg gcctttggga tccccaggac
121 ccaaggcagt gatggagggg ctccaggact ttgcctcaag tacagccaaa ggaagattcc
181 cgccaagggt gtccgcagct accggaagca ggaaccaagc ttaggctgct ccatcccgagc
241 tatcctgttc ttgccccgca agcgtctctc gccagagcta tgtgcagacc caaaggagct
301 ctgggtgcag cagctgatgc agcatctgga caagacacca tccccacaga aaccagccca

```

```

361 gggctgcagg aaggacaggg gggcctccaa gactggcaag aaaggaaagg gtcctcaaagg
421 ctgcaagagg actgagcggg cacagacccc taaagggcca tagccagtg agcagcctgg
481 agccctggag accccaccag cctcaccaac gcttgaagcc tgaacccaag atgcaagaag
541 gaggtatgc tcaggggccc tggagcagcc accccatgct ggccttgcca cactctttct
601 cctgctttaa ccaccccatc tgcattccca gctctaccct gcatggctga gctgcccaca
661 gcaggccagg tccagagaga ccgaggaggg agagtctccc agggagcatg agaggaggca
721 gcaggactgt ccccttgaag gagaatcatc aggaccctgg acctgatacg gctcccaggt
781 acacccacc tcttcttgt aaatatgatt tatacctaac tgaataaaaa gctgttctgt
841 cttcccaccc gc

```

//

```

LOCUS      AF055467      1481 bp      mRNA      PRI      06-AUG-1998
DEFINITION Homo sapiens monotactin-1 mRNA, complete cds.
ACCESSION  AF055467
NID        g3395775
KEYWORDS
SOURCE     human.
ORGANISM   Homo sapiens
            Eukaryota; Metazoa; Chordata; Vertebrata; Mammalia; Eutheria;
            Primates; Catarrhini; Hominidae; Homo.
REFERENCE  1 (bases 1 to 1481)
AUTHORS    Youn,B.S., Zhang,S., Broxmeyer,H.E., Antol,K., Fraser,M.J. Jr.,
            Hangoc,G. and Kwon,B.S.
TITLE      Isolation and characterization of LMC, a novel lymphocyte and
            monocyte chemoattractant human CC chemokine, with
            myelosuppressive
            activity
JOURNAL     Biochem. Biophys. Res. Commun. 247 (2), 217-222 (1998)
MEDLINE     98308096
REFERENCE  2 (bases 1 to 1481)
AUTHORS     Youn,B.S. and Kwon,B.S.
TITLE       Direct Submission
JOURNAL     Submitted (24-MAR-1998) Microbiology and Immunology, Indiana
            University, School of Medicine, 605 Barnhill Dr. Medical
            Science
            Bldg., Indianapolis, IN 46202, USA
FEATURES    Location/Qualifiers
            source          1..1481
                        /organism="Homo sapiens"
                        /db_xref="taxon:9606"
                        /chromosome="17"
            5'UTR          1..34
            CDS             35..397
                        /note="Mtn-1; LMC; lymphocyte and monocyte
                        chemoattractant
                        CC chemokine"
                        /codon_start=1
                        /product="monotactin-1"
                        /db_xref="PID:g3395776"

```

/translation="MKVSEAAALLVLILIIITSASRSQPKVPEWVNTPTSCCLKYYEK

VLPRRLVVGYRKALNCHLPAIIFVTKRNREVCTNPNDWVQEIYKDPNLPPLPTRNLS

TVKIIITAKNGQPQLLSQ"

398..1481

```

3'UTR
BASE COUNT      412 a      362 c      302 g      405 t
ORIGIN

```

```

1 gcacgagctg aagctgtact gcctcgctga gaggatgaag gtctccgagg ctgccctgtc
61 tctccttgtc ctcatcetta tcattacttc ggcttctcgc agccagccaa aagttcctga
121 gtgggtgaac accccatcca cctgtgcctt gaagtattat gagaagtgtg tgccaaggag
181 actagtgggt ggatacagaa aggccctcaa ctgtcacctg ccagcaatca tcttcgtcac
241 caagaggaac cgagaagtct gcaccaaccc caatgacgac tgggtccaag agtacatcaa
301 ggatcccaac ctacctttgc tgcctaccag gaacttgctc acggttaaaa ttattacagc
361 aaagaatggg caacccacgc tcctcaactc ccagtgtatga ccaagcttta gtggaagccc
421 ttgtttacag aagagagggg taaactatga aaacagggga agccttatta ggctgaaact
481 agccagtcac attgagagaa gcagaacaat gatcaaaata aaggagaagt attcgaata
541 ttttctcaat cttaggagga aataccaaag ttaagggacg tgggcagagg tacgtctttt
601 tatttttata tttatatatt tttttttttg agatagggtc ttactctgtc acccaggctg
661 gagtgcagtg gtgtgatctt ggctcacttg atcttggtc actgtaacct ccacctccca
721 ggctcaagtg atcctccac cccacctcc cgagttagct ggactacagg cttgcgccac
781 cacacctggc taatttttgt atttttggtg gagacgggat tctaccatgt tgcccaggct

```

```

841 ggtctcaaac tcgtgtgccc aagcaatcca cctgcctcag ccttccaaaa gtgctgggct
901 tacaggcgtg agccaccaca tccggccagt ccactcttaa tacacagaaa aatatatttc
961 acatccttct cctgctctct ttcaattcct cacttcacac cagtacacaa gccattctaa
1021 atacttagcc agtttccagc cttccagatg atctttgccc tctgggtctt gaccatttaa
1081 gagccccata gaactcttga ttttctctgt ccacttttat gggatttttc tggatctata
1141 ttttcttcaa ttattctttc attttataat gcaacttttt cataggaagt ccggtaggga
1201 atattcacat taatcatttt tgcagagact ttgctagatc ctctcatatt ttgtcttctt
1261 cagggtggca ggggtacaga agtgcctgat tggttttttt tttttttgag agagagagag
1321 aagaagaaga agaagagaca caaatctcta cctcccatgt taagctttgc aggacaggga
1381 aagaaagggt atgagacacg gctagggtaa actcttagtc caaaacccaa gcatgcaata
1441 aataaaactc ccttatttga caaaaaaaaa aaaaaaaaaa a

```

//

```

LOCUS      HSRNAATAC      557 bp      RNA      PRI      06-JUL-1995
DEFINITION H.sapiens mRNA for ATAC protein.
ACCESSION  X86474
NID        g895846
KEYWORDS   ATAC gene.
SOURCE     human.
ORGANISM   Homo sapiens
            Eukaryotae; mitochondrial eukaryotes; Metazoa; Chordata;
            Vertebrata; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE  1 (bases 1 to 557)
AUTHORS    Muller,S., Dorner,B., Korthauer,U., Mages,H.W., D'Apuzzo,M.,
            Senger,G. and Kroczeck,R.A.
TITLE      Cloning of ATAC, an activation-induced, chemokine-related
molecule  exclusively expressed in CD8+ T lymphocytes
JOURNAL     Eur. J. Immunol. 25 (6), 1744-1748 (1995)
MEDLINE     95339892
REFERENCE   2 (bases 1 to 557)
AUTHORS     Kroczeck,R.A.
TITLE       Direct Submission
JOURNAL     Submitted (20-APR-1995) R.A. Kroczeck, Molecular Immunology,
            Robert-Koch-Institute, Nordufer 20, 13353 Berlin, FRG
FEATURES    Location/Qualifiers
            source      1..557
                        /organism="Homo sapiens"
                        /db_xref="taxon:9606"
                        /tissue_type="peripheral blood"
                        /cell_type="lymphocyte"
                        /chromosome="1"
                        /map="q23"
            gene        25..369
                        /gene="ATAC"
            CDS          25..369
                        /gene="ATAC"
                        /codon_start=1
                        /product="CD8+T cell specific protein"
                        /db_xref="PID:g895847"
                        /db_xref="SWISS-PROT:P47992"

```

/translation="MRLILALLGICSLTAYIVEGVGSEVSDKRTCVSLLTQRLPVSR

IKTYTITEGSLRAVIFITKRLKVCADPQATWVRDVVRSMRKSNTNRNMIQTKPTGT

QQSTNTAVTLTG

polyA_signal 469..474

polyA_signal 534..539

BASE COUNT 157 a 139 c 112 g 149 t

ORIGIN

```

1 gcacagctca gcaggacctc agccatgaga cttctcatcc tggccctcct tggcatctgc
61 tctctcactg catacattgt ggaagggtga gggagtgaag tctcagataa gaggacctgt
121 gtgagcctca ctaccacagc actgccggtt agcagaatca agacctacac catcacggaa
181 ggctccttga gagcagtaat ttttattacc aaacgtggcc taaaagtctg tgctgatcca
241 caagccacat ggggtgagaga cgtgggtcagg agcatggaca ggaaatccaa caccagaaat
301 aacatgatcc agaccaagcc aacaggaacc cagcaatcga ccaatacagc tgtgactctg
361 actggctagt agtctctggc accctgtccg tctccagcca gccagctcat ttcactttac
421 acgctcatgg actgagttta tactgccttt ttatgaaagc actgcatgaa taaaattatt
481 cctttgtatt tttactttta aatgtcttct gtattcactt atatgttcta attaataaat
541 tatttattat taagaat

```

//

LOCUS HSU85767 563 bp mRNA PRI 01-APR-1997
 DEFINITION Human myeloid progenitor inhibitory factor-1 MPIF-1 mRNA, complete
 cds.
 ACCESSION U85767
 NID g1916249
 KEYWORDS
 SOURCE human.
 ORGANISM Homo sapiens
 Eukaryotae; mitochondrial eukaryotes; Metazoa; Chordata; Vertebrata; Eutheria; Primates; Catarrhini; Hominidae; Homo.
 REFERENCE 1 (bases 1 to 563)
 AUTHORS Patel,V.P., Kreider,B.L., Li,Y., Li,H., Leung,K., Salcedo,T., Nardelli,B., Pippalla,V., Gentz,S., Thotakura,R., Parmelee,D., Gentz,R. and Garotta,G.
 TITLE Molecular and functional characterization of two novel human C-chemokines as inhibitors of two distinct classes of myeloid progenitors
 JOURNAL J. Exp. Med. (1997) In press
 REFERENCE 2 (bases 1 to 563)
 AUTHORS Li,H. and Patel,V.P.
 TITLE Direct Submission
 JOURNAL Submitted (17-JAN-1997) Cell Biology, Human Genome Sciences, 9410
 Keywest Ave., Rockville, MD 20850, USA
 FEATURES Location/Qualifiers
 source 1..563
 /organism="Homo sapiens"
 /db_xref="taxon:9606"
 CDS 31..393
 /note="myeloid progenitor inhibitory factor-1"
 /codon_start=1
 /product="MPIF-1"
 /db_xref="PID:g1916250"
 /translation="MKVSVAAALSCLMLVTALGSQARVTKDAETEFMMSKLPLENPVLL
 DRFHATSADCCISYTPRSIPCSLLESYFETNSECSKPGVIFLTKKGRRFCANPSDKQV
 QVCMRMLKLDTRIKTRKN"
 BASE COUNT 164 a 143 c 117 g 139 t
 ORIGIN
 1 ctcagccagc cctgcctgcc caccaggagg atgaagggtct ccgtggctgc cctctcctgc
 61 ctcagtcttg ttactgccct tggatcccag gcccggtgca caaaagatgc agagacagag
 121 ttcattgatgt caaagcttcc attggaaaat ccagtacttc tggacagatt ccatgctact
 181 agtgctgact gctgcatctc ctacacccca cgaagcatcc cgtgttcact cctggagagt
 241 tactttttaa cgaacagcga gtgctccaag ccgggtgtca tcttcctcac caagaagggg
 301 cgacgtttct gtgccaaccc cagtataaag caagtccagg tttgcatgag aatgctgaag
 361 ctggacacac ggatcaagac caggaagaat tgaacttgtc aaggtgaagg gacacaagtt
 421 gccagccacc aactttcttg cctcaactac cttcctgaat tattttttta agaagcattt
 481 attcttgtgt tctggattta gagcaattca tctaataaac agtttctcac ttttaaaaaa
 541 aaaaaaaaaa aaaaaaaaaa aaa
 //

LOCUS HSU85768 360 bp mRNA PRI 01-APR-1997
 DEFINITION Human myeloid progenitor inhibitory factor-1 MPIF-2 mRNA, complete
 cds.
 ACCESSION U85768
 NID g1916251
 KEYWORDS
 SOURCE human.
 ORGANISM Homo sapiens
 Eukaryotae; mitochondrial eukaryotes; Metazoa; Chordata; Vertebrata; Eutheria; Primates; Catarrhini; Hominidae; Homo.
 REFERENCE 1 (bases 1 to 360)
 AUTHORS Patel,V.P., Kreider,B.L., Li,Y., Li,H., Leung,K., Salcedo,T., Nardelli,B., Pippalla,V., Gentz,S., Thotakura,R., Parmelee,D., Gentz,R. and Garotta,G.
 TITLE Molecular and functional characterization of two novel human C-

C

chemokines as inhibitors of two distinct classes of myeloid progenitors
 J. Exp. Med. (1997) In press
 REFERENCE 2 (bases 1 to 360)
 AUTHORS Li, H. and Patel, V. P.
 TITLE Direct Submission
 JOURNAL Submitted (17-JAN-1997) Cell Biology, Human Genome Sciences, 9410
 Keywest Ave., Rockville, MD 20850, USA

FEATURES
 source Location/Qualifiers
 1..360
 /organism="Homo sapiens"
 /db_xref="taxon:9606"
 CDS 1..360
 /note="myeloid progenitor inhibitory factor-2"
 /codon_start=1
 /product="MPIF-2"
 /db_xref="PID:g1916252"

/translation="MAGLMTIVTSLFLGVCAHHIIPSGSVVIPSPCCMFFVSKRIPE
 NRVVS YQLSSRSTCLKGGVIFTTKKGQFCGDPKQEWVQRYMKNLDAKQKASPRARA
 VAVKGPVQRYPGNQTTCTC"
 BASE COUNT 85 a 106 c 96 g 73 t
 ORIGIN
 1 atggcaggcc tgatgaccat agtaaccagc cttctgttcc ttggtgtctg tgcccaccac
 61 atcatcccta cgggctctgt ggtcataccc tctccctgct gcatgttctt tgtttccaag
 121 agaattcctg agaaccgagt ggtcagctac cagctgtcca gcaggagcac atgcctcaag
 181 ggaggagtga tcttcaccac caagaagggc cagcagttct gtggcgaccc caagcaggag
 241 tgggtccaga ggtacatgaa gaacctggac gccaagcaga agaaggcttc ccctagggcc
 301 agggcagtggt ctgtcaaggg ccctgtccag agatatcctg gcaaccaaac cacctgctaa
 //

LOCUS HUMSDF1A 1847 bp mRNA PRI 26-DEC-1996
 DEFINITION Human pre-B cell stimulating factor homologue (SDF1a) mRNA, complete cds.
 ACCESSION L36034
 NID g1220363
 KEYWORDS intercrine; intercrine CXC subfamily; pre-B cell stimulating factor
 SOURCE homologue; alpha-chemokine.
 ORGANISM human.
 Homo sapiens
 Eukaryotae; mitochondrial eukaryotes; Metazoa; Chordata; Vertebrata; Eutheria; Primates; Catarrhini; Hominidae; Homo.
 REFERENCE 1 (bases 1 to 1847)
 AUTHORS Shirozu, M., Nakano, T., Inazawa, J., Tashiro, K., Tada, H., Shinohara, T. and Honjo, T.
 TITLE Structure and chromosomal localization of the human stromal cell-derived factor 1 (SDF1) gene
 JOURNAL Genomics 28 (3), 495-500 (1995)
 MEDLINE 96039262

FEATURES
 source Location/Qualifiers
 1..1847
 /organism="Homo sapiens"
 /db_xref="taxon:9606"
 /clone="h5"
 /cell_line="FLEB14-14"
 sig_peptide 80..142
 /gene="SDF1a"
 CDS 80..349
 /codon_start=1
 /product="pre-B cell stimulating factor homologue"
 /db_xref="PID:g1220364"

/translation="MNAKVVVVLVLVLTALCLSDGKPVSLSYRCPCRFFESHVARANV
 KHLKILNTPNCALQIVARLKNNNRQVCIDPKLKIQYILEKALNK"
 gene 80..346
 /gene="SDF1a"
 mat_peptide 143..346

```

/gene="SDF1a"
/product="pre-B cell stimulating factor homologue"
BASE COUNT      459 a      471 c      417 g      500 t
ORIGIN
1  tctccgtcag cgcgattgcc cgctcggcgt cgggccccgc acccgtgttc gtccgccccg
61  ccgcccgcgc gcccgcgcca tgaacgccaa ggtcgtggtc gtgctgggtc tcgtgctgac
121  cgcgctctgc ctcagcgacg ggaagcccgt cagcctgagc tacagatgcc catgccgatt
181  cttcgaaaagc catgttgcca gagccaacgt caagcatctc aaaattctca acactccaaa
241  ctgtgccctt cagattgtag cccggctgaa gaacaacaac agacaagtgt gcattgaccc
301  gaagctaaag tggattcagg agtacctgga gaaagcttta aacaagtaag cacaacagcc
361  aaaaaggact ttccgctaga cccactcgag gaaaactaaa accttgtgag agatgaaagg
421  gcaaagacgt gggggagggg gccttaacca tgaggaccag gtgtgtgtgt ggggtgggca
481  cattgatctg ggatcgggcc tgagggttgc agcattttaga ccctgcattt atagcatacg
541  gtatgataatt gcagcttata ttcatccatg ccctgtacct gtgcacgttg gaacttttat
601  tactgggggtt tttctaagaa agaaattgta ttatcaacag cattttcaag cagttagttc
661  cttcatgatac atcacaatca tcattctctc cattctcatt ttttaaatca acgagtactt
721  caagatctga atttggcttg tttggagcat ctctctgtct cccctgggga gtctgggac
781  agtcagggtg tggtttaaca gggagctgga aaaagtgtcc ttcttccaga cactgaggct
841  ccgcagcagc cgcacctccc aagagggaagg cctctgtggc actcagatac cgactggggc
901  tggggcgccg ccactgcctt caccctctct ttcaaaccct agtgattggc tctgtgggct
961  ccatgtagaa gccactatta ctgggactgt ctcagagacc cctctcccag ctattcctac
1021  tctctccccg actccgagag catgcttaat cttgcttctg ctctcattt ctgtagcctg
1081  atcagcgccg caccagccgg gaagagggtg attgctgggg ctctgtgccc gcacccctct
1141  cctcccaggg cctgccccac agctcggggc ctctgtgaga tccgtctttg gcctcctcca
1201  gaatggagct ggccctctcc tggggatgtg taatgggtccc cctgcttacc cgaaaagac
1261  aagtcctttac agaatacaat gcaattttaa atctgagagc tcgcttgagt gactggggtt
1321  gtgattgcct ctgaagccta tgtatgccat ggaggcacta acaaactctg aggtttccga
1381  aatcagaagc gaaaaaatca gtgaataaac catcatcttg ccactacccc ctcctgaagc
1441  cacagcaggg gttcagggtc caatcagaac tgttggcaag gtgacatttc catgcataga
1501  tgcatgccac agaaggtcct ggtgttatgt gtaacttttt gcaaggcatt tttttatata
1561  tatttttgtg cacatttttt tttacgattc tttagaaaac aaatgtattt caaaatatat
1621  ttatagtcga acaagtcata tatatgaatg agagccatat gaatgtcagt agtttatact
1681  tctctattat ctcaaactac tggcaatttg taaagaaata tatatgatat ataaatgtga
1741  ttgcagcttt tcaatgttag ccacagtgtg ttttttcact tgtactaaa ttgtatcaaa
1801  tgtgacatta tatgcactag caataaaatg ctaattgttt catggta
//

```

```

LOCUS      HUMSDF1B      3524 bp      mRNA      PRI      26-DEC-1996
DEFINITION Human pre-B cell stimulating factor homologue (SDF1b) mRNA,
complete cds.
ACCESSION  L36033
NID        gl220365
KEYWORDS   intercrine; intercrine CXC subfamily; pre-B cell stimulating
factor
SOURCE      human.
ORGANISM    Homo sapiens
Eukaryotae; mitochondrial eukaryotes; Metazoa; Chordata;
Vertebrata; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE  1 (bases 1 to 3524)
AUTHORS     Shirozu,M., Nakano,T., Inazawa,J., Tashiro,K., Tada,H.,
Shinohara,T. and Honjo,T.
TITLE       Structure and chromosomal localization of the human stromal
cell-derived factor 1 (SDF1) gene
JOURNAL     Genomics 28 (3). 495-500 (1995)
MEDLINE     96039262
FEATURES
    source          Location/Qualifiers
                    1..3524
                    /organism="Homo sapiens"
                    /db_xref="taxon:9606"
                    /clone="h17"
                    /cell_line="FLEB14-14"
    sig_peptide      80..142
                    /gene="SDF1b"
    CDS              80..361
                    /codon_start=1
                    /product="pre-B cell stimulating factor homologue"
                    /db_xref="PID:gl220365"

```

```

/translation="MNAKVVVVVLVLVLTALCLSDGKPVSLSYRCPCRFFESHVARANV
KHLKILNTPNCALQIVARLKNNNRQVCIDPKLKWIQEYLEKALNKRFKM"

```

```

gene      80..358
          /gene="SDF1b"
mat_peptide 143..358
          /gene="SDF1b"
          /product="pre-B cell stimulating factor homologue"
BASE COUNT      903 a      886 c      793 g      942 t
ORIGIN
1   tctccgctcag cgcgattgcc cgctcggcgt cgggcccccg acccgtgctc gtccgccccg
61  cccgccccccc gcccgcgcca tgaacgccaa ggtcgtggtc gtgctgggtc tctgtctgac
121 cgcgctctgc ctcagcgacg ggaagcccg cagcctgagc tacagatgcc catgccgatt
181 cttcgaaaag catgttgcca gagccaacgt caagcatctc aaaattctca acactccaaa
241 ctgtgccctt cagattgtag cccggctgaa gaacaacaac agacaagtgt gcattgacct
301 gaagctaaag tggattcagg agtacctgga gaaagcttta aacaagaggt tcaagatgtg
361 agaggggtcag acgcctgagg aacctttaca gtaggagccc agctctgaaa ccagtgttag
421 ggaagggcct gccacagcct cccctgccag ggcagggccc caggcattgc caagggcttt
481 gttttgcaca ctttgccata ttttcacat ttgattatgt agcaaaatac atgacattta
541 tttttcattt agtttgatta ttcatgttca ctggcgacac gtagcagctt agactaaggc
601 cattattgta cttgccttat tagagtgtct ttccacggag ccactcctct gactcagggc
661 tcctgggttt tgtattctct gagctgtgca ggtggggaga ctgggctgag ggagcctggc
721 cccatgggtc gccctagggt ggagagccac caagagggac gcctgggggt gccaggacca
781 gtcaacctgg gcaaacctta gtgaaggctt ctctctgtgg gatgggatgg tggagggcca
841 catgggaggc tcacccctt ctccatccac atgggagccg ggtctgcctc ttctgggagg
901 gcagcagggc taccctgagc tgaggcagca gtgtgaggcc agggcagagt gagaccagc
961 cctcatcccg agcacctcca catctccac gttctgctca tcattctctg tctcatccat
1021 catcatgtgt gtccacgact gtctccatgg ccccgcaaaa ggactctcag gaccaaagct
1081 ttcatgtaaa ctgtgcacca agcaggaat gtaaatgtct tgtgttacct gaaaacactg
1141 tgcacatctg tgtcttgtgt ggaatattgt ccattgtcca atcctatggt tttgttcaaa
1201 gccagcgctc tctctgtgta ccaatgtctt gatgcatgca ctgttcccc tgtgcagccg
1261 ctgagcgagg agatgtcctt tggggccctt gatgagcag ctgacagag ccgtggctct
1321 ttgggggtgaa ctacctgggt tccccactg atcacaaaaa catgggtggg ccatgggcag
1381 agcccaaggg aattcggtgt gcaccagggt tgacccaga ggattgtctg cccatcagtg
1441 ctccctcaca tgtcagtacc ttcaaaactag ggccaagccc agcactgctt gagggaaaca
1501 agcattcaca acttgttttt ggttttttaa acccagtcca caaaaatacc aatctggac
1561 atgaagattc tttcccaatt cacatctaac ctcatcttct tcaccatttg gcaatggcat
1621 catctcctgc cttcctcctg ggccctctct gctctgcgtg tcacctgtgc ttctggccct
1681 tcccacagga catttctcta agagaacaat gtgctatgtg aagagtaagt caacctgcct
1741 gacatttgga gtgttcccc ctccactgagg gcagtcagata gagctgtatt aagccactta
1801 aaatgttcac ttttgacaaa ggcaagcact tgtgggtttt tgttttgttt ttcattcagt
1861 cttacgaata cttttgccct ttgattaaag actccagtta aaaaaattt taatgaagaa
1921 agtggaaaac aagggaagta aagcaaggaa actatgtaac atgtaggaaag taggaagtaa
1981 attatagtga tghtaatctt aattgttaact gttcgtgaat ttaataatct gtagggtaat
2041 tagtaacatg tghtaagtat tttcataagt atttcaaatt ggagcttcat ggcagaaggg
2101 aaacccatca acaaaaattg tcccttaaac aaaaattaaa atcctcaatc cagctatggt
2161 atattgaaaa aatagagcct gagggatctt tactagttat aaagatacag aactcttcca
2221 aaaccttttg aaattaacct ctactatac cagtataatt gagttttcag tggggcagtc
2281 attatccagg taatccaaga tattttaaaa tctgtcacgt agaacttgga tggactgtcc
2341 cccaatccat gaaccaagac cattgaattc ttggttgagg aaacaaacat gaccttaaat
2401 ctgactaca gtcaggaaag gaatcatttc tatttctcct ccatgggaga aaatagataa
2461 gagtagaaac tgcagggaaa attatttgca taacaatttc tctactaaca atcagctcct
2521 tctggagac tgcccagcta aagcaatatg catttaaata cagtcttcca ttgcaaggg
2581 aaaagtctct tgtaatccga atctcttttt gcttcgaac tgctagtcaa gtgcgtccac
2641 gagctgttta ctagggatcc ctcatctgtc cctccgggac ctggtgctgc ctctacctga
2701 cactcccttg ggctccctgt aacctcttca gaggccctcg ctgccagctc tgtatcagga
2761 cccagaggaa ggggcccagag gctcgttgac tggctgtgtg ttgggattga gtctgtgcca
2821 cgtgtatgtg ctgtggtgtg tccccctctg tccaggcact gagataccag cgaggaggct
2881 ccagagggca cttgtcttgt tattagagat tacctcttga gaaaaagct tccgcttgga
2941 gcagaggggc tgaatagcag aagggttgac ctccccaac cttagatgtt ctaagtcttt
3001 ccattggatc tcattggacc ctcccatggt gtgatcgtct gactggtgtt atcaccgtgg
3061 gctccctgac tgggagttga tgccttttcc cagggtctac acccttttcc agctggatga
3121 gaatttgagt gctctgatcc ctctacagag cttccctgac tcattctgaa ggagcccat
3181 tcctgggaaa tattccctag aaacttccaa atcccctaag cagaccactg ataaaaacct
3241 gtgaaaaatt tgttattttg caacctcgct ggactctcag tctctgagca gtgaatgatt
3301 cagtgttaaa tgtgatgaat actgtatttt gtattgtttc aagtgcactc cccagataat
3361 gtgaaaaatg tccaggagaa ggccaatttc tatacgagc gtgctttaa aaataataa
3421 gaaacaactc tttgagaac aacaatttct acttgaagt cataccaatg aaaaaatgta
3481 tatgcactta taattttcct aataaagttc tgtactcaaa tgta

```

//

```

LOCUS      HSJ002211      663 bp      mRNA      PRI      11-MAR-1998
DEFINITION Homo sapiens cDNA for a CXC chemokine.
ACCESSION  AJ002211

```


NID g2832410
 KEYWORDS CXC chemokine.
 SOURCE human.
 ORGANISM Homo sapiens
 Eukaryota; Metazoa; Chordata; Vertebrata; Mammalia; Eutheria;
 Primates; Catarrhini; Hominidae; Homo.
 REFERENCE 1 (bases 1 to 663)
 AUTHORS Legler, D.F., Loetscher, M., Roos, R.S., Clark-Lewis, I.,
 Baggiolini, M.
 and Moser, B.
 TITLE B cell-attracting chemokine 1, a human CXC chemokine expressed
 in lymphoid tissues, selectively attracts B lymphocytes via
 BLR1/CXCR5
 JOURNAL J. Exp. Med. 187 (4), 655-660 (1998)
 MEDLINE 98130629
 REFERENCE 2 (bases 1 to 663)
 AUTHORS Moser, B.
 TITLE Direct Submission
 JOURNAL Submitted (05-NOV-1997) Moser B., University of Bern, Theodor
 Kocher Institute, Freiestrasse 1, CH-3012 Bern, SWITZERLAND
 FEATURES
 source Location/Qualifiers
 1..663
 /organism="Homo sapiens"
 /db_xref="taxon:9606"
 /cell_type="PBL"
 sig_peptide 35..100
 /gene="BCA-1"
 CDS 35..364
 /gene="BCA-1"
 /codon_start=1
 /product="CXC chemokine"
 /db_xref="PID:e1249325"
 /db_xref="PID:g2832411"
 /translation="MKFISTSLLLMLLVSSLSFVQGVLEVYYTSLRCRCVQESSVFIP
 RRFIDRIQILPRGNGCPRKEIIVWKKNSIVCVDPQAEWIQRMMEVLRKRSSSTLPVP
 VFKRKIP"
 gene 35..364
 /gene="BCA-1"
 mat_peptide 101..361
 /gene="BCA-1"
 BASE COUNT 176 a 136 c 145 g 198 t 8 others
 ORIGIN
 1 cagagctcaa gctcgaactc tacctccaga cagaatgaag ttcattctga catctctgct
 61 tctcatgctg ctgggtcagca gccctctctc agtccaagggt gttctggagg tctattacac
 121 aagcttgagg tgtagatgtg tccaagagag ctccagtctt atccctagac gtttcattga
 181 tcgaattcaa atcttgcccc gtgggaatgg ttgtccaaga aaagaaatca tagtctggaa
 241 gaagaacaag tcaattgtgt gtgtggaccc tcaagctgaa tggatacaaa gaatgatgga
 301 agtattgaga aaaagaagtt ctcaactct accagttcca gtgtttaaga gaaagattcc
 361 ctgatgctga tatttccact aagaacacct gcattctctc cttatccctg ctctgggatt
 421 ttagtcttgt gcttagttaa atcttttcca gggagaaaga acttccccat acaaataagg
 481 catgaggact atgtaaaaat aaccttgag gagctggatg gggggccaaa ctcaagcttc
 541 tttactcca caggcacctc attntacact tgggggtttt gcnttcttn tttcntcagg
 601 gggggggaaa gtttcttttg gaaantagtt nttccagttt ttaggtatta cagggttntt
 661 ttt
 //
 LOCUS HSHUMIG 2545 bp RNA PRI 16-NOV-1993
 DEFINITION H.sapiens Humig mRNA.
 ACCESSION X72755 S60728
 NID g311375
 KEYWORDS chemokine; cytokine; Humig gene; secreted protein.
 SOURCE human.
 ORGANISM Homo sapiens
 Eukaryotae; mitochondrial eukaryotes; Metazoa; Chordata;
 Vertebrata; Eutheria; Primates; Catarrhini; Hominidae; Homo.
 REFERENCE 1 (bases 1 to 2545)
 AUTHORS Farber, J.M.
 TITLE Direct Submission
 JOURNAL Submitted (22-MAR-1993) J.M. Farber, Johns Hopkins Univ. School

of

Medicine, Ross 1147, 720 Rutland Avenue, Baltimore, MD 21205,

USA

REFERENCE 2 (bases 1 to 2545)

AUTHORS Farber, J.M.

TITLE HuMig: a new human member of the chemokine family of cytokines

JOURNAL Biochem. Biophys. Res. Commun. 192 (1), 223-230 (1993)

MEDLINE 93236577

FEATURES

source

Location/Qualifiers

1..2545

/organism="Homo sapiens"

/db_xref="taxon:9606"

/germline

/dev_stage="child"

/tissue_type="leukaemia"

/cell_type="monocyte"

/cell_line="THP-1"

/clone_lib="THP-1/IFN-gamma cDNA"

/clone="H-1-3"

misc_feature

13..19

/note="cis-acting element; putative"

gene

40..417

/gene="Humig"

CDS

40..417

/gene="Humig"

/codon_start=1

/db_xref="PID:g311376"

/db_xref="SWISS-PROT:Q07325"

/translation="MKKSGVLFLLGIILLVLIGVQGTTPVVRKGRCSISTNQGTIHLQ

SLKDLKQFAPSPSCEKIEIIATLKNVQTCCLNPDSADVKELIKKEKQVSQKKKQKNG

KKHQKKKVLKVRKSQRSRQKKTT"

BASE COUNT

755 a

581 c

457 g

752 t

ORIGIN

```

1 atccaataca ggagtgactt ggaactccat tctatcacta tgaagaaaag tgggtgttctt
61 ttccctcttg gcatcatctt gctgggtctg attggagtg c aaggaaacccc agtagtgaga
121 aagggtcgct gttcctgcat cagcaccaac caagggacta tccacctaca atccttgaaa
181 gaccttaaac aatttgcccc aagcccttcc tgcgagaaaa ttgaaatcat tgctacactg
241 aagaatggag ttcaaacatg tctaaaccca gattcagcag atgtgaagga actgattaaa
301 aagtgggaga aacaggtcag ccaaaagaaa aagcaaaaaga atgggaaaaa acatcaaaaa
361 aagaaagtgc tgaaagtctg aaaatctcaa cgttctcgtc aaaagaagac tacataagag
421 accacttcac caataagtat tctgtgttaa aaatgttcta ttttaattat accgctatca
481 ttccaaagga ggatggcata taatacaaa gcttattaat ttgactagaa aattttaaac
541 attactctga aattgtaact aaagttagaa agttgatttt aagaatccaa acgttaagaa
601 ttgttaaagg ctatgattgt ctttgttctt ctaccacca ccagtgaat ttcataatgc
661 ttaaggccat gatttttagc atacctatgt ctacacagat gttcacccaa ccacatccca
721 ctcaacaacag ctgcctggaa gagcagccct aggcctccac gtactgcagc ctccagagag
781 tatctgaggc acatgtcagc aagtcctaag cctgttagca tgctggtag ccacagcagt
841 tgaattgag ctggacctca ccaagctgct gtggccatca acctctgtat ttgaatcagc
901 ctacaggcct cacacacaat gtgtctgaga gattcatgct gattgttatt gggatcacc
961 actggagatc accagtgtgt ggctttcaga gcctccttcc tggctttgga agccatgtga
1021 ttccatcttg cccgctcagg ctgaccactt tatttctttt tgttccccct tgcttcattc
1081 aagtcagctc ttctccatcc taccacaatg cagtgccttt ctctctccca gtgcacctgt
1141 catatgctct gatttatctg agtcaactcc tttctcatct tgtccccaac cccccacaga
1201 agtgctttct tctcccaatt catctctact cagtccagct tagttcaagt cctgcctctt
1261 aataaaacct ttttggaacac acaaattatc ttaaaactcc tgtttcactt ggttcagtac
1321 cacatgggtg aacactcaat ggtaactaa ttcttgggtg tttatcctat ctctccaacc
1381 agattgtcag ctcttgagg ccaagagcca cagtatatct ccctgtttct tccacagtgc
1441 ctaataatac tgtggaacta ggttttaata attttttaat tgatgttgtt atgggcagga
1501 tggcaaccag accattgtct cagagcaggt gctggctctt tcctggctac tccatgttgg
1561 ctagcctctg gtaacctctt acttattatc ttcaggacac tcactacagg gccacgggat
1621 gatgcaacat ccttgtcttt ttatgacagg atgtttgtct agcttctcca acaataagaa
1681 gcacgtggta aaacacttgc ggatattctg gactgttttt aaaaaatata cagtttaccg
1741 aaaatcatat aatcttacaa tgaaaaggac ttatagatc agccagtgc caaccttttc
1801 ccaaccatac aaaaattcct ttccccaag gaaaagggtt ttctcaataa gcctcagctt
1861 tctaagatct aacaagatag ccaccgagat ccttatcgaa actcatttta ggcaaatatg
1921 agtttttatt tccgtttact tgtttcagag tttgtattgt gattatcaat taccacacca
1981 tctcccatga agaaagggaa cgggtgaagta ctaagcgcta gaggaagcag ccaagtcggt
2041 tagtggaagc atgattggtg cccagtttagc ctctgcagga tgtggaaacc tcctccagg
2101 ggaggttcag tgaattgtgt aggagaggtt gtctgtggcc agaattttaa cctatactca

```

```

2161 ctttcccaaa ttgaatcact gctcacactg ctgatgattt agagtgtgtt cgggtggaga
2221 tcccacccga acgtcttata taatcatgaa actccctagt tccttcattg aacttccctg
2281 aaaaatctaa gtgtttcata aatttgagag tctgtgacct acttaccttg catctcacag
2341 gtagacagta tataactaac aaccaaagac tacatatgtt cactgacaca cacgttataa
2401 tcatttatca tataatatac tacatgcata cactctcaaa gcaaataatt tttcacttca
2461 aaacagtatt gacttgata ccttgtaatt tgaaatattt tctttgtaa aatagaatgg
2521 tatcaataaa tagaccatta atcag

```

//

```

LOCUS      HSHUMIG      2545 bp      RNA      PRI      16-NOV-1993
DEFINITION H.sapiens Humig mRNA.
ACCESSION  X72755 S60728
NID        g311375
KEYWORDS   chemokine; cytokine; Humig gene; secreted protein.
SOURCE     human.
ORGANISM   Homo sapiens
            Eukaryotae; mitochondrial eukaryotes; Metazoa; Chordata;
            Vertebrata; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE  1 (bases 1 to 2545)
AUTHORS    Farber, J.M.
TITLE      Direct Submission
JOURNAL    Submitted (22-MAR-1993) J.M. Farber, Johns Hopkins Univ. School
of         Medicine, Ross 1147, 720 Rutland Avenue, Baltimore, MD 21205,
USA
REFERENCE  2 (bases 1 to 2545)
AUTHORS    Farber, J.M.
TITLE      HuMig: a new human member of the chemokine family of cytokines
JOURNAL    Biochem. Biophys. Res. Commun. 192 (1), 223-230 (1993)
MEDLINE    93236577
FEATURES   Location/Qualifiers
            source          1..2545
                        /organism="Homo sapiens"
                        /db_xref="taxon:9606"
                        /germline
                        /dev_stage="child"
                        /tissue_type="leukaemia"
                        /cell_type="monocyte"
                        /cell_line="THP-1"
                        /clone_lib="THP-1/IFN-gamma cDNA"
                        /clone="H-1-3"
            misc_feature    13..19
                        /note="cis-acting element; putative"
            gene            40..417
                        /gene="Humig"
            CDS             40..417
                        /gene="Humig"
                        /codon_start=1
                        /db_xref="PID:g311376"
                        /db_xref="SWISS-PROT:Q07325"

```

/translation="MKKSGVLFLGIIILLVIGVQGTPVVRKGRCSISTNQGTIHLQ

SLKDLKQFAPSPSCEKIEIIATLKNVQTCNLPDSADVKELIKKEKQVSQKKKQKNG
KKHQKKKVLKVRKSQRSRQKKTT

```

BASE COUNT      755 a      581 c      457 g      752 t
ORIGIN

```

```

1 atccaataca ggagtgactt ggaactccat tctatcacta tgaagaaaag tgggtgttctt
61 ttcctcttgg gcatcatctt gctgggtctg attggagtgc aaggaacccc agtagtgaga
121 aagggtegct gttcctgcat cagcaccac caagggacta tccacctaca atccttgaaa
181 gaccttaaac aatttgcccc aagcccttcc tgcgagaaaa ttgaaatcat tgctacactg
241 aagaatggag ttcaaactatg tctaaaccca gattcagcag atgtgaagga actgattaaa
301 aagtgggaga aacaggtcag ccaaaaagaa aagcaaaaaga atgggaaaaa acatcaaaaa
361 aagaaagttc tgaaagtctg aaaaatctca cgttctcgtc aaaaagaagac tacataagag
421 accacttcac caataagtat tctgtgttaa aaatgttcta ttttaattat accgctatca
481 ttccaaagga ggatggcata taatacaaa gcttattaat ttgactagaa aatttaaaac
541 attactctga aattgttaact aaagttagaa agttgatttt aagaatccaa acgttaagaa
601 ttgttaaagg ctatgattgt cttgttctt ctaccaccca ccagttgaat ttcacatgc
661 ttaaggccat gattttagca ataccatgt ctacacagat gttcacccaa ccacatccca
721 ctcacaacag ctgcctggaa gagcagccct aggtctccac gtactgcagc ctccagagag
781 tatctgaggc acatgtcagc aagtcctaag cctgttagca tgctgggtgag ccaagcagtt

```

```

841 tgaattgag ctggacctca ccaagctgct gtggccatca acctctgtat ttgaatcagc
901 ctacaggcct cacacacaat gtgtctgaga gattcatgct gattgttatt gggatcacc
961 actggagatc accagtggtg ggctttcaga gcctcctttc tggcttttga agccatgtga
1021 ttccatcttg cccgctcagg ctgaccactt tatttctttt tggtccctt ggcttcattc
1081 aagtcagctc ttctccatcc taccacaatg cagtgccttt ctctctcca gtgcacctgt
1141 catatgctct gatttatctg agtcaactcc ttctcatct tgccccaac accccacaga
1201 agtgctttct tctcccaatt catcctcact cagtccagct tagttcaagt cctgcctctt
1261 aaataaacct ttttggacac acaaattatc ttaaaactcc tgtttcactt gggtcagtac
1321 cacatgggtg aacactcaat ggtaactaa ttcttgggtg tttatcctat ctctccaacc
1381 agattgtcag ctcccttgagg gcaagagcca cagtatatct ccctgtttct tccacagtgc
1441 ctaataatac tgtggaacta ggttttaata attttttaat tgatgttgtt atgggcagga
1501 tggcaaccag accattgtct cagagcaggt gctggctctt tcctggctac tccatgttgg
1561 ctagcctctg gtaacctctt acttattatc ttcaggacac tcactacagg gaccagggat
1621 gatgcaacat ccttgtcttt ttatgacagg atgtttgctc agcttctcca acaataagaa
1681 gcacgtggta aaacacttgc ggatattctg gactgttttt aaaaaatata cagtttaccg
1741 aaaatcatat aatcttacia tgaaaaggac tttatagatc agccagtgac caaccttttc
1801 ccaaccatac aaaaattcct tttcccgaag gaaaagggtt ttctcaataa gcctcagctt
1861 tctaagatct aacaagatag ccaccgagat ccttatcgaa actcatttta ggcaaatatg
1921 agttttattg tccgtttact tgtttcagag tttgtattgt gattatcaat taccacacca
1981 tctcccatga agaaagggaa cgggtgaagta ctaagcgcta gaggaagcag ccaagtcggt
2041 tagtggaagc atgattgggtg cccagttagc ctctgcagga tgtggaaacc tccctccagg
2101 ggaggttcag tgaattgtgt aggagaggtt gtctgtggcc agaatttaaa cctatactca
2161 ctttcccaaa ttgaatcact gctcacactg ctgatgattt agagtgtgtt ccggtggaga
2221 tcccacccga acgtcttata taatcatgaa actccctagt tccttcatgt aacttccctg
2281 aaaaatctaa gtgtttcata aatttgagag tctgtgaccc acttaccttg catctcacag
2341 gtagacagta tataactaac aaccaaagac tacatatgtt cactgacaca caggttataa
2401 tcatttatca tatatatata tacatgcata cactctcaaa gcaaataatt tttcacttca
2461 aaacagtatt gacttgata ccttgtaatt tgaaatattt tctttgttaa aatagaatgg
2521 tatcaataaa tagaccatta atcag

```

//

```

LOCUS      AF002985      995 bp      mRNA      PRI      01-NOV-1997
DEFINITION Homo sapiens putative alpha chemokine (H174) mRNA, complete
cds.
ACCESSION  AF002985
NID        g2580585
KEYWORDS
SOURCE     human.
ORGANISM   Homo sapiens
            Eukaryotae; Metazoa; Chordata; Vertebrata; Mammalia; Eutheria;
            Primates; Catarrhini; Hominidae; Homo.
REFERENCE  1 (bases 1 to 995)
AUTHORS    Jacobs,K.A., Collins-Racie,L.A., Colbert,M., Duckett,M.,
            Golden-Fleet,M., Kelleher,K., Kriz,R., LaVallie,E.R.,
            Merberg,D.,
            Spaulding,V., Stover,J., Williamson,M.J. and McCoy,J.M.
TITLE      A genetic selection for isolating cDNAs encoding secreted
proteins
JOURNAL    Gene 198 (1-2), 289-296 (1997)
MEDLINE    98036061
REFERENCE  2 (bases 1 to 995)
AUTHORS    Jacobs,K.A., Collins-Racie,L.A., Colbert,M., Duckett,M.,
            Golden-Fleet,M., Kelleher,K., Kriz,R., LaVallie,E.R.,
            Merberg,D.,
            Spaulding,V., Stover,J., Williamson,M.J. and McCoy,J.M.
TITLE      Direct Submission
JOURNAL    Submitted (07-MAY-1997) Genetics Institute, 87 Cambridge Park
            Drive, Cambridge, MA 02140, USA
FEATURES   Location/Qualifiers
            source          1..995
                        /organism="Homo sapiens"
                        /db_xref="taxon:9606"
                        /cell_type="PHA and PMA activated human peripheral
blood
            gene            mononuclear cells"
                        1..995
                        /gene="H174"
            CDS              88..372
                        /gene="H174"
                        /codon_start=1
                        /product="putative alpha chemokine"

```

/db_xref="PID:g2580586"

/translation="MSVKGMAIALAVILCATVVQGFPMFKRGRCLCIGPGVKAVKQVAD
IEKASIMYPSNNCDKIEVITLKENKGQRCLNPKSKQARLIKKVERKNF"

BASE COUNT 382 a 170 c 194 g 249 t
ORIGIN
1 gaattcggcc aaagaggcct acttccaaga agagcagcaa agctgaagta gcagcaacag
61 caccagcagc aacagcaaaa aacaaacatg agtgtgaagg gcatggctat agccttggct
121 gtgatattgt gtgctacagt tgttcaaggc ttcccatgt tcaaaagagg acgctgtctt
181 tgcattaggcc ctggggtaaa agcagtgaaa gtggcagata ttgagaaagc ctccataatg
241 taccgaagta acaactgtga caaaatagaa gtgattatta ccctgaaaga aaataaagga
301 caacgatgcc taaatcccaa atcgaagcaa gcaaggctta taatcaaaaa agttgaaaga
361 aagaattttt aaaaaatca aaacatatga agtcctggaa aagggcatct gaaaaaccta
421 gaacaagttt aactgtgact actgaaatga caagaattct acagtaggaa actgagactt
481 ttctatgggt ttgtgacttt caacttttgt acagtattgt gaaggatgaa aggtgggtga
541 aaggacaaaa aacagaaata cagtcttctt gaatgaatga caatcagaat tccactgccc
601 aaaggagtc aacaattaaa tggatttcta ggaaaagcta ccttaagaaa ggctgggtac
661 catcggagtt tacaaagtgc ttacacgttc ttacttgggt tattatacat tcatgcattt
721 ctaggctaga gaaccttcta gatttgatgc ttacaactat tctgtgtgta ctatgagaac
781 atttctgtct ctagaagtta tctgtctgta ttgatcttta tgctatatta ctatctgtgg
841 ttacagtggg gacattgaca ttattactgg agtcaagccc ttataagtca aaagcaccta
901 tgtgtcgtaa agcattcctc aaacatttaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa
961 aaaaaaaaaa aaaaaaaaaa aaaaaaagcg gccgc

//

LOCUS AF030514 1371 bp mRNA PRI 17-JUN-1998
DEFINITION Homo sapiens interferon stimulated T-cell alpha chemoattractant precursor, mRNA, complete cds.
ACCESSION AF030514
NID g3219692
KEYWORDS
SOURCE human.
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Vertebrata; Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1 (bases 1 to 1371)
AUTHORS Cole, K.E., Strick, C.A., Paradis, T.J., Ogborne, K.T., Loetscher, M., Gladue, R.P., Lin, W., Boyd, J.G., Moser, B., Wood, D.E., Sahagan, B.G. and Neote, K.
TITLE Interferon-inducible T cell alpha chemoattractant (I-TAC): a novel non-ELR CXC chemokine with potent activity on activated T cells through selective high affinity binding to CXCR3
JOURNAL J. Exp. Med. 187 (12), 2009-2021 (1998)
MEDLINE 98290735
REFERENCE 2 (bases 1 to 1371)
AUTHORS Cole, K.E., Strick, C.A. and Sahagan, B.G.
TITLE Direct Submission
JOURNAL Submitted (20-OCT-1997) Molecular Sciences, Pfizer, Inc., Eastern Point Road, Groton, CT 06340, USA
FEATURES
source Location/Qualifiers
1..1371
/organism="Homo sapiens"
/db_xref="taxon:9606"
/chromosome="4"
/cell_type="astrocytes"
sig_peptide 70..132
CDS 70..354
/note="chemokine; I-TAC"
/codon_start=1
/product="interferon stimulated T-cell alpha chemoattractant precursor"
/db_xref="PID:g3219693"
/translation="MSVKGMAIALAVILCATVVQGFPMFKRGRCLCIGPGVKAVKQVAD
IEKASIMYPSNNCDKIEVITLKENKGQRCLNPKSKQARLIKKVERKNF"
mat_peptide 133..351
/evidence=not_experimental

```

        /product="interferon stimulated T-cell alpha
        chemoattractant"
BASE COUNT      487 a      228 c      244 g      411 t      1 others
ORIGIN
1   ctcccttccaa gaagagcagc aaagctgaag tagcagcaac agcaccagca gcaacagcaa
61  aaaacaaaaca tgagtgtgaa gggcatggct atagccttgg ctgtgatatt gtgtgctaca
121 gttgttcaag gcttcccat gttcaaaaga ggacgctgtc tttgcatagg ccctggggta
181 aaagcagtga aagtggcaga tattgagaaa gcctccataa tgtaccaag taacaactgt
241 gacaaaatag aagtgattat taccctgaaa gaaaataaag gacaacgatg cctaaatccc
301 aaatcgaagc aagcaaggct tataatcaaa aaagttgaaa gaaagaattt ttaaaaatat
361 caaaacatat gaagtcttgg aaaagggcac ctgaaaaacc tagaacaagt ttaactgtga
421 ctactgaaat gacaagaatt ctacagtagg aaactgagac ttttctatgg ttttgtgact
481 ttcaactttt gtacagttat gtgaaggatg aaaggtgggt gaaaggacca aaaacagaaa
541 tacagtcttc ctgaatgaat gacaatcaga attccactgc ccaaaggagt ccagcaatta
601 aatggatttc taggaaaagc taccttaaga aaggctgggt accatcggag tttacaaagt
661 gctttcacgt tcttacttgt tgtattatac attcatgcat ttctaggcta gagaaccttc
721 tagatttgat gcttacaact attctgttgt gactatgaga acatttctgt ctctagaagt
781 tatctgtctg tattgatctt tatgctatat tactatctgt ggttacagtg gagacattga
841 cattattact ggagtcaagc ccttataagt caaaagcatc tatgtgtcgt aaagcattcc
901 tcaaacattt tttcatgcaa atacacaytt ctttcccaa atatcatgta gcacatcaat
961 atgtagggaa acattcttat gcatcatttg gtttgtttta taaccaattc attaatgta
1021 attcataaaa tgtactatga aaaaaattat acgctatggg atactggcaa cagtgcacat
1081 atttcataac caaattagca gcaccggtct taatttgatg tttttcgaat tttattcatt
1141 gagatgtttt gaagcaatta ggatctgtgt gtttactgta ctttttgttt tgatccgttt
1201 gtataaatga tagcaatatc ttggacacat ttgaaataca aaatgttttt gtctacaaaa
1261 gaaaaatgtt gaaaaataag caaatgtata cctagcaatc acttttactt tttgtaattc
1321 tgtctcttag aaaaatacat aatctaatac aaaaaaaaaa aaaaaaaaaa a

```

//

```

LOCUS      AF030514      1371 bp      mRNA      PRI      17-JUN-1998
DEFINITION Homo sapiens interferon stimulated T-cell alpha chemoattractant
            precursor, mRNA, complete cds.
ACCESSION  AF030514
NID        g3219692
KEYWORDS
SOURCE     human.
ORGANISM   Homo sapiens
            Eukaryota; Metazoa; Chordata; Vertebrata; Mammalia; Eutheria;
            Primates; Catarrhini; Hominidae; Homo.
REFERENCE  1 (bases 1 to 1371)
AUTHORS    Cole,K.E., Strick,C.A., Paradis,T.J., Ogborne,K.T.,
Loetscher,M., Gladue,R.P., Lin,W., Boyd,J.G., Moser,B., Wood,D.E.,
Sahagan,B.G.
            and Neote,K.
TITLE      Interferon-inducible T cell alpha chemoattractant (I-TAC): a
novel      non-ELR CXC chemokine with potent activity on activated T cells
            through selective high affinity binding to CXCR3
JOURNAL    J. Exp. Med. 187 (12), 2009-2021 (1998)
MEDLINE    98290735
REFERENCE  2 (bases 1 to 1371)
AUTHORS    Cole,K.E., Strick,C.A. and Sahagan,B.G.
TITLE      Direct Submission
JOURNAL    Submitted (20-OCT-1997) Molecular Sciences, Pfizer, Inc.,
Eastern    Point Road, Groton, CT 06340, USA
FEATURES
            Location/Qualifiers
            source      1..1371
                        /organism="Homo sapiens"
                        /db_xref="taxon:9606"
                        /chromosome="4"
                        /cell_type="astrocytes"
            sig_peptide  70..132
            CDS          70..354
                        /note="chemokine; I-TAC"
                        /codon_start=1
                        /product="interferon stimulated T-cell alpha
                        chemoattractant precursor"
                        /db_xref="PID:g3219693"

```

```

/translation="MSVKGMALAVILCATVVQGFPMFKRGRCLCIGPGVKAVKQAD
IEKASIMYPSNCDKIEVIIITLKENKGQRCLNPKSKQARLIKKVERKNF"
mat_peptide 133..351
/evidence=not_experimental
/product="interferon stimulated T-cell alpha
chemoattractant"
BASE COUNT 487 a 228 c 244 g 411 t 1 others
ORIGIN
1 ctccttccaa gaagagcagc aaagctgaag tagcagcaac agcaccagca gcaacagcaa
61 aaaacaaaca tgagtgtgaa gggcatggct atagccttgg ctgtgatatt gtgtgctaca
121 gttgttcaag gcttcccat gttcaaaaaga ggacgctgtc ttgtcatagg ccctggggta
181 aaagcagtga aagtggcaga tattgagaaa gcctccataa tgtaccaag taacaactgt
241 gacaaaatag aagtgattat taccctgaaa gaaaataaag gacaacgatg cctaaatccc
301 aaatcgaagc aagcaaggct tataatcaaa aaagttgaaa gaaagaattt ttaaaaatat
361 caaaacatat gaagtcctgg aaaagggcat ctgaaaaacc tagaacaagt ttaactgtga
421 ctactgaaat gacaagaatt ctacagtagg aaactgagac ttttctatgg tttgtgact
481 ttcaactttt gtacagttaa gtgaaggatg aaaggtgggt gaaaggacca aaaacagaaa
541 tacagtcttc ctgaatgaat gacaatcaga attccactgc ccaaaggagt ccagcaatta
601 aatggatttc taggaaaagc taccttaaga aaggctgggt accatcggag tttacaaagt
661 gctttcacgt tcttacttgt tgtattatac attcatgcct ttctaggcta gagaaccttc
721 tagatttgat gcttacaact attctgttgt gactatgaga acatttctgt ctctagaagt
781 tatctgtctg tattgatctt tatgtctatat tactatctgt gggtacagtg gagacattga
841 cattattact ggagtcgaag ccttataagt caaagcatc tatgtgtcgt aaagcattcc
901 tcaaacattt tttcatgcaa atacacaytt ctttcccaa atatcatgta gcacatcaat
961 atgtagggaa acattcttat gcatcatttg gtttgtttta taaccaattc attaaatgta
1021 attcataaaa tgtactatga aaaaaattat acgctatggg atactggcaa cagtgcacat
1081 atttcataac caaattagca gcaccggtct taatttgatg tttttcaact tttattcatt
1141 gagatgtttt gaagcaatta ggatatgtgt gtttactgta cttttgtgtt tgatccgttt
1201 gtataaatga tagcaatata ttggacacat ttgaaataca aaatgttttt gtctacaaa
1261 gaaaaatgtt gaaaaataag caaatgtata cctagcaatc acttttactt tttgtaattc
1321 tgtctcttag aaaaatacat aatctaatac aaaaaaaaaa aaaaaaaaaa a
//

```

```

LOCUS AF030514 1371 bp mRNA PRI 17-JUN-1998
DEFINITION Homo sapiens interferon stimulated T-cell alpha chemoattractant
precursor, mRNA, complete cds.
ACCESSION AF030514
NID g3219692
KEYWORDS
SOURCE human.
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Vertebrata; Mammalia; Eutheria;
Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1 (bases 1 to 1371)
AUTHORS Cole,K.E., Strick,C.A., Paradis,T.J., Ogborne,K.T.,
Loetscher,M., Gladue,R.P., Lin,W., Boyd,J.G., Moser,B., Wood,D.E.,
Sahagan,B.G. and Neote,K.
TITLE Interferon-inducible T cell alpha chemoattractant (I-TAC): a
novel non-ELR CXC chemokine with potent activity on activated T cells
through selective high affinity binding to CXCR3
JOURNAL J. Exp. Med. 187 (12), 2009-2021 (1998)
MEDLINE 98290735
REFERENCE 2 (bases 1 to 1371)
AUTHORS Cole,K.E., Strick,C.A. and Sahagan,B.G.
TITLE Direct Submission
JOURNAL Submitted (20-OCT-1997) Molecular Sciences, Pfizer, Inc.,
Eastern Point Road, Groton, CT 06340, USA
FEATURES
source Location/Qualifiers
1..1371
/organism="Homo sapiens"
/db_xref="taxon:9606"
/chromosome="4"
/cell_type="astrocytes"
sig_peptide 70..132
CDS 70..354
/note="chemokine; I-TAC"
/codon_start=1

```

/product="interferon stimulated T-cell alpha
chemoattractant precursor"
/db_xref="PID:g3219693"

/translation="MSVKGMAIALAVILCATVVQGFPMFKRGRCLCIGPGVKAVKQAD
IEKASIMYPSNNCDKIEVIITLKENKGQRCLNPKSKQARLIKKVERKNF"
mat_peptide 133..351
/evidence=not_experimental
/product="interferon stimulated T-cell alpha
chemoattractant"

BASE COUNT 487 a 228 c 244 g 411 t 1 others
ORIGIN
1 ctccttccaa gaagagcagc aaagctgaag tagcagcaac agcaccagca gcaacagcaa
61 aaaacaaaca tgagtgtgaa gggcatggct atagccttgg ctgtgatatt gtgtgctaca
121 gttgttcaag gcttcccat gttcaaaaga ggacgctgtc ttgcatagg ccctggggta
181 aaagcagtga aagtggcaga tattgagaaa gcctccataa tgtacccaag taacaactgt
241 gacaaaatag aagtgtattat taccctgaaa gaaaataaag gacaacgatg cctaaatccc
301 aaatcgaagc aagcaaggct tataatcaaa aaagttgaaa gaaagaattt ttaaaaatat
361 caaaacatat gaagtctctgg aaaagggcat ctgaaaaacc tagaacaagt ttaactgtga
421 ctactgaaat gacaagaatt ctacagtagg aaactgagac ttttctatgg ttttgtgact
481 ttcaactttt gtacagttat gtgaaggatg aaaggtgggt gaaaggacca aaaacagaaa
541 tacagtcttc ctgaatgaat gacaatcaga attccactgc ccaaaggagt ccagcaatta
601 aatggatttc taggaaaagc taccttaaga aaggctgggt accatcggag tttaacaagt
661 gctttcacgt tcttacttgt tgtattatac attcatgcat ttctaggcta gagaaccttc
721 tagatttgat gcttacaact attctgttgt gactatgaga acatttctgt ctctagaagt
781 tatctgtctg tattgatctt tatgtatat tactatctgt ggttacagtg gagacattga
841 cattattact ggagtcaagc ccttataagt caaaagcatc tatgtgtcgt aaagcattcc
901 tcaaacattt tttcatgcaa atacacaytt ctttcccaa atatcatgta gcacatcaat
961 atgtagggaa acattcttat gcatcatttg gtttgtttta taaccaattc attaaatgta
1021 attcataaaa tgtactatga aaaaaattat acgctatggg atactggcaa cagtgcacat
1081 atttcataac caaattagca gcaccggctc taatttgatg tttttcaact tttattcatt
1141 gagatgtttt gaagcaatta ggatatgtgt gtttactgta ctttttgttt tgatccgttt
1201 gtataaatga tagcaatata ttggacacat ttgaaatata aaatgttttt gtctaccaa
1261 gaaaaatggt gaaaaataag caaatgtata cctagcaatc acttttactt tttgtaattc
1321 tgtctcttag aaaaatacat aatctaata caaaaaaaaa aaaaaaaaaa a

//

LOCUS HSMDNCF 1560 bp RNA PRI 31-MAR-1995
DEFINITION Human mRNA for MDNCF (monocyte-derived neutrophil chemotactic
factor).
ACCESSION Y00787
NID g34518
KEYWORDS cytokine.
SOURCE human.
ORGANISM Homo sapiens
Eukaryotae; mitochondrial eukaryotes; Metazoa; Chordata;
Vertebrata; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1 (bases 1 to 1560)
AUTHORS Matsushima, K.
TITLE Direct Submission
JOURNAL Submitted (03-MAY-1988) Matsushima K., National Cancer
Institute, Bldg 560, Rm 31-19, Frederick, MD 21701
REFERENCE 2 (bases 1 to 1560)
AUTHORS Matsushima, K., Morishita, K., Yoshimura, T., Lavu, S.,
Kobayashi, Y.,
Lew, W., Appella, E., Kung, H.F., Leonard, E.J. and Oppenheim, J.J.
TITLE Molecular cloning of a human monocyte-derived neutrophil
chemotactic factor (MDNCF) and the induction of MDNCF mRNA by
interleukin 1 and tumor necrosis factor
JOURNAL J. Exp. Med. 167 (6), 1883-1893 (1988)
MEDLINE 88258376
COMMENT for overlapping sequence see M17016 - M17017.
FEATURES Location/Qualifiers
source 1..1560
/organism="Homo sapiens"
/db_xref="taxon:9606"
/cell_type="monocyte"
/clone_lib="lambda gt10"
sig_peptide 102..182
/note="signal peptide (AA -27 to -1)"


```

CDS
102..401
/codon_start=1
/product="MDNCF precursor (AA -27 to 72)"
/db_xref="PID:g34519"
/db_xref="SWISS-PROT:P10145"

/translation="MTSKLAVALLAFLISAALCEGAVLPRSAKELRCQCIKTYSKPF
HPKFIKELRVIESGPHCANTEIIVKLSDGRELCLDPKENWVQRVVEKFLKRAENS"
mat_peptide 183..398
/note="mat. MDNCF (AA 1 - 72)"
BASE COUNT 526 a 247 c 281 g 506 t
ORIGIN
1 ctccataagg cacaaacttt cagagacagc agagcacaca agcttctagg acaagagcca
61 ggaagaaacc accggaagga accatctcac tgtgtgtaaa catgacttcc aagctggccg
121 tggctctctt ggcagccttc ctgatttctg cagctctgtg tgaagggtgca gttttgccaa
181 ggagtgtctaa agaacttaga tgtcagtgtc taaagacata ctccaaacct ttccacccca
241 aatttatcaa agaactgaga gtgattgaga gtggaccaca ctgcgccaac acagaaatta
301 ttgtaaagct ttctgatgga agagagctct gtctggaccc caaggaaaac tgggtgcaga
361 ggggttggtg gaagtttttt aagagggtct agaattcata aaaaaattca ttctctgtgg
421 tatccaagaa tcagtgaaga tgccagttaa acttcaagca aatctacttc aacacttcat
481 gtattgtgtg ggtctgttgt aggggttgcca gatgcaatac aagattccctg gttaaatttg
541 aatttcagta aacaatgaat agtttttcat tgtaccatga aatatccaga acatacttat
601 atgtaaaagta ttatttattt gaattctcaa aaaacaacaa ataattttta aatataagga
661 ttttcctaga tattgcacgg gagaatatac aaatagcaaa attgggccaag gggccaagag
721 aatatccgaa cttaattttc aggaattgaa tgggtttgct agaattgtgat atttgaagca
781 tcacataaaa atgatgggac aataaatttt gccataaagt caaatttagc tggaaatcct
841 ggattttttt ctgttaaatc tggcaaccct agtctgctag ccaggatcca caagtccttg
901 ttccactgtg ccttggtttc tcctttattt ctaagtggaa aaagtattag ccaccatctt
961 acctcacagt gatgttgtga ggacatgtgg aagcacttta agttttttca tcataacata
1021 aattattttc aagtgttaact tattaacctt tttattattt atgtatttat ttaagcata
1081 aatattttgt caagaatttg gaaaaataga agatgaatca ttgattgaat agttataaag
1141 atgttatagt aaatttattt tatttttagat attaaatgat gttttattag ataaatttca
1201 atcagggttt ttagattaaa caaacaacaa attgggtacc cagttaaatt ttcatctcag
1261 atatacaaca aataattttt tagtataagt acattattgt ttatctgaaa ttttaattga
1321 actaacaatc ctagtttgat actcccagtc ttgtcattgc cagctgtgtt ggtagtgtct
1381 tgttgaatta cggaataatg agttagaact attaaaacag ccaaaactcc acagtcaata
1441 ttagtaattt cttgctggtt gaaacttgtt tattatgtac aaatagattc ttataatatt
1501 atttaaatga ctgcattttt aaatacaagg ctttatattt ttaactttaa aaaaaaccgg

```

//

```

LOCUS      HSINFGFR      1172 bp      RNA      PRI      21-MAR-1995
DEFINITION Human mRNA for gamma-interferon inducible early response gene
(with      homology to platelet proteins).
ACCESSION  X02530 M17752
NID        g33917
KEYWORDS   interferon response; signal peptide.
SOURCE     human.
ORGANISM   Homo sapiens
            Eukaryotae; mitochondrial eukaryotes; Metazoa; Chordata;
            Vertebrata; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE  1 (bases 1 to 1172)
AUTHORS    Luster,A.D., Unkeless,J.C. and Ravetch,J.V.
TITLE      Gamma-interferon transcriptionally regulates an early-response
gene
            containing homology to platelet proteins
JOURNAL     Nature 315 (6021), 672-676 (1985)
MEDLINE     85240552
REFERENCE  2 (bases 1 to 1172)
AUTHORS     Luster,A.D.
TITLE       Direct Submission
JOURNAL     Submitted (29-JUL-1986) to the EMBL/GenBank/DDBJ databases
COMMENT     Data kindly reviewed (29-JUL-1986) by Luster A.D.
FEATURES
    source   Location/Qualifiers
            1..1172
            /organism="Homo sapiens"
            /strain="(U 937 histiocytic lymphoma cell line)"
            /db_xref="taxon:9606"
    misc_RNA 1
            /note="cap site"

```

sig_peptide 67..129
 /note="pot. signal peptide (aa-21 to -1)"
 CDS 67..363
 /note="early response precursor polypeptide (aa-21 to 77)"
 /codon_start=1
 /db_xref="PID:g33918"
 /db_xref="SWISS-PROT:P02778"

/translation="MNQTAILICCLIFLTLSGIQGVPLSRTVRCISISNQPVNPRS

LEKLEIIPASQFCPRVEIIATMKKKGEKRCCLNPESKAIKNLLKAVSKEMSKRSP"

mat_peptide 130..360
 /note="mature early response polypeptide (aa 1-77)"
 old_sequence 1138..1141
 /note="ugaa was uga in [1]"
 /citation=[1]
 old_sequence 1146..1148
 /note="caa was ca in [1]"
 /citation=[1]
 misc_feature 1155..1160
 /note="pot. polyA signal"
 polyA_site 1172
 /note="polyA site"

BASE COUNT 384 a 231 c 208 g 349 t
 ORIGIN

```

1 gagacattcc tcaattgctt agacatattc tgagcctaca gcagaggaac ctccagtcctc
61 agcaccatga atcaaaactgc gattctgatt tgctgcctta tctttctgac tctaagtggc
121 attcaaggag tacctctctc tagaaccgta cgctgtacct gcatcagcat tagtaatcaa
181 cctgttaatc caaggctctt agaaaaactt gaaattattc ctgcaagcca attttgtcca
241 cgtgttgaga tcaattgctac aatgaaaaag aagggtgaga agagatgtct gaatccagaa
301 tcgaaggcca tcaagaattt actgaaagca gttagcaagg aaatgtctaa aagatctcct
361 taaaaccaga ggggagcaaa atcgatgcag tgcttccaag gatggaccac acagaggctg
421 cctctcccat cacttcccta catggagtat atgtcaagcc ataattgttc ttagtttgca
481 gttacactaa aagggtgacca atgatggcca ccaaatcagc tgctactact cctgtaggaa
541 gggttaagtgt catcatccta agctattcag taataactct accctggcac tataatgtaa
601 gctctactga ggtgctatgt tcttagtgga tgctctgacc ctgcttcaaa tatttccctc
661 acctttccca tcttccaagg gtactaagga atctttctgc tttgggggtt atcagaatc
721 tcagaatctc aaataactaa aaggatgcca atcaaatctg ctttttaaa aatgctctt
781 acttcatgga cttccactgc catcctccca aggggcccac attcttccag tggctacctc
841 catacaattc caaacacata caggaaggta gaaatatctg aaaaatgtat tgtaagtatt
901 cttatttaat gaaagactgt acaaaagtata agtcttagat gtatatattt cctatatgt
961 tttcagtgtc catggaataa catgtaatta agtactatgt atcaatgagt aacaggaaaa
1021 ttttaaaaat acagatagat atatgctctg catgttacat aagataaatg tgctgaatgg
1081 ttttcaataa aaaatgaggt actctcctgg aaatattaag aaagactatc taaatgttga
1141 aagatcaaaa gggttaataaa gtaattataa ct

```

//

LOCUS SYNRP4A 225 bp DNA SYN 15-JUN-1989
 DEFINITION Human recombinant platelet factor 4 (PF4) gene, complete cds.
 ACCESSION M20901
 NID g209285
 KEYWORDS platelet factor; platelet factor 4.
 SOURCE Synthetic oligonucleotide DNA, clone pIN-III-ompA-2.
 ORGANISM artificial sequence.
 REFERENCE 1 (bases 1 to 225)
 AUTHORS Barone,A.D., Ghrayeb,J., Hammerling,U., Zucker,M.B. and Thorbecke,G.J.
 TITLE The expression in Escherichia coli of recombinant human platelet factor 4, a protein with immunoregulatory activity
 JOURNAL J. Biol. Chem. 263, 8710-8715 (1988)
 MEDLINE 88243725
 FEATURES Location/Qualifiers
 source 1..225
 /organism="artificial sequence"
 /db_xref="taxon:29278"
 CDS <1..>225
 /note="recombinant platelet factor 4"
 /codon_start=2

```

        /transl_table=11
        /db_xref="PID:g209286"

/translation="ASMEAEDGDLQCLCVKTTTSQVRPRHITSLEVIKAGPHCPTAQL
              IATLKDGRKICLDLQAPLYKKI IKLLESGS"
BASE COUNT   59 a    59 c    51 g    56 t
ORIGIN       HindIII site.
              1 agcttctatg gaagctgaag aagacgggtga cctgcagtgc ctgtgcgtta aaactacttc
              61 tcagggttcgt ccgcgtcata tcacttctct ggaagttatc aaagctggtc cgcattgccc
              121 gactgctcag ctgatcgcta ctctcaaaga cggtcgtaaa atctgcctgg acctgcaggg
              181 tccgctgtac aaaaaaatca tcaaaaaact gctggaatct ggatc
//

LOCUS       HUMGRO             1050 bp    mRNA                PRI      11-JUN-1993
DEFINITION  Human gro (growth regulated) gene.
ACCESSION   J03561
NID         g183622
KEYWORDS    gro gene; tumor cell.
SOURCE      Human bladder tumor cell (T24) cDNA to mRNA.
  ORGANISM  Homo sapiens
            Eukaryotae; mitochondrial eukaryotes; Metazoa; Chordata;
            Vertebrata; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1 (bases 1 to 1050)
  AUTHORS   Anisowicz, A., Bardwell, L. and Sager, R.
  TITLE     Constitutive overexpression of a growth-regulated gene in
            transformed Chinese hamster and human cells
  JOURNAL   Proc. Natl. Acad. Sci. U.S.A. 84, 7188-7192 (1987)
  MEDLINE   88041072
COMMENT     Draft entry and computer-readable sequence kindly submitted by
            R. Sager (20-NOV-1987).
FEATURES    Location/Qualifiers
             source            1..1050
                                /organism="Homo sapiens"
                                /db_xref="taxon:9606"
             sig_peptide       54..140
                                /note="signal peptide (put.); putative"
             CDS                54..377
                                /note="gro protein"
                                /codon_start=1
                                /db_xref="PID:g306806"

/translation="MARAALSAAPSNPRLLRVALLLLLLVAAGRRAAGASVATELRQC
              SDKSN"
              mat_peptide      141..374
                                /note="gro mature protein (put.); putative"
BASE COUNT   270 a    246 c    239 g    295 t
ORIGIN       52 bp upstream of NcoI site.
              1 ctgcgcagct cttccgctcc tctcacagcc gccagaccgc cctgctgagc cccatggccc
              61 gcgctgctct ctccgcgcgc cccagcaatc cccggctcct gcgagtggca ctgctgctcc
              121 tgctcctggt agccgctggc cggcgcgtag caggagcgtc cgtggccact gaactgcgct
              181 gccagtgtct gcagaccctg cagggaattc accccaagaa catccaaagt gtgaacgtga
              241 agtcccccg accccactgc gccc aaaccg aagtcatagc cacactcaag aatgggcgga
              301 aagcttgctt caatcctgca tccccatag ttaagaaaat catcgaaaag atgctgaaca
              361 gtgacaaatc caactgacca gaaggaggga ggaagctcac tgggtggctgt tcctgaagga
              421 ggccctgccc ttataggaac agaagaggaa agagagacac agctgcagag gccacctgga
              481 ttgtgcctaa tgtgtttgag catcgcttag gagaagtctt ctatttattt atttattcat
              541 tagttttgaa gattctatgt taatatttta ggtgtaaaat aattaagggt atgattaact
              601 ctacctgcac actgtcctat tatattcatt ctttttgaaa tgtcaacccc aagttagttc
              661 aatctggatt catatttaat ttgaaggtag aatgttttca aatgtttctc agtcattatg
              721 ttaatatattc tgaggagcct gcaacatgcc agccactgtg atagaggctg gcggatccaa
              781 gcaaatggcc aatgagatca ttgtgaaggc aggggaatgt atgtgcacat ctgttttgta
              841 actgtttaga tgaatgtcag ttgttattta ttgaaatgat ttcacagtgt gttgtcaaca
              901 tttctcatgt tgaacttta agaactaaaa tgttctaata atcccttgga cattttatgt
              961 ctttcttgta aggcatactg cttgttttaa tggtagtttt acagtgtttc tggcttagaa
              1021 caaaggggct taattattga tgttttcgga
//

LOCUS       HUMGROB5          1110 bp    mRNA                PRI      07-MAR-1995
DEFINITION  Human cytokine (GRO-beta) mRNA, complete cds.

```

ACCESSION M36820
 NID g183628
 KEYWORDS cytokine.
 SOURCE Human lymphocyte, cDNA to mRNA, clone GRO-beta.
 ORGANISM Homo sapiens
 Eukaryotae; mitochondrial eukaryotes; Metazoa; Chordata;
 Vertebrata; Eutheria; Primates; Catarrhini; Hominidae; Homo.
 REFERENCE 1 (bases 1 to 1110)
 AUTHORS Haskill, S., Peace, A., Morris, J., Sporn, S.A., Anisowicz, A.,
 Lee, S.W., Smith, T., Martin, G., Ralph, P. and Sager, R.
 TITLE Identification of three related human GRO genes encoding
 cytokine functions
 JOURNAL Proc. Natl. Acad. Sci. U.S.A. 87 (19), 7732-7736 (1990)
 MEDLINE 91017578
 COMMENT Draft entry and computer-readable sequence for [Proc. Natl.
 Acad. Sci. U.S.A. (1990) In press] kindly submitted
 by S.Haskill, 20-JUL-1990.
 FEATURES
 source Location/Qualifiers
 1..1110
 /organism="Homo sapiens"
 /db_xref="taxon:9606"
 /clone="GRO-beta"
 /tissue_type="monocyte and lymphocyte"
 gene 75..398
 /gene="GRO-beta"
 CDS 75..398
 /gene="GRO-beta"
 /codon_start=1
 /product="cytokine gro-beta"
 /db_xref="PID:g183629"

/translation="MARATLSAAPSNPRLLRVALLLLLLVAASRRAGAPLATELRQ

CLQTLQGIHLKNIQSVKVKSPGPHCAQTEVIATLKNQKACLNPASPMVKKIIEKMLK
 NGKSN"

BASE COUNT 300 a 247 c 247 g 316 t
 ORIGIN

```

1 gacagagccc gggccacgga gctccttgcc agctctcttc ctcgcacagc cgctcgaacc
61 gcctgctgag ccccatggcc cgcgccacgc tctccgccgc ccccagcaat ccccggtccc
121 tgcgggtggc gctgctgctc ctgctcctgg tggccgccag ccggcgcgca gcaggagcgc
181 ccctggccac tgaactgcgc tgccagtgtc tgcagacctc gcagggaatt cacctcaaga
241 acatccaaag tgtgaagggt aagtcctccg gaccccaact cgcccaaacc gaagtcatag
301 ccacactcaa gaatgggcag aaagcttgct tcaacccgc atcgcccatg gtttaagaaa
361 tcatcgaaaa gatgctgaaa aatggcaaat ccaactgacc agaaggaagg aggaagctta
421 ttggtggctg ttcctgaagg aggccctgcc ttacaggaac agaagaggaa agagagacac
481 agctgcagag gccacctggc ttgcgcctaa tgtgtttgag catacttagg agaagtcttc
541 tatttattta tttatttatt tattgtttg ttttagaaga ttctatgta atattttatg
601 tgtaaaataa ggttatgatt gaattacttt gcacactctc ccattatatt tattgtttat
661 tttagggtcaa acccaagtta gttcaatcct gattcatatt taatttgaag atagaagggtt
721 tgcagatatt ctctagtcac ttgttaatat ttcttcgtga tgacatatca catgtcagcc
781 actgtgatag aggctgagga atccaagaaa atggccagta agatcaatgt gacggcaggg
841 aaatgtatgt gtgtctatgt tgaactgta aagatgaatg tcagttgtta tttattgaaa
901 tgatttcaca gtgtgtgggc aacatttctc atgttgaagc tttaagaact aaaatgttct
961 aaatatccct tggcatttta tgtctttctt gtaagatact gccttgttta atgttaatta
1021 tgcagtgttt ccctctgtgt tagagcagag aggtttcgat atttattgat gttttcacia
1081 agaacaggaa aataaaatat ttaaaaatat
  
```

//

LOCUS HUMGROG5 1064 bp mRNA PRI 07-MAR-1995
 DEFINITION Human cytokine (GRO-gamma) mRNA, complete cds.
 ACCESSION M36821
 NID g183632
 KEYWORDS cytokine.
 SOURCE Human lymphocyte, cDNA to mRNA, clone GRO-gamma.
 ORGANISM Homo sapiens
 Eukaryotae; mitochondrial eukaryotes; Metazoa; Chordata;
 Vertebrata; Eutheria; Primates; Catarrhini; Hominidae; Homo.
 REFERENCE 1 (bases 1 to 1064)
 AUTHORS Haskill, S., Peace, A., Morris, J., Sporn, S.A., Anisowicz, A.,

TITLE Lee, S.W., Smith, T., Martin, G., Ralph, P. and Sager, R.
 cytokine Identification of three related human GRO genes encoding
 functions
 JOURNAL Proc. Natl. Acad. Sci. U.S.A. 87 (19), 7732-7736 (1990)
 MEDLINE 91017578
 COMMENT Draft entry and computer-readable sequence for [Proc. Natl.
 Acad. Sci. U.S.A. (1990) In press] kindly submitted
 by S.Haskill, 20-JUL-1990.
 FEATURES Location/Qualifiers
 source 1..1064
 /organism="Homo sapiens"
 /db_xref="taxon:9606"
 /clone="GRO-gamma"
 /tissue_type="lymphocyte and monocyte"
 gene 78..398
 /gene="GRO-gamma"
 CDS 78..398
 /gene="GRO-gamma"
 /codon_start=1
 /product="cytokine GRO-gamma"
 /db_xref="PID:g183633"
 /translation="MAHATLSAAPSNPRLRLRVALLLLLLVGSRRAAGASVVTELRCQC
 LQTLQGIHLKNIQSVNVRSPGPHCAQTEVIATLNGKKACLNPA SPMVQKII EKILNK
 GSTN"
 BASE COUNT 281 a 237 c 239 g 305 t 2 others
 ORIGIN
 1 cacagccggg tgcagggcac ctccccngcc agctctcccg cattctgcac agcttccccga
 61 cgcgtctgct gagcccccattg gcccacgcca cgtctctccg cgcgcccgagc aatccccggc
 121 tcctgcccgt ggcgctgctg ctcttgctcc tgggtggcag cgggcgcgca gcaggagcgt
 181 ccgtgggtcac tgaactgcgc tgccagtgc tgcagacact gcagggaatt cacctcaaga
 241 acatccaaag tgtgaatgta aggtcccccg gacccactg cgcccaaacc gaagtcatag
 301 ccacactcaa gaattgggaag aaagcttgct tcaaccccg atcccccatg gttcagaaaa
 361 tcacgaaaaa gatactgaac aaggggagca ccaactgaca ggagagaagt aagaagctta
 421 tcagcgtatc attgacactt cctgcagggt ggccctgcc cttaccagag ctgaaaaatga
 481 aaaagagaac agcagctttc tagggacagc tggaaaggga cttaattgtt ttgactattt
 541 cttacgaggg ttctacttat ttatgtattt atttttgaaa gcttgtattt taatatttta
 601 catgctgtta tttaaagatg tgagtgtgtt tcatcaaaca tagctcagtc ctgattattt
 661 aattggaata tgatgggttt taaatgtgtc attaaactaa tatttagtgg gagaccataa
 721 tgtgtcagcc accttgataa atgacagggt ggggaactgg agggtngggg gattgaaatg
 781 caagcaatta gtggatcact gttagggtta ggggaatgat gtacacatct attttttata
 841 cttttttttt taaaaaagaa tgtcagttgt tatttattca aattatctca cattatgtgt
 901 tcaacatttt tatgctgaag ttcccttag acattttatg tcttgcttgt agggcataat
 961 gccttgttta atgtccattc tgcagcgttt ctctttccct tggaaaagag aatttatcat
 1021 tactgttaca ttgtacaaa tgacatgata ataaaagttt tatg
 //
 LOCUS HUMCTAP3 673 bp mRNA PRI 06-MAR-1995
 DEFINITION Human connective tissue activation peptide III mRNA, complete
 cds.
 ACCESSION M54995 M38441
 NID g181175
 KEYWORDS connective tissue activating peptide-III; platelet basic
 protein;
 thromboglobulin.
 SOURCE Human platelet, cDNA to mRNA, clone lambda-c[1,2].
 ORGANISM Homo sapiens
 Eukaryotae; mitochondrial eukaryotes; Metazoa; Chordata;
 Vertebrata; Eutheria; Primates; Catarrhini; Hominidae; Homo.
 REFERENCE 1 (bases 1 to 673)
 AUTHORS Wenger, R.H., Wicki, A.N., Walz, A., Kieffer, N. and Clemetson, K.J.
 TITLE Cloning of cDNA coding for connective tissue activating peptide
 III
 from a human platelet-derived lambda gt11 expression library
 JOURNAL Blood 73 (6), 1498-1503 (1989)
 MEDLINE 89229374
 FEATURES Location/Qualifiers
 source 1..673

```

/organism="Homo sapiens"
/db_xref="taxon:9606"
/tissue_type="platelet"
/clone="lambda-cl"
/cell_type="platelet"
/tissue_type="blood"
/tissue_lib="lambda-gtl1"
/map="4p13-q21"
gene 67..453
      /gene="PPBP"
sig_peptide 67..168
            /gene="PPBP"
            /note="G00-127-391"
CDS 67..453
     /gene="PPBP"
     /codon_start=1
     /db_xref="GDB:G00-127-391"
     /product="connective tissue activating peptide III"
     /db_xref="PID:g181176"

/translation="MSLRDLTPSCNSARPLHALQVLLLLSLLLTALASSTKGQTKRN
LAKGKEESLSDLYAELRCMCIKTTSGIHPKNIQSLEVIGKGTCHNQVEVIATLKDGR
KICLDPDAPRIKKIVQKLAGDESAD"
mat_peptide 196..450
            /gene="PPBP"
            /note="G00-127-391"
            /product="connective tissue activating peptide III"
mat_peptide 208..450
            /gene="PPBP"
            /note="G00-127-391"
            /product="beta-thromboglobulin"
polyA_site 673
           /gene="PPBP"
           /note="G00-127-391"
BASE COUNT      202 a      149 c      139 g      183 t
ORIGIN
    1 gggcaactca ccctcactca gaggtcttct ggttcttgaa acaactctag ctcagccttc
   61 tccaccatga gcctcagact tgataccacc ccttcctgta acagtgcgag accacttcat
  121 gccttgacag tgctgctgct tctgtcattg ctgctgactg ctctggcttc ctccacaaaa
  181 ggacaaacta agagaaactt ggcgaaaaggc aaagaggaaa gtctagacag tgacttgat
  241 gctgaactcc gctgcatgtg tataaagaca acctctggaa ttcattccaa aaacatccaa
  301 agtttggaag tgatcgggaa aggaacccat tgcaaccaag tcgaagtgat agccacactg
  361 aaggatggga ggaaaatctg cctggaccca gatgctccca gaatcaagaa aattgtacag
  421 aaaaaattgg caggtgatga atctgctgat taattgttc tgtttctgcc aaacttctt
  481 aactccacag aagggtagaa ttttgaaacc ttgattttct agagttctca tttattcagg
  541 atacctattc ttactgtatt aaaatttgga tatgtgttcc attctgtctc aaaaatcaca
  601 ttttattctg agaaggttgg ttaaaagatg gcagaaagaa gatgaaaata aataagcctg
  661 gtttcaacc tct
//

```

```

LOCUS      HUMENA78A      2177 bp      DNA      PRI      31-JAN-1996
DEFINITION Homo sapiens neutrophil-activating peptide 78 (ENA-78) gene,
            complete cds.
ACCESSION  L37036 Z46254
NID        g607030
KEYWORDS   ENA-78 gene; homologue; neutrophil-activating factor;
            neutrophil-activating peptide 78.
SOURCE     Homo sapiens DNA.
ORGANISM   Homo sapiens
            Eukaryotae; mitochondrial eukaryotes; Metazoa; Chordata;
            Vertebrata; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE  1 (bases 1 to 2177)
AUTHORS    Walz,A., Burgener,R., Car,B., Baggiolini,M., Kunkel,S.L. and
            Strieter,R.M.
TITLE      Structure and neutrophil-activating properties of a novel
            inflammatory peptide (ENA-78) with homology to interleukin 8
JOURNAL     J. Exp. Med. 174 (6), 1355-1362 (1991)
MEDLINE     92078844
REFERENCE  2 (bases 1 to 2177)
AUTHORS     Walz,A.

```

TITLE Direct Submission
 JOURNAL Submitted (14-OCT-1994) A. Walz, University of Bern, Theodor
 Kocher
 Institute, Freiestr. 1, Bern, Switzerland 3012
 REFERENCE 3 (bases 1 to 2177)
 AUTHORS Corbett, M.S., Schmitt, I., Riess, O. and Walz, A.
 TITLE Characterization of the gene for human neutrophil-activating
 peptide 78 (ENA-78)
 JOURNAL Biochem. Biophys. Res. Commun. 205 (1), 612-617 (1994)
 MEDLINE 95091791

FEATURES
 source Location/Qualifiers
 1..2177
 /organism="Homo sapiens"
 /db_xref="taxon:9606"
 /cell_type="lymphoblastoid cells"
 /clone="4H2, 178C11, 106C1"
 /chromosome="4"
 /clone_lib="Chromosome 4 cosmid library of Riess et

al.
 gene 539..1747
 /gene="ENA-78"
 CAAT_signal 539..547
 /gene="ENA-78"
 TATA_signal 675..681
 /gene="ENA-78"
 exon <803..911
 /gene="ENA-78"
 /number=1
 CDS join(803..911,1046..1178,1289..1372,1729..1747)
 /gene="ENA-78"
 /note="homologue to interleukin-8"
 /codon_start=1
 /product="neutrophil-activating peptide 78"
 /db_xref="PID:g607031"

/translation="MSLLSSRAARVPGPSSSLCALLVLLLLLTQPGPIASAGPAAAVL

RELRCVCLQTTQGVHPKMISNLQVFAIGPQCSKVEVVASLKNGKEICLDPEAPFLKKV

intron IQKILDGKNKEN"
 912..1045
 /gene="ENA-78"
 /number=1
 exon 1046..1178
 /gene="ENA-78"
 /number=2
 intron 1179..1288
 /gene="ENA-78"
 /number=2
 exon 1289..1372
 /gene="ENA-78"
 /number=3
 intron 1373..1728
 /gene="ENA-78"
 /number=3
 exon 1729..>1747
 /gene="ENA-78"
 /number=4

BASE COUNT 539 a 512 c 496 g 630 t
 ORIGIN

```

1 gaattctcag taagcggact taccaaagta ggtgatctgt aggggagtta acaaaattca
61 gtggtccttt caggccactg acttcaagtg gcaagagaca aggggtctctt gttatcatgt
121 tatcttggtt tccaaagctg gttgaagtc agagattcat aaagtcattc aagaaacctta
181 gaatgacctg cctgcaagaa gacaggaagg actttcagtt tatagcaatt caaacatgaa
241 taacatttcc tgattaatag taataataat tagaaaggat tgactttcag aaatttttct
301 caaatcaagg ctectgttac ttgggttcca cttttctct ctagaaggag aggaggagca
361 tctcccagat gctgcgtgct ccagaaaaagc cggcatccct agcccgtctt ggcacaggcc
421 atgaggcgct gctgaatcct gctgaatagc tactcccttc tagctggagc cacagctccc
481 tccaccgcgg aacagggtta caacgtccct ctcggtagag gtgcacgcag ctcctcctgg
541 ccaccctccc caccagttcc cattgtctgg ccccccctcc ccaacctctt ctttccacac
601 tgccccatga gttcagggaa ttccccagc atcccaaagc ttgagtttcc tgtcagtggg
661 gagagatgag tgtagataaa aggagtgcag aaggaacgag gaagccacag tgctccggat
```

```

721 cctccaatct tcgctcctcc aatctccgct cctccacca gttcaggaac ccgcgaccgc
781 tcgcagcgct ctcttgacca ctatgagcct cctgtccagc cgcgcgcccc gtgtccccgg
841 tccttcgagc tccttggtcg cgctgttggt gctgtgtctg ctgctgacgc agccagggcc
901 catcgccagc ggtgagagcg catggcgcg cgacgcact cgcactcggg cacagaggtg
961 catcccagcc tctgcggggg cgctgcgttc cagggaactc tcccagcaac ctgccctata
1021 aaggggtgtct ctctttcttc cccagctggg cctgccgctg ctgtgttgag agagctgcgt
1081 tgcggtttgtt tacagaccac gcaaggagtt catcccaaaa tgatcagtaa tctgcaagtg
1141 ttgcccatag gcccacagtg ctccaagggt gaagtgtgtg aagttctgtg ctgctgtgtc
1201 cgctgtgacc ttggcaagag agaaaatccc cagcctgggt ctccaacctt ggtatctcat
1261 gagtgtatct tctttttctt tccttcagag cctccctgaa gaacgggaag gaaattgtc
1321 ttgatccaga agcccccttt ctaaagaaa gcatccagaa aattttggac gggacttgt
1381 cactttgac tttgtgggtt ctaaatctga tctagggaga ccatagactt cacaagggtc
1441 ttattctctg tacgatttaa gtaacacttt tcatgtttag aattaaaagg ttgttgaatt
1501 gggaaaagtt ttctggattg tcctgggaaa atataacca cttacatgta attacttgag
1561 caattacaca cagcttgtca ctaagttagt tttttgtttt acccattgct tttattgatt
1621 tttgtattct ccttttttac caaacatcat aaacgctgag ttttgacaag ggtggagtag
1681 aaaggagtg gaaaaatggt taaactaata taacattttt ctcaacagt gaaacaagga
1741 aaactgatta agagaaatga gcacgcatgg aaaagtttcc cagtcttcag cagagaagtt
1801 ttctggaggt ctctgaaccc aggggaagaca agaaggaaag attttgttgt tgtttgttta
1861 tttgttttcc cagtagttag ctttcttctt ggattcctca ctttgaagag tgtgaggaaa
1921 acctatgttt gccgcttaag ctttcagctc agctaataa gtgttttagc tagtacctct
1981 gctatttctt gttattttat ctgctatgct attgaagttt tggcaattga ctatagtgtg
2041 agccagggaat cactggctgt taatctttca aagtgtcttg aattgtagtg gactattata
2101 tttccaagaa atatttcctt agatattaac tgagaaggct gtggatttaa tgtggaaatg
2161 atgtttcata agaattc

```

//

LOCUS HSGCP2 254 bp RNA PRI 04-MAR-1997
 DEFINITION H.sapiens mRNA for granulocyte chemotactic protein.
 ACCESSION Y08770
 NID g1769436
 KEYWORDS cell surface receptor; CXC chemokine; GCP-2 gene; granulocyte chemotactic protein.
 SOURCE human.
 ORGANISM Homo sapiens
 Eukaryotae; mitochondrial eukaryotes; Metazoa; Chordata; Vertebrata; Eutheria; Primates; Catarrhini; Hominidae; Homo.
 REFERENCE 1 (bases 1 to 254)
 AUTHORS Froyen,G., Proost,P., Ronsse,I., Mitera,T., Haelens,A., Wuyts,A.,
 Opdenakker,G., Van Damme,J. and Billiau,A.
 TITLE Cloning, bacterial expression and biological characterization of recombinant human granulocyte chemotactic protein-2 and differential expression of granulocyte chemotactic protein-2 and epithelial cell-derived neutrophil activating peptide-78 mRNAs
 JOURNAL Eur. J. Biochem. 243 (3), 762-769 (1997)
 MEDLINE 97210779
 REFERENCE 2 (bases 1 to 254)
 AUTHORS Froyen,G.F.V.
 TITLE Direct Submission
 JOURNAL Submitted (10-OCT-1996) G.F.V. Froyen, Rega Institute, University of Leuven, Minderbroedersstraat 10, B-3000 Leuven, BELGIUM
 FEATURES Location/Qualifiers
 source 1..254
 /organism="Homo sapiens"
 /db_xref="taxon:9606"
 /haplotype="diploid"
 /tissue_type="embryonic"
 /rearranged
 /cell_type="fibroblast"
 /cell_line="E6SM (embryonic strain - skin and muscle)"
 gene 1..254
 /gene="GCP-2"
 exon <1..131
 /gene="GCP-2"
 /number=2
 CDS <1..234
 /gene="GCP-2"


```

/codon_start=1
/product="granulocyte chemotactic protein"
/db_xref="PID:e283124"
/db_xref="PID:g1769437"

/translation="GPVSAVLTELRCCTCLRVTLRVNPKTIGKLQVFPAGPQCSKVEVV
              ASLKNGKQVCLDPEAPFLKKVIQKILDSGNKKK"
      exon      132..215
                /gene="GCP-2"
                /number=3
      exon      216..254
                /gene="GCP-2"
                /number=4
      3'UTR      235..254
                /gene="GCP-2"
BASE COUNT      66 a      64 c      70 g      54 t
ORIGIN
      1 ggtcctgtct ctgctgtgct cacggagctg cgttgcactt gtttacgcgt tacgctgaga
      61 gtaaacccca aaacgattgg taaactgcag gtgttccccg caggcccgca gtgctccaag
      121 gtggaagtgg tagcctccct gaagaacggg aagcaagttt gtctggaccc ggaagccctt
      181 tttctaaaga aagtcattca gaaaattttg gacagtggaa acaagaaaaa ctgagtaaca
      241 gtcgacgcgg ccgc

//

LOCUS      D63789      5669 bp      DNA      PRI      27-DEC-1996
DEFINITION Human DNA for SCM-1beta precursor, complete cds.
ACCESSION  D63789
NID        g1754608
KEYWORDS   SCM-1beta; SCM-1beta precursor.
SOURCE     Homo sapiens placenta DNA, clone:hg44.
ORGANISM   Homo sapiens
            Eukaryotae; mitochondrial eukaryotes; Metazoa; Chordata;
            Vertebrata; Mammalia; Eutheria; Primates; Catarrhini;
            Hominidae;
            Homo.
REFERENCE  1 (sites)
AUTHORS   Yoshida,T., Imai,T., Kakizaki,M., Nishimura,M. and Yoshie,O.
TITLE     Molecular cloning of a novel C or gamma type chemokine, SCM-1
JOURNAL   FEBS Lett. 360 (2), 155-159 (1995)
MEDLINE   95180438
REFERENCE  2 (sites)
AUTHORS   Yoshida,T., Imai,T., Takagi,S., Nishimura,M., Ishikawa,I.,
            Yaoi,T.
            and Yoshie,O.
TITLE     Structure and expression of two highly related genes encoding
            SCM-1/human lymphotactin
JOURNAL   FEBS Lett. 395 (1), 82-88 (1996)
MEDLINE   97002294
REFERENCE  3 (bases 1 to 5669)
AUTHORS   Yoshida,T.
JOURNAL   Unpublished (1995)
REFERENCE  4 (bases 1 to 5669)
AUTHORS   Yoshida,T.
TITLE     Direct Submission
JOURNAL   Submitted (07-AUG-1995) to the DDBJ/EMBL/GenBank databases.
Tetsuya
            Yoshida, Shionogi Institute for Medical Science; 2-5-1,
            Mishima,
            Settsu, Osaka 566, Japan (E-
            mail:teyoshid@fl.lab.shionogi.co.jp.
            Tel:06-382-2612, Fax:06-382-2598)
FEATURES
      source      Location/Qualifiers
                  1..5669
                  /organism="Homo sapiens"
                  /db_xref="taxon:9606"
                  /chromosome="1"
                  /clone="hg44"
                  /map="1q23"
                  /tissue_type="placenta"
      TATA_signal  2154..2158
      exon        2197..2278

```

```

/number=1
prim_transcript 2197..5349
gene 2218..5230
/ gene="SCM-1beta"
CDS join(2218..2278,4075..4189,5062..5230)
/ gene="SCM-1beta"
/ codon_start=1
/ product="SCM-1beta precursor"
/ db_xref="PID:d1010504"
/ db_xref="PID:g1754609"

/translation="MRLILALLGICSLTAYIVEGVGSEVSHRRTCVSLTTQRLPVSR
IKTYTITEGSLRAVIFITKRLKVCADPQATWVRDVRSMDRKSNTNRNMIQTKPTGT
QQSTNTAVTLTG"
intron 2279..4074
/ gene="SCM-1beta"
/ number=1
exon 4075..4189
/ gene="SCM-1beta"
/ number=2
mat_peptide join(4077..4189,5062..5227)
/ gene="SCM-1beta"
intron 4190..5061
/ gene="SCM-1beta"
/ number=2
exon 5062..5349
/ number=3
BASE COUNT 1702 a 1058 c 1248 g 1661 t
ORIGIN

```

```

1 ggatccagga ggataacaag ggaatctcct actctcaaag agtctgccat ctagtgggag
61 acgcaggaat gtaattgagt aggagaacac aatgagattc gttgcagaac agccatgaga
121 acagaacaaa gttctaagag agcataaagg ggtggcacia cttaatTTTA tcaaaaaaat
181 tcaggaaaac ttatacagag aggaggagtt tacaagtaac tatgtaggga gctgtcatgg
241 gtattccagt taaaggaaac atgtgaggag cataaaagag gctggcccat tgggttggct
301 gcacatgtat gtgtttgtta aggtttggga gtgtgtgagt gaatggtgga aggtgagctt
361 gaaaggaaag cagtactaga tcttgagcat tcttatatat cacaatgaaa gatttgaaat
421 acatcctgta ggcattggaa gttagcaaaa gaggttctca gtagggaat ggcatgatta
481 gattgaggct ttacagtgat taccctggca aagctgcaga gaacagactg agaggaggcc
541 ctgggtctggg taaccagtta gtccactgta atttgcctaa catttgagca gtgtggggag
601 aaaggaggac acatctcaaa ggactaccta gaaggatatac ttagtccagt ttggttgaga
661 atgacatgta ggtggatagc aatgagtcta agatgatccc tatatatcag tatttggaaa
721 ttagatggaa gagaacacat tgctccatgc taaggactaa tatgaggaga agcagtttga
781 atagaagatg tgtccagtgt tcaaggagtg attgtgcagt aaggtagaga tcattaaaga
841 gccagtttga agtttagaat gaagtctggg tgaaaaatca aatgcgatta gtgggaagtc
901 tcttagaggt taacctatac tttttatgaa aacataggaa tttatttca tattccctaa
961 tagcaaaagg cctttaacta cacatatatt taataaatac attttataga tacctatgta
1021 aaataaaaga caaccaccac acaacaaact cagtggcaga aaagttccag tgcattcagt
1081 atattttaaa tctactgggg gtattgcaaa tcaaatTTTt attttggag actatatggc
1141 aatataataa aagagctata aagatgatca tatcattttt cccagtaatc ctactcctgg
1201 ttattaaagg gaagtaattc agtgtatatt aatgaaatcg accttatagt tctgatcttt
1261 ataataagtt ataagaaaat ggtttaactt gtatgtgtat atatttactc gaagtagaaa
1321 tatgaaggct aaaaaaatgg gaagatattt aaattgggtg taaaacagca tttaaaatta
1381 ccacaattat gagaacacat gtatgccaat gcagattcac tggaaaaata ttgaaaatga
1441 aaactgtcag atggtaagat tataatttta tttctttttt aatttgaaat aaattggtaa
1501 cagcacagct ttcaaaaagc ttctataaat gtgtatgtta agttgtaata aagcaaacac
1561 atgcatgtaa gacatgctta aacagttatt taattgtttc ttgggtacct ggggagatgg
1621 ggtgaagaaa ggggggtgac ttgaatgaag gtggaggaga aaaatgagaa ccaagaaagc
1681 aaaggatcga gaagctcagt gtggcagcag cctctcttcc cctcctgaga gagtcaaagg
1741 gtggcatcag ggactcatga tccatgggtg tggaagcctc atgtcacact ggatgtcaca
1801 tgagggtggga tggaacacag tgaccacccc acctcatttc ctttacagct tccgtggggg
1861 ccatggcagt gaacagcctt caggcatgtc tacggtggaa gatctgaatt caggctgggtg
1921 gcaggagaca acacaaccac gttttctttt atgcatgcat ttggtttaat tgacacatta
1981 accacagaca aaggggtaaa gggccacaagg cgatagggtta gtatgaacag ggaaggggac
2041 attttttttt tttaagaaaa ataaaagcat cagtattgca aagactttcc atgatcctat
2101 acccacctcg aaagccccct ctaccacag gaagtgcact gaccattgga ggcataaaag
2161 agatcctcaa agagcccgat cctcactctc cctgcacagc tcagcgggac ctgagccatg
2221 agacttctca tcttgccctc ccttggcatc tgctctctca ctgcatacat tgtggaaggt
2281 aagtggagaa gctgtctgtg agataaagaa tagggaggga aggcaggtgg gcacacattt
2341 tgggtttgac tgggtttttg actggactaa actgctgtct ccaggggagc cttaaacttc
2401 ccatgtgcaa gaaaggaatg atgattttga ctgtagaggg cttcgtaaac ttccaaaaa

```

```

2461 gggagaattt gattagtatc tgggctccta cttttcctaa ttgggtaatt tcaggtaaat
2521 tccttaacca ctcagggcct gtgcttattt atgtataaac tgaatagaat aagagacatg
2581 atcacctgag attaagatta aataaatatt atgggttatt taataacatc agatttcctt
2641 acaagcagta attttttgat taatgttagc tatggattag aggtgatgat tataaatgca
2701 tttgtaggtt ttgcccattt aatatatagt ttgataaatt atcaaaatct tagagagttc
2761 agttacaata tggggatgca ccagaggatg tatgtttctg agcaaatcaa tgttttcaat
2821 acaaaacctg tgtgaaggcg acagtagtgc ttgctgtgga ctggaatgtcc cagctttgcc
2881 ttccttcccc ttgataatgc aataagggac ccccatTTTA ggacgcagga caggcagaaa
2941 gataaccagc ttgatggggt ccacaccatg tgcaatcact accagctgag acttcttgtt
3001 ttccagcaag gtggtgatga tgttaacccc tgctcaaaga acagggtgatt tcctagtggg
3061 gacaacccct ttgctagcag cttttcttctc agcctggggc aacagctctc gcttcttctc
3121 ttgctttgtc tctggtcagt acttgttgat cagcttaagt ggctgagtag ctgtttgggg
3181 gtctaaggct tgggtgaact ggtaaatggc agaaggcatt ttcagctgct tatagaggat
3241 agctctttgc agctggaacc agatatagcg gggccatttc acaagcagt ggaggtctct
3301 tttgggctgg atgtcctgtc caatgcctgc ctaagaaaac tcttaggcct tttctcacac
3361 agcggtttca tcactttctt agcctctctc ttctcacga cggcagggac tggggccact
3421 tctttccttt ggccttcttt cttttcagca tcttaggcag ctgacagaga gggaaatttg
3481 accatTTTaaa aagggggaaca cctttattta ctcagtcaaa agcatgcttc cttccctcac
3541 tgaatgttgc cttgcctaga gtactcttca cgcattactc tgtcatctca cttatggtac
3601 tgaacatgt tgcactattt gaaatgatct tttctgtttg cctgtctctg gcctggctcc
3661 ctcagtgaag gatattgctt atgaaaacag ggataatgtc tgtcttaata aaacatgtgg
3721 gacacaacag gcaccattgt ataattgaat gaatgcgtgt cactggggca tttgtagcc
3781 gtcccaaatg tctaagtga aatatacaca gagacgggat aacatcttgt tatTTTctct
3841 cagcatgaaa ttcttgaaac aattctgttg attgagtttt taaattagtc aaatatttac
3901 taagaatctg tgacgggcaa gagattcggg atgcctatca gtcctctctt ccccaaaaa
3961 gcaaatggcc ttatattctc acaacattct cagagtaatt taacagacga ttgttctgt
4021 gatctgggta attgctttat ttttaattgt ctgttgtttt tttttcctca tcagggttag
4081 ggagtgaagt ctcacatagg aggacctgtg tgagcctcac taccagcga ctgccagtta
4141 gcagaatcaa gacctacacc atcacggaag gctccttgag agcagtaatg tgagtctgcc
4201 tcctcagaag ttgggctggg tgggtacctc gaggtataga aatacactct atagaaatgc
4261 tgccatcctc agggaaaagta ggtcagcata gaggaacacc tcaacttaac caaaaacctc
4321 tttagttttc cttatcaacc atgtctttct gcagcccaac cgaatagcga ttattgcaga
4381 aattgggctg ccaaagaaag aatagaagtc ctctctattt tgtcttagtg gaagagtctg
4441 ttgaatactg tgcacagctc tgagatctgg gtttagagat ggctggctca tgtcagggtt
4501 tccctgcaag cctcactgga gttgggggat cttagggttg agttaggcag agtcccatc
4561 tttatcagtt gccatatttc aagaaaatga gtcaatgcac aacctacatg gtccctttct
4621 tctaccagaa tctcatTTTT agaagtaata actcttccca atacatatgt caagctttgc
4681 tctaaagaat gaaaatgtaa aaatcacctt tttaaaaaaa ataagatgag tattttcaaa
4741 tttgaaaagg aagagggttat ataataatgg aactagatgg cctcaaatgt ctttttgtaa
4801 caacatttgg tgacatggat gagaaaagga gcctgtgaat tatgggtgaa aaagggtctg
4861 gatactactt gcagatattt ctcttttatg ttaaaataga tggcagaaga aggggtctca
4921 tttatgatct catggctctg aaagactatt tcttgcaatg atttctgcac aagatctctt
4981 catgtctgcc ctgatcttaa ctctgacctc tgaggctttg agaactgggc taacttcate
5041 tgtcttttcc ttgctgttaca gttttattac caaacgtggc ctaaaagtct gtgctgatcc
5101 acaagccacg tgggtgagag acgtgggtcag gagcatggac aggaatccca acaccagaaa
5161 taacatgatc cagaccaagc caacaggaac ccagcaatcg accaatcag ctgtgacctc
5221 gactggctag tagtctctgg caccctgtcc gtctccagcc agccagctca tttacttta
5281 caccctcatg gactgagatt atactcacct tttatgaaag cactgcatga ataaaaattt
5341 tcttttgat ttttactttt aaatgtcttc tgtattcact tatatgttct aattaataaa
5401 ttatttatta ttaagaatag ttccctagtc tattcattat atttagggaa aggtagtgtg
5461 tcattgttgt ttgatttctg acctgtgacc tctctttgat ggtaaccata atggaagaga
5521 ttctggctag tgtctatcag aggtgaaagc tatatcgatc actcttagag tccagcttgt
5581 aatggttctt tacacatcag tcacaagtta cagctgtgac aatggcaaca atttgagatc
5641 tatttcaact tgtctctata atagaattc

```

//

```

LOCUS      D63790      5660 bp      DNA      PRI      27-DEC-1996
DEFINITION Human DNA for SCM-1alpha precursor, complete cds.
ACCESSION  D63790
NID        G1754610
KEYWORDS   SCM-1alpha precursor; SCM-1 alpha.
SOURCE     Homo sapiens placenta DNA, clone:hg40.
ORGANISM   Homo sapiens
            Eukaryotae; mitochondrial eukaryotes; Metazoa; Chordata;
            Vertebrata; Mammalia; Eutheria; Primates; Catarrhini;
Hominidae; Homo.
REFERENCE  1 (sites)
AUTHORS    Yoshida,T., Imai,T., Kakizaki,M., Nishimura,M. and Yoshie,O.
TITLE      Molecular cloning of a novel C or gamma type chemokine, SCM-1
JOURNAL    FEBS Lett. 360 (2), 155-159 (1995)

```

MEDLINE 95180438
 REFERENCE 2 (sites)
 AUTHORS Yoshida,T., Imai,T., Takagi,S., Nishimura,M., Ishikawa,I.,
 Yaoi,T.
 and Yoshie,O.
 TITLE Structure and expression of two highly related genes encoding
 SCM-1/human lymphotactin
 JOURNAL FEBS Lett. 395 (1), 82-88 (1996)
 MEDLINE 97002294
 REFERENCE 3 (bases 1 to 5660)
 AUTHORS Yoshida,T.
 JOURNAL Unpublished (1995)
 REFERENCE 4 (bases 1 to 5660)
 AUTHORS Yoshida,T.
 TITLE Direct Submission
 JOURNAL Submitted (07-AUG-1995) to the DDBJ/EMBL/GenBank databases.
 Tetsuya
 Yoshida, Shionogi Institute for Medical Science; 2-5-1,
 Mishima,
 Settsu, Osaka 566, Japan (E-
 mail:teyoshid@f1.lab.shionogi.co.jp,
 Tel:06-382-2612, Fax:06-382-2598)
 FEATURES Location/Qualifiers
 source 1..5660
 /organism="Homo sapiens"
 /db_xref="taxon:9606"
 /chromosome="1"
 /clone="hg40"
 /map="1q23"
 /tissue_type="placenta"
 TATA_signal 640..644
 exon 683..764
 /number=1
 prim_transcript 683..5340
 CDS join(704..764,4064..4178,5053..5221)
 /codon_start=1
 /product="SCM-1alpha precursor"
 /db_xref="PID:d1010505"
 /db_xref="PID:g1754611"
 /translation="MRLILALLGICSLTAYIVEGVGSEVSDKRTCVSLLTQRLPVSR
 IKTYTITEGSLRAVIFITKRGLKVCADPQATWVRDVRSMDRKSNTNRNMIQTKPTGT
 QQSTNTAVTLTG"
 intron 765..4063
 /number=1
 exon 4064..4178
 /number=2
 mat_peptide join(4066..4178,5053..5218)
 /note="SCM-1alpha mature peptide"
 intron 4179..5052
 /number=2
 exon 5053..5340
 /number=3
 BASE COUNT 1623 a 1139 c 1175 g 1723 t
 ORIGIN
 1 aagcttctat aaatgtgtat gttaagtgtt aataaagcaa acacatgcat gtagacatgc
 61 ttaaacagtt atttaattgt ttcttgggta cctggggaga tggggtgaag aaaggggggt
 121 gacttgaatg aaggtggagg agaaaaatga gaaccaagaa agcaaaggat cgagaagctc
 181 agtgtggcag cagctctctt cccctcctga gagagtcaaa ggggtggcatc agggactcat
 241 gatccatggt tgtggaagcc tcatgtcaca ctggatgtca catgaggtgg gatggaacac
 301 agtgaccacc ccacctcatt tcctttacag ctcccggtgg gggccatggc agtgaacacc
 361 ttcaggcatg tctacggcgg aatatctgaa ttcaggctgg tggcaggaga caacacaacc
 421 acgttttctt ttatgcatgc atttggttta attgacacat taaccacaga caaaggggta
 481 aaggccacaa ggcgttaggt tagtatgaac agggaaaagg gacttttttt ttttttttta
 541 agaaaaataa aagcatcagt attgcaaaga ctttccatga tcctacaccc acctcgaaag
 601 cccctctca ccacaggaag tgcactgacc actggaggca taaaagaggt cctcaaagag
 661 cccgatctc actctccttg cacagctcag caggacctca gccatgagac ttctcatcct
 721 ggccctcctt ggcactctgt ctctcactgc atacattgtg gaaggtaagt ggagaagctg
 781 tctgtgagat aaagaacagg gaggcaaggc aggtgggcac acattttggg tttgactcag
 841 gttatgactg gactaatctg ctttccccag gggagcctta aacttcccat gtgcaagaaa

```

901 ggaatgatga ttttgactgt agagggttc gtaaaacttc aaaacagggg gaatttgatt
961 agtatctggg ctcctacttt tcctaattgg gtaatttcag gtaaatccct taaccactca
1021 gggcctgtgc ttatttatgt ataactgaat agtataacag acttgatcac ctgagattaa
1081 gattaaataa atattatggg ttatttaata acatcagatt tccttacaag cagtaatttt
1141 ttgattaatg tttagctatgg attagagggtg atgattataa atgcatttgt aggttttgcc
1201 catttaatat atagtttggat aaattatcaa aatcttagag agttcagtta cgtatgtggg
1261 atgcaccatt ggatgtatgt tctggagtaa atcaatgttt tcaatacaaa actaagcccc
1321 aaatgactgg aagttcaaac cttcatgtcc agaaaaatcaa tattaccctc aagtacgtgg
1381 gggactctgt tagtaatgcc atgactatta ctatttatga gaaattttct gtttttgtaa
1441 gagaacatac aataataact actaccaa atacacagcac cttatacaca gttcaataaa
1501 cctgcaagac acatccaggt aagattcaga tataccgagc cttacctga gattcagta
1561 ggtattttctt aaggattgat ttttcctatg actggagggtg aatctgtcga cttatttgtg
1621 ttctagtggg taggcttatt acttagacta tgatattata acttaataat ggggtcccaa
1681 ggggttccat gaataaagggt ggctaagtct ggaagtcctt gaaattatgg ataaaaaaa
1741 aaaatactga tgaacaaaaa gagtttgatt actacattag gccacatgtt gctacctggc
1801 tggcattttg ctgagacaat gggcatacca tttgagggag actcagatct gagtagggga
1861 aaggagctct ataagtccca ctgggtgctta gcttcttaca taaaaaaatg aggggaaacg
1921 gtctctgctt tgactcaatt ttgcaacctg agtgaagggtg atatttttaa aaataacaca
1981 gacactcaaa cattgctgac aataaggaaa aggtcttgtg gtttcaagca taacaggatt
2041 ccttgagtct taggagtcga cttcagatac ttacacagaga gaaatattgt ttcttaataa
2101 tgagagaaac agagaaaaaa cccagatttt tcctctttca ttggctacag aaacaattca
2161 ccaactaaaaa taaattggga aaggtagagg atagcaatgt gcagactggc attgagagtg
2221 aagaaatgat gaagaaaagc acacaatgaa cactctttgt ttagtccctt gctttaaaaa
2281 atgccttctg atattagcaa cactacagac caatgttggc cattatcagt ggttacttta
2341 gatgcttttt agctgcctat ttccctggga agcaaagacc agtgtctaca gctaaggaga
2401 aaatcagcac ttgaaaactt ggattagatt tcacccaacc cttaacagta ttaattctcc
2461 caagttattt ttctcatgac aatgtttttt tgattctcta cacttaatag ttaattctct
2521 ttgggcccatt actattgggg atgcataattt aagggtctgac ttctttttat atatatctta
2581 ccttttacca tttattaatt ttttgagag tttttattat ttttatgtac agaaaaactca
2641 acagtgtaca ttttaaccag tttagtggca agttcctctg cctttgtctat tccagcttg
2701 gcattgtgag ccacagattt tggactcggg acattgcaga tctcatcata tccgtcattg
2761 taatttgtcc tgatagcttc caccagctta gccaaagctc ctttgtcttc cgtgttaact
2821 tgggtgaagg ccacagtgtt gcttccctgt gactggatgt cccagtcttg ccttcttacc
2881 ccttgataat gcattaaggg acccccatt ttaggacaca ggacagacag aaagttaacc
2941 agcttgatgg ggtccacacc atgtgcaata ccagctgagc cttcttcttt tccagcaagg
3001 tgggtgatagt gttaaacctt gctcaaagaa cagggtgatt cctagtgagg acaacctctt
3061 tgctagcagc tttcttctca gcctgggcca acagtctctg cttcttctct tgctttgtct
3121 ctgggtcagta cttgtggatc agcttaagtg gctgagtagc tgtttggggg tctaaggctt
3181 ggggtgaactg gttaatggca gaaggcactt tcagctgctt atagaggata gctctttgca
3241 gctggaacca gatatagcgg ggccatttca caaagcagcg gaggtccctt ttgggctgga
3301 tgtcctgtcc aatgcctgcc taagaaaact cttaggcctt ttctcacaca gcggtttcat
3361 cactttctta gcctcctgct tctcaccgac ggcagggtct ggggccattt tcttctttt
3421 ggccatcttt cctttcagca tcttaggcag ctgacagaga gagacatttg accattttaa
3481 aaggagaaca cctttattta gtctgtcaaa agcatgtctt cttccctcac tgaatgttgc
3541 cttgcctaga gtactcttca cgcattactc tgtcttctca ctatggtact gtaacatgtt
3601 gcactatttg aaatgatctt ttctgtttgc ctgtctgtct cctggctcct tcatgagaga
3661 gatattgctt atgaaaacag gagtaatgtc tgccttagtaa aacatgtggg acacaacagg
3721 caccattgta taaatgaatg aatgcgtgtc actggggcat ttgctagcgg tcccaaatgt
3781 ctaagtga aaatacacag agacgggata acatcttgtt attttctctc agcatgaaat
3841 tcctgaaaca attctgttga ttgagttttt aaattagtea aatatttact aagaatctgt
3901 gacgggcaag agattcggga tgcctatcag tctctctctt ccccaaaaag caaatggcct
3961 taaattctca caacattctc agagtaattt aacagatgat tgttccctgt atctggataa
4021 ttgctttatt ttttaattgtc tgttgttttt ttttccctac cagggtgtagg gagtgaagtc
4081 tcagataaga ggacctgtgt gagcctcact acccagcgac tggcggttag cagaatcaag
4141 acctacacca tcacggaagg ctccttgaga gcagtaatgt gactctgctt cctcagaagt
4201 tgtgtcgggt ggggtatctag aagtatagaa atacactctg tagaaatgct gccgtcctca
4261 ggaagagtag gtcagcatag aggaacacct caacttaacc aaaaacctct ttagttttcc
4321 ttatcaatca tgtcttctg cagcccaacc gaatagcgat tattgcagaa attgggctgc
4381 caaagaaaga atagaagtcc tctctatttt agcttagtgg aagagtctgt tgaatactgt
4441 gcacagctct gagacctggg tttagagatg actggcccat gtcagggttt cctgcaagc
4501 ctcaactggg ttggggggtc tttagggtga gtcaggcaga gtccctactt tttatcagtt
4561 gccatatttc aagaaaatga gtcaatgcac aacctacatg gtccctctct ctaccagaat
4621 ctcattttta gaagttaata actcttctca acatgtaatt gcaagcttta ctctaaaaaa
4681 tgaaaatgta aaaatcactt tttattttaa aaataagatg aatatttttt aatttgaaaa
4741 ggaagaggtt atgtaataat ggaactagtt ggctcctcag tctttttgtt acaactttg
4801 gtgacatgga tgagaaaagg accctgtgaa ttattgtgaa caaaggggct ggatactact
4861 tgcagatatt actcctttat gttaaaaatg atggcagaa aaggggtact atttatgac
4921 tcatggctct gaaagactat ttcttgcaat aatttctgca caagatctct tcatgtctgc
4981 cctgatctta actcctgacc ctgaggcttt gagaatgtgg ctaacttcgt ctgtcttttc
5041 cttgcgttac agttttatta ccaaacgtgg cctaaaagtc tgtgtgtatc cacaagccac
5101 atgggtgaga gacgtggtca ggagcatgga caggaaatcc aacaccagaa ataacatgat

```

```

5161 ccagaccaag ccaacaggaa cccagcaatc gaccaatata gctgtgactc tgactggcta
5221 gtagtctctg gcaccctgtc cgtctccagc cagccagctc atttcacttt acacgctcat
5281 ggactgagtt tatactcacc ttttatgaaa gcactgcatg aataaaatta ttcctttgta
5341 tttttacttt taaatgtctt ctgtattcac ttatatgttc taattaataa attatttatt
5401 attaagaata gttccctagt ctattcatta tatttaggga aaggtagtgt atcattgttg
5461 ttgtatttct gaccttgtac ctctctttga tggtaacat aatggaagag attctggcta
5521 gtgtctatca gaggtgaaag ctatatcaat ctctcttaga gtccagcttg taatggttct
5581 ttacacatca gtcacaagtt acagctgtga caatggcaac aatttgagat gtatttcaac
5641 ttgtctctat aatagaattc

```

//

```

LOCUS      HSU91835      1635 bp      mRNA      PRI      21-MAR-1997
DEFINITION Human CX3C chemokine precursor, mRNA, alternatively spliced,
            complete cds.
ACCESSION  U91835
NID        g1899258
KEYWORDS
SOURCE     human.
ORGANISM   Homo sapiens
            Eukaryotae; mitochondrial eukaryotes; Metazoa; Chordata;
            Vertebrata; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE  1 (bases 1 to 1635)
AUTHORS    Bazan,J.F., Bacon,K.B., Hardiman,G., Wang,W., Soo,K., Rossi,D.,
            Greaves,D.R., Zlotnik,A. and Schall,T.J.
TITLE      A new class of membrane-bound chemokine with a CX3C motif
JOURNAL    Nature 385 (6617), 640-644 (1997)
MEDLINE    97177111
REFERENCE  2 (bases 1 to 1635)
AUTHORS    Bazan,J.F., Bacon,K.B., Hardiman,G., Wang,W., Rossi,D.,
            Greaves,D.R., Zlotnik,A. and Schall,T.J.
TITLE      Direct Submission
JOURNAL    Submitted (03-MAR-1997) Molecular Biology, DNAX Research
Institute,
            901 California Ave., Palo Alto, CA 94304-1104, USA
FEATURES   Location/Qualifiers
            source          1..1635
                               /organism="Homo sapiens"
                               /db_xref="taxon:9606"
            CDS             80..1273
                               /note="membrane-tethered chemokine module"
                               /codon_start=1
                               /product="CX3C chemokine precursor"
                               /db_xref="PID:g1899259"

/translation="MAPISLSWLLRLATFCHLTVLLAGQHHGVTKCNITCSKMTSKIP
VALLIHYQQNQASCGKRAIILETRQHRFLFCADPKEQWVKDAMQHLDROAAALTRNGGT
FEKQIGEVKPRTPPAAGGMDESUVLEPEATGESSSLEPTPSSQEAQRALGTSPELPTG
VTGSSGCTRLPPTPKAQDGGPVGTELFRVPPVSTAATWQSSAPHQGPSPSLWAEAKTSEA
PSTQDPSTQASTASSPAPEENAPSEGQRVWGGQSPRPENSLEREEMGPVPAHTDAFQ
DWGPGSMAHVSVPVSSEGTSPREPVASGSWTPKAEPIHATMDPQRLGLVLTVPVDA
QAATRRQAVGLLAFLGLLFCGLGVAMFTYQSLQGCPRKMAGEMAEGRLYIPRSCGSNSY
VLVPV"
            sig_peptide     80..151
            mat_peptide     152..1270
                               /product="CX3C chemokine"
            misc_feature    152..379
                               /note="encodes chemokine module"
            misc_feature    380..1102
                               /note="encodes glycosylation stalk"
            misc_feature    1103..1159
                               /note="encodes transmembrane helix"
            misc_feature    1160..1270
                               /note="encodes intracellular domain"
            3'UTR           1274..1635
                               /note="alternatively spliced; long transcript can be

```

found

in GenBank Accession Number U84487*
 BASE COUNT 338 a 544 c 464 g 289 t
 ORIGIN

```

1 ggcacgaggg cactgagctc tggcgctgg ctctagccgc ctgcctggcc cccgccggga
61 ctcttgccca ccctcagcca tggctccgat atctctgtcg tggctgctcc gcttggccac
121 cttctgccat ctgactgtcc tgctggctgg acagcaccac ggtgtgacga aatgcaacat
181 cacgtgcagc aagatgacat caaagatacc tgtagctttg ctcatccact atcaacagaa
241 ccaggcatca tgcggcaaac gcgaatcat cttggagacg agacagcaca ggctgttctg
301 tggcgacccg aaggagcaat gggtaagga cgcgatgcag catctggacc gccaggctgc
361 tggcctaact cgaaatggcg gcaccttcga gaagcagatc ggcgaggtga agcccaggac
421 cacccttgcc gccgggggaa tggacgagtc tgtggtcctg gagcccgaa gacaggcga
481 aagcagtagc ctggagccga ctcttcttcc ccaggaagca cagaggggcc tggggacctc
541 ccagagctg ccgacgggcg tgactggttc ctcagggacc aggtctcccc cgacgcaaaa
601 ggctcaggat ggaggcctg tgggcacgga gcttttccga gtgcctcccc tctccactgc
661 cgccacgtgg cagagtctg cccccacca acctggggcc agcctctggg ctgaggcaaaa
721 gacctctgag gccccgtcca cccaggacct ctccaccag gcctccactg cgtcctcccc
781 agccccagag gagaatgctc cgtctgaagg ccagcgtgtg tggggtcagg gacagagccc
841 caggccagag aactctctgg agcgggagga gatgggtccc gtgccagcgc acacggatgc
901 cttccaggac tgggggctg gcagcatggc ccagctctct gtggtccctg tctcctcaga
961 agggaccccc agcagggagc cagtggcttc aggcagctgg acccctaagg ctgaggaaacc
1021 catccatgcc accatggacc cccagaggct gggcgctcct atcactcctg tccctgacgc
1081 ctaggctgcc acccgaggc agggggtggg gctgtggtcc ttccttggcc tctcttctg
1141 cctgggggtg gccatgttca cctaccagag cctccagggc tgcctcgaa agatggcagg
1201 agagatggcg gagggccttc gctacatccc ccggagctgt ggtagtaatt catatgtcct
1261 ggtgcccgtg tgaactcctc tggcctgtgt ctagtgtttt gattcagaca gctgctggg
1321 atccctcatc ctcataccca cccccacca agggcctggc ctgagctggg atgattggag
1381 gggggaggtg ggtacctcca ggtgcacaag ctccaagctc ccaggcattc cccaggaggc
1441 cagccttgac cattctccac cttccaggga cagagggggt ggctcccaa ctcacccag
1501 cccaaaact ctctctgct gctggctggt tagaggttcc ctttgacgcc atccagccc
1561 caatgaacaa ttatttatta aatgcccagc cccttctgaa aaaaaaaaaa aaaaaaaaaa
1621 aaaaaaaaaa aaaaa

```

//

LOCUS HSU84487 3310 bp mRNA PRI 15-MAR-1997
 DEFINITION Human CX3C chemokine precursor, mRNA, alternatively spliced,
 complete cds.
 ACCESSION U84487
 NID g1888522
 KEYWORDS
 SOURCE human.
 ORGANISM Homo sapiens
 Eukaryotae; mitochondrial eukaryotes; Metazoa; Chordata;
 Vertebrata; Eutheria; Primates; Catarrhini; Hominidae; Homo.
 REFERENCE 1 (bases 1 to 3310)
 AUTHORS Bazan, J.F., Bacon, K.B., Hardiman, G., Wang, W., Soo, K., Rossi, D.,
 Greaves, D.R., Zlotnik, A. and Schall, T.J.
 TITLE A new class of membrane-bound chemokine with a CX3C motif
 JOURNAL Nature 385 (6617), 640-644 (1997)
 MEDLINE 97177111
 REFERENCE 2 (bases 1 to 3310)
 AUTHORS Bazan, J.F., Bacon, K.B., Hardiman, G., Wang, W., Rossi, D.,
 Greaves, D.R., Zlotnik, A. and Schall, T.J.
 TITLE Direct Submission
 JOURNAL Submitted (07-JAN-1997) Molecular Biology, DNAX Research
 Institute,
 901 California Ave., Palo Alto, CA 94304-1104, USA
 FEATURES
 source Location/Qualifiers
 1..3310
 /organism="Homo sapiens"
 /db_xref="taxon:9606"
 CDS 80..1273
 /note="membrane-tethered chemokine module"
 /codon_start=1
 /product="CX3C chemokine precursor"
 /db_xref="PID:g1888523"

/translation="MAPISLSWLLRLATFCHLTVLLAGQHHGVTKCNITCSKMTSKIP
 VALLIHYQQNQASCGKRAIILETRQHRFLFCADPKEQWVKDAMQHLDRQAAALTRNGGT"

FEKQIGEVKPRRTTPAAGGMDESIVLEPEATGESSSLEPTSSQEAQRALCTSPLEPTG

VTGSSGTRLPTPKAQDGGPVGTLEFRVPPVSTAATWQSSAPHQPGPSLWAEAKTSEA

PSTQDPSTQASTASSAPEENAPSEGQRVWQGGQSPRPENSLEREEMGPVPAHTDAFQ

DWGPGSMAHVSVPVSSEGTSPREPASGSWTPKAEPIHATMDPQRLGVLITPVPDA

QAATRRQAVGLLAFLGLLFCGLGVAMFTYQSLQGCPRKMAGEMAELRYIPRSCGSNSY

VLVPV"

sig_peptide 80..151

mat_peptide 152..1270

misc_feature 152..379

misc_feature 380..1102

misc_feature 1103..1159

misc_feature 1160..1270

3'UTR 1274..3310

deposited as GenBank Accession Number U91835"

BASE COUNT 659 a 1051 c 916 g 682 t 2 others

ORIGIN

```

1  ggcacgaggg  cactgagctc  tgcgcgctgg  ctctagccgc  ctgcctggcc  cccgccggga
61  ctcttgccca  ccctcagcca  tggctccgat  atctctgtcg  tggctgctcc  gcttggccac
121  cttctgccat  ctgactgtcc  tgctggctgg  acagcaccac  ggtgtgacga  aatgcaacat
181  cacgtgcagc  aagatgacat  caaagatacc  tgtagctttg  ctcatccact  atcaacagaa
241  ccaggcatca  tgcggcaaac  gcgcaatcat  ctggagacg  agacagcaca  ggtgtttctg
301  tgccgacccg  aaggagcaat  gggtaagga  cgcatgcag  catctggacc  gccaggctgc
361  tgccctaact  cgaataggcg  gcaccttcca  gaagcagatc  ggcgaggtga  agcccaggac
421  caccctgcc  gccgggggaa  tggacgagtc  tgtggtcctg  gagcccgaag  ccacaggcga
481  aagcagtagc  ctggagccga  ctcttcttc  ccaggaagca  cagaggccc  tggggacctc
541  cccagagctg  ccgacggcg  tgactggttc  ctacaggacc  aggtccccc  cgacgccaaa
601  ggctcaggat  ggagggcctg  tgggcacgga  gcttttccga  gtgcctcccc  tctccactgc
661  cgccacgtgg  cagagttctg  ctccccacca  acctgggccc  agcctctggg  ctgaggcaaa
721  gacctctgag  gccccgtcca  ccaggacccc  ctccaccag  gcctccactg  cgtcctcccc
781  agcccagag  gagaatgctc  cgtctgaagg  ccagcgtgtg  tggggtcagg  gacagagccc
841  caggccagag  aactctctgg  agcgggagga  gatgggtccc  gtgccagcgc  acacggatgc
901  cttccaggac  tgggggctg  gcagcatggc  ccacgtctct  gtggtcctct  tctcctcaga
961  agggaccccc  agcagggagc  cagtggcttc  aggcagctgg  acccctaagg  ctgaggaaac
1021  catccatgcc  accatggacc  ccagaggct  gggcgtcctt  atcactctg  tccctgacgc
1081  ccaggctgcc  acccgaggc  aggcgggtgg  gctgctggcc  ttccttggcc  tctcttctg
1141  cctgggggtg  gccatgttca  cctaccagag  cctccagggc  tgccctcgaa  agatggcagg
1201  agagatggcg  gagggccttc  gctacatccc  ccggagctgt  ggtagtatt  catatgtcct
1261  ggtgcccgtg  tgaactctc  tggcctgtgt  ctagtgttt  gattcagaca  gctgctggg
1321  atccctcatc  ctcataccca  cccccacca  agggcctggc  ctgagctggg  atgattggag
1381  gggggagggt  ggatcctcca  ggtgcacaag  ctccaagctc  ccaggcattc  cccaggaggc
1441  cagccttgac  cattctccac  ctccaggga  cagagggggt  ggcctcccaa  ctcaccccag
1501  ccccaaaact  ctctctgtgt  gctggctggt  tagaggttcc  ctttgacgcc  atcccagccc
1561  caatgaacaa  ttatttatta  aatgcccagc  ccctctgac  ccatgctgcc  ctgtgagtac
1621  tacagtcctc  ccattctcaca  catgagcatc  aggccaggcc  ctctgcccac  tccctgcaac
1681  ctgattgtgt  ctcttggtcc  tgctgcagtt  gccagtcacc  ccggccacct  gcggtgctat
1741  ctccccagc  cccatcctct  gtacagagcc  cagcctccca  ctggtgacat  gcttttctt
1801  gcatgaggct  agtgtggtgt  ttcctgggca  ctgcttccag  tgaggctctg  cccttggtta
1861  ggsattgtgg  gaaggggaga  taagggtatc  tggtagcttt  cctcttgggt  ctacactgtg
1921  ctgagctctga  aggtgggtt  ctgacctag  ttccaccatc  aagccaccaa  catactccca
1981  tctgtgaaag  gaaagagggg  ggttaaggaa  acctgtcccc  ctgacaacac  tcattgacct
2041  gaggcccttc  tctccagccc  ctggatgcag  cctcacagtc  cttaccagca  gaggccttca
2101  gacagtcctc  gccaatggac  taacttgtct  ttggaccttg  agggccagag  ggcctgcarg
2161  ggagtggatt  gatagcacag  acctgcccct  gtgggcccc  aaatggaaa  gggcagagca
2221  gagaccatcc  ctgaaggccc  cgcccaggct  tagtactga  gacagcccg  gctctgcttc
2281  ccataccccc  ctaagaggga  gggagggtc  cagacacatg  tccaagaagc  ccaggaaagg
2341  ctccaggagc  agccacattc  ctgatgcttc  ttcaagagac  cctgcaggca  gccaggccac
2401  aagacccttg  tgggtcccac  ccacacacgc  cagattcttt  cctgaggctg  ggctcccttc
2461  ccactctctc  cactccttga  aaacactgtt  ctctgcccct  caagaccttc  tcttcaacct
2521  ttgtccccac  cgacagacgg  accaggggat  ttccatgatg  ttttccatga  gtccccgtgt
2581  tgtttctgaa  agggacgcta  cccgggaagg  gggctgggac  atgggaaagg  ggaagtgtga

```



```

2641 ggcataaagt caggggttcc cttttttggc tgctgaaggc tcgagcatgc ctggatgggg
2701 ctgcaccggc tggcctggcc cctcagggtc cctgggtggc gctcacctct cccttggatt
2761 gtccccgacc cttgccgtct acctgagggg cctcttatgg gctgggttct acccaggtgc
2821 taggaacact ctttcacaga tgggtgcttg gaggaaggaa acccagctct ggtccataga
2881 gagcaaaacg ctgtgctgcc ctgcccaccc tggcctctgc actcccctgc tgggtgtggc
2941 gcagcatatt caggaagctc agggccctgg ctccaggtgg gtcactctgg cagctcagag
3001 aggggtgggag tgggtccaat gcactttgtt ctggctcttc caggctggga gagcctttca
3061 ggggtgggac accctgtgat ggggccctgc ctcttttgtg aggaagccgc tggggccagt
3121 tgggtccctt tccatggact ttgttagttt ctccaagcag gacatggaca aggatgatct
3181 aggaagactt tggaaagagt aggaagactt tggaaagact ttccaaccc tcatcaccaa
3241 cgtctgtgcc attttgtatt ttactaataa aattttaaag tcttgtgaaa aaaaaaaaaa
3301 aaaaaaaaaa

```

//

```

LOCUS      HSU91746      1430 bp      mRNA      PRI      12-MAR-1998
DEFINITION Homo sapiens IL-10-inducible chemokine (HCC-4) mRNA, complete
            cds.
ACCESSION  U91746
NID        g2581780
KEYWORDS
SOURCE     human.
ORGANISM   Homo sapiens
            Eukaryotae; mitochondrial eukaryotes; Metazoa; Chordata;
            Vertebrata; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE  1 (bases 1 to 1430)
AUTHORS    Hedrick,J.A., Helms,A., Gorman,D. and Zlotnik,A.
TITLE      Identification of a novel human CC chemokine upregulated by IL-
10
JOURNAL    Blood (1998) In press
REFERENCE  2 (bases 1 to 1430)
AUTHORS    Hedrick,J.A., Helms,A., Gorman,D. and Zlotnik,A.
TITLE      Direct Submission
JOURNAL    Submitted (02-MAR-1997) Immunology, DNAX Research Institute,
901        California Ave, Palo Alto, CA 94304, USA
FEATURES   Location/Qualifiers
            source          1..1430
                               /organism="Homo sapiens"
                               /db_xref="taxon:9606"
                               /chromosome="17"
            gene            1..1430
                               /gene="HCC-4"
            CDS              1..363
                               /gene="HCC-4"
                               /note="CC or beta chemokine family member"
                               /codon_start=1
                               /product="IL-10-inducible chemokine"
                               /db_xref="PID:g2581781"

```

/translation="MKVSEAALSLVLILIITSASRSQPKVPEWVNTPTSCCLKYYEK

VLPRRLVVG YRKALNCHLPAIFVTKRNREVCTNPNDWVQEI KDPNLP LLPTRNLS
TVKIITAKNGQPQLLSQ"

BASE COUNT 401 a 351 c 293 g 385 t

ORIGIN

```

1 atgaaggtct ccgaggctgc cctgtctctc cttgtcctca tccttatcat tacttcggct
61 tctcgcagcc agccaaaagt tcttgagtgg gtgaacaccc catccacctg ctgcttgaag
121 tattatgaga aagtgttgcc aaggagacta gtgggtgggac acagaaaggc cctcaactgt
181 cacctgccag caatcatctt cgtcaccaag aggaaccgag aagctctgac caaccccaat
241 gacgactggg tccaagagta catcaaggat cccaacctac ctttctgccc taccaggaac
301 ttgtccacgg ttaaaattat tacagcaaaag aatgggtcaac cccagctcct caactcccag
361 tgatgaccag gctttagtgg aagcccttgt ttacagaaga gaggggtaaa cctatgaaaa
421 cagggggaagc cttattaggg tgaactagc cagtcacatt gagagaagca gaacaatgat
481 caaaataaag gagaagtatt tcgaatatct tctcaatctt aggaggaaat accaaagtta
541 agggacgtgg gcagaggtag gctcttttat ttttatattt atatttttat ttttttgaga
601 taggtcttac tctgtcaccc aggtgggagt gcagtgggtg gatcttggct cacttgatct
661 tggtctactg taacctccac ctcccagggt caagtgtacc tcccaccca gcctcccag
721 tagctgggac tacaggcttg cgccaccaca cctggctaatt ttttgtattt ttggtagaga
781 cgggattcta ccatgttgcc caggctggtc tcaaaactcg gtgcccagc aatccacctg
841 cctcagcctt ccaaaagtgc tgggattaca ggcgtgagcc accacatccg gccagtgcac
901 tcttaataca cagaaaaata tatttcacat ccttctctg ctctctttca attctcact

```

961 tcacaccagt acacaagcca ttctaaatac ttagccagtt tccagccttc cagatgatct
1021 ttgccctctg ggtcttgacc cattaagagc cccatagaac tcttgatttt tcctgtccat
1081 ctttatggat ttttctggat ctatatcttc ttcaattatt ctttcatttt ataatgcaac
1141 tttttcatag gaagtccgga tgggaatatt cacattaatc atttttgag agactttgct
1201 agatcctctc atattttgtc ttcctcaggg tggcaggggt acagagagtg cctgattgga
1261 aaaaaaaaaa aaagagagag agagagaaga agaagaagaa gagacacaaa tctctacctc
1321 ccatgttaag ctttgagga cagggaaaga aagggtatga gacacggcta ggggtaaact
1381 cttagtccaa aaccaagca tgcaataaat aaaactccct tatttgacaa

//

INTERNATIONAL SEARCH REPORT

 International application No.
PCT/US98/26291

A. CLASSIFICATION OF SUBJECT MATTER

IPC(6) : Please See Extra Sheet.

US CL : Please See Extra Sheet.

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 424/84, 85.1, 184.1, 186.1, 188.1, 278.1; 514/2, 8, 12, 44; 530/300, 324

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched
NONEElectronic data base consulted during the international search (name of data base and, where practicable, search terms used)
Please See Extra Sheet.

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	US 5,141, 867 A (IVANOFF et al.) 25 August 1992, see entire document.	22-32, 45-55
A	ENG et al. The Stimulatory Effects of Interleukin (IL)-12 On Hematopoiesis Are Antagonized by IL-12-induced Interferon γ In Vivo. J. Exp. Med. May 1995, Vol.181, pages 1893-1898, see entire document.	1-21, 33-44
A	ORANGE et al. Mechanism of Interleukin 12-mediated Toxicities during Experimental Viral Infections: Role of Tumor Necrosis Factor and Glucocorticoids. J. Exp. Med. March 1995, Vol.181, pages 901-914, see entire document.	1-21, 33-44

☒ Further documents are listed in the continuation of Box C.
 ☐ See patent family annex.

* Special categories of cited documents	*T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
A document defining the general state of the art which is not considered to be of particular relevance	*X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
E earlier document published on or after the international filing date	*Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*A* document member of the same patent family
O document referring to an oral disclosure, use, exhibition or other means	
P document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search

25 MARCH 1999

Date of mailing of the international search report

15 APR 1999

 Name and mailing address of the ISA/US
Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

PREMA MERTZ

Telephone No. (703) 308-0196

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US98/26291

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WU et al. Receptor-mediated in Vitro Gene Transformation by a Soluble DNA Carrier System. The Journal of Biological Chemistry. 05 April 1987, Vol.252, No. 10, pages 4429-4432, see entire document.	22-32, 45-55

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US98/26291

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

2. ☐ Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:

3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

Please See Extra Sheet.

1. ☒ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:

4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US98/26291

A. CLASSIFICATION OF SUBJECT MATTER:

IPC (6):

C07K 14/47, 14/52; C12N 15/12, 15/19, 15/63; A61K 38/16, 38/19, 48/00

A. CLASSIFICATION OF SUBJECT MATTER:

US CL :

424/84, 85.1, 184.1, 186.1, 188.1, 278.1; 514/2, 8, 12, 44; 530/300, 324

B. FIELDS SEARCHED

Electronic data bases consulted (Name of data base and where practicable terms used):

APS, CAN ONLINE, MEDLINE, CAPLUS

search terms: chemokine, vaccination, immunogenic, antigen, HIV, efficacy, macrophage-derived chemokine, stromal cell-derived factor, monocyte chemotactic protein, composition, administration

BOX II. OBSERVATIONS WHERE UNITY OF INVENTION WAS LACKING

This ISA found multiple inventions as follows:

This application contains the following inventions or groups of inventions which are not so linked as to form a single inventive concept under PCT Rule 13.1.

Group I, claims 1-21, 33-44, drawn to a method to enhance the efficacy of a vaccine in a subject comprising administering an antigen and one or more chemokines and a composition thereto.

Group II, claims 22-32, 45-55, drawn to a method to enhance the efficacy of a vaccine in a subject comprising administering nucleic acid sequences encoding one or more antigens and nucleic acid sequences encoding one or more chemokines.

The inventions listed as Groups I-II do not relate to a single inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons:

The inventions listed as Groups I-II do not relate to a single inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons:

Pursuant to 37 C.F.R. § 1.475 (d), the ISA/US considers that where multiple products and processes are claimed, the main invention shall consist of the first invention of the category first mentioned in the claims and the first recited invention of each of the other categories related thereto. Accordingly, the main invention (Group I) comprises the first-recited product and method, a method to enhance the efficacy of a vaccine in a subject comprising administering an antigen and one or more chemokines and a composition thereto. Further pursuant to 37

C.F.R. § 1.475 (d), the ISA/US considers that any feature which the subsequently recited products and methods share with the main invention does not constitute a special technical feature within the meaning of PCT Rule 13.2 and that each of such products and methods accordingly defines a separate invention.